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Preface 
The onset of diabetes mellitus is characterized by various symptoms, aU the result of 
a disturbed glucose metabolism, The main symptoms are thirst and an excessive production 
of urine. The disturbed glucose metabolism underlying these symptoms is due to an absolute 
deficiency of insulin secretion (type 1 diabetes mellitus), a reduction in its biological effec-
tiveness (type 2 diabetes mellitus) or a combination of these factors. Type 1 diabetes mellitus 
is predominantly manifesting in children, and needs to be treated by life-long exogenous 
insulin administration to prevent high blood glucose levels. Type 2 diabetes mellitus occurs 
classically in adults, and is relatively milder in its appearance; usually, exogenous insulin 
administration is not required. This thesis concerns type 1 (insulin-dependent) diabetes mel-
litus (type I diabetes). 
In the Netherlands, the annual incidence of type I diabetes among children younger 
than 14 years was 14.3 per 100,000 in the period li'OI11 1993·1995. Compared to earlier stud· 
ies, the incidence has increased and the clinical manifestation has shifted to younger ages. 
Although the possibility of exogenous insulin administration has largely reduced the risk for 
short-term complications, such as diabetic ketoacidosis and hyperglycaemic coma, over 70% 
of patients will develop long-tenn complications. These include microangiopathy, that may 
cause problems with the kidney-function and the vision, and macropangiopathy, that leads to 
an elevated risk of developing major cardiovascular problems. The quality of life of diabetes 
patients can be profoundly reduced because of these complications. In addition, the life-
expectancy of diabetes patients is considerably shorter than that of healthy persons. The risk 
of developing long-term complications may be signiticantly reduced by normalizing blood 
glucose levels. However, this requires intensive individual treatment and significant changes 
in lifestyle. Consequently, the disease a has large emotional and social impact on the Hfes of 
patients and their family. In addition, diabetes has seriolls economic consequences, because 
of the costs of the treatment and lost productivity due to hospital admission, 
Therefore, prevention and cure of the disease are major goals of diabetes research. 
In order to achieve thesc goals, a thorough knowledge is required about the mechanisms via 
which diabctes develops, The studies described in this thesis describe such a mechanism. 
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Chapter 1.1 
Destination type 1 diabetes: 
routes and detours in humans, 
BB rats and NOD mice 
• 
Judith G.M. Rosmalen 
Pieter J.M. Leenen 
Heml110 A. Drexhage 
Department of Immunology, Erasmus Ul1iversi~v. Rotterdam, The Netherlal1ds 
Chapter l. I 
The ancient Egyptians already recognized the key finding of the disease we now knmv 
as diabetes mellitus: glucose intolerance. The first diagnostic test for this disease involved 
counting the number of bees attracted to a patient's urine, indicating the excess presence of 
glucose. The pancreatic nature of the disease was not discovered until 1889, ,vhen a research 
assistant noted that flies were especially attracted to urine of dogs ,vithaut a pancreas. In 
1921, the discoVCIY of insulin explained this observation, a discovery that was rewarded with 
the Nobel Prize for physiology in 1923 for Banting and Macleod. With the discovery of 
insulin, it also became clear that diabetes is a chronic disease needing life-long treatment. Tn 
its variolls forms, diabetes affects aboll! 5% of the popllJatioll in most western societies, 
Today, two major types of diabetes mellitus are recognized, designated type 1 and type 2 dia-
betes. Type I diabetes mellitus is caused by an absence of insulill~ "whereas type 2 diabetes 
mellitus is related to an insensitivity for insulin. This review will focus on type 1 (insulin-
dependent) diabetes mellitus (type 1 diabetes). 
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Symptoms of type 1 diabetes result from an absolute lack of insulin due to an autoim~ 
mune destruction of the B cells in the pancreatic islets of Langerhans. At least two observa-
tions indicate that autoimmunity is initiated long before clinicalmanifestatioll of diabetes. 
First, both T cell reactivity and autoantibodies against B cells can be detected several years 
before clinical onset in humans (1-3). Second) changes in the insulin response to glucose chal-
lenge may occur long before clinical onset (2). Several 8utoantigens appear to be involved in 
the autoimmune destruction (4-6). The absence of insulin results in hyperglycem.ia and severe 
catabolism with release of free fatty acids il-om adipose tissue and hepatic overproduction of 
ketones. Unless they are given exogenous insulin, affected individuals progress to excessive 
weight loss, ketoacidosis and dehydration and will finally die. 
The causes oftype 1 diabetes are largely unknown. The concordance in identical twins 
varies from 25-50% (7,8), indicating that both environmental and genetic factors are 
involved. Tn addition, there is a large difference in diabetes incidence between countries, 
probably related to genetic variations, as well as influence of temperature, differences in diet 
and hygienic circumstances (9, I 0). Among the genetic £1ctorS related to diabetes, the 
strongest genetic association is with the M,uor Histocompatibility Complex (MHC) (11,12), 
but also other immune function genes appear to be involved (13). It is thus not surprising that 
several other autoimmune diseases have been described to be associated ''lith type 1 diabetes 
(14-18). In contrast to most other autoimmune diseases, the incidence in males and females 
is similar overall, but dependent on the subpopulation the ratio varies from 0.3-2.1 (I8). The 
clinical features of type 1 diabetes development are summarized in Table 1. 
Tahle 1: Clinical features of diabetes in NOD mice, DB nits and humans. 
Lean-body habitus 
Sex distribution 
Ketoacidosis 
Duration of insulitis 
Islet (auto)antibodies 
Lymphopenia 
Associated autoimmunity 
NOD mouse 
± 
Long 
± 
Thyroiditis 
Parathyroiditis 
Hemolytic anemia 
Adrenalitis 
In1cstinal nephritis 
Sialoadenitis 
Dacryoadenitis 
Colitis 
~'fyositis 
Neuritis 
Meningitis 
Osteomyelitis 
BB rat 
+ 
F=~'[ 
+ 
Short 
± 
+ 
Thyroiditis 
Gaslritis 
Human 
+ 
F=M, but depends on 
sllbpoplliation 
+ 
Short to long 
+ 
Hashimolo's thyroiditis 
Graves' disease 
Adrenalitis 
Addison's disease 
Gastrilis 
Rheumatoid nrtluitis 
Vitiligo 
Pernicious anemia 
Polyelldocrine syndroms 
Primary myxedema 
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Despite many years of extensive research, the pathophysiology underlying type I dia-
betes has remained largely obscure. The main reason for this is that clinical symptoms of dia-
betes do not develop until more than 80-90% of the f3 cell mass is destroyed. Since patients 
therefore do not present before the autoimmune attack is virtually finished, the steps that lead 
to the autoimmune attack remain unclear. 
In order to gain more insight into the pathogenic mechanisms leading to f3 cell 
destruction,_ animal models have been developed. Amongst these are the nonobese diabetic 
(NOD) mouse and the BioBrccding (BB) rat. Both NOD mice and BB rats spontaneously 
develop a disease resembling human type I diabetes. These models provide us ,vith the 
opportunity to study early phases in the process leading to diabetes. Moreover, the possibil-
ity of modifying their genetic background facilitates the study of genes that are potentially 
involved in diabetes development. Also other experiments aimed at the manipulation of the 
onset of diabetes would be ethically and technically impossible in humans, but can be per-
formed in experimental animals. 
There is, however, an important difference between human type 1 diabetes and its ani-
mal models. In contrast to NOD mice and BB rats, human type I diabetes patients differ sig-
nificantly in genetic background as well as environment. Therefore, it is highly unlikely that 
processes leading to type I diabetes are comparable among patients. The animal models can 
thus be envisaged as case reports, and will probably not be representative of all human 
patients. Theretore, a prerequisite for the correct interpretation of observations from animal 
models in relation to human disease is a good knowledge of the aspects in which the models 
do or do not resemble the human disease process. 
To enable a proper comparison of the animal models \vith human type I diabetes, this 
review will focus on the actual processes that take place at the cellular level in the pancreas 
in human type 1 diabetes and its animal counterparts. lvlore specific, we will discuss the cells 
and cell products and their most likely roles in the pathophysiological process leading to dia-
betes. Given the vast literature on human type I diabetes and the animal models resembling 
the disease, the genetics of the disease and specific immune defects leading to autoimmuni-
ty are beyond the scope of this review. Other animal models for type I diabetes wiII also not 
be discussed here. 
NOD mOllse 
Autoimmune diabetes in NOD mice 
The NOD mouse was bred at the Shionogi Research Laboratories in Aburahi, Japan 
from a female mouse displaying severe glycosuria, which belonged to the CTS-subline of 
outbred ICR mice. An inbred strain was derived by brother-sister matings (19). Early in the 
program of inbreeding, an NrnC-incompatible control line was developed from the CTS-sub~ 
line of outbred ICR mice, now designated the non obese nondiabetic (NON) mOllse (20). 
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A Ilonobese diabetes-resistant (NOR) strain was also developed, This NOD-related MHC-
syngeneic recombinant strain possesses ~12% C57IKsJ (BKs)-derived genes and therefore 
has a unique combination of resistance and susceptibility genes (21-23). NOR mice arc resist-
ant to both spontaneous and cyclophosphamide-induced diabetes (see below) and display 
only a mild inflammatory infiltrate surrounding the islets, so-called peri-insulitis, up to 
9 months of age (21-24), Furthermore, the NOD mouse has been backcrosscd to the 
C.B.-17scid mouse, resulting in the NODscid mouse. This mouse lacks functional T and 
B lymphocytes and consequently develops neither lymphocyte insulitis nor diabetes (25). 
Currently, several colonies of NOD mice arc maintained throughout the world (26). 
Although they are supposed to be genetically identical, a direct comparison of diabetes inci-
dence in tvt'O substrains maintained in a common environment indicated that substrain diver-
gence is occurring (20), This is not surprising, given the likelihood that inbred NOD colonies 
worldwide are accumulating independent genetic mutations that \vill eventually lead to sub-
strain divergence, Substrain and environmental differences lead to significant variation with 
respect to incidence of diabetes, time of onset and ratio of female to male diabetic mice, Tn 
the original colony, and in most derived colonies, the females arc more prone to diabetes 
development than the males, and especially the incidence in male mice is variable (20). The 
differences between colonies indicate the importance of environmental factors in the 
development of diabetes, such as gnotobiotic environment, temperature and diet (18,26,27), 
The first pathological symptom in NOD mice is the accumulation of leukocytes 
around the islets. This so-called peri-insulitis may be evident as early as 2-3 weeks of age 
(28,29), preceding diabetes symptoms by many weeks, The autoimmune reaction is directed 
against several Hutoantigens (4,6,24), Usually, NOD females become diabetic at about 
19 weeks of age, while males become diabetic at about 24 weeks of age (26). By 30 \veeks, 
typically 80% of fcmale and 20% of male mice have become diabetic (18,27), 
Cyclophosphamide treatment can be used to compress and synchronize diabetes development 
in NOD mice. Administration of cyclophosphamide to NOD mice results in predictable 
acceleration of ~,cell destruction leading to diabetes within 7 to 14 days and hypcrglycemia 
occurring in 60% oHemale NOD mice (30,31), Onset of both spontaneous and induced dia-
betes is marked by the appearance of moderate glycosuria and by a nOll-fasting plasma glu-
cose higher than 250 mg/dl. Both glycosuria and hyperglycemia become progressively more 
severe over a 3-4 week period during which weight loss and polyuria also occur. In addition 
to becoming severely hyperglycemic, diabetic mice are ketonemic, but, in contrast to human 
diabetes patients and BB rats, not ketoacidotic (32). Diabetic animals can survive for up to a 
month \vithout exogenous insulin, but eventually insulin is required for survival (18,20), 
The main genetic component determining the susceptibility for diabetes in NOD mice 
is the MHC, but other genes involved in immune function also playa significant role (33), 
1ndeed, in addition to insulitis and diabetes, NOD mice develop several other local inflam-
matory processes (20,26) (Table 1). Furthermore, they show an increased incidence of a wide 
spectrum of neoplasms, in particular lymphomas, but also other tumors (20,26). The main 
clinical features of the NOD mouse model are sUlllmarized in Table 1. 
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AI'C initiate the islet attack 
In NOD mice, there arc several indications that insulitis is initiated by professional 
antigen-presenting cells (APC), including B cells (Table 2).These APC inliltrate the islets of 
Langerhans, independent of coincident T cell migration. In the islets, they pick up islet anti-
gens, which they present in the pancreas-draining lymph nodes to T cells .. Most likely, A PC 
arc needed for the generation of B cell-specific effector T cells. 
Table 2: Evidence that APe initiate the islet attack in NOD mice and BB rats, 
NOD mOllse 
Spontaneous insulilis in young NOD is primarily 
mcdiate-d by an influx of DC ;lIld M\(l that precedesT 
cell accumulation in islets (34,35). 
In both NODscid and NOR mice, there is an aCCll-
mulation of DC and r.,·f41 arolltld the islets without 
[IllY accumulation ofT cells (36,37). 
Peri-insulitis is absent in NOD mice depleted of 
phagocytic cells (including r ... trp and DC precursors) 
by means of silica treatment early in diabctes 
development, even after acceleration with 
cyclophosphamide (38). However, silica has no 
en-Cd aner onset of invasive insulitis (38-40). 
Thc blockade of r-,·t$ adhesion-promoting type-3 
complement receptor (CR3 or CDllb/CDIS) in 
vivo before adoptive transfer not only prevents 
intra-islet infiltration by "M$, but also by T cells and 
inhibits diabetes development, although the mono-
clonal antibody 5C6 that is used docs nol bind 10 T 
cell, (4t). 
Peri-insulitis is absent in young NOD mice defi-
cient in B cells, a defect that can be restored by 
transfer of B cells but not by immunoglobulin infu-
sions (42). 
BH rat 
l ... Iyeloid cell intlux precedes the ini1ltralioll ,vith 
Iymphocytcs during spontaneous il1sulilis (43-4R). 
Trcatmcnl of DP-BR rats with silica, that almost 
completely prevents disease manifestation (49), 
suppresses both 1\[$ and lymphoc)1e infiltration 
(48,50). 
ConA-activatcd splenocytes from long-tcfln silica 
trcaled DP-BB rats do not induce insulitis or dia-
betes in DP-BB neonates; in contrast to those from 
untreated DP-BB rats, probably as a result of a 
decrease in the number of i\,r$-dependent T lym-
phocytes and a reduction in NK cell cytotoxicity 
(5 t). 
The cause of early APC intiltration is unknown. It has been hypothesized, based on 
human and BB rat studies, that virus-induced interferon-a (IFN-a) expression may be 
involved (52-54). Retroviruses have been suggested as possible candidate viruses for the 
triggering of () cell specific autoimmunity in NOD mice. Indeed, retrovirus particles, retro-
viral DNA and retI'Qviral proteins have been detectcd in pancrcatic islets of NOD mice 
(28,55-58). NOD B cells, in contrast to NON j3 cells, express not only type A, but also type 
C patiicles (57). 
The pathophysiological relevance of the presence of these retroviruses is, however, 
unclear. Theoretically, virus-induced IFN-a expression can function as the trigger for APC 
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infiltration, but the evidence argues against this scenario, First, IFN-a expression in NOD 
islets could not be dctccted (53). Second, it has been shown that administration of polyion-
isinic-polycytidilic acid (poly 1IC), a synthetic double-stranded polyribonucleotide that elic-
its inflammatory responses analogolls to those observed during viral infection' and that 
induces IFN-(,{ expression in islets, prevents the development of diabetes in NOD mice (59). 
Thus, it seems unlikely that virus-induced IFN-n expression by NOD B cells is involved in 
the attraction of early infiltrating APe. Alternatively, the presence of a virus could possibly 
induce autoimmunity due to the presence of molecular mimicry between retroviral proteins 
and j) cell autoantigens (60). 
Several studies have investigated the type and location of early infiltrating APC in 
more detail. MCP and DC, potentially functioning as APC and involved in early peri-insulitis, 
are either constitutively present in the pancreas and subsequently home to the islets, or are 
recruited from the circulation. In the normal pancreas, APC expressing one or more of the 
markers CDllb (61-63), F4/80 (35,61-63), SER-4 (61), ER-MP23 (35), MOMA-I (35) and 
CDI3 (ER-BMDMI) (35) are present. Thcy are usually found in different locations: lining 
the exocrine pancreatic acini, in connective tisslles, in the perivascular area and around nor-
mal islets (35,61,62). Only CD 13+ APC are present, at low frequencies, within normal islets 
(35). From 3-4 weeks onwards, increased numbers of APC are found in NOD pancreas, main-
ly surrounding the islets and scattered in the exocrine region and in perivascular sites 
(28,35,62). These APC include the pancreas-derived cells expressing one or more of the 
markers F4/80 (35,62,63), CD II b (35,62,63), ER-MP23 (35) and MOMA-I (35). Moreover, 
low numbers of newly attracted Mac-2+ (35) and ER-HR3+ (35) cells and high numbers of 
CDllc + (N418) DC (36), NLDC-145+ DC (64) and Blvf8+ M<jl (35) start accumulating 
around the islets. 
Early infiltrating APC have been shown to produce tumor necrosis factor-a (TNF-a) 
in NOD and NODscid micc (36). It has been hypothesized that an early and local production 
ofTNF-a in the islets acts to enhance the islets antigenicity and the subsequent activation of 
disease-causing lymphocytes (65-67). _Moreover, since TNF-a in combination with other 
cytokines may be cytotoxic to B cells (see below), early expression of this cytokine may 
induce paliial j) cell dysfilllction or destruction, facilitating uptake of P cell antigens by APC. 
In this respect, treatment of newborn NOD mice with neutralizing anti-TNF antibodies 
inhibits the development of both insulitis and diabetes (65). 
As pointed out before, early infiltrating APC are thought to leave the pancreas and 
present antigen to lymphocytes in the pancreas-draining lymph nodes. These subsequently 
activated lymphocytes will then migrate to the pancreas. 
Leukocyte trnffic into the pancreas: highways of adhesion molecules 
Infiltration or migration of lymphocytes into tissues generally occurs from postcapil-
1ary venules (68,69). Indeed, several authors report the presence of lymphocytes within pan-
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creatic postcapillalY vcnufes of NOD mice (28,70-73), These vcnules show significant mor-
phological alterations, which include dilation and activation of endothelium with local trans-
tonnation to hypertrophic cells (35,74). This High Endothelial Venule (HEV)-tonnation is 
probably the consequence and not the cause of the lymphocyte infiltration, since the mor-
phological changes are usually present near infiltrating lymphocytes (72) and can also be 
found after T cell transfer in newborn NOD mice (75). The presence of mononuclcm: leuko-
cytes within the lumen of postcapillary veBules is observed only as long as illsulitis is pres-
ent and may be explained as a recruitment ofeells afthe immune system from the blood (71). 
All infiltrating mononuclear cells utilize vascular address ins and other adhesion mol-
ecules on these postcapillary venules to enter the pancreas, The upregulation of all these vas-
cular adhesion molecules is limited to vessels that are adjacent to or surrounded by intlam-
matOlY cells (76). Thus, vascular adhesion molecule upregulation is also caused by local 
stimulation and cytokine release by the infiltrating leukocytes, The adhesion molecule pairs 
and their most likely role in diabetes development are summarized in Table 3. 
Table 3: Involvement of pairs of adhesion molecules in diabl'f('s dewloplllent in NOD mice and humans. To 
the b('st of ou!' Imowledge, there are no data on the DD rat. 
Adhesion p<lir 
1hdCA1,[-I1LPAl' ... f-l 
PNAd/L-selectin 
ICAM-l/CR3 
ICAl\'l-IJLFA-1 
VCAM-IIVLA-4 
LFA-3/CD2 
Function 
Leukocyte extravasation 
eukoc}1e extravasation 
ymphoc}1e trafl1eking in LN 
i'\'f~ extravasation 
Leukoc}1e extravasation 
Antigen presentation 
cell destruction 
Leukocyte extravasation 
Entry CD4+ T cells into islets 
Lymphocyte traft-icking in LN 
Antigen presentation 
NOD mOllse 
+ 
(76-8t) 
+ 
+ 
(79,81-83) 
+ 
+ 
+ 
-? 
(4 t,6t ,72,76,78,85-92) 
+ 
+ 
+ 
(64,78-82,86,92,98,99) 
? 
Human 
? 
? 
(84) 
'! 
+ 
(93-97) 
'! 
(93,94) 
(93,95,96) 
The tirst pair of adhesion molecules that is upregulated from 4 to 5 weeks onwards on 
endothelium and leukocytes in the NOD pancreas is MAdCAM-lIa4fl7(LPAM-l) 
(76,78,79,81). Another adhesion pair that is upregulated already in early stages ofinsulitis is 
PNAd/L-sclectin (also designated MEL-14, LECAM-I, LAM-l and CD62L) (76,78,86). 
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Both MAdCAM-I/LPAM-I and PNAd/L-selectin are involved in early leukocyte extravasa-
tion. 
In later stages of insulitis, expression of lCAM-I, which is normally absent on islet 
endothelial cells (72,76,78,85,86), is increased (86,87). ICAM-l probably has several roles in 
the development of insulitis, partly dependent on the ligand that it binds. The JCAM-l/CR3 
(also designated l\1ac-l and eDIlb/CDIS) interaction is involved in intra-islet infiltration by 
monocytes and monocyte-derived cells (41). A second ICAM-l-Iigand that is important in the 
insulitis process is LFA-l, that is expressed on virtually all islet-infiltrating cells 
(76,78,85,87). Unstimulated T cells are unable to use LFA-J for binding to endothelial cells 
(88), but activation of T cells by various stimuli has been demonstrated to result in an 
enhanced utilization of LFA-I (lOO). Besides a role in leukocyte extravasation, the 
ICAM-IILFA-l pathway is probably involved in other processes during insulitis. The 
obsclved ICAM-l hyperexpression on the T cell surface call enhance antigen presentation by 
APC to T cells by facilitating the adhesion. Moreover, interactions between two T cells can 
also be mediated by bi-directional LFA-I and ICAM-l interactions (61,76,87). Finally, a role 
for the ICAM-I/LFA-I pathway in fl cell destmetion has been suggested, but this is contro-
versial. Freshly isolated pancreatic endocrine cells from young NOD mice without insulitis 
do not express ICAM-l, but induction of lCAM-1 by inflammatory cytokines (IFN-y, 
TNF-n, IL-IP) il1 vitro has been reported and may theoretically occur in the inflamed islets 
as well (85,91). Cytotoxic T cells may use LFA-l to interact ,vith inflammation-induced 
ICAM-I on fl cells, which facilitates target cell lysis. In lavor of this hypothesis, ICAM-l 
expression on NOD-derived insulinoma cells enhances the susceptibility of these cells to 
CTL-mediated lysis (85). Moreover, if the ICAM-lILFA-I interaction is blocked only during 
late and not during early stages of insulitis, there is partial protection from the development 
of spontaneous diabetes (85,87). The controversy concerning the role of LFA-I/ICAM-I in 
fl cell destmction is fueled by the fact that blocking the ICAM-lILFA-l interaction lails to 
prevent diabetes induced by cyclophosphamide and induced by transfer of diabetogenic 
splenocytes or islet-derived mononuclear cells (87,92). Moreover, several investigators have 
not been able to detect ICAM-I ill silll on diabetic NOD islet cells (61,76,78,87). Even after 
cyclophosphamide-accelerated insulitis, ,,,hich is characterized by a massive locallFN-y pro-
duction, ill silll ICAM-l expression was not found (86). In contrast, one study using immu-
noelectron microscopy has shown ICAM-l+ islet cells adjacent to lymphocytes. Such local-
ization ofICAM-l ,vould be diflicult to detect by light microscopy, since the expression was 
limited to cells lacing infiltrating lymphocytes that strongly expressed ICAM-I on their sur-
face (85). In conclusion, these studies indicate that the ICAM-IILFA-l interaction may be 
involved, but is not essential in p cell destruction in late stages. 
Anothcr adhesion pair that is upregulated when the pancreas is already infiltrated, is 
VCAM-IIVLA-4 (64,81,86,92). VCAM-l is induced in islets with moderate infiltrates 
(64,81,86,92). VLA-4 is constitutively expressed on leukocytes, and the VCAM-IIVLA-4 
interaction may therefore be implicated in the entry of cells into the pancreas (78,82). 
However, as for LFA-l, VLA-mediatcd adhesion depends upon the activation status of the 
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individual cells (99). Remarkably, after blocking the VCAM-IIVLA-4 interaction, CD4+ 
T cells remained at the outcr edges of the islet, while CDS+ T cells pcnctrated into the islet 
(92). Thus, the VCAM-INLA-4 pathway may playa role in entIy of cells into the pancreas 
and also in allowing entty of CD4+ T into islets. 
The IYlllphoid actors: llIajor roles forT and B, but not NK ccIls 
The lymphoid cells in insulitis consist ofB and T lymphocytes and NK cells. In NOD 
mice, B cells appear to be essential for antigen presentation and T cells for insulitis expan-
sion. NK cells arc probably not crucially involved in NOD diabetes. 
Several researchers have observed B lymphocytes infiltrating the NOD pancreas 
(63,78,101,102). Usually, they are not dctected at the early stages of ill filtration, but increase 
in number with the progression of the lesion (29,74,75,78). During the later stages ofspon-
taneous insulitis and during insulitis recurrence in islet grafts, B lymphocytes represent about 
30% of infiltrating cells (78,101,102). In addition to B lymphocytes, a few plasma cells were 
observed in some studics (28,29,74). Both B lymphoc)1es and plasma cells are repOlied to 
be situated in the periphcry of infiltrating cell masses (28,29,103). Occasionally, B lympho-
cytes form a lymphoid follicle-Iikc structure (74,104). In cyclophosphamide-accelerated dia-
betes, B cells are virhlally absent (105). 
B cells play an essential role in the pathogenesis of autoimmune diabetes, NOD mice 
made deficicnt for B lymphocytes, either genetically (42, I 06, I 07) or by treatment with spe-
cific antibody (108,109), are resistant to diabetes development. Theoretically, B cells can bc 
involved in two stages of diabetes development. If they develop into plasma cells, they can 
contribute to diabetes pathogenesis via their ability to secrete auto-antibodies that bind pan-
creatic 13 cells. Alternatively, B cells may be involved as APC in the stimulation ofT cells. 
Several studies suggest that the role of B cells in the presentation of autoantigcns is essential 
in diabetes pathogenesis, whereas the production of auto-antibodies is merely an epiphe-
nomenon. In B cell-deticient NOD mice, diabetes susceptibility is restored if these mice are 
reconstituted with B lymphocytes, but not by infusions of immunoglobulins from diabetic 
NOD donors (42). Moreover, B cell-deficient mice have no spontaneous T cell responsc to 
cel1ain ~ cel1 autoantigens, while responses to control antigens are intact (42,110). This incli-
cates that B cells are essential for the .development of T cell reactivity against specitic ~ cell 
antigens. The specificity for autoantigens may be the result of the unique capability ofB cells 
to take up antigens selectively (42,110). Finally, NOD mice with a B ceIl-restricted I_Ag7 
deficiency (NOD BCIlD), and thus with B cells incapable of antigen presentation, are resist-
ant to diabetes development, although rare foci of peri-insulitis are present in old animals 
(I I I). Therefore, B cells appear to be essential APC for the initiation of certain B ceIl autore-
active T cell responses. Purified T cells tI-om NOD donors can efficiently transfer disease to 
either B cell-depleted neonatal recipients or NODscid recipients (I 12,1 I3). Thus, once dia-
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betogenic T lymphocytes have been generated, they can clearly mediate destruction of pan-
creatic p cells in the absence ofB cells. 
The production of uuto-antibodies by B cells thus appears not to be essential for dia-
betes pathogenesis. This docs not mean that autoantibodies are not involved at all, as they the-
oretically can contribute to B cell damage. Auto-antibodies to islet cells can already be found 
in serum of NOD females i1-om 2 to 3 weeks of age. It is, however, unclear whether these IgG 
antibodies are endogenous or of maternal origin (114,115). Natural binding of these auto-anti-
bodies to the ~ cell surface has been detected at the same age (114,116), although one study 
did not find immunoglobulin deposition in the pancreas (29). There is, however, no evidence 
that these auto~antibodies are pathogenic. Complement-mediated islet cell lysis does not 
occur, since NOD and NODscid mice, as approximately 30% of mouse strains, lack comple~ 
ment activity due to a deficiency in C5, and therefore can not form the C5b-9 membrane 
attack complex (117-119). 
B cells are thus essential for the development of diabetes in NOD mice, most likely in 
their capacity as APC. Several observations indicate that T cells are also crucial in the process 
leading to diabetes in NOD mice. Diabetes can be transferred by splenic T cells from diabet-
ic (75,113,120-125) or prediabetic (113) mice and by particular T cell clones (126-131). In 
reverse, diabetes does not develop in mice made T cell deficient, either genetically (25,132) 
or by experimental treatments (133-135). In addition, cyclosporin (136) and FK-506 (137), 
which amongst others suppress cytokine production by CD4+ T lymphocytes, suppress dia~ 
betes development. 
Indeed, most studies report T cells to be the dominant cell population in infiltrates of 
NOD mice with spontaneous insulitis (29,63,78, I 03), in NOD or NODscid mice after adop-
tive transfer (75, 1 05,138), and in NOD mice after diabetes acceleration by cyclophosphamide 
(105,139). 
What is the phenotype of the T cells present in the infiltrates? In virtually all studies, 
higher numbers ofCD4+ cells than CD8+ cells are found in the pancreas, both in spontaneous 
disease (29,87,103) and after transfer (75,140), However, in spleen and peripheral lymph 
nodes, CD4+ cells are also more prominent than CDS+ cells. The one study that has com-
pared the CD4/CD8 ratio in the pancreas with that in the spleen has found that the ratio in 
pancreases with spontaneous disease is higher than the ratio in spleen, suggesting selective 
accumulation of CD4+ T cells in the lesions (78). During the development of spontaneous 
insulitis, however, a progressive decrease in the proportion of CD4+ cells and consequently 
an increase in the fraction of CDS+ cells took place (63,78). In T cell or splenoc)1e transfer 
studies and in islet transplantation studies, a similar or even lower CD4/CDS ratio is found in 
pancreas compared to spleen (75, I 0 1,138). This again suggests a role for CD8+ T cells in 
() cell destl11ction, since both adoptively transferred diabetes and diabetes recurrence in islet 
grafts reflect the late stages of the disease. Taken together, these in situ studies thus suggest 
a role for CD4+ cells in early phases of insulitis, and a role for CDS+ cells in islet destruc-
tion. 
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Early transfer studies provided evidence that both CD4+ and CDS+ T cells are 
required to provoke or accelerate disease. This holds true when either spienocytes fl'om dia-
betic or prediabetic NOD donors or autoreactive NOD islet-derived CD4+ and CDS+ T cell 
clones are transferred into irradiated young NOD or NODscid recipients (113,122-125,141), 
CD4+ T cells, alone, can invade the islets, but, in general, diabetes develops only when 
CDS+ T cells are also present. CDS+ T cells, alone, do not infiltrate the islets 
(113,124,125,142) and therefore appear to require signals ti'Olll CD4+ T cells to effect p cell 
damage, This hypothesis is supported by the thrding that CD4+ T cells precede CDS+ T cells 
in entering into the islets when whole spienocytes from diabetic donors arc transferred into 
healthy recipients (61,75), Hence, CD4+ T cells seem to facilitate the initial entty ofCDS+ 
T cells into the islets, The picture therefore emerges that both CD4 and CDS+ T cells are 
essential: CD4+ T cells especially in the initiation phase and CDS+ T cells in fl cell destruc-
tion. Supportive evidence for this view is presented in Table 4. 
Table 4: E\'ideol'{' that, in NOD mire, C04+ T crlls initiate insulitis, whereas CDS+ T cells are involyed in 
J3 cell destruction. 
CDS+ T cell lines and clol1es have becn isolated with in vitro and in vivo cytotoxic activity against B cells 
(126,131,141,143,146), 
Although tronsfer orthe 1"3 cell reactive CD4+ T cell clone BDC2.S by itself is able to induce diabetes in young 
NOD mice, cotransfer of CDS-enriched T cells was required to induec disease in NODscid mice (128) 
The need for CD4+ T cell help in diabetes transfer experiments can be overcome by high Humbers of in vitro 
activated cloned autoreaetivc CDS+ T cells (126,142). 
l .... fononuclear cells dissociated from NOD islets lind cultured in the presence of IL-2 are composed mainly of 
H-2Kd-restricted CDS+ T cells exhibiting a lytic activity to islets (144). Depletion of CD4+ T cells trom these 
islet-derived cells did not inJIucnce islet cell lysis in vitro, whereas depletion ofCDS+ T cells almost completely 
abolished it (144). 
Electron microscopic findings indicate that CD8+ T cells directly attack the pancreatic islets of NOD mice 
(147), 
Diabetes, but not insulitis incidence, is reduced when adult NOD mice arc injected with antibodies ag'linst r .... IHC 
class I or CDS (14S). Conversely, both insulitis and diabetes are pre\'ented when adult NOD mice arc treated 
with anti-CD4 (149). 
NOD mice lacking the CIITA (class II tronsactivator) molecule are deticient in ivfHC class II expression and 
peripheral CD4+ T cells. CDS+ T cells from these mice lire only able to transfer insulitis and diabetes to 
NODscid re.cipients if NOD CD4+ T cells are present (142). 
CD8+ T cells probably play an additional role in the autoimmune response. NOD 
mice carrying a null mutation at the f32-microglobulin (P2-~t) locus, and thereby lacking 
MHC class I molecules and CD8+ T cells, are not only diabetes- but also insulitis-resistant 
(150-153), This may indicate that CDS+ T cells also playa role in the initiation of insulitis, 
Moreover, the development ofinsulitis is severely inhibited when NOD mice are treated \vith 
an anti~CD8 monoclonal antibody during a discrete age window fiom about 2 to 5 weeks 
after birth (154), Transfer studies indicate that CD4+ T cells from these protected mice, 
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although they ,vere isolated atter repopulation of the CDS compartment, arc not capable of 
transferring insulitis (154). This indicates that CD4+ T cells somehow need CD8+ T cells dur-
ing a discrete age window to be capable of initiating insulitis. 
A more precise definition of the role ofCDS+ T cells comes from the observation that 
in certain situations, the absolute need for CDS+ T cells in diabetes development can be over-
come. For example, when large numbers of cloned CD4+ T cells arc transferred, not all of 
these clones need CD8+ T cells to provoke disease (127,130, ISS, 156). This apparent lack of 
CD8+ T cell requirement may be explained by recruitment of host CD8+ T cells. However, 
similar observations have been made in transfer studies in \vhich the host was deficient in 
CD8+ T cells. When only CD4+ T cells isolated from diabetic NOD mice are transferred into 
NODsdd recipients, both insulitis and diabetes develop, while this is not the case when pre-
diabetic splenocytes are used (113). Similarly, certain islet-reactive CD4+ T cell clones iso-
lated from diabetic NOD mice are able to transfer diabetes to NODscid recipients (128,129). 
Moreover, the complete depletion of CD8+ T cells does not affect insulitis development in 
a T cell receptor transgenic mouse strain with a CD4+ T cell repertoire highly skewed for an 
anti-islet cell reactivity (157). Finally, destmetion of syngeneic islet gralls by spontaneously 
diabetic NOD mice can be prevented by depletion of CD4+, but not CD8+ cells of the host 
(158). These studies suggest that the need for CDS+ T cells in disease initiation can be over-
come when large numbers of autoreaetive CD4+ T cells andlor highly activated CD4+ T cells 
are present. This suggests that CDS+ T cells playa role in the generation of autoreactive 
CD4+ T cells, possibly by initiating B cell necrosis (113). This early fl cell death apparently 
leads to the release of autoantigens, resulting in the priming and expansion of autoreactive 
CD4+ T cells. 
In contrast to what is observed for T cells, no or only few NK cells are found located 
close to islet cells and scallered among infiltrating cells in NOD mice (29,74,138). One ill 
vitro study has noted a small number of asialo-GM J + cells, presumably NK cells, in islet-
derived leukocytes, which are able to lyse NK-sel1sitive targets (144). However, anti-asialo-
GM I only slightly reduced the cytotoxicity of islet-derived cells to NOD islet cells, arguing 
against a major role for NK cells in f3 cell cytotoxicity. lvloreover, in this ill vitro study, the 
immune attack against NOD islet cells has been demonstrated to be MHC-restrieted (144). It 
therefore seems unlikely that NK cells playa significant role as cytotoxic effector ceUs in islet 
destruction. 
To summarize the role of lymphoid cells, both Band CD8+ T cells seem to be Crtl-
cially involved in the initiation of insulitis, the fonner as APC and the latter as inducers of 
early antigen release, CD4+ T cells come into play thereafter, and activate CD8+ T cells for 
final ~ cell cytotoxicity, There is no evidence that autoantibodies or NK cells are important 
in B cell destruction. 
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The Thl-Th2 paradigm in illsulitis expansion 
The type of cytokines that is produced in an insulitis process determines the final out-
come of the f3 cell-directed autoimmune reaction. In general, if Thl cytokines slich as 
IFN-y arc produced by islet-infiltrating monolluclear cells, B cell destruction occurs and dia-
betes will develop. If, on the other hand, Th2 or Th3 cytokines snch as IL-4, IL-IO and TGF-
f3 are produced, there is protection from B cell destl11ction and diabetes. Evidence for this 
notion comes from both histological and functional studies. 
Early peri-insulitis in NOD mice is characterized by a dominance of cells producing 
Th2 cytokines (159-162). However, later stages of insulitis arc associated with a clear shifl 
towards Thl cytokine profiles (163-167). The acceleration of diabetes devclopment induced 
by treatment of NOD mice with cyclophosphamide also correlates with an increased expres-
sion ofIFN-y (139,161,168,169), while Th2 cytokines are still present (160, 161). In addition, 
diabetes development in different mouse strains can be correlated with cytokine profiles in 
the islets, Low incidence NOD mice, such as mice originating fi'om low incidence colonies, 
NOR mice and male NOD mice, have elevated levels ofTh2 and/or decreased levels ofThl 
cytokines in islet-infiltrating mononuclear cells compared to high incidence NOD mice 
(34,37,139,164,165,170). In conclusion, these data indicate that the progression to invasive 
insulitis and j3 cell destruction requires Th 1 cells in islet lesions. 
In addition to these descriptive studies, functional studies have underlined a role for 
Th I in fl cell destruction and Th2 in diabetes protection. fl cell-specific Thl clones efficiently 
transter disease to syngencic young NOD recipients, whereas Th2 c10ncs do not (157,171). 
In NODscid mice, Th2 clones have been able to cause generalized pancreatitis, islet cell 
necrosis and diabetes, but the histopathological process in these animals is completely i:fif-
ferent from the spontaneous NOD insulitis (172). In addition, neutralizing Thl cytokines 
byinjection of specific antibodies, or by counterrcgulatory Th2 cytokines, prevents j3 cell 
destruction (139,168,173-180). Moreover, treatments known to prevent diabetes in NOD 
mice are associated with decreases in Thl and/or increases in Th2 cytokine expression 
(162,164,165,181-189). 
Interestingly, the skewed ThllTh2 balance found in islet-associated mononuclear 
cells is not reflected in the spleen, as has been shown both in islets during spontaneous insuli-
tis (164) and in islet grafts with recurrcnt diabetes (101). This suggests that the ThlITh2 bal-
ance produced by islet-infiltrating cells may bc regulated locally in the islet. Alternatively, 
the recrnitment ofThl and Th2 cells may be difterent. In this regard, there is a striking dit~ 
ferencc in the spatial distribution oflFN-y+ and IL-4+ cells even within the infiltrate: IL-4+ 
cells OCClir throughout the infiltrated area, while IFN-y+ cells are restricted to areas adjacent 
to B cells (161). Apparently, Th I, but not Th2, cells demonstrate an attraction towards B cells, 
probably related to a unique dependence of Thl activation on islet antigen specificities or 
quantities present on or near B cells, 
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Thus, the conversion from a Th2- to a Th I-type-infiltrate is essential for the transition 
from peri-insulitis to destructive insulitis and thus for diabetes development. There are t\VO 
major candidate factors that can promote this transition: IL-12 and IL-18 (also designated 
IFN-y inducing factor or IGIF). Both cytokines are exclusively produced in Mq, and other 
APC, and both have been shown to drive Th I responses. Several studies indicate that IL-12 
and IL-18 arc indeed involved in the activation ofIhl cells in NOD mice. The lIpregulation 
ofIL-12 and IL-18 expression in the insulitis lesion correlates with the development OfSPOll-
taneous diabetes, cyclophosphamide-accelerated diabetes and reCllrrent diabetes in islet grafts 
in NOD mice, possibly via the induction ofThl cytokines (161,169,188,190). Moreover, the 
daily treatment of prediabetic NOD mice with large doses of I L-12 results in a rapid pro-
gression towards insulitis and diabetes, coinciding ''lith an increased Th I cytokine production 
by islet infiltrating cells (191). In contrast, a low dose ofIL-12 or IL-18 suppresses both spon-
taneous and cyclophosphamide-accelerated diabetes development, probably because such 
a dose is too low to effectuate a Th 1 response, but high enough to trigger counterregulation 
by the immune system, limiting Th I reactivity (163,192,193). The administration of an IL-12 
antagonist results in an increase ofTh2 activity and is associated with a reduction in sponta-
neous and cyeIophosphamide-accelerated diabetes (194). Moreover, the cyclophosphamide-
accelerated diabetes development is suppressed in NOD mice ,,,ith a disrupted IL-12 gene 
(195). A fhlCtion of animals still developed diabetes, possibly due to IL-18-mediated Thl 
induction and subsequent ~ cell destruction and disease development (190). 
In summary, the progression from benign to destructive insulitis appears to occur via 
the release of Thl-activating cytokines such as IL-12 and IL-18. Since these cytokines are 
exclusively produced by Mq, and other APC, these data suggest that APC within islets drive 
the progression from a non-destructive insulitis towards diabetes. Further evidence for the 
crucial role of APC comes from the observation that T cells in a M!fJ-depleted environment 
lose their ability to differentiate into j3 cell-cytotoxic T cells. This T cell differentiation block 
is associated with a decreascd Thl/Th2 ratio and can be abrogated by IL-12 (196). 
The hypothesis of aberrant MHC exprcssion "cvisitcd 
The expression of MHC-peptide complexes on islet cells is essential for the suscepti-
bility of these cells to autoimmune attack. In NOD mice, both an islet hyperexpression of 
MHC class I molecules and an aberrant islet expression of:tvIHC class II molecules have been 
suggested to be involved in diabetes pathogenesis. 
In normal pancreas and in the pancreas of young NOD mice, MHC class T is only 
weakly expressed, mainly on the vascular endothelium and on constitutively present M$ (61). 
However, MHC class I hyperexpression is induced on endocrine islet cells and adjacent 
exocrine tissue during the development of spontaneous (61,63) and cyclophosphamide-accel-
erated insulitis (56). This hyperexpression is especially associated with inliltrates (56,61), and 
the infiltrating cells themselves also exhibit strong MHC class I labeling (56,61). 
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The association between islet MHC class I hyperexpression and the presence of infil-
trates suggests that the hyperexpression is induced by cytokines produced by the infiltrate. 
Several studies suggest IFN-y to be involved. IFN-y has been shown to induce MHC class I 
expression on islet cells in vUro (197). Moreover, anti-IFN-y, which is knmvn to decrease the 
degree of insulitis and to prevent hyperglycemia, markedly reduces expression ofMHC class 
Ion islel cells (56). Finally, MHC class I upregulalion is nol found in NOD mice wilh fl cells 
that are unresponsive to IFN-y due to dominant negative mutant IFN-y receptors, despite the 
presence of insulitis (198). Together, these fi ndings clearly indicate the in vivo relevance of 
IFN-y for MHC class I induclion. 
Another factor that can theoretically induce:MHC class I hyperexpression is infection 
with viruses (199). \Ve already discussed the observation of the presence of retrovirus in 
NOD islets. However, retrovirus expression is unlikely to be the direct stimulus for MHC 
class I overexpression as this overexpression is delayed for 1 week after cyclophosphamide 
treatment, whereas type C retrovirus has been amplified by PCR fl-om NOD mouse islets 
immediately after administration of cyclophosphamide (56,139). Moreover, retrovirus 
expression in islets would not explain why exocrine cells, not observed to express retrovirus 
parlicles, also overexpress MHC class I (56). 
In conclusion) islet MHC class I hyperexpression is induced by cytokines produced 
by the infiltrating cells. Although lvIHC class I overexpression may not be required for initi-
ation of insulitis) it may playa role in the amplification and full development of the pathol-
ogy. In this respect, it is likely that ovcrexpression ofMHC class I facilitates the targeting of 
MHC class \ reslricled cytoloxic T cells to islet autoantigens (63). 
For MHC class II expression) an aberrant expression on islet cells has been suggest-
ed to contribute to diabetes development in NOD mice. In the normal pancrcas, either from 
young NOD or from control mice, MHC class II is expressed by M<P or DC present in the 
exocrine pancreas and also sporadically present within the islet (200)201). Endocrinc cells 
are MHC class II negative (6\,200,201). During the development of insulitis, MHC class II 
expression is induced on ductal epithelial cells and vascular endothelium both during spon-
taneous insulitis (72) and aftcr adoptive transter of diabetogenic splenocytes or T cells 
(61,75). Moreover, MHC class II is also expressed by infiltrating cells (bolhAPC and lym-
phocytes) in spontaneous insulitis) cyclophosphamide-accelerated insulitis and after adop~ 
tive transfer (29,56)61 )72,73) I 02). The observation that vessel~associatcd MHC class II 
expression can be induced by the injection of effector cells, as is the case in adoptive trans-
fer models, suggests that this expression is a consequence of the eft-ector phase rather than 
an initial triggering event. In this sense, vessel-associated MHC class II expression seems to 
parallel the expression of vascular address ins, a phenomenon which also is induced by the 
infillraling cells (see before). 
The expression of MHC class TI on endocrine cells is relevant) since it has been pro-
posed that ~ cells may become APC after aberrant induction of MHC class 11 on their mem w 
brane (by) for instance, a viral intection). This is summarized in the so~called "aberrant MHC 
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class II hypothesis of endocrine HlltoimmunityH (202). However, most studies report that 
endocrine cells remain lvIHC class 11 negative during the development of insulitis. This is the 
case for endocrine cells during both spontaneolls and cyclophosphamide-accelerated and dur-
ing adoptively transferred insulitis (56,61,64,75,102,201). Only two studies show an induc-
tion ofMHC class 1I on fl cells in NOD females from early insulitis onwards (63,203). In one 
of those shldies (203), the same expression was seen in control pancreases, thus raising ques-
tions about the specificity of the staining. The contradictOlY findings about 1vll-IC class II 
expression on endocrine cells arc at least partly related to the use of different antibodies to 
detcct it. Another cause may be the presence of MHC class Il+ leukocytes in islet cell popu-
lations. Islet cells in NOD mice express MHC class II at all time points when examined by 
FACS-analysis (204). However, subsequent double slainings showed that this ivlHC class II 
expression could be attributed 10 CD45+ intra-islet leukocytes at all ages in the NOD mouse 
(205). In SUllllllaty, expression of MHC class II is probably nol induced on endocrine cells 
during diabetes development in NOD mice. 
Even ifivIHC class 1I is expressed on endocrine cells, several observations suggest that 
the significance of f3 cells presenting antigens in NOD insulitis Jllay be questioned. In NOD 
mice given IFN-y together "with TNF-Cl., a significant and uniform induction ofMHC class T 
and :MHC class II Oil ductal and acinar exocrine cells is found, as well as low level TvfHC 
class I on ~ cells (69). However, this endocrine !vlHC class IT expression does not lead to an 
activation or enhancement of j1 cell autoimmunity, in contrast, it may actually suppress it. 
Moreover, induction oflvlHC class n on islet cells before transplantation by incubation with 
TNF-a did not induce a rapid rejection, but in contrast prolonged the survival of islet al1o-
grafts (206). Indeed, several studies using transgene-directed expression ofMHC antigens on 
f) cells suggest that non-lymphoid cell expression ofMHC class 1I is not stimulatory and may 
in fact be lolerogenic (207-209). Thus, the abnormal expression of MHC class I or MHC 
class II antigens by endocrine cells per se is insufficient to induce an autoimmune response. 
Moreover, it is not only insufiicient but also not required, since insulitis and diabetes can be 
generated even when both the vascular endothelium and pancreatic j3 cells are genetically 
incapable of both MHC class 1- and MHC class ll-restricted autoanligen presentation (64). 
In conclusion, MHC class II-restricted presentation of autoantigens by f) cells does not 
seem to playa major pathogenic role in the triggering of NOD insulitis. In ul1ll1anipulated 
NOD mice, MHC class II is most likely not expressed by jl cells at all, while artillcially 
induced expression actually attenuates the autoimmune process. 
CDS+ T cells and M<jJ are major suspects for 11 cell destruction 
Several cellular mechanisms have been proposed to operate in () cell killing. These 
include CD8+ T cells that may e/tect p cell damage by the release of pore-forming molecules 
or by Fas-mediated apoptosis. Moreover, CD4+ T cells in conjunction ''lith M$ are also able 
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to cause j1 cell death. The soluble factors that playa role in this latter mechanism will be dis-
cussed in the next paragraph. 
The first mechanism by which j) ccJ[s can be destroyed is via direct interaction with 
cytotoxic CDS+ T cells. As outlined earlier in this review, CDS+ T cells indeed play an 
essential role in j1 cell destruction, although the mechanism is still incompletely understood. 
Cytotoxic CD8+ T cells may effect t3 cell damage by the release of granzymc and pore- form-
ing molecules such as perforin (also designated cytolysin). Alternatively, the induction of 
Fas-mediated apoptosis can cause f3 cell death. Several studies indicate that pore-forming 
molecules may be more essential for diabetes development ill NOD mice than Fas-mediated 
apoptosis. 
CDS+ cells expressing perf orin are found in islets during spontaneous as well as 
transferred diabetes (138,159). In transfer recipient mice, perforin is mainly expressed in 
islet inflanunatOlY cells before and during onset of glycosuria, whieh suggests a correlation 
with islet cell lysis (138). However, only a small percentage «10%) of islet-infiltrating 
CDR+ T cells acquired detectable levels of perforin antigen (138). Also the gene for 
granzyme A is expressed ill vivo in islet-infIltrating cells during development of autoimmune 
diabetes in NOD mice (103). Similar to CD8+ T cells expressing perforin, granzyme A 
mRNA + cells occur at a very low frequency, but the number of granzyme A mRNA + cells 
increases with the development of insulitis (103). It should be realized that even a low inci-
dence of cells expressing pore-forming molecules over a longer period of time may be suf-
ficient to mediate considerable tissue damage and, therefore, may be relevant to autoimmune 
insulitis in NOD mice (103). This is cel1ainly true for perforill, since perforin-deficient NOD 
mice show a significantly delayed and reduced diabetes incidence (210). 
Besides pore-forming molecules, CD8+ T cells can use FasL to kill Fas + ~ cells. 
\Vhereas normal mOllse islets do not express Fas, its expression can be induced by pro-
inflammatory cytokines such as lL-1 and TNF-C,( (211-213). The upregulatian of Fas by 
cytokines is independent of NO production (213), in contrast to what has been suggested for 
human islets (214).111 vivo, Fas expression is increased in islets of NOD females at 15 weeks 
of age as compared to NOD males (215). Fas + j1 cells can be killed by FasL + T cells. 
Alternatively, islet cells may commit "suicide" due to cytokine-induced simultaneous 
expression of Fas and FasL. However, the latter possibility is excluded by the finding that 
NOD islet p cells are FasL-, in contrast to earlier reports in which antisera with doubtful 
specificity for FasL have been used (213). On basis of these observations, Fas-mediated 
apoptosis may be a major mechanism of ~ cell destruction by CD8+ T cells in NOD mice. 
Indeed, results from some early studies suggest that Fas is essential for diabetes 
development in NOD mice. Fas- NOD/PI' mice arc resis(ant to spontaneons disease 
(212,216,217) and disease transferred by a CDS+ T cell clone (212) or diabetogenic splena-
cytes (216,217). Hmvever, the absence ofinsulitis in these mice complicates the interpreta-
tion of these findings, since it can be expected that infiltrating cells home to the islet but are 
unable to kill fl cells. One study has suggested that the absence of insulitis is related to 
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a block in the initiation of B cell autoimmunity (217). In such a scenario, transferred autore-
active T cells may initially damage !3 cells through the Fas-FasL system, and then subse-
quently destroy fragile target cells by other mediators such as perforin and cytokines. Arguing 
against the involvement of the FaslFasL system in the initiation ofinsulitis is the finding that 
Fas staining on B cells can not be detected in young mice (213). However, it should be rea-
lized that Fas-expressing B cells may be short-lived because of their rapid destruction by 
FasL + T cells, and may therefore not he easily detectable. Alternatively, the diabetes resist-
ance of Fas- NOD/pr mice could be explained by the substantially altered T and B cell inullu-
nity that characterizes these mice. The finding that NOD spleen cells arc unable to survive in 
NOD/PI' mice further complicates the interpretation of the transfer studies (216). Therefore, 
instead of transferring diabetogenic NOD splenocytes into NODlj),. mice, NODipl' islets have 
been transplanted into NOD mice to study diabetes recurrence as a model for the effector 
phase of" cell killing. Although NOD/pI' fl cells can resist autoimmune attack somewhat bet-
tcr than NOD B cells, they can not reverse diabetes in spontaneously diabetic recipients and 
are eventually destroyed (216,2IS,219). Moreover, islet-specific cloned T cells destroy Fas-
islets as efficiently as Fas + islets (218). In addition, administration of anti-FasL antibody does 
not influence the development of either cyclophosphamide- or adoptive transfer-accelerated 
diabetes (219). Also, ill1'ill'O, anti-Fas antibody and FasL transfected cclls do not exeli cyto-
toxicity against" cell lines or pancreatic islets (220). 
In conclusion, it is unlikely that Fas-mediated lysis is a major effector pathway in the 
tinal phases of j1 cell destruction. A role in the initiation phase of this destruction, however, 
can not be excluded. The generation of transgenic mice with FasL-insensitive (3 cells, but with 
a FasL sensitive immune system and thus a normal immune function, should ultimately pro-
vide conclusive evidence. 
In contrast to direct cytotoxicity by CDS+ T cells, CD4+ T cells call111cdiate autoim-
Illune j) cell destruction in a manner analogous to a delayed type hypersensitivity (DTH) 
response that docs not require cell-cell contact. As described earlier, in some cases CD4+ 
T cells alone can transfer insulitis and diabetes and mediate graft rejection without the need 
lor CDS+ T cells. Sincc both MHC-lIlatched and mismatched islet grafts in NOD mice have 
been shown to be destroyed by CD4+ T cells, killing is not mediated via direct MHC class II-
restricted CD4+ T cell cytotoxicity (ISS). In addition, j) cells do not express MHC class II 
(see before). CD4+ T cell induced fl cell damage may thus be mediated by factors such as 
IL-I, TNF-a and IFN-y secreted by the T cells themselves and / or by locally activated M<j> 
(158,221). Recently, it has been suggested that a similar interaction may occur between CDS+ 
T cells and M<j> (222). Both ill vitro and ill vivo studies suggest a role for M<j> in linal " cell 
killing. [11 vitro, activatcd M<j> decrease glucosc-induced insulin release (223). 111 vivo, the 
inl1ux ofBMS+ M<j> correlates with destructive insulitis (35,104). The selective destruction of 
~ cells, \vith sparing of other islet cell types, may then be interpreted as a selective sensitivi-
ty of p cells to damage mediated by soluble £1ctors, although this does not rule out the con-
tribution of j) cell-specific cytotoxic CDS+ T cells. Indeed, blocking the effects of 
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Mcp-derived TNF only partially protects NOD mice from diabetes; blocking perforin effects 
in addition, results in complete prevention (224). 
Cytokines and free radicals arC major ~ cell destructive weapons 
Several cytokines have been related to p cell destruction in the NOD mouse. The most 
important of these are IL-I, TNF -« and IFN -yo To study their role in diabetes development, 
the kinetics of their production have been related to j3 cell destruction, 
IL-If3 mRNA levels ill isolated islet-infiltrating mononuclear cells progressively 
increase from 5 weeks of age to diabetes onset, indicating a possible role in [3 cell destruc-
tion (164). However, IL-I f\ mRNA levels in islet-infiltrating cells are identical for NOD 
females and males at all ages (159,164) and in islet grafts of complete Freund's adjuvant 
(CFA)-protected and control animals during diabetes recurrence (189), In contrast, IL-ln 
mRNA levels increase from 5 \'leeks of age to onset of diabetes, and arc higher in islet-
derived mononuclear leukocytes from diabetes-prone NOD females than in those from CFA-
protected NOD females or NOD males (165). It should, hmvever, be realized that an increase 
in mRNA levels does not automatically lead to an increase in biologically active protein, so 
these studies should be interpretcd with caution. 
Statistically significant difterences arc not found for TNF-a in islet-infiltrating cells 
in islet grafts from mice with recurrent diabetes versus recurrent prediabetes (10 1), for dia-
betes-prone NOD femalcs and NOD males at all ages (159,164), and for CFA-protected and 
control animals during spontaneous diabetes (164) and islet grafi rejection (IS9). Thus, 
TNF-a does not appear to mediate final ~ cell destruction. In contrast, as discussed before, 
TNF-mediated cytotoxicity is essential for the initiation of diabetes (65). NODscid mice that 
are deficient in TNF receptor I (p55/TNF-RI) arc protected li'Oln diabetes transfer by spleno-
cytes ti'Oll1 miec that are transgenic for a diabetogenic T cell reccptor (2IS). In addition, the 
specilic lack ofTNF-RI on islet cells altered the ability of cioncd diabetogenic CD4+ T cells 
to establish insulitis and subsequently destroy islet I} cells (2IS). Thus, in this T cell recep-
tor-transgenic NOD mouse model, an islet response to TNF-C{ is essential for the propaga-
tion of the CD4+ autoreactive T cells and subsequent diabetes development. The nature of 
this response could be an increase in antigen delivery either in direct response to TNF-o.: or 
as a result of islet cell death (2IS). 
[ntra-islet TNF-" can be produced by intiitrating Mcp as well as T lymphocytes. In 
early studies, T cells were shown to produce TNF-n mRNA in late stages of insulitis and 
i1 cell destruction (103,225,226). Furthermore, studies in NOR mice have shown that TNF-" 
mRL'lA correlates with CD3£ transcripts (37), linking TNF-n production to the presence of 
T cells. However, one study shm'ls that TNF-a protein expression in situ in both early and 
late stages correlates vcry well with CDllc+, F4/S0+ and Mac-I+ APC labeling, and poor-
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Iy with CD4+ and CD8+ T labeling (36). Alternatively. based on studies using u and j3 cell 
lines. it has been suggested that j3 cells, but not u cells, may be induced by IL-I to produce 
TNF-u, which would then be taken up by APC (227,228). Because TNF-u has bcen shown 
to potentiate j3 cell cytotoxicity ofIL-1 and IFN-y (229), TNF-u production ill situ by [1 cells 
Illay be selfhdestructive. It is, however, unclear whether the responses of Q and B celllincs are 
representative for the reactions of normal islet Q and j) cells, let alone for the reactions of islet 
a and B cells that have already been exposed to insulitis. In summary, APChderivcd TNF-a 
may be essential in the initiation of insulitis, whereas T ccll- and p cell-derived TNF-CJ; may 
contribute to final B cell destruction. 
\Ve described earlier that the COil version from peri-insulitis to destructive insulitis is 
associated with the production ofIFN-y. The most important sources of IFN-y in NOD insuli-
tis arc CD4+ and CDS+ T cells (37,101,l59). Furthermore, NK cells can also contribute to 
IFN-y production (101), but we argued before that NK cells do not appear to play an impor-
tant role in diabetes pathogenesis. In vitro studies suggest that IFN-y may have a direct role 
in B cell destruction (229). However, ill vivo, the lack of local (and systemic) IFN-y, in 
IFN-y gene-targeted NOD mice, delays but does not prevent diabetes development (230). 
I\10reover, islets deficient in IFN-y receptor undergo normal diabetes development in a T cell 
receptor-transgenic NOD mouse model (218). This suggest that, at least in this model, IFN-y 
does not play an essential role in B cell destruction. 
It has become clear that cytokines may contribute to f3 cell damage. The exact mech-
anism by which cytokines exert cytotoxic effects on /3 cells has not been clarified complete-
ly. In Fitm experiments suggested that cytokine-induced inducible nitric oxide synthase 
(iNOS) expression, \vhieh generates the free radical nitric oxide (NO) f1-om L-arginine, might 
be involved (231,232). Alternatively, oxidative stress could playa role. 
1t is of interest that the kinetics of iNOS expression during spontaneous insulitis in 
NOD mice closely correlate with those of IFN-y expression (160,163,165). Also, a correla-
tion between IL-la mRNA levels and iNOS mRNA levels has been described (165). This 
suggests that cytokines slich as lL-1 C( and IFN-y induce iN OS and NO. The ;11 vivo treatment 
of NOD mice with lL-1 B, in contrast to treatment with either IFN-y or TNF-u, leads to iNOS 
uprcgulation within the pancreas (233). 
The kinetics of NO prodnction not only correlate with those of cytokine production, 
but also with those of B cell destmction. An enhanced NO production is observed in NOD 
mouse islets after disease transfer (234). Moreover, levels of iNOS expression in mononu-
clear leukocytes increase during spontaneous diabetes development (165) and after diabetes 
acceleration by cyclophosphamide (160). In addition, mRNA levels for iNOS are higher in 
mononuclear leukocytes from islets of diabetes-prone NOD females than in those from CFA-
protccted NOD females and NOD males (165). 
Functional data also indicate a role for NO in J1 cell destruction. 111 vitro experiments 
demonstrate that M$-induced 13 cell lysis does not occur in the absence of L-arginine, which 
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is needed for NO production, or in the presence of the iNDS antagonist N(G)-monomcthyl-
L-arginine (L-NMA) (232,235,236). This indicates that NO is essential for islet eelllysis that 
is induced ill vitro in normal islet cells by :M$. In contrast, in vivo, treatment of NOD mice 
with the iNOS inhibitors L-NMA or aminogu3nidine (AO) has no or only weak eftects on 
spontaneous diabetes development and diabetes transfer (234,237). The weak inhibitory 
effects of iNOS inhibitors in vivo may, however, be related to simultaneous downrcglllation 
of the activities of other isofonns of NO synthase, with undefined influences on immune 
function (237). 
Several cells may be the source of NO, Immunohistochemistry shows colocalization 
of iNOS and the IVIe.p-marker F4/80, while no iN OS expression is observed in endocrine cells 
(238). Other studies localized iNOS in both B cells and M<jJ (165,233). Remarkably, while 
cytokine-induced NO production is toxic to islets ;,/ vitro, exogenously supplied NO is not, 
even at higher concentrations than those produced by islet cells. Based on these observ"atiol1s, 
it has been suggested that NO production by islet cells themselves is required for cytotoxic-
ity (213). However, islets deficient in iNOS are destroyed with similar kinetics and magni-
tude as wild-type islets after transfer of diabetogenic CD4+ T cells, indicating that islet iNOS 
gene expression is not critical in this transfer model (218). This result does not rule out a role 
for NO produced by endocrine cells during spontaneolls diabetes development. Thus, both 
~ cells and Mcp are sites of iNOS expression during diabetes development.In conclusion, it 
appears that NO (generated by iN OS), may contribute to p cell destruction. 
In vivo studies indicate thatoxidative stress may also playa role. The idea that oxygen 
free radicals play an essential role in (1 cell destruction is supported by the finding that trans-
genic j3 cell-expression in NOD mice of thioredoxin (TRX), a redox (reduction/oxidation)-
active protein that neutralizes oxygen radicals, protects f3 cells in vivo against autoimmune 
destruction (239). Furthermore, antioxidants protect against diabetes reellrrence in islet 
grafts in NOD mice (240) and prevent spontaneous diabetes development in NOD mice 
(241). Together, these findings point to a perhaps even more important role for oxygen free 
radicals than for NO in fl cell destmction. 
Ultima!e fl cell dea!h: apop!osis 01' necrosis? 
The final question to be discussed in this context concerns the mechanism of j3 cell 
death in the NOD mouse: inflicted cell death as in necrosis or programmed cell death as in 
apoptosis. Both in vitro and in vivo studies of f1 cell death favor the apoptotic mechanism. 
III vitro, inflammatory cytokines (IL-I, TNF and IFN~y) induce apoptosis in the 
mouse insulilloma ceHlines BTCI and NlT-1 (242,243). Interestingly, the glucagonoma cell 
line aTel shmvs more resistance to cytokine-indllced apoptosis than BTCI cells, possibly 
related to higher levels of the anti-apoptotic molecule BcI-2 (242). It is, however, question-
able whether a and f3 cells that are SUlTollhded by infiltrating cells show the same reactions 
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as cell lines. For example, apoptosis in response to TNF~a has becn observed in NIT-l cells, 
whereas apoptosis of primary I~ cells requires both TNF-u. and lFN-y (244). 
Several studies investigated the direct evidence of ~ cell apoptosis in vivo. Islet cell 
apoptosis as determined by the Tdt-mediated dUTP nick end labeling (TUNEL)-assay is pres-
ent in NOD mice, but does not colocalize directly with insulin-containing cells (245). Another 
study described a low frequency of apoptotic cells within the reduced insulin-containing islet 
area, but the apoptotic phenomena rarely colocalized with ~ cells (246). Colocalization of 
apoptosis and insulin-containing cells has been shown in a transgenic T cell receptor NOD-
model of rapidly accelerated ~ cell destruction (247), but it is unclear whether the pathogen-
ic mechanism in this model is representative of spontaneous diabetes development in NOD 
mice. It is, however, conceivable that the rarity of detectable apoptotic fJ cells in spontaneolls 
prediabetic mice ''lith pronounced insulitis reflects the relatively long and slow destruction 
phase in combination with the rapid clearance of apoptotic ~ cells (246,248). Indeed, apop-
to tic f3 cells have been demonstrated after diabetes acceleration via either cyclophosphamide 
treatment or adoptive transfer (2 I 9)46). Apoptosis 'vas, however, not absolutely specific for 
islet f3 cells but involved rare 0; cells as well (219). In conclusion, experimental data suggest 
that apoptosis is the major mechanism of f3 cell death, although it can not be excluded that 
~ cells also die by necrosis. 
The highway to autoimlllune diabetes in NOD mice 
In summary, we suggest that the following sequence of events precedes clinicalmanw 
ifestation of diabetes ill NOD mice. The first sign of autoimmunity in NOD mice, the accuw 
mulation of leukocytes around the islets termed peri-insulitis, is recognizable at about 
3 ''leeks of age. This initiation is mediated by professional APC, including B cells, although 
B cells are rarely found in histological samples at such early time points. The reasons for the 
early APC accumulation are not known. Although rctrovil'l1ses have been found in NOD 
islets, it is highly unlikely that virus-induced IFNwC( expression plays a major role. In these 
early periwinsulitis stages, CDS+ T cells also appear to be involved. They may cause early 
f3 cell death and concomitant release of autoantigens, necessary for the priming and expanw 
sion of autorcactive CD4+ T cells. Early infiltrating APC leave the pancreas and present 
autoantigen to lymphocytes in the pancreas draining lymph nodes. The subsequent migration 
of these activated lymphocytes into the pancreas causes the formation of BEY and the upreg-
ulation of adhesion molecules. Initially, mainly CD4+ T cells are present, of both the Thl and 
the Th2 type. 
As the insulitis progresses, a shift towards Th I cytokine promes takes place. This shift 
is under the influence of IL-12 and lL-18, which are both exclusively produced by Mrp and 
DC. Peri-insulitis progresses to insulitis, in which lymphocytes and Mrp infiltrate into the 
islets. :Nloreover, a progressive decrease in the proportion of CD4+ T cells parallel to an 
increase in the fraction of CD8+ T cells takes place. Thl-derived lFN-y induces MHC class I 
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hypcrexpression on islet cells. This facilitates the targeting ofMHC class I-restricted CDS+ 
T cells to islet autoantigens. MHC class II, [fexpressed by ~ cells at all, does not playa major 
pathogenic role in the NOD prediabetes. 
In the final j3 cell killing, two major mechanisms are recognized. The first is the 
killing of~ cells by CDS+ T cells using perforin. The second is killing mediated by the coop-
eration ofCD4+ T cells and M<jJ. In this latter mechanism, TNF-a and IL-l may be impor-
tant cell products. Moreover, :Mcp~derived NO and oxygen radicals may playa role. Fas~ 
mediated killing is probably neither involved in killing by CDS+ T cells, nor by CD4+ T cells 
in conjunction with M$. The ultimate j1 cell 'death most likely occurs via apoptosis, although 
necrosis may also be present. NOD mice typically become diabetic at about 19 ''leeks of age, 
illustrating the velY long prediabetic period. 
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Figure 1: Prediabetic islet inJ:iltwtes in a IO-week-old f(:!tnule NOD mouse. (a) CDllc+ DC; (b) Bl'VtS+ :Mq,; (c) 
CD3+ T cells; and (d) anti-insulin. 
Figure 1 shows prediabetic infiltrates in a female NOD mouse. The insulin staining 
(Fig. ld) shows two islets: a large islet accompanied by a large infiltrate and a small islet that 
is relatively unaftected. The small islet is still in the initiation phase ofinfiltration, with accu-
mulated DC (Fig. la) and M<jJ (Fig. 1 b). The accumulation ofT cells is relatively limited (Fig. 
Ie). Clearly, a large intIltrate is present near the large islet, with many DC (Fig. la) and M", 
(Fig. Ib) and also numerous lymphocytes (Fig. Ie). Despite this massive inftllration, islet 
fUllction is still preserved, as shown by the anti-insulin staining (Fig. ld). 
36 
------------------- Destination diabetes: routes and detours 
BB rat 
Autoimmune diabetes in BB rats 
The founding animal of the BB rat strain was discovered in an outbred \Vistar colony 
of the BioBrecding LaboratOlY in Ottawa, Canada (249,250), All BB rats are descendants of 
the original Ottawa line, but different colonies vary with respect to the frequency and sever-
ity of diabetes, probably at least partly due to genetic differences (251), Early in the program 
of inbreeding, in the fifth generation, animals that failed to develop diabetes were selected to 
start a control line of nondiabetic BB rats, This line is now designated the diabetes-resistant 
(DR-)BB rat, in contrast to the diabetes-prone (DP-)BB rat (252). Less than 1% ofDR-BB 
rats spontaneously develop diabetes. 
Insulitis in DP-BB rats is evident 7-10 days before diabetes onset. NIany autoantigcns 
are involved during disease development (253). About 50-80% of DP-BB rats develop dia-
betes; the mean age of an set is about 14 weeks. The diabetes incidence in males and females 
is similar (254). Clinical onset of diabetes is abrupt and characterized by weight loss, hyper-
glycemia, and elevated levels of circulating ketones and free fatty acids (249). Affected ani-
mals die within 2 weeks unless exogenous insulin is given. 
DP-BB rats differ from human diabetes patients and NOD mice in that they are severe-
ly Iymphopenic. The lymphopenia is due to thc ~JlP gene, one of the three known gene loci 
involved in diabetes development in the BB rat. Another important gene locus determining 
diabetes susceptibility is the MHC (255). The lymphopenia of the DP-BB rat affects alllym-
phocyte subsets to some degree, but of pmiicular importance is a complete absence ofT lym-
phocytes expressing the RT6 surface alloantigen (256). Normally, RT6 is expressed on -70% 
of suppressor/cytotoxic and 50% of helper/inducer T lymphocytes in the rat (257). 
In contnlst, DR-BB rats arc not Iymphopenic and have normal numbers ofT lympho-
cytcs that express the RT6 surface antigen (258). When a cytotoxic anti-RT6 antibody is 
injected into 30-day-old DR-BB rats, >50% of RT6-depleted rats becomes diabetic within 
4 weeks (259). Similar to spontaneous insulitis in DP-BB, insulitis is evident 7-10 days 
before diabetes onset in RT6-depleted DR-BB. In contrast, depIction ofRT6+ cells in 60-day-
old animals fails to produce diabetes. These results suggest that the RT6+ T lymphocyte pop-
ulation in 30-day-old animals is exerting a regulatOlY influcnce on the population of effector 
T lymphocytcs responsible for fl cell destmction (260). Diabetes can also be induced in 
DR-BB rats by low-dose irradiation, cyclophosphamide, viral infection, or administration of 
poly IIC (IS). 
In addition to insulitis and diabetes, DP-BB rats develop thyroiditis (261) and gastri-
tis (262) and are predisposed to lymphocytic malignancy (263-265). The incidence of associ-
ated autoimmunity depends on the sublinc of DP-BB rats. Moreover, concomitant with the 
development of severe lymphopenia, DP-BB are sllsceptible to environmental pathogens 
(18). The main clinical features of the BB rat model are summarized in Table 1. 
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In summary, BB rats differ from NOD mice and humans in that they are severely IYI11-
phopcnic. Moreover, they show a shorter preclinical period during which insulitis is present 
than NOD mice, suggesting a more progressive insulitis process. In addition, as is the case 
in humans, the incidence in males and females is similar, whereas in NOD mice females are 
more diabetes-prone than males. 
AI'C initiate the islet attack 
In BB rats, professional APC cells also appear to drive insulitis onset, independent of 
coincident T cell migration. A summary of findings supporting this notion is given in Table 2. 
Several studies have looked at the type of myeloid cells present in normal pancreas 
and infiltrating the pancreas in BB rats. In the pancreas of control rats, 11 Ft t 9+ DC are 
detected, mainly in the exocrine tissue. In addition, occasional DC are present in some ves~ 
scls of the pancreas (47) and a few can be observed in and around the islets (46). In addition, 
E02+ (44,46,47) and E03+ (44,45,47) M<j> are present predominantly in the exocrine tissue 
of the pancreas, although they are also observed in some islets (47). One study did not find 
E03+ M<j> at all (46). EOI+ M<j> are also present, although in much smaller numbers (44). 
DC and M$ are the predominant cells in islet lesions, both in early stages of sponta~ 
neous disease and in diabetes recurrence in islet grafts in DP-BB and RT6-depleted DR-BB 
(44,45,266,267). When specific stainings to search for the prescnce of OC are uscd, it is 
found that these cells are the majority of early infiltrating cells (46,47). Most initially infil-
trating M<j> appear to be EO I +:£02- (44), later an increase in E02+ and E03+ cells is found 
(46,4 7). E02+ M<j> are not likely to be crucially involved in diabetes development in BB rats, 
since there is no correlation between the distribution ofED2+ cells and the onset of diabetes 
in individual DP-BB animals (44). In addition, ED2+ cells are not significantly increased in 
RT6-depleted BB rats as compared to control (267). 
Initially, DC and Mt{l are situated around, and in later stages also within the islets in 
OP-BB rats (46,47). In the RT6-depleted DR-BB rat, it has been observed that, whilc non-
lymphoid cells dominate the ilislIlitis lesion, non-lymphoid cells and T cells tend to entcr the 
islets simultaneously (267). The localization of non-lymphoid cells around the islets may 
explain the discrepancy between histological studies and tlow-cytometric analyses of cell 
populations present in the inflltrate, since flow-cytometric studies show only low numbers of 
M<j> in isolated islcts (268). 
One study did not show major difterences in the number of Mt{l per unit area of 
exocrine pancreatic tissue between nOflnoglycemic DP-BB and \Vistar rats f1-olll 70-130 days 
of age (43), although significant difTerences with regard to Mq, phcnotype were found. This 
observation may be taken as an indication that int1anllUatOl)1 M$ do not constitute an addi-
tional immigrating cell population, but may represent resident tissue M$ which have been 
activated and converted into cytotoxic effector cells. 
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The cause of myeloid cell infiltration into the islets is unknown, but IFN-o; expression 
by j1 cells may playa role. IFN-u activates both NK cells (269) and Mq, (270). IFN-u can 
already be found in j1 cells of 30-day-old DP-BB rats, whereas it is never found in DR-BB 
p cells (53). Moreover, treatment ofDR-BB rats with poly VC induces islet lFN-u expression 
and diabetes, and similar treatment of young DP-BB rats accelerates diabetes development 
(53). In line with these t1ndings, anti-IFN-u treatment slightly delays diabetes onset in 
DP-BB rats (27 I). Thus, IFN-a may be involved in the initiation of pancreatic APC accumu-
lation. It is speculated that IFN-a expression can lead to the presentation of nco-epitopes, 
either via an effect on the antigen processing or presentation pathway, or through an effect on 
the three-dimensional structure of antigens (53). Theoretically, IFN-a expression can be 
virus-induced. However! both DR-BB and DP-BB rats arc maintained in similar specificd 
pathogen free (SPF) conditions. It is thus not likely that viruses can explain the difference in 
IFN-a expression and subsequent diabetes development between DP-BB and DR-BB rats. 
The presence of retroviruses can not be excluded! but has not been described to our knowl-
edge. 
In summary, in BB rats, as in NOD mice! APC appear to initiate insulitis. The cause 
ofthe early APC int1ltration may be related to TFN-a expression by p cells in BB rats, where-
as IFN-a does not seem to be involved in NOD mice. In BB rats, there are no indications for 
a viral etiology of diabetes. Tn NOD mice, the presence of retroviruses has been described, 
but it is so far unclear whether these viruses are important for the pathogenesis of the disease. 
Leukocyte tran1c into the pancreas 
In the BB rat, little is known about the process of leukocyte extravasation into the pan-
creas. One study observed mononuclear cell infiltration in DP-BB about 14-21 days before 
onset of diabetes in peri-vascular sites (44). Also in RT6-depleted DR-BB rats, an accumula-
tion of monolluclear cells at peri-vascular sites in some lobules has been noted during early 
stages of insulitis (267). Another study detected early peri-vascular int1ltration of EDI+ 
monocyte-like cells in the vicinity of islets following early accumulation of DC around the 
islets in DP-BE rats (46). It has been suggested that the peri-vascular infiltration of EDI+ 
cells may represent an early attraction of precursor cells for both DC and Mq, (46). There are 
so .G1r no indications for the formation of high endothelium in pancreatic venules! since no 
morphological changes could be recognized in capillaries of diabetic DP-BB rats in two stud-
ies (264,272). To the best of our knowledge, no studies have been reported yet about the 
involvement of specific adhesion molecules in the BB rat insulitis. 
In SUl11l11al)\ peri-vascular accumulations! indicating leukocyte recruitment, can be 
found in BB rats! as is the case in NOD mice. However, in contrast to NOD mice, HEY have 
not been described. This dinerence may be related to the relatively minor lymphocyte intll-
tration in BB rats compared to NOD mice. 
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The lymphoid actors: major roles for T, but not nand NK cells 
In BB rats, lymphoid cells also come into play after the early accumulation of APC. 
In contrast to \vhat is observed in the NOD mouse model, in which both Band T cells are 
crucial, in the BB rat only T cells seem to playa prominent role in the pathogenic process. 
In both the BB rat and the NOD mouse, there is no evidence that NK cells play an important 
role, 
It is highly unlikely that B cells playa major role in diabetes development in the BB 
rat. B cells are virtually absent in the infiltrates in early stages (44,45). In late stages llnd in 
islet grafts in DP-BB rats, they can only be found in low numbers (44,45,266,268), and few 
plasma cells can be identified among infiltrating B cells (273), One study reported that T and 
B lymphocytes appear to occupy distinct areas in the infiltrates (273), Also in the RT6-
depleted DR-BB, only velY few B cells are found in the infiltrates (267), B cells can either 
function as APe, or mediate ~ cell destruction via the production of autoantibodies. 
Autoantibodies reactive with islet cells are indeed present in the majority of animals at wean-
ing, an age at which neither 11l0rphologicalnor metabolic evidence of diabetes is detected yet 
(274). There is, however, no evidence that these auto-antibodies are pathogenic, since pre-
activated B lymphocytes from diabetic DP-BB rats are unable to induce disease upon trans-
fer (276). Moreover, BB rats can become diabetic even when B lymphocytes are depleted 
from birth (275), Thus, B lymphocytes do not seem to have a crucial role in antigen presen-
tation, nor in f3 cell destruction during the development of diabetes in the BB rat. In contrast, 
in the NOD mouse, B cells are essential in antigen presentation, but there is no evidence for 
a major contribution of B cells to ~ cell destruction. 
In contrast to B cells, T cells are crucially involved in the process leading to diabetes 
in the BB rat. Despite the profound lymphopenia in the BB rat, significant numbers ofT cells 
arc found in infiltrates in both DP-BB and RT6-depleted DR-BB especially in later stages of 
insulitis (44-47,266,268,277), Insulitis and diabetes can be transferred to young DP-BB rats 
or immunosuppressed :MHC-compatible Wistar rats by mitogen-activated splenocytes of dia-
betic DP-BB rats (278-281), Conversely, diabetes in DP-BB and in RT6-depleted DR-BB 
rats is prevented by depletion ofT lymphocytes (282-285), Moreover, disease development 
in DP-BB rats can be prevented by treatments that suppress CD4+ T cytokine production, 
such as cyclosporin-A (286-288) and FK506 (289,290), Cyclosporin-A also prevents dia-
betes in RT6-depleted DR-BB rats (291), Together, these findings underline the crucial role 
ofT cells in the development of diabetes in the BB rat, 
Only a minority ofT cells in early lesions arc OX22+, suggesting that the first T cells 
that arrive belong to the OX-22- memory T cell subset. As the disease progresses, naive 
CD45RA + T cells are also recruited into the lesions (267), Both CD4+ T cells (44,45,47,266-
268) and CD8+ T cells (45,47,268) are found in DP-BB rats both during spontaneous insuli-
tis and diabetes recurrence in islet gratts and in RT6cdepieted DR-BB, The histological 
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analysis of CD4+ versus CDR+ cells in the rat, however, is complicated by the fact that, in 
contrast to the situation in the mouse, rat lllonocytes and MCP can express the CD4-antigcll, 
whereas rat NK cells are CDS+ 
Functional studies have shed light on the roles of T cell subsets DP-BB and RT6-
depleted DR-BB rats. One can hypothesize that CD4+ T cells playa role only in the initia-
tion of insulitis, providing help to CDS+ T cells. In agreement with this hypothesis, recurrent 
autoimmunity in DP-BB rat recipients of islet transplants can be prevented by treatment with 
anti-CDS, but not anti-CD4 (292). This suggests that CD4+ T cells are not crucially involved 
in late phases of ~ cell destruction in DP-BB rats, Further evidence against a direct cytotox-
ic role for CD4+ T comes from the absence of MI-IC class II expression on pancreatic 
endocrine cells (see later). The observation that transfer of insulitis and diabetes may be 
accomplished using only the CD4+ splenocyte population li"OIll diabetic DP-BB rats (276) 
can be explained by recruitment of host CD8+ T cells, because adoptive transfer is impossi-
ble when either recipients or donors arc depleted ofCD8+ cells (281). Thus, CD4+ T cells 
appear to be predominantly involved with initiation of the autoimmune process in BB rats, as 
is the case in NOD mice. 
The role ofCDS+ cells in diabetes pathogenesis in BE rats is less obvious. Since both 
CDS+ T cells and NK cells are CDS+ and most intervention studies ,viII thus affect the func-
tion of both cell types, CD8+ T cells and NK cells will be discussed in combination. Whereas 
NK cells are virtually absent in early insulitis in DP-BB rats (44,45), in late insulitis sub-
stantial numbers ofNK cells are present (44,45), and NK cells may even be the predominant 
cell population in late insulitis in DP-BB (268,293). Also in the RT6-depleted DR-BB, NK 
cells are present predominantly in late insulitis (267,293). HOlVever, NK cells in islets of 
DP-BB are nearly five times more abundant as compared to islets of RT6-dcplcted DR-BB 
(293). In RT6-depleted DR-BB rats, CDS+ T cells are reported to be six times more abundant 
than NK cells. 
Based on these observations, early studies have suggested that the critical effectors for 
fl cell destruction may be NK cells for DP-BB and CD8+ T cells for RT6-depleted DR-BB 
rats. Functional studies, lIsing anti-NK antibodies directed against asialo-GMl, seem to sup-
port this hypothesis. DP-BB rat splenocyte cytotoxicity to islets ill vitro can be blocked by 
asialo-GMI treatment in vitro (294) or in vivo (295). In line with this, anti-asialo-GMI anti-
body treatment prevents recurrent autoimmune diabetes in diabetic DP-BB rat islet recipients 
(267,296). However, asialo-GMI has turned out also to be present on CDS+ T eells, chal-
lenging the interpretation of all studies that used anti-asialo-GMI to study NK cells (297). 
\Vhen using monoclonal antibody 3.2.3, that recognizes a molecule that is exclusively pres-
ent on NK cells, NK cell depletion had no effect on spontaneous diabetes development in 
DP-BB rats (298,299), nor on adoptively transferred diabetes (2SI). NK depletion with anti-
NKR-P I also had no effect on disease development in both DP-BB and RT6-depleted DR-BB 
rats (300). In contrast, recurrent autoimmunity in DP-BB rat recipients of islet transplants can 
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be prevented by treatment with anti-CDS, suggesting an important role for CDS+ T cells in 
B cell destruction during diabetes development in BB rats (292). 
Tn conclusion, CDS+ T cells play an important role in the final B cell destruction in 
DP-BB and RI6-depleted DR-BB rats. As in NOD mice, there is no evidence for a major 
role for NK cells in the development of diabetes in BB rats. 
The Th 1-Th2 paradigm in inslllitis expansion 
In the BB rat, early phases of peri-insulitis correlate with a significant expression of 
both Ihl and Ih2 eytokines (30 I). With the progression of insulitis, Ih I immune reactivity 
increases in both DP-BB and RI6-depleted DR-BB (301-304). Moreover, islet mononuclear 
leukocyte levels ofIFN-y mRNA are significantly higher in DP-BB and diabetic rats than in 
DR-BB rats (303). Ihese studies suggest that destructive infiltrates are associated with Ih I 
cytokilles, whereas non-destructive infiltrates are associated ,,,ith Th2 cytokines. Indeed, 
treatments that exacerbate disease correlate with enhanced IFN-y and decreased IL-IO gene 
expression (305), whereas protective treatments are associated with the reduction in Thl 
andlor the induction ofIh2 cytokine production (30 I ,303,306,307). In line with these obser-
vations, treatment with antibodies against IFN-y prevents diabetes in DP-BB (308). 
IL-12 is likely to playa role in the shift li"OI11 Ih2 to Ihl, since IL-12 mRNA is pres-
ent both before and during disease onset and levels increase during insulitis in qP-BB and 
RI6-depleted DR-BB (301,302). 
In summary, cytokine expression during the progression of insulitis in both the 
DP-BB and the RI6-depleted DR-BB rat is comparable to the eytokine expression as 
observed in the NOD mouse. Early insulitis involves cytokincs of the Thl and the Th2 type; 
the progression to destructive insulitis is associated with an upregulation of cytokines of the 
Thl type. In this conversion to destruction, APC-derived cytokines such as IL-12, and in the 
NOD mice IL-18, appear to be involved. 
The hypothesis of aberrant .~.rIHC expression revisited 
Several studies have investigated the expression of MHC-peptide complexes during 
diabetes development in the BB rat. Immullohistochemistry shows endocrine cells to be 
either negative or vety slightly positive in prediabetic DP-BB rats and Wistar controls. 
However, newly diabetic animals, including DP-BB rats, RI6-depleted DR-BB rats, DP-BB 
rats after disease transfer and animals ''lith diabetes recurrence after islet grafting, demon-
strate markedly enhanced MHC class I staining on endocrine cells (48,266,267,277,309). In 
addition, MHC class I expression has been quantified by means of mRNA levels, and it has 
been found that these levels are significantly enhanced in newly diabetic DP-BB rats (277). 
However, a proportion of the enhancement in MHC class I mRNA is probably attributable to 
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the high level of MHC class I gene expression in infiltrating inflammatory cells, the remain-
der representing enhancement within the islet (277). Besides MHC class I overexpression in 
endocrine cells, enhancement is also seen on ductal epithelium (266,309) and on capillary 
endothelium (309). Enhanced wIRe class I expression is always associated with the presence 
of inflammatory inliltrate and can be induced by leukocytes in young DP-BB (266,277,309). 
Interestingly, endothelial IvlHC class I hyperexpression in vitro is only significantly induced 
by RT6- T cells isolated from RT6-depleted DR-BB and not by T cells from untreated DR-
BB rats (310). In addition, islets from silica-treated animals that do not show lymphocyte 
infiltration, rarely shm'1:MIIe class I hyperexpression (48). Together, these observations sug-
gest that MHC class I hyperexpression is a consequence of the int1anullatory infiltrate and is 
not involved in the initial recruitment of inflammatory cells. This MHC class I hyperexpres-
sionll1ay be essential for CDS+ T cell-mediated cytotoxicity towards p cells. The kinetics of 
MHC class I hyperexpression thus follow the same pattern in the BB rat as in the NOD 
mOllse. 
As is the case for NOD mice, the induction of MHC class II on BB endocrine cells ill 
vivo during diabetes development is controversial. Native endocrine islet cells of several rat 
strains including DP-BB and DR-BB are MHC class II-negative (266,311,312). IFN-y is 
known to induce MHC class II on pancreatic islet endocrine cells ill vitro (313,314). 
However, in most ill vivo studies, MHC class II antigen expression on endocrine cells can 
either not be observed during spontaneolls diabetes and diabetes recurrence in islet grafts 
(272,277,294,315), or MHC class II is only observed on f3 cells surrounded by mononuclear 
infiltrates (309), In some cases, MHC class 11+ p ceBs are observed in late stages of disease 
(46,273). However, it is controversial whether p cells are the actual source of this observed 
IvIHC class II expression, The interpretation ofthese histological studies is complicated, since 
in vitro studies on rat islet cells have demonstrated that non-endocrine cells with MHC class 
11 expression can exhibit insulin immunoreactivity in cytoplasmic vacuoles (316). Moreover, 
it is possible that light microscopy does not have a high enough resolution to distinguish prop-
erly between MHC class II on protl1lsions of DC surrounding B cells, and MHC class 11+ 
cytomcmbranes of p cells themselves. Indeed, MHCn+ mononuclear cells dispersed within 
the islet have been observed, both in normal pancreas (311 ,315,317) and during the 
development of diabetes in DP-BB and RT6-deplcted DR-BB (48,266,267,272,277). On the 
RNA level, de novo appearance of transcript homologolls to both I-A and I-Ea chain genes 
in islet RNA preparations from prediabetic DP-BB can be found (277). Since TCR-j) chain 
and IFN-y gene transcript, which are indices for intiltration, appeared concomitantly) it was 
concluded that infiltrating cells, and not the endocrine cells, are the major source of MHC 
class II transcripts (277). 
MHC class 11 can also be induced on non-endocrine pancreatic cell types. Induction of 
MHC class II on ductal epithelial cells has been found, depending on the strain of the donor 
(266,315). MHC class II is reported to be absent on normal endothelium 
(310,311,315,317,318), although one study did lind endothelial MHC class II expression 
43 
Chapter 1.1 
(319), Both induction of MHC class II on islet grafts (266) and the contrary (315) have been 
described, possibly related to a diftcrcncc in the antibodies used. Moreover, as is the case for 
MHC class I, RT6- T cells isolated from RT6-deplctcd DR-BB can induce endothelial MHC 
class II expression ill vitro (310). 
1n summary, the data presented here suggest that h1HC class II is not induced on 
endocrine cells in BB rats ill vivo. Instead, the observed expression lllay be accounted for by 
infiltrating mononuclear leukocytes and other non-endocrine pancreatic cells. This is com-
parable to what is observed in the NOD mouse, 
CDS+ T cells and M<jl are major suspects for p cell destt'llctioll 
As explained earlier, CDS+ T cells are probably crucial for p cell destruction in both 
DP-BB and RT6-depleted DR-BB rats, One mechanism by which CDS+ T cells may effect 
11 cell cytotoxicity is the secretion of perforin, In acutely diabetic DP-BB and RT6-depleted 
DR-BB rats, about 60% of islets contain perforin mRNA, whereas no perforin mRNA-
expressing cells can be found in 30 day old non-diabetic DP-BB or non-depleted DR-BB rat 
islets (293), The number of perforin-cxpressing cells is comparably low in diabetic DP-BB 
and RT6-depleted DR BB: about three perforin-expressing cells per positive islet (293), The 
frequency of perf orin-expressing cells is low, but this docs not necessarily mean that perforin 
is not crucial in diabetes development in BB rats. In vUro assays have shown that perf orin is 
cytotoxic in a dose-dependent manner to rat islet cells, but not to thyrocytes) indicating 
a specific susceptibility of p cells for pertorin-mediated C)10toxicity (320), It should be 
stressed) however) that as yet no data exist proving that perforin is cytotoxic to j) cells at con-
centrations that may be present in inflamed islets. To the best of our knowledge) the role of 
Fas-mediated killing has not been studied in BB rats. 
The role of CD8+ T cells in Il cell cytotoxicity does not rule out other etIector mech-
anisms. The likelihood that additional cell types may be involved in B cell destruction in BB 
rats is supported by results fl'om transplantation studies (321,322). After transplantation) 
MHC-incompatible grafts afe significantly less vulnerable to autoimmune attack than !vlHC-
compatible grafIs. Hmvever) \vhen transplantation is performed in recipients previollsly 
talerized to the graft MHC, both MHC-compatible and MHC-incompatible grafts are equal-
ly susceptible to destruction (322), This indicates that MHC-restricted (T cell-mediated) and 
MHC-non-restricted (M4>- mediated) mechanisms may cause B cell destruction. In this 
respect, the SB rat is comparable to the NOD mOllse. 
Several ill vivo and ill vitro observations support a role for MC:P in j) cell destruction in 
the BB rat, as is the case in the NOD mouse. 111 vitro, activated M4> arc cytotoxic to syngeneic 
rat islet cells and not to cells !i'mil other tissues (323), Activated peritoneal M<jl from normal 
\Vistar and Lewis rats are able to kill freshly isolated rat islet cells (324). Killing was) how-
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ever, not fl cell-specific and included" and b cells at the periphery of the islets (324), in con-
trast to the ill vivo situation during diabetes development. III vivo, a correlation between Mcf> 
infIltration and f3 cell destruction is observed, since an attraction of"~IItP can be observed in 
late insulitis (46,47). Moreover, biopsies show that Mq, are infIltrating the islets of rats that 
subsequently develop diabetes, whereas they are Imv to absent in biopsies from animals that 
do not progress to diabetes (43). Tn conclusion, MtP may be important eft-ector cells for the 
11nal11 cell destruction. 
Cytoldnes and free radicals arc major j) cell destructive weapons 
As outlined before, MCP arc able to lyse islet cells ill vitro. Electron microscopic stud-
ies of cocultures of1v1$ and islet cells have revealed that islet cell lysis is not mediated via a 
direct contact with Mq" but via the release of cytotoxic mediators (235,324,325). Mq,-mcdi-
ated injury is probably caused by cytokine release, and the most likely candidates for such 
destructive cytokines are lL-J, TNF-a and T cell-derived lPN-yo 
IL-I is cytotoxic to rat B cells ill vilro (326-336). This efleet can be potentiated by 
adding TNF-n (337,338) andlor T cell-derived IFN-y (277,339). In line with this, anti-TFN-y 
can prevent diabetes in DP-BB by ini111encing cytotoxicity towards islet cells, but it can also 
intervene with the disease process via an influence on the Th I/Th2 balance (308). 
Besides cytokines, it appears that NO (generated by iNOS) may contribute to p cell 
destruction in BB rats. Pancreatic iNOS expression correlates with t3 cell destruction, since it 
is present in adult DP-BB but not young insulitis-lj'ee DP-BB, DR-BB or Wi star rats (340). 
[/1 vitro studies have demonstrated that rat islets are sensitive to the cytotoxic effects of NO 
(341,342). Accordingly, inhibition of NO-synthesis suppresses the cytotoxicity of activated 
Tvlcp and cytokines against islet cells ill vitro and is effective in preventing B cell death 
(235,343-346). III vivo, the expression of iNOS is not detected in pancreatic islets without 
lymphocytic intiltration, nor in \Vistar or DR-BB rats, whereas islets with advanced infiltra-
tion express iNOS at high levels (340). In addition, inhibitors of NO synthesis have proved 
to be eHective in preventing diabetes ill vivo (347,348). Tn conclusion, NO may contribute to 
p cell destruction. 
Several cell types may be responsible for the NO production. iNOS staining is found 
in areas of ED 1 + Mcp infiltration, although no direct colocalization has been shown (340). 
Thus, 1\1cp themselves appear a likely source of NO. Alternatively, .Mcp may induce adjacent 
endothelial (349) or endocrine B cells (346,350) to secrete NO by activation via inflammato-
ry cytokines. Cytokines, such as IFN-y and TNF in conjunction with LPS, appear to inhibit 
insulin secretion from islets by stimulating the release of IL-l from intra-islet Jvlcp, \"hich sub-
sequently induces the expression of iNOS by fl cells (344,346). Exactly the same mechanism 
has been found for mouse islets. 
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Stimulation of NO production, however, may not be sufticient for j) cell destruction, 
since cytokinc-induced major increases in NO production have been observed that did not 
affect ~ cell function (351). Conversely, cytokine-induccd ~ cell changes independent of NO 
production have also been described (351-353). 
Thus, additional factors besides NO are involved in cytokine-mcdiated 13 cell destruc-
tion. As in NOD mice, it has been suggested that cytokinc-induced free oxygen radical for-
mation in 13 cells is involved in ~ cells destruction in BB rats (354,355). Indeed, free radical 
scavengers protect rat islets from cytokine-induced damage ;11 vitro (356). Moreover, in 
DP-BB rats, partial suppression and delayed onset ofhyperglyccll1ia are achieved by in vivo 
treatment with free radical scavengers (357).111 conclusion, NO formation and oxygen free 
radicals arc likely involved in cytokine-illduced 11 cell damage. Again, in this respect the 
BB rat shows the same results as the NOD model. 
Ultimate p cell death: apoptosis 01' nccrosis'? 
At least two cellular mechanisms, induced by the events described above, can be 
responsible for () cell death: necrosis and apoptosis. In isolated rat islets and in rat insulino-
ma cells, IL-l-induced NO production induces apoptosis (35R,359). Moreover, the cytokine 
combination of IL- I, TNF and IFN-y also induced apoptosis in rat islets and rat insulinoma 
cells (243). In vitro results are thus in favor of apoptosis, but a contribution of necrosis to 
p cell death in vivo during diabetes development cannot be excluded. 
The highway to autoimmune diabetes in BB rats 
In BB rats, APe appear to initiate insulitis onset, independent of coincident T cell 
migration. The initial APe infiltration may be related to IFN-u expression by j3 cells. The 
cause of the IFN-a expression is unknmvll, but it is unlikely that it is virus-induced. After 
picking up islet-antigens, APe travel to the pancreas draining lymph nodes to present these 
antigens to lymphocytes. B cells do not appear to participate in this antigen presentation. 
T cells enter the pancreas, but formation of HEV has not been observed, although peri-vas-
cular accumulations of lymphocytes are present. There is no phase of peri-insulitis; leuko-
cytes immediately start to infiltrate the islets. 
B cells can be found in the pancreatic inflammatory infiltrates. However, they do not 
appear to play all essential role in diabetes pathogenesis. The contr3l)' is true for T cells, 
despite the profound lymphopenia of the BB rat. Both CD4+ and CDS+ T cells are impor-
tant, the fonner mostly in the initiation of insulitis and the latter in ~ cell destruction. 
NK cells are present in high numbers within the infiltrates, especially in DP-BB rats, but may 
nonetheless not be essential for diabetes development. Initially, CD4+ T cells secrete both 
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Th 1 and Th2-type cytokincs. Conversion to mainly Th I-type cytokines takes place under 
intluence ofIL-12. Pancreatic infiltration upregulates MHC class I on endocrine and exocrine 
cells, thus lacilitating CD8+ T cell-mediated cytotoxicity, Aberrant expression of MHC class 
II on p cells does probably not occur, 
Killing of j3 cells takes place via different mechanisms. CDS+ T cells exert their 
actions by perforill-mediated cytotoxicity. It is unknown whether Fas-mediated mechanisms 
also playa role in CD8+ T cell-mediated fl cell destruction, CD4+ T cells together with Mq, 
also participate in f3 cell destl1lction via the secretion of cytokines and other products. 
Candidates arc the cytokines IFN-y, TNF-u and IL-l, but NO and oxygen free radicals may 
also be involved. In vitro results favor B cell death by apoptosis, but no in vivo evidence has 
been reported. Diabetes occurs within t\VO weeks after insulitis-initiation; thus the prediabet-
ic phase takes place within a limited time span . 
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Figure 2: Prediabetic islet inmtrate in a BB rat. (a) EDI+ i\ltjl; (b) ED3+ i\ltjl; (c) CD4+T cells; and (d) RT1B+ APC. 
Figure 2 shows a representative example of an infiltrate in a DP-BB rat. It can be clear-
ly seen that the infiltrate is small, in contrast to the infiltrates in NOD mice. There is no sep-
arate phase ofperi-insulitis, inflammatory leukocytes immediately intiltrate into the islet and 
dishlrb the islet architechlre, Mq, (Fig, 2a and 2b) and T cells (Fig, 2c for CD4+ T cells) are 
present in equal numbers, in contrast to the situation in NOD mice, where T cells constihlte 
the majority of the infiltrate. Also, numerous APC arc present throughout the infiltrate (Fig. 
2d). These infiltrates in the BB rat are relatively aggressive, since the prediabetic phase is 
only 7-10 days in BB rats, as compared to many weeks in NOD mice. 
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Human type 1 diabetes 
Type 1 diabetes in humans 
Before reviewing human diabetes pathogenesis, we wish to underline a concern that 
should be kept in mind when interpreting findings related to human diabetes pathogenesis. 
As stated before, symptoms of diabetes in humans do not develop until the majority of pan-
creatic p cells is destroyed. The disease process therefore will have been initiated long before 
its clinical manifestation (360). This is evidenced by the tact that, during this preclinical peri-
od, autoantibodies arc circulating, T cell responses to p cell antigens can be found and 
changes in the response to glucose challenge arc evident (l-3), Most studies concerning 
autoimmune processes occurring in the pancreas in human type I diabetes usc autopsy mate-
rial. It should therefore be stressed that these observations inevitably represent end-stage dis-
ease manifestations. Thus, limited information is available about the initiation phase in 
human diabetes, Moreover, only few reports are available concerning the expansion phase of 
human insulitis. These reports have been published during the entire last centmy. Techniques 
employed in these studies thus vary considerably, and make these studies diftlcult to com-
pare, Finally, as outlined below, it is very likely that human type J diabetes patients are het-
erogeneous in the causes of and maybe the processes leading to the disease, All these factors 
complicate research on processes leading tot type 1 diabetes in humans. 
APC initiate the islet attack? 
In human type I diabetes, the role of M$ and DC in the initiation of insulitis is less 
clear than in the animal models due to the virtual impossibility of studying the initiation 
phase. However, indirect evidence suggests that myeloid cells are involved. In normal pan-
creas, a small but significant number of myeloid cells has been found located among acini 
and ducts (93). M$ and DC are also observed in pancreatic infiltrates in virtually all type I 
diabetes patients (93,214,361-365), Tn one case, no monocytes or M<jJ could be found in the 
infiltrate using antibodies against CDllc and CDI4 (366), Overall, M<j> in pancreatic infil-
trates tend to be fe\ver in number than lymphocytes in most cases of diabetes (93,95,214,363-
365,367,368), although a predominance of ]VI", over lymphocytes has also been described 
(95,364), This does not, however, mle out a predominant influx oflvl<jJ and DC at the initia-
tion of insulitis, since these cases represent end-stage disease. 
The reason for the initiation of autoimmunity is unclear. Several studies suggest that 
virus-induced TFN-a expression by islet cells is involved. IFN-u has been found in endocrine 
cells in a propOIiion of islets in diabetic (54,369) and prediabetic (369) pancreases, In one of 
these studies, only 13 cells stain strongly (54)_ Another study shows that IFN-a and to lesscr 
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extent IFNwf3 and IL-6 are also present in control pancreases, but, in contrast to diabetic pan-
creases, in no case the combination (93). Furthermore, a significant increase in the level of 
IFN-u mRNA has been found in the pancreas of diabetes patients as compared with controls 
(52). Endocrine IFN-a expression may result in local changes in expression of MHC and 
adhesion molecules. However, during viral pancreatitis, no clear correlation behveen IFN-C( 
expression by p cells and the level of expression of MHC class I by adjacent cells has been 
found (54). 
The exact kinetics ofIFN-u. expression during human insulitis are not clear, due to the 
scarcity of prediabetic material. It is, however, unlikely that the expression ofJFN-C( is entire-
ly due to local inflammatioll) since IFN-u expression does not occur in other situations with 
massive leukocyte accumulation in the pancreas) such as chronic pancreatitis or graft-versus-
host-disease (54). Also) the disturbances in glucose homeostasis are an unlikely cause of 
IFN-C( expression) since pancreatic lPN-a expression is not observed in type 2 diabetes (54). 
Only in viral pancreatitis comparable IFN-a expression has been found) lending support to 
the hypothesis of a viral etiology for human type I diabetes (54). Also the combination of 
lPN-a) IPN-(1 and IL-6 expression) that has been found in diabetic pancreases) can be 
explained by a viral infection (93). 
Coxsackie B enteroviruses are the most obvious candidates for such an infection. 
Coxsackie virus-specific IgNf responses and viral RNA arc more common in recent onset 
patients than in controls (370-372) .. Moreover) Coxsackie B virus) cultured from a diabetic 
pancreas) has been able to cause diabetes in normal mice (373). In addition) Coxsackie B 
viruses callse endocrine cell necrosis in the human pancreas (374,375). Besides Coxsackie B 
enteroviruses, mumps vints) cytomegalovirus and congenital rubella may be involved in 
some cases of diabetes (376-379). Moreover, the infection of human insulinoma cells with 
measlcs, mumps and rubella vims induces the expression of cytokines (notably) IL-l and 
IL-6) and upregulates IvIHC molecules (380}) which can make them more prone to autoim-
mune attack. 
Tn contrast to these studies, other studies have failed to reveal any evidence of infec-
tion by the candidate viruses in collected autopsy diabetic pancreases (93,381,382). It is espe-
cially important to note that there have been no reports in the last 20 years of a virus cultured 
from an autopsy pancreas of a patient with recent-onset type I diabetes. Moreover) although 
there is a marked tropism of Coxsackie viruses for the endocrine pancreas and inflammatory 
changes accompany islet infection) these changes are qualitatively different frol11 the ones 
found in recent onset type I diabetes. Especially the presence of numerous granulocytes after 
Coxsackie infection (382) represents a completely diftercnt situation from the prediabetic 
inflammatory process, since only a few polymorphs are found in most diabetic autopsy pan-
creases (383-388). However) two cases have been reported in which an extensive intiltration 
of polymorphonuclear leukocytes was observed (389). In one of these cascs) an acute diffuse 
pancreatitis is seen) with necrosis of some of the large ducts and an extensive infiltration of 
polymorphs in the interstitial tissue) especially involving the interlobular tissue. In these last 
two cases) an aClite vi11ls infection may have caused diabetes directly. Hmvever) a direct 
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cytolytic effect ofvirllses is less likely to be compatible wilh the long pre-clinical period that 
precedes diabetes in most patients. It should be realized that a B cell reduction up to 80% can 
be compensated for by the remaining B cells. Virus infections or stress may then lead to 
a sudden collapse of insulin secretion. A vjrus or anti-viral IgtvI being detected at diabetes 
onset docs therefore 110t prove that type 1 diabetes is of viral origin, since diabetes 
development has presumably been initiated long before its clinical manifestation (390). 
In conclusion, the evidence is against a direct cytolytic effect for virus'es resulting in 
diabetes. It remains possible that viruses that infect the pancreas cause subclinical j3 cell 
damage, The resulting release of autoantigens and cytokines within the pancreas may break 
tolerance towards B cell autoantigens and ultimately lead to type 1 diabetes (391), The obser-
vation that maternal enterovi11ls infections are a risk factor for childhood diabetes in off-
spring may fit into such a scenario (392-394), Viruses can) however, also act as initiators of 
autoimmunity via the presence of molecular mimicry: structural similarities between viral 
and () cell proteins, Functional cross-reactivity for T cells has been described for an epitope 
shared by the major diabetes autoantigen GAD and the Coxsackie B P2C protein, Moreover) 
an IA-2 epitope has been reported to show sequence similarity (but not identity) with VP7) 
a major immunogenic protein of human rota virus and with epitopes from other viruses that 
have been implicated in the pathogenesis of type 1 diabetes (395), Several other cross-reac-
tivities between viral and B cell proteins have been described (396-398). However) '''lith 
emerging knowledge of human and viral and microbial DNA sequences) the chances of find-
ing sequence similarities are increasing. Such a hit may be coincidental until functional 
cross-reactivity has been demonstrated. Ivloreover, most studies are based on similarities in 
the primary protein structure, neglecting the h'lct that the tertiary structure Illay be of higher 
physiological significance. In addition) direct evidence sllPP0l1ing the role of mimicry in the 
pathogenesis has never been provided, 
Finally) viruses may also initiate type I diabetes by the activation of autoreactive T 
cel1s by a retroviral superantigen. The enrichment ofV~7-canying T cel1s in recent onset dia H 
betes patients, the subsequent cloning of a superanligen encoded by HERV-KIO 
(lDD1HK1222) and the demonstration that this virus mediates a V()7-biased sllperantigen 
effect on {ymphocytes has led to the hypothesis that retrovirally encoded sllpcrantigens are 
involved in type 1 diabetes (399,400). However) later studies have consistently shown that 
this possibility is not likely, given the lack of difference in JDDMKj 222 expression and in 
seroreaetivity to the IDDMKj 222 protein between patients and controls (401-407). 
FUlihermore, the putative V/17-sl,ecil1c stimulation of the IDDMj 222 protein has also been 
contradicted (403). ' 
In summary, APC may initiate insulitis in humans, as is the case in NOD mice and BB 
rats, although there is no direct evidence for such a scenario, The initial APC infiltration can 
be related to IFN-a expression by B cells in humans) like in BB rats but in contrast to NOD 
mice. In most human diabetes cases and in animal diab,etes) an acute viral infection does not 
seem to be involved in the endocrine IFN-a expression and initiation of diabetes. The pres H 
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ence of retroviral particles has only been described in NOD mice, but it is so far unclear 
whether these viruses arc impOIiant for diabetes development in these mice. In humans, no 
conclusive evidence for a retroviral initiation of type 1 diabetes has been found. 
Leukocyte traffic into the pancreas: highways of adhesion molecules 
It is conceivable that the pancreaswinfiltrating APC pick up antigens and present them 
to T cells in the pancreas-draining lymph nodes. These T cells can subsequently home to the 
islets, using adhesion molecules. In two studies, peri-vascular infiltrates were observed in 
autopsy pancreases (84,408). Local differentiation of the endothelium toward a marc HEV-
like morphology was found in both cases, with a parallel accllmulation of mononuclear cells 
around those vessels. Since high endothelium is never detected in venules devoid ofperi~vas~ 
cular infiltrates, and since not all venules with peri~vaseular infiltrates display HEV mor~ 
phology (408), it seems reasonable to assume that the differentiation towards HEV-morphol-
ogy is the result rather than the cause ofperi-vasclliar infiltration. These findings suggest that 
such venules are sites of active extravasation in vivo (84). 
The formation of HE V is comparable to the NOD mOllse and contrasts with the situa-
tion in the BB rat, where HEV formation has not been observed. 
In human type 1 diabetes, it is difticult to define the exact order in ,vhich adhesion 
molecules are implicated in leukocyte extravasation into the pancreas. Several adhesion mol~ 
ecules (summarized in Table 3) arc thought to be involved in the development of diabetes, 
since their expression patterns change during disease development. It should be realized that 
the difterences between normal and diabetic pancreas may be due to the diabetic state per se, 
since the expression of adhesion molecules is known to be influenced by glucose levels (409). 
In normal pancreas, ICArvI~ I is expressed on capilialY endothelium and epithelium of 
some ducts (93). In autopsy diabetic pancreases, expression of ICA1vI-1 is increased on 
endothelial cells in islets (93-95) as ,yell as in many blood vessels in the exocrine pancreas 
(94). This increase in ICA1vl-1 expression is found in association with islets with insulitis and 
residual insulin contcnt (93). Since LFA-l is expressed on infiltrating cells, ICAM-IILFA-I 
is at least one pathway by which endothelial cells may control inflanlluatOlY cell influx into 
the pancreas in a non-tissue specific manncr (93). Thc ICAM-I/LFA-l adhesion pair might 
also playa role in antigen presentation and in ~ cell cytotoxicity. Infiltrating cells remain 
ICAM-l negative (94,95), so bi-directional LFA-IIICAM-I interactions on APC and T lym-
phocytes are probably not involved in enhancing local antigen presentation during insulitis. 
Several studies have considered a role for the ICAM-lfLFA-l interaction in ~ cell cytotoxic-
ity, since induction of ICAM-l 011 endocrine cells in vitro by proinilal111uatOlY cytokines 
(TNF-a and IFN~y) has been reported (96,97). However, as is the case in normal pancreas 
(96), islet cells are always ICAM-I negative in diabetic pancreas (94,95), thus making a role 
for ICAM-I in p cell cytotoxicity unlikely. 
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LFA-3 and its T cell-restricted ligand CD2 are suggested to be responsible for the co-
stimulating activity provided by non-professional APC, such as endothelial cells and ~ cells, 
in antigen presentation experiments (410). The expression ofLFA-3 on pancreatic endothe-
lial cells is controversial; it was reported to be increased in endothelial cells of one patient 
(95), while another study showed comparable staining to control pancreas (93). More con-
sistency exists regarding t1 cell expression: LFA-3 was absent frolllnormal p cells (96) and 
islet cells of a recent onset diabetes patient (95) and was not inducible on islet c~I1s by proitl-
flammatOlY cytokines ill vitro (96). In conclusion, LFA-3 is probably not crucial in antigen 
presentation by non-professional APe during human diabetes development. 
In contrast to what has been found in the NOD mouse, VCArvI-l is not expressed on 
endothelium in islets or in exocrine areas of the diabetic pancreas or control pancreases 
(93,94), making a role ofVCAM-lNLA-4 interactions in leukocyte extravasation unlikely. 
However, VCAwI-lIVLA-4 interactions may be involved at another level, since in normal 
pancreas, a small number ofVCAM-I+ DC-like cells can be found (93). Moreover, in nor-
mal pancreas, VLA4 is expressed on epithelium and walls of ducts and vessels (93). It is 
therefore possible that the VCAM-l/VLA-4 interaction is involved in DC extravasation into 
the pancreas and the islets. The role ofVCAM-l in human diabetes development needs fur-
ther clarification. 
PNAd expression has not been observed in endothelial cells in diabetic pancreas, sug-
gesting that the PNAd/L-selectin pathway is not necessarily functioning in human diabetic 
pancreas (84). Anti-E-sclectin also did not stain any venules in diabetic or control pancreas-
es (94). 
In conclusion, similarities and differences exist in adhesion pathways between insuli-
tis developing in humans and in NOD mice, whereas adhesion pathways have not been stud-
ied in detail in BB rats. In the NOD, the MAdCAM-IILPAM-1 interaction, PNAdlL-selectin 
and ICArvf-CR3 are involved in early phases of leukocyte extravasation. In humans, in con-
trast, the PNAdlL-selectin patll\vay does not appear to be involved, whereas the other two 
have not been studied. In both NOD and humans, the ICAM-IILFA-I interaction is proba-
bly important, in humans mainly in leukocyte extravasation, in NOD mice also in antigen 
presentation. In both humans and NOD mice, ICAIvl-IILFA-1 interactions are probably not 
involved in p cell destruction. In NOD mice, but not in humans, the VCAM-lIVLA-4 path-
way also appears to playa role in leukocyte extravasation. 
The 1)'lllphoid actors: major roles for T, and probably Band NK cells 
Lymphoid eclls playa prominent role in the development of type I diabetes in 
humans. In normal human pancreas, a small but consistent number of lymphocytes can be 
fOllnd among acini and duets (93). Lymphocytes are obsetved in all diabetes autopsy pan-
creases with insulitis, and are thought to play important roles in human diabetes 
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development. NK cells have not been extensively studied in human diabetes, In one study, 
NK cells were reported to be absent in human insulitis (93), 
Considering the presence ofB cells in the infiltrates, an extensive amollnt of variabil-
ity exists, B cells arc present in some cases (94,95,361,364,366,367,387) and absent in oth-
ers (93,95,363), Usually, B cell numbers are lower than T cell numbers, although two repOlis 
describe almost equal numbers of T and B cells (94,364), Only in few patients, B lympho-
cytes predominate (364), Plasma cells are usually not observed (93,366,383-385,387), In two 
cases, organized accumulations of lymphoid cells have been fbund, with germinal center for-
mation in one (383) and clusters ofB lymphocytes in the other (361), Also, HEV and RFDI+ 
interdigitating cells are found in the T cell zones (361), 
B cells may either be involved as APC, or mature into autoantibody-secreting plasma 
cells. These autoantibodies may be involved in f) cell destruction, although variable results 
have been obtained regarding the deposition of autoantibodies in the diabetic pancreas. 
Autoantibody deposition on islet cells was not found in several patients (93,363,411), 
although scarce and interstitial immunoglobulin deposits could be found in one of these cases 
(93). Also arguing against the involvement of autoantibodies in the destruction is the obser~ 
vation that the serum of one of these patients failed to stain his own viable islets (93). In con~ 
trast, an abnormal deposition ofIgG on the outer membrane of endocrine cells was found in 
another study (366). Functional studies suggest that autoantibodies may contribute to diabetes 
development in some patients. 1slet-cell-surface-antibody (ICSA)+ sera from diabetes 
patients caused significant lysis of cultured rat islet cells in the presence of complement, 
whereas ICSA - sera did not (412). In general, the evidence is nonetheless against a patho~ 
genic role tor auto~antibodies in human diabetes development. Despite transplacental trans~ 
fer of maternal auto~antibodies, children with diabetic mothers have a lower chance of devel-
oping diabetes than children with diabetic fathers (7). Furthermore, transplacental transfer of 
maternal antibodies does not lead to an accelerated onset of type I diabetes in those children 
who will eventually develop type 1 diabetes eM. Knip, personal communication). Moreover, 
human B lymphocytes producing diabetes-associated auto~antibody do not cause islet dam-
age upon transfer to (complement-competent) scid mice (413), 
The same variability as observed for autoantibody involvement applies to the involve-
ment of complement. Contrasting reports exist on the deposition of complement components 
in the pancreas. In some patients, no deposition of component C3 or the membrane attack 
complex on islet cells ,vas found (93,363). In another patient, however, a proportion of cells 
in all sections showed abnormal depositions of C9 (366), indicating that in this patient, com-
plement-mediated islet cell lysis may have occurred. In general, type I diabetes is not asso-
ciated with complemcnt activation (414). 
In conclusion, autoantibodies in some human patients may contribute to B cell destruc-
tion. In the majority, however, they do not secm to playa pathogenic role. This is similar to 
the situation in BB rats and NOD mice. In the latter, this may be related to a complement-
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deticiency. \Vhether B cells are involved as APC, as observed in NOD mice, but not the SS 
rat, is unclear for human diabetes. 
T cells in pancreatic infiltrates have been studied extensively and arc present in all 
cases of human diabetes. At the onset of diabetes, T cells are abundant among islet-infiltrat-
ing cells. The same obSClvation has been made during diabetes recurrence in diabetes 
patients transplanted \vith pancreas isografts or HLA-identical allografts (362,363,415). 
Indications for the essential role ofT cells come from the observation that cyclosporin treat-
ment prolongs endogenolls insulin production (416,417). Moreover, antibodies directed 
against T cells (anti-thymocyte globulin) have positive eftects on metabolic control, although 
only short-term (418). In addition, recurrent autoimmunity in islet transplants can be pre-
vented ifthe immunosuppressive therapy includes anti-thymocyte globulin (419). The essen-
tial role ofT cells in human diabetes is thus comparable to their role in both NOD mice and 
BB rats. 
Less consensus exists about the subtype ofT cells present in the inflammatOlY infil-
trates. The predominant T cell in the pancreatic infiltrates is in most cases CD8+ (93-
95,362,363,366), in agreement with a role for CDS+ T cells in late stages of insulitis. 
However, a predominance ofCD4+ T cells in insulitis has also been observed (214,361). In 
addition, a human CD4+ T cell clone has been described which lyses MHC class II-compat-
ible islet cells (420), suggesting that CD4+ T cells are able to destroy ~ cells by direct cyto-
toxicity. 
These observations are in contrast to observations made in animal models. \Vhereas 
CDS+ T cells are more abundant than CD4+ T cells in human insulitis, in both BB rats and 
NOD mice CDS+ T cells are present in lower numbers than CD4+ T cells. This may suggest 
that CD8+ T cell cytotoxicity is more prominently involved in human type 1 diabetes than 
in the animal models. In both BB rats and NOD mice, hmvever, CD8+ cells do appear to play 
important roles in diabetes development. Moreover, the human data represent cnd-stage 
insulitis, and in late stages in NOD mice, the accumulation ofCD8+ T cells is also increased. 
In some human ca.ses, CD4+ T cells are present in higher numbers than CD8+ T cells. These 
cascs thus follow the kinetics observed in the animal models. 
The Thl-Th2 paradigm in insulilis expansioll 
Also in human diabetes, indications exist for a selective involvement ofThl cells in 
islet destruction. IFN-y mRNA is expressed at high levels in the pancreas ofdiabetcs patients, 
while IL-4 mRNA is lacking (421), suggesting a dominance ofThl cells in pancreatic intil-
trates. In accordance \vith this, IFN-y is expressed in silu by 40% of the lymphocytes during 
diabetes and 45% during prediabetes (365). FUl1hennorc, fl cell antigen responses of antigen-
specific T cell lines generated fl'011l diabetes patients have been shown to be associated with 
IFN-y and TNF-a production, suggestive of a Thl-like phenotype (422). In addition, all T 
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ccll cloncs of CD4-CDS- Va24JaQ+ T cells, which are presumed to promote Th2 rather than 
Th 1 bias, that were isolated from diabetes patients secreted only IFN-y upon stimulation. In 
contrast, almost all clones from the at risk non-progressors and controls secreted both IL-4 
and IFN-y. It was therefore suggested that Thl cell mediated tissue damage is initially regu-
lated by T cells producing both Thl and Th2 cytokines and that the loss of the capacity to 
secrete IL-4 is correlated with type I diabetcs (423), The transition to an almost exclusively 
Th J type infiltrate possibly involves IL-12, In conjullction with this, levels of this cytokine 
are significantly higher in islet cell antigen (ICA)+ relatives of diabetes patients than in C011-
trois (350), The initial presence of both Th2 and Thl cytokines, and the conversion to a Thl-
type destructive infiltrate under influence of IL-12 call thus be found in human diabetes 
patients, BB rats and NOD mice. 
Not all studies are in agreement with a Thl/Th2 disbalance in pancreatic infiltrates. 
One study did not find any T cell cytokines, including IL-2, IL-4, IL-IO and IFN-y, in pan-
creas tissue using RT-PCR (93), Another study was not able to detect TNF-a or IL-2 mRNA 
in control or diabetes pancreases, and found highly variable expression of IL~lf), IL-4 and 
IL-6 mRNA with no pattern emerging from the comparison of the tour diabetic and the four 
non-diabetic individuals (52). These discrepancies probably reflect heterogeneity in human 
diabetes pathogenesis. 
The hypothesis of aberrant "'lHC expression revisited 
Also in humans, several studies have compared the expression of !vlHC molecules in 
diabetic pancreas to that in normal pancreas. In normal pancreas, expression of MHC class I 
and MHC class II is found on capillary endothelium (93,424,425), Furthermorc, MHC class 
I and occasionally MHC class [[ is found on ductal cells (93,424,425), Endocrine cells in nor-
mal pancreas are either negative or weakly positive for MHC class I and MHC class II 
(93,424,425), MHC class [[ has also been found in islets on rarc DC-like cells (93), 
In diabetic autopsy pancreases, an increased expression of MHC class I is tound on 
endothelial cells within and around islets (93,95,411,426) and on ductal epithelium (93), 
Furthermore, all studies tind a marked increase in MHC class I expression on islet cells in 
a propOIiion of islets in diabetes patients (93-95,366,369,411,425,426) and also in a predia-
betic individual (369), Some studies rcport the endocrine MHC class I hyperexprcssion to be 
independent of the presence of lymphocytic infiltration (366,369), others rcport MHC class I 
hyperexpression prcfcrentially in islets with insulitis (93,95,365), This discrepancy may be 
explained by the observations that infiltrates can be quite focal and may thus be easily missed. 
Alternatively) one study showed that all insulin-containing islets with insulitis overexpressed 
MHC class T, while this ,vas not necessarily true for inflamed insulin~deficient islets. 
However, MHC class I hyperexpression also occurred in non~inflal1led insulin-containing 
islets from diabetes patients (425), These kinetics suggest that MHC class I hyperexpression 
precedes insulitis, and ceases again after the destruction of[) cells. This complex relationship 
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between insulitis and MHC class I hyperexprcssion may explain the contrasting findings 
about the association of insulitis and MHC class 1 hyperexpression. 
MHC class I hyperexpression is not only observed in ~ cells, but also in <I and 0 cells 
(94,411,425), Most MHC class I hyperexpressing islets contain residualll cells (54,369,425), 
suggesting that j) cells in those islets are secreting a substance that has a paracrine eilect 
inducing hyperexpression of MHC class I on adjacent endocrine cells. Candidate for slich 
a substance is IFN-a, and indeed a strong correlation behveen IFNa expression and MHC 
class I hyperexpression is found (54,369). However, during viral pancreatitis, 110 clear COf-
relation between IFN-n expression by 11 cells and the degree of expression of MHC class I 
by adjacent cells could be found (54), arguing against IFN-<I as sole determinant for MHC 
class I hyperexpression, In addition, IFN-y produced by intiltrating cells can causc islet 
endocrine cells to express MHC class I at elevated levels (427,428), However, during chron-
ic pancreatitis, MHC class 1 hypcrcxpression is not observed, although comparable numbers 
of IFN-y producing T cells are present as found in diabetic autopsy pancreases (365), argu-
ing against an essential role for IFN-y in MHC class 1 hyperexpression. 
In conclusion, MHC class I hyperexpression by endocrine cells is present in humans, 
comparable to BB rats and NOD mice. However, in humans it may precede insulitis, where-
as "MHC class I hyperexpression is induced by infiltrating cells in the animal models. 
As expected, MHC class II expression is fOllnd in the mononuclear cell infiltrate of 
inflamed islets (94,361-363,366-368,387), Enhanced MHC class II reactivity is also 
observcd on vascular eudotheliulll (94,95,362,363,366,368,387,411,426), Variable results 
have been obtained with regard to the expression of MHC class II on endocrine cells. MHC 
class II is reported to be either negative on endocrine cells (94,362,367,387) or positive 
specit1cally on a fraction of 11 cells in some patients (93,366,411,425), Since only a fraetion 
of f3 cells hyperexpress MHCII, their presence may be missed because of a limited localiza-
tion. Alternatively, the observed islet MHC class II expression may be accounted to by intra-
islet leukocytes, as is the case in animal diabetes. When MHC class II is seen on endocrine 
cells, islets expressing MHC class II without evidence for insulitis are also observed 
(368,425,429), This observation has led to the suggestion that on aberrant expression of 
MHC class II on 13 cells precedes insulitis, similar to the kinetics of MHC class I expression, 
and is therefore not entirely induced by the inflammatory infiltrate. Although a focal inflam-
matory infiltrate may be missed, it is indeed unlikely that inflammatol)' cytokines are entire-
ly responsible for a positive endocrine MHC class II expression, Aberrant MHC class II 
expression is absent on 13 cells in pancreatic infiaml1latOlY diseases (425). Moreover, in flam-
matOlY mediators in in vitro studies failed to induce "MHC class II expression selectively on 
p cells, but instead also induced MHC class II expression on other pancreatic endocrine cells 
(427,428,430,431), Finally, pro-inflammatory cytokines sueh as IFN-y may not be able to 
cause human f3 cells to express MHC class II in vivo at all, given the observation that dia-
betes recurrence after transplantation of an identical twin pancreas did not involve MHC 
class II expression by 11 cells, whereas IFN-y lVas significantly expressed (363), 
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In conclusion, intra~islet MHC class 11 expression has been observed in the human dia-
betic pancreas. However, it has not been convincingly shmvll that intra-islet MHC class II is 
expressed on endocrine cells, as opposed to intra-islet leukocytes. If MHC class 1I is aber-
rantly expressed on endocrine islet cells, intlammatory cytokines arc not likely to be the only 
cause. In BB rats and NOD mice, MHC class II molecules arc most likely not induced at all 
on endocrine cells. 
An alternative explanation for the expression of MHC class I and MHC class II mol-
ecules on islet cells comes from the observation that normal ductal cells express chromo-
granin, C-pcptide, glutamic acid decarboxylase (GAD) and unexpectedly :tvIHC class I and 
!villC class II (93). Neogenesis of islets from ductal cells is typical of acute onset type I dia-
betes and probably represents an attempt to replace the destroyed fl cells. The MHC-express-
ing cells found in recent onset human type 1 diabetes may thus represent regenerating B cells. 
In accordance with this, the ability of IFN-y and TNF-n to induce MHC class II on fl cells is 
relatcd to the differentiation state of the p cell (431). In conclusion, although MHC expres-
sion is also present "in islets not aft-ectcd by insulitis, it could be a consequence of the inflamH 
matory process rather than a cause, 
CDS+ T cells and M<j> arc major sllspects for fl cell destruction 
In human type 1 diabetes development, the composition of the insulitis appears to be 
heterogeneous. For example, in some patients CDS+ T cells predominate, whereas in others 
CDS+ T cells or B cells comprise the major lymphocyte population. It is conceivable that 
these differences in cell involvement in the insulitis process also result in different non-mutu-
ally exclusive B cell killing mechanisms. Indeed, indications have been found for several pos-
sible killing strategies. It has been discussed before that autoantibody- and/or complement-
mediated B cell killing mechanisms may playa role in diabetes development, in contrast to 
what is observed in animal models. In addition to these pathways, CDS+ T cells and M$ con-
tribute to f3 cell destruction in human type 1 diabetes patients. 
In one study, human CDS+ T cells were shown to specifically inhibit insulin release 
by mOllse islct cells cultured ill vitro (432), but the interpretation of these data is complicat-
ed by the absence of MHC restriction in this model. In addition, prediabetic twins have ele-
vated levels of HLA-DR+CDS+ T cells as compared to control subjects and low-risk twins 
(433). Sillce these cells have the same cytotoxic phenotype as the predominant cell type fOllnd 
in the islets at diagnosis, the circulating cells may have a role in the pathogenesis of islet dam-
age (433). CDS+ T cells may cause fl cell damage by the release ofpore-fonning molecules, 
sllch as perforin, and by Fas-mediated apoptosis induction. 
Variable results have been obtained concerning the expression of perforin in diabetic 
autopsy pancreas. In one case, CDS+ T cell cytotoxicity ,vas supported by detection of per-
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forin transcripts (93), In another case, however, perf orin was not found in infiltrating cells 
(369), Thus, in this case, cytotoxicity mediated by perforin was not playing a major role in 
fl cell destruction, but Fas-induced apoptosis could have been the major fl cell killing mech-
anism (369). 
Normal islet cells do not express Fas (434-436), but normal fl cells do express FasL 
constitutively as shown by Western blot (434). This situation seems to differ ti"om that in 
rodents, where FasL expression is reportedly absent from the endocrine pancreas under nor-
mal circumstances. However, immunohistochemical studies also failed to detcct FasL 
expression in humans (214,436). IL-l increases Fas-expression and apoptosis in normal f3 
cells stimulated by anti-Fas. Normally, anti-Fas does not induce apoptosis because of a lack 
of Fas-expression of normal fl cells (214,434,435). It has been suggested that a selective 
expression ofFas in fl cells, primed by IL-Ifl-induced NO, may be responsible for their spe-
cific killing as T cells expressing FusL may promote an MHC unrestricted destruction of 
Fas+ byst~nder fl cells, while sparing neighboring Fas- a and 1\ cells (214). Thus, after ill 
vitro cytokine treatment, human islet cells are primed to undergo apoptosis by the simulta-
neous presence of both Fas and FasL. In vivo, a clear correlation has been fOllnd between 
Fas-expression and insulitis in biopsy specimens of recent onset typel diabetes patients, sug-
gesting that inflammatOlY cylokines secreted by islet-intlltrating cells induce Fas expression 
on endocrine cells (436). In one diabetes patient, extensive apoptosis among Fas+ B cells 
located in proximity to FasL-expressing T lymphocytes infiltrating the islets was observed 
(2 14). However, another study described 6 patients with Fas + j3 cells and FasL + T eells, with 
no evidence of islet cell apoptosis (436). It h~s been suggested that this absence of apopto-
sis can be explained by the velY short term of completion of apoptosis. 
In conclusion, in some human diabetes patients FaslFasL-induced apoptosis may be 
involved in B cell death. In NOD mice, Fas/FasL interactions are probably not crucial for dia-
betes development, whereas these interactions have not been studied in the DB rat. The 
mechanisms of f3 cell destruction, as observed in animalmodeis, may therefore not be rep-
resentative for all human patients. In humans, functional Fas expression is induced on B cells 
by NO. In contrast, NO has no effect on either a Fas expression or Fas-mediated apoptosis 
of NOD mouse islet cells. This suggests a species ditference in the effects of cytokines and 
cell-death-inducing agents on islet cells. 
Besides CD8+ T cell-mediated cytotoxicity, CD4+ T cells or products ofT cells and 
M<j>, such as IL-l, TNF and IFN-y, appear to play the main role in fl cell destruction. It 
should, however, be realized that cytokine-induced islet cell destruction is not selective for 
fl eells, but involves other endocrine islet cells as well (437). 
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Cytoldnes and free radicals are major ~ cell destructive weapons 
TNF-a, IL-l and IFN-y are important cytokincs for 13 cell destruction. Evidence for an 
ill vivo role of both TNF and IL-l comes from a study in identical twins of diabetes patients. 
In twins who subsequently developed diabetes, levels of circulating TNF -a and IL-I a are ele-
vated above the normal range more frequently than in those who do not (438). In newly diag-
nosed type I diabetes patients, an increase ofTNF-a (438-442), IL-Ia (438) and IFN-y (438) 
plasma levels can be observed. Further evidence supporting an ill vivo role for IFN-y comes 
li'om the detection oflFN-y in diabetes autopsy pancreases (365,443). 
In vitro shldies suggest a mechanism by which these cytokines can cooperate. IL-l is 
cytotoxic to B cells in cultured human islets (332,334,437), an effect that can be amplilied by 
adding TNF-a (444) and/or IFN-y (437). It is suggested that resident islet M<j>, activated by 
inflammatory stimuli such as cytokincs and cellular damage, may inflict (3 cell damage by 
releasing IL-\ in human islets (445). 
The role of NO in ~ cellMdestruction during human diabetes development has not been 
resolved yet. Several studies support a role for NO in cytokine-mediated fl cell destruction. 
Cultured human islets are susceptible to the destl1lctive effects DfNO (341,446). In addition, 
cytokine-induced changes in j3 cell function can be inhibited by iNOS inhibitors (445,447). 
In contrast, other studies suggest that cytokine-induced NO production in human islet 
cells may be neither necessary nor sufficient to destroy islet fl cells. Cytokine-indueed j3 cell 
destruction independent of NO has been described (434,448-451). Moreover, eytokine-
induced iNOS expression and nitrite formation that ,,,ere not associated with eft-eets on the 
function of cultured human islets have been observed (450,451). Therefore, other mediators 
of cytotoxic cytokine effects on human islets are also involved. As is the case for BB rats and 
NOD mice, oxygen free radicals may playa role. 
The role of NO in cytokine-indueed j3 cell damage has been compared with that of 
oxygen free radicals in one ill vitro study (448). The combination of IL-lf3, TNF-a and 
IFN-y induces significant increases in malondialdehyde (MDA), an end product of lipid per-
oxidation, and nitrite, and significant decreases in insulin and DNA in islets. These changes 
can be inhibited by an antioxidant but not by the iNOS-inhibitor L-NMA, although the latter 
does prevent cytokineMinduced nitrite production. These results suggest that cytokines may be 
toxic to human islet j3 cells by inducing oxygen free radicals, which cause lipid peroxidation 
and aldehyde production in the islets (448). Indications for a role for oxidative damage to 
13 cells in vivo have also been found. The total plasma antioxidant status is significantly low-
ered in ICA + subjects when compared to both ICA- and healthy subjects, while no signilicant 
difference is found between ICA + subjects and recently diagnosed diabetes patients (452). In 
conclusion, oxygen tl-ee radicals can also mediate eytokineMillduced j1 cell destruction. 
In summary, the same cytokines, IL-l, TNF-a and IFN-y, afe suggested to be impli-
cated in ~ cell death in human islets and in NOD mice and BB rats. They may work via the 
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induction of NO production or oxygen free radicals. However, in vilro cytokine-induced 
iNOS expression in human islet cells differs !l'om that in rodent islet cells. \Vhile iNOS 
mRNA and NO production is induced by IL-l~ alone in rodent insulin-producing celis, a 
combination of two (IL- I Band IFN-y) or three (+ TNF-a) c)10kines is required for iN OS 
activation in human pancreatic islets (453). Moreover, addition of cytokine combinations to 
isolated rodent islets can lead to the destruction of j3 cells within 24h (454,455); in human 
islet cell preparations, the cytotoxic effect is first noticed after more than 3 days of exposure 
(451). Thus, rodent islet cells appear more sensitive to cytokine-induced !3 cell destruction 
than human islet cells. 
Ultimate B cell death: apoptosis 01' nccrosis? 
The final question is whether human p cell death is achieved via necrosis or apopto-
sis. The fact that cytokines (IL- I fl,TNF-o,IFN-y) exert fl cell cytotoxicity iii vitro by induc-
ing apoptosis fitvors the latter option (434,451). One ill situ study reported an extensive apop-
tosis among Fas + j) cells located in proximity to FasL expressing T lymphocytes intiltrating 
the islets (214). 
In addition to apoptosis, necrosis may also occur in some cases. In vitro, p cell dam-
age caused by peroxynitrite occurs via necrosis (446). In a diabe,tes autopsy pancreas, no 
apoptotic cells were observed by EM (93), although this may be due to the low frequency of 
apoptotic cells in a disease with a long pre-clinical period. In conclusion, both j) cell apop-
tosis and necrosis may be involved in human type I diabetes. 
The highway to type 1 diabetes in humans 
The summalY of the pathogenesis of type 1 diabetes in humans is somewhat more 
complicated than in NOD mice and BB rats, since virtually nothing is known about the early 
events responsible for the initiation of insulitis. Viral infections are not likely to cause acute-
onset diabetes, but may result in subclinical j3 cell damage, that could trigger autoimmunity. 
In recent-onset diabetes, an expression of IFN-u by islet cells can be found, which may trig-
ger an immune response. The subsequent extravasation of leukocytes into the pancreas leads 
to the formation of pancreatic HEV and the upregulation of adhesion molecules on vascular 
and endocrine cells. 
Accumulated lymphocytes consist of both T and B cells; especially the amount of B 
cells varies beh'leen patients. It is not likely that B cells are major B cell destructors by means 
of autoantibody production. The predominant T cell within the inflltrates is CDS+. The evi-
dence suggests that CD4+ T cells initially produce Th I and Th2 cytokines. A shift to Th I 
cytokines takes place in conjunction \'lith the appearance of destructive insulitis. This transi-
tion may be related to the presence oflL-12. I'vfHC class I hyperexpression on islet cells can 
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make them easy targets for CDS+ T cell cytotoxicity. It is not likely that this hyperexpression 
is entirely the result of cytokines (notably IFN-y) produced by infiltrating cells, as it may well 
be present before the initiation of insulitis. These same kinetics apply to the expression of 
intra-islet MHC class 11, although it has not been convincingly shown that endocrine cells arc 
the source of intra-islet MHC class II expression. 
Final B cell destruction involves both CDS+ T cells, using FasL and perforin to induce 
cytolysis, and CD4+ T cells in conjunction ,,,ith 1\1$. The !vl<P products involved in the latter 
mechanism include TNF, IL-I, IPN-y, NO and oxygen fi'ce radicals, The major effector mech-
anisms may differ between individuals. Both apoptosis and necrosis lead to tinal ~ cell death. 
Comparing human and animal diabetes pathogenesis 
Tn contrast to experimental animals, human type I diabetes patients are heterogeneous 
with regard to genetics and environmental factors influencing diabetes development. It can 
thus be argued that each of these animal diabetes models represents a small subgroup of type 
t diabetes patients. However, with regard to the pathogenesis of the disease, the NOD mouse 
and the BB rat exhibit remarkable similarities. It is conceivable that the etiology of autoim-
mune diabetes development may be different between these experimental animals, but the 
mechanisms leading to disease are comparable. The same may apply for type 1 diabetes 
developing in humans: although the calise of the disease may differ between individual 
patients and between patients and animals, the routes leading to disease are remarkably sim-
ilar. Therefore, \ve will discuss a bird's-eye view of diabetes pathogenesis, and the exceptions 
found in humans and experimental animals. Figure 3 represents a putative general scheme for 
the pathogenesis of type 1 diabetes and its animal model, based on the evidence provided in 
this review. 
The initiation of insulitis is dependent on the influx into the pancreas and/or homing 
to the islet periphery of DC and M$ in both NOD mouse and BB rat. In humans, this may be 
similar, but this is difficult to prove. The reason for this initial accumulation of potential APC 
is not known, but has been suggested to be related to the presence of IFN-a in both humans 
and BB rats, but not in NOD mice. In both humans and BB rats, it is highly unlikely that this 
IFN-a expression is caused by viral infection. Tn these early phases, CDS+ T cells are also 
required tor the expansion of autoreactive CD4+ T cells in both NOD mice and BB rats. 
Early infiltrating APC presumably pick up antigens in the pancreas to present them in 
the pancreas draining lymph nodes to lymphocytes. In this antigen presentation, B cells 
appear to playa crucial role in the NOD mouse but not in the BB rat, although it should be 
realized that the role of B cells has been more extensively studied in the fonner than in the 
latter. Leukocytes enter the pancreas via several difterent adhesion molecule pairs. 
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Figure 3: Putative general scheme for the pathogenesis of type 1 diabetes and its animal models. 
In both animal models and human diabetes, T cells playa crucial role in the expan-
sion of the insulitis. These T cells in animal and human diabetes initially produce both Th2 
and Thl cytokines. As soon as they lose their capability to produce Th2 cytokines, the infil-
trates become destructive for f3 cells. In this conversion to destruction, the APC-derived 
cytokinc IL-I2 plays a role in humans, BB rats and NOD mice, In NOD mice, IL-IS is also 
important; the role of this cytokinc is not studied yet in BB rats and human type 1 diabetes 
patients. 
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In both animal and human diabetes, MHC class I overexpression on endocrine cells is 
seen, Endocrine 1vIHC class TI expression is 110t present in the BB rat and the NOD mouse, 
while the source of intra-islet IvfHC class II expression in human type I diabetes patients has 
not been convincingly determined. MHC (over)exprcssion may facilitate {3 cell killing. 
Final I' cell destl1lction can follow differcnt pathways, partly dependent on the dia-
betes model. Autoantibodies appear not to be pathogenic in animal models, although they 
may be in some patients. Direct cytotoxicity by CD4+ T cells is also not likely to playa role 
in the majority oflhe cases. The major destruction mechanisms in animal and human diabetes 
are direct cytotoxicity by CD8+ T cells and CD4+/M<j> DTH reactions resuiting in local pro-
duction of IL-I! TNF and IFN-y. Pore-forming rnolecules sllch as perforin arc involved in 
CDS+ T cell-mediated cytotoxicity in NOD mice, BB rats and human diabetes patients. Pas 
seems not essential in B cell killing in the NOD mouse, but Illay be involved in some human 
patients. In hUlllans, functional Fas expression is induced on B cells by NO. In contrast, NO 
has no effect on either Fas expression or Fas-mediated apoptosis of NOD mouse islet cells. 
This suggests a species difference in the effects of cytokines and cell-death-inducing agents 
on islet cells. 
Cytokine-mediated ~ cell destruction in human and animal diabetes probably involves 
the production of NO and oxygen radicals by B cells themselves andlor the infiltrating intlam-
matory cells, in particular activated Mcp. However, rodent islet cells appear to be more sensi-
tive to cytokine-induced f~ cell destruction than human islet celis, III vUro studies on islet 
death should, however, be interpreted with caution, The fact that cytokines are able to kill 
f3 cells, does not mean that they are also achwlly important in 13 cell killing in vivo. Moreover, 
the normal islets used in these in vitro shldies may not be representative for the responses of 
islets that are already aficcted by an inflammatory process. The final B cell death occurs most 
likely via apoptosis, but necrosis may also be involved. 
Diabetes research today faces major challenges, \Vith the increasing incidence of type 
diabetes, the need for prevention strategies also increases. More knowledge about the initi-
ation phase of diabetes is essential for prevention of the disease. Moreover, the possibility to 
identifY individuals at risk for diabetes obliges us to search for strategies to inhibit an ongo-
ing, but not yet fully developed pathology. Therefore, knowledge of the development of 
insulitis and the initiation of destruction is essential and should be expanded. Finally, the ulti-
mate goal of diabetes research is to cure those that are already affected. For this purpose, 
a 13 cell could possibly be engineered that is resistant to recurrent diabetes and can thus be 
transplanted into diabetic patients. In this case, it is essential to have a thorough knowledge 
of the relevance of the possible killing strategies in order to prevent them. Experimental ani-
mals, in particular the BB rat and the NOD mouse, are useful to study prevention! but essen-
tial to investigate potential abrogation and reversal of developing human type I diabetes. 
In 1901, Opie was the first one to note a connection between damage to the islets of 
Langerhans and the development of diabetes. Almost 100 years later, the exaet mechanisms 
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that cause islet damage have started to be unraveled, mainly because of the use of cxperi~ 
mental animals. Insight into these mechanisms is of major importance for diabetes research. 
In Qur opinion, a continued eff011 of parallcl research into human and experimental animal 
diabetes eventually will bring cure for this disease to reality. 
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Chapter 1.2 
The immune system has evolved to protect the body against a multitude of harmful 
intruders. At the same time, an effective immune response to the own body is blocked; we are 
self-tolerant. Two important mechanisms deal with T cell tolerance, Central tolerance induc-
tion during T cell development in the thymus ensures the deletion of autoreactive T cells. 
Peripheral tolerance induction ensures that potentially self-reactive T ceils, which escaped 
central deletion, are not harmful to the body. However, T cell tolerance induction sometimes 
fails, as is the case in T cellmcdiated autoimmune diseases. Type I diabetes mellitus (type 1 
diabetes) is a classical example of a T cell mediated autoimmune disease. Several aberrations 
in immune regulation, which may have consequences for tolerance induction, have been 
described in both human diabetes patients and in animal models for autoimmune diabetes. In 
this review, we summarize how proposed immune defects may be implicated in the loss of 
T cell tolerance towards self in human and animal autoimmune diabetes, in particular in the 
NOD mOllse and the BB rat. For this purpose, we will discuss the tolerance-inducing mech-
anisms that an autoreactive T cell should encounter from is genesis to its pathogenesis in 
order of appearance. 
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Central tolerance 
Central T cell tolerance is effectuated during thymic development of T cells. The spe-
cialized environment of the thymus ensures that a lIseful, non-damaging repertoire of T cells 
is generated from 8M-derived pro-thymocytes. For this purpose, the entire spectrum of T 
cells is selected for those cells recognizing peptides in the context of MHC with suftleient 
aftinity (positive selection) but with limited aftinity for selt~peptidcs associated with MHC 
molecules (negative selection). Classically, it is thought that the cortical epithelial network 
mediates positive selection whereas HtvI-derived DC and epithelial cells in the thymic medul-
la playa role in the deletion process of negative selection. Thus, the question arises whether 
dysfunctional T cell selection in the thymus plays a role in the development of autoimmune 
diabetes. Indeed, several defccts in central tolerance induction have been found to be associ-
ated with diabetes development (Table I). 
Tllblc 1: Defects that might hamper Ilositiyc and ncgntivc sel('ction during centnl! tolcrance induction in 
NOD mice (l\1, DB rllts (B) and humans (II) (for rcferences see text). 
Positive selection 
Negative selection 
Thymic epithelium 
Selection-hi as towards 
high-affinity CD4+ T 
cells because of poor 
peptide binding of dia-
betes-associated MHC 
class II haplotypes (N, 
H) 
lack of positive selec-
tion of regulatory T 
cells (N) 
disturbed reticulum 
structure with loss of 
corticoll1cdullary junc-
tion that is essential for 
negative selection (N) 
large reticulum-free 
areas without j'vfHC 
hamper negative selec-
tion (N,B) 
lack of negative selec-
tion of autoreacliYe 
CD4+ T cells related 10 
diabetes-associa ted 
j"fHC class II haplo-
type (N) 
ThymicAPC 
defects in antigen 
degradation lead to 
suboptimal antigen 
processing (N,H) 
lack of negative selec-
tion of autoreactive 
T cells related to dia-
betes-associated MHC 
haplotype (N) 
Thymoc)1es 
hyporesponsiveness to 
TCR-stimulation leads 
to disturbed tolerance 
induction (N) 
disturbed apoplosis 
induction (N) 
genetic link towards 
a poptosis-associa ted 
molecules (II) 
increased apoptosis 
rate (B) 
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Positive selection in the thymus of diabetes-prone individuals biases for high nftinity T 
cells nnd n Inck of l'egulntol'Y T cells 
The purpose of positive selection is to generate a T cell repertoire that is able to rec-
ognize antigenic peptides in the context of self-MHC. Positive selection depends on the lym-
phostromal interaction of developing thymocytes with the thymic cortical epithelial stroma. 
In this process, the newly rearranged TCR complex expressed on devcloping CD4+CDS+ 
thymocytcs interacts with MHC expressed on cortical thymic epithelium (TE), 
It has been shown thai TE has a crucial role in the development of diabetes. Grafting 
of puritled TE li·om NOD embtyos to newborn C57BLl6 nude mice results in the 
development of insulitis (I). Thus, T cell education by the NOD thymic epithelium is sum-
cient to induce autoimmune infiltration in the pancreas of normal mice. Given that epitheli-
um has a unique function in mediating positive selection that can not be mediated by bone 
marrow-derived cells, such as DC (2), these findings suggest that an anomaly in thymic pos-
itive selection ofT cells contributes to diabetes development in NOD mice. The exact identi-
ty of this anomaly in thymic positive selection is at present unktlO\vn. Since grafted TE 
appears to induce tolerance in allogeneic recipients because it selects for regulatory CD4+ 
T cells (3), it has been suggested that NOD TE fails to select an appropriate repelioire ofrcg-
ulatory T cells. This aberrant function of the NOD TE may relate to unique diabetes-associ-
ated MHC molecules, which genes are the primary genetic components that determine sus-
ceptibility to diabetes in both humans and experimental animals. A possible role for :MHC 
expressed on TE in the hampered positive selection of regulatory T cells has been studied by 
making NOD mice diabetes-resistant by the transgenic expression of a protective MHC class 
II haplotype. These studies indicate that protective MHC class 11 alleles may indeed act 
through positive selection of regulatory T cells (4,5). Thus, TE expressing diabetes-associat-
ed MHC molecules may fail to positively select regulatOlY T cells. 
In addition to this lack of selcction of regulatory T cells, diabctcs-associated MHC 
class II molecules expressed on TE may induce positive selection that is biased towards high-
affinity T cells. Diabetes-associated MHC class II molecules have special features compared 
to protective ones; the most obvious one is the expression of a non-Asp amino acid at posi-
tion 57 of the ~ chain. Approximately 85-90% of type I diabetes patients under the age of 17 
is homozygous for expression of the DQll 57 non-Asp haplotype; susceptibility is also asso-
ciated with a lack of Asp at position 57 in the DRIJ chain (6). Similarly, NOD mice are 
homozygous for a non-Asp amino acid, serine, at position 57 of the p chain of the murine 
counterpart of DQ, I_Ag7 (7). NotelVorthy, the requirement of a non-Asp amino acid at 
B chain position 57 for diabetes development is not observed in the BB rat. However, also in 
the BB rat, an essential role in the development of diabetes has been found for genes map-
ping to the MHC class II region of the RTlu haplotype (8). Studies iu NOD mice have iudi-
cated that diabetes-associated MHC haplotypes may positively select for high-aftinity T cells. 
The diabetes-associated MHC class II haplotypes I-Ag7 in NOD mice (9) aud HLA-DQ3.2 
in humans (10) appear to bind peptides with low avidity. Results of several groups suggest 
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that unstable I_Ag7 -peptide complexes produce an effectively decreased density of MHC-
peptide complexes on thymic APC. This reduced MHC class 11 expression would positively 
select for a population of T cells with high TCR affinity to attain the avidity threshold 
required in thymic positive selection (II). 
In sUllllllmy\ NOD TE expressing diabetes-associated :tvIHC molecules positively 
selects for a T cell repertoire with a bias towards high-aftlnity T cells and a lack of regulato-
ry T cells. 
Negative selection in the thymus of diabetes-prone individuals results in a high fre-
quency of 3utoreactive T cells, due to all abenllnt organization ofTE, antigen process-
ing defects and thymocyte apoptosis defects 
The purpose of negative selection is to generate a repertoire ofT cell specificities that 
lacks autoreactive cells. In this process, TCR on developing T cells interact with MHC-pep-
tide complexes on TE and/or BM-derived APC, resulting in the deletion of self-reactive 
T cells. 
BM-derived APC, in pal1icular thymic medulla!)' DC, play an imp0l1ant role in the 
negative selection process. Several defects in the function of BM-derived APC have been 
found in human and animal diabetes, as will be discllssed further in this review. It is often 
sllggested that these defects may impair thymic negative selection of high affInity T cells. 
However, it should be realized that it is not clear to which extent adult peripheral blood mono-
cyte-derived DC functionally mirror thymic DC. In fact, the composition of the thymic APC 
popUlation differs li'OIl} that of peripheral BM-derived APC (12). Apart from BM-derived 
APC, medullary TE can mediate clonal deletion and thus negative selection. Major defects 
have been tound in thymic stroma in animal diabetes. In NOD mice, the normal structure of 
the thymus is disturbed, since subtypes of epithelial cells that are normally restricted to the 
mednlla are found in the NOD thymic cortex as well (13). Repositioning of medullary epithe-
lial cells may implicate that T cells are undergoing negative selection processes at an abnor-
mal stage ofT cell development. This aberrant timing ofT cell education may result in a loss 
of tolerance, since the choice between tolerance and immunity depends on the state of differ-
entiation of the lymphocyte at the time it encounters its cognate antigen (14). Disorganization 
of the thymic epithelium also leads to the loss of the corticomedullaty junction prior to the 
development of diabetes (15). The corticomedullary junction is thought to represent the 
anatomic location of negative selection and, as a consequence, disturbances in this region 
may hamper negative selection (15). In addition, large reticulum-free areas are found in thy-
muses of both NOD mice and BB rats; these areas are devoid of epithelial cells and MHC 
expression (13,16-18). Interestingly, the size of reticulum-free areas is larger in thymi of dia-
betes-prone BB rats compared to thymi of diabetes-resistant BB rats (17). Studies using trans-
genic, chimeric and KO mice have shown that tolcrization of autoreactive thymocytes 
requires appropriate expression of MHC moleculcs by medullmy stromal cells (15). Since 
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optimal anatomical organization of thymic medullary stroma with an appropriate expression 
ofMHC molecules is required for tolerance induction, the described aberrations in TE organ~ 
izatioll may predispose to the development of autoimmunity. 
Besides their disturbed thymic expression, the structure of diabetes~associated MHC 
molecules in itself may affect negative selection processes. Studies lIsing NOD mice double 
transgenic for an l_Ag7 -restricted diabetogenic TCR and a diabetes-resistant MHC class II 
haplotype indicate that protective MHC alleles may act through negative selection of autore-
active T cells (19), Moreover, additional diftcrcnces are present bet\veen protective and sus-
ceptible MHC class II alleles. Peptide-binding studies indicate that susceptible MHC class" 
molecules present different epitopes of the major autoantigen GAD65 to T cells compared to 
resistant MHC class II molecules (20). Cross-immunization experiments lIsing peptides 
revealed that the protective GAD-epitopes were immunogenic in animals with slisceptible 
alleles. However) a panel of epitope-spccific I-Ag? restricted T cell hybridomas obtained 
from these animals respond only to GAD65 peptide, but not to the whole protein, suggesting 
that antigen processing differences exist between mice with different MHC class II alleles 
(20). In summary, unique diabetes-associated MHC class II molecules may fail to mediate 
deletion of autoreactive CD4+ T cells. 
Antigen processing defects have been suggested to ailect the negative selection of 
autoreactive CDS+ T cells. These defects involve the MHC-linked genes Tap 1 and Tap2, both 
of which encode proteins that contribute to MHC class I processing (21-23). H'owever, also 
defects in the function of tile proteasome may affect antigen processing and MHC class I pres-
entation in NOD mice and human type 1 diabetes patients. In general, two major forms of the 
protcasome exist: the standard proteasome, consisting of the catalytic subunits B I, (32 and f}5, 
and the immunoproteasome, consisting of the subunits LMP2 (I> 1 i), MECL I (j)2i) and LMI'7 
(J15i). Iml11ulloproteasomes are induced by IFN-y and may be constitutively expressed in 
mature DC (24). The iml11ul1oprotcasol11c is more efficient than the standard proteasomc in 
processing a number of antigenic peptides (25). Leukocytes of humans \'lith type 1 diabetes 
and NOD mice appear to be disturbed in the production of the LMP2 Il subunit of the 
inUl1Ulloproteasome (21,23,26). The reduced LMP2 activity is associated with an altered sub-
strate specitlcity ofillll11Ulloproteasomes (21)3). In the thymus, the reduced LMP2 activity 
may thus directly interfere with the preparation of peptides for MHC class 1 education of 
CDS+ T cells, and both the NOD mouse and diabetic human exhibit partial ablation of this 
pathway (27). Thus, defects in the expression of proteins involved in antigen processing, snch 
as Tap t, Tap2 and LMP2, may result in an inappropriate preparation of peptides for MHC 
class I-mediated education and thus in an inadequate negative selection of CD8+ T cells. 
Finally, defects in the thymocytes themselves contribute to an inadequate negative 
selection in the thymus. Negative selection in diabetes-prone animals appears to be hampered 
by both hyporesponsiveness of thymocytes npon TCR stimulation, and by impaired apopto-
sis induction in thYlllocytes. Thymocytes from NOD mice respond weakly to anti-CD3-
induced proliferation, compared with thymocytes tI-om several control mice (28). Defective 
TCR-l1lediated cell death in activated NOD thymocytes appears to be associated with a block 
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in Ras activation and defective signaling along the PKC/Ras/MAPK pathway (29). The block 
in Ras activation is accompanied proximally by an impaired recruitment ofTCR-CD3-~-asso­
ciated tyrosine kinase ZAP70 to membrane-bound TCRl; (30). Interestingly, this impaired 
membrane-recruitment of ZAP70 may have implications for apoptosis induction, since both 
TCR~ and membrane-localized ZAP-70 arc required for the upreguiation of FasL. 
Accordingly, T cells that display impaired recruitment of ZAP-70 in the plasma membrane 
\"ill be unable to undergo Fas-mediated apoptosis and negative selection will be impaired 
(31), Thus, aberrations in the TCR-signaling patlnvay in NOD mice may impair apoptosis 
induction during negative selection. 
Several studies indicate that apoptosis defects are indeed present in NOD mice and 
human diabetes patients. Functionally, NOD thymocytes exhibit a genetically determined 
resistance to the induction of apoptosis by a variety of stimuli (32-34). This may be related to 
an upregulation of the anti-apoptotic protein Bcl-x on NOD thymocytes (34). The contribu-
tion of defects in thymocyte apoptosis induction to the loss of tolerance during human dia-
betes development is hard to test experimentally. However, genetic studies indicate a role for 
apoptosis-relatcd molecules in human diabetes development. The apoptosis-associated mole-
cule Fas-associated death domain protein (FADD)/MORTI is candidate for diabetes suscep-
tibility region IDDM4 (35) and CTLA-4 for IDDM 12 (36). It is conceivable that these genet-
ic defec"ts may influence thymic negative selection. In contrast to humans and NOD mice, 
thymocytes in BB rats display an increased apoptosis rate, resulting in a profound deficiency 
in peripheral T cells (37-39). Analysis of peripheral lymphocyte populations in thymus and 
BM chimeras revealed that the abnormal BB thymus is not responsible for the inll11unodeti-
ciency, but that the lymphopenia delect resides within the lymphocyte precursor pool (40). 
The increased death rate in BB thymocytes is at least in part the result of the ~)llJ1phopelli(l 
(!l'p) mutation, although also other genes in the BB rat appear to be involved (39). 
In summary, negative selection in diabetes-prone individuals is hampered by defects 
in all participating cells. The organization of the TE is disturbed, and large areas devoid of 
MHC expression can be found in animals prone to develop diabetes. The role of defects in 
thymic bone matTmv-derived APC clearly deserves further attention. Furthermore, the unique 
diabetes-associated MHC class II molecules may fail to negatively select autoreactive CD4+ 
T cells. Meanwhile, abnormalities in proteins involved in MHC class I processing negative-
ly affect the preparation of peptides for the clonal deletion of autoreactive CDS+ T cells. 
Finally, defects in thymocytes themselves contributing to inadequate negative selection 
include both hyporesponsiveness of thymocytes upon TCR stimulation and impaired apopto-
sis induction in thymocytes. The impaired negative selection in the thymus likely results in a 
high frequency of auto reactive T cells in the periphery. NOD mice indeed contain a high num-
ber of autoreactive T cells in the periphel)" as has been demonstrated by the possibility to 
break peripheral tolerance to self-pep tides (41) and by limiting dilution assays (42). This 
increased frequency of autoreactive peripheral T cells may strongly interfere with peripheral 
tolerance, since one of the major factors that reverses indifference and leads to autoimmuni-
ty is an increase in the frequency of auto reactive T cells (14). 
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Peripheral tolerance 
The outcome of central tolerance induction in diabetes-prone individuals is a T cell 
repertoire that is skewed tmvards high-affinity Hutoreactive T cells. Peripheral tolerance 
mechanisms should prevent activation of these cells in the periphery. However, several mech-
anisms operative in peripheral tolerance induction show defects that further contribute to the 
loss of self-tolerance leading to diabetes development. These defects include a hampered 
induction of activation-induced cell death (AI CD), resistance towards cytokine withdrawal 
death and a fUllctional deticiency of regulatory T cells (sulllmarized in Table 2). 
Tahle 2: Defects thnt 11111)' hamper ntet'luHlisms of peri ph ern I tolerance induction in NOD mice (N), BB rats 
(ll) find humans (ll) (for refcrcncl's see text). 
AICD 
C}10kine withdrawal death 
Regulatory T cells 
Pcripheral APC 
Immature APC with antigen 
processing dejects resuit in poor 
T cell stimulation, thus hamper-
ing AICD (N,B,H) 
Constitutive PGS2 expression 
leads to inhibition ofT cell IL-2 
signailrnnstiuelion (N,B,H) 
Aberrant APC maturation 
results in poor stimulation of 
regulatory T cells (N,B,H) 
Abscncc of l-E shins Thl/Th2 
c}1okinc balnncc in direction of 
Thl (N) 
Tcells 
TCl{ signaling defects may 
result in disturbed apoplosis 
indw.:tion (N,H) 
T cells abcmmtly survive sevcre 
IL-2 deprivation (N,H) 
Absence of regulatory NKT 
cells in poor stimulation of reg-
ulatory (N,B,H) 
Lyp mutation resuits in abscnce 
of regulatory RT6+ T cells (8) 
AICD: severely hampered by a combination of constitutive APC PGS2 expression and 
T cell apoptosis defccts 
AICD is the result of the interaction between peripheral APC and T cells. AICD is 
achieved upon APC-mediated TCR stimulation accompanied by simultaneous ligation of 
death receptors such as Fas and other TNF receptor family members (43). 
APC defects may predispose to autoimmunity through quantitative reduction in sig-
tis required forAICD, since activation-driven T cell death requires quantitatively more stim-
ulation than antigen-driven T cell proliferation (44). Several studies suggest that APC in dia-
betes-prone individuals may be unable to fulfill the T cell stimulation requirements for AICD. 
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An aberrant M<r and DC maturation, putatively resulting in an impaired APC function, is 
associated with diabetes in NOD mice, BB rats and humans. NOD BM-derived progenitor 
cells of granulocytes and ll1onocytes proliferate poorly in response to several myeloid growth 
factors, including IL-3, GM-CSF and IL-5 as compared to progenitor cells derived from nor-
ma! mice (26,45,46). Several studies suggest that these defects in myelopoiesis in NOD mice 
may impair both Mq, (45-48) and DC (49) maturation, The immaturity of splenic DC freshly 
isolated from BB rats is evidenced phenotypically by a low MHC class II and CD80 expres-
sion and fUllctionally by a relatively high phagocytic activity as well as poor T cell stimula-
tion capacity (50). Also human diabetes patients and high-risk relatives show disturbances in 
APC maturation as they have an impaired yield and function of blood monocyte-derived DC 
(51,52), Moreover, expression of CD80 mld CD86, but not HLA-DR, is decreased on DC 
li'om high-risk relatives of type I diabetes patients (51), Thus, it appears that Mq, and DC mat-
uration is disturbed in human type 1 diabetes as well as its animal models. The observed APC 
immaturity might hamper AICD, since immature APC have been recognized as relative poor 
T cell stimulators as compared to mahlre and activated APC (53,54). 
Several studies suggest that also other feahlres of APC in diabetes-prone individuals 
may interfere with the relatively high APC stimulus that is required for AICD, A decreased 
ability to process antigens can contribute to less effective antigen presentation. NOD mouse 
splenic M<jl have a lmver concentration of intracellular glutathione compared to diabetes-
resistant NOR mice. Since glutathione is involved in the degradation of antigens, these low 
levels result in less eiJicient processing and lower levels ofT cell activation (55). The lack of 
immllnoproteasomes in diabetes-prone individuals, discussed before, may further contribute 
to impaired processing and thus to suboptimal T cell activation and the lack of AleD. In sum-
mary, various types of antigen processing defects in APC probably disturb the induction of 
ATCD because these defects result in a SUboptimal T cell stimulation. 
In addition to maturational abnormalities and antigen processing defects, an aberrant 
constitutive prostaglandin synthase 2 (POS2) expression in APC may influence AICD induc-
tion in human diabetes patients, BB rats and NOD mice. rVfifJ f}'om NOD mice and BB rats are 
able to produce high levels of immullosuppressive factors, such as prostaglandins (PO) and 
leukotriens (56,57). Constitutive expression of the normally inducible enzyme POS2 in MifJ 
leads to an enhanced prostanoid metabolism in female NOD mice (58). A similar aberrant 
constitutive expression of PGS2 is found in monocytes of patients with type 1 diabetes and 
humans at increased risk of developing diabetes (58), and thus seems to be a general phe-
nomenon occurring during diabetes development. The aberrant POS2 expression that is found 
during diabetes development may directly hamper AICD, since PG are able to suppress T cell 
TL-2 signal transduction \vhich is, in tUI'Il, critical for the activation of T cells and thus for 
AICD (58), These findings suggest that a constitutive PGS2 expression and in consequence a 
high PO production in APC of diabetes-prone individuals hampers AICD via an inhibition of 
T cell IL-2 signaling, 
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AICD may also be disturbed due to abnormalities in signal-transduction pathways in 
the T cells themselves. Patterns of unresponsiveness and decreased cytokine secretion have 
been observed in anti-TCRlCD3-activated NOD peripheral T cells, similar to what was found 
in NOD thymocytes (59). If peripheral T cells show the same signaling defects as described 
for thymocytes, these defects may result in the same apoptosis disturbances. In line ,vith this, 
NOD peripheral lymphocytes have been found to exhibit a genetically determined resistance 
to the induction of apoptosis by several stimuli (32,34,60-63). Accordingly, these T cells are 
relatively resistant to undergo AleD. Also in recent onset diabetes patients, a defect in the sig-
nal transduction pathway of the TcR/CD3 complex was shown, resulting in ineflective PKC 
activation and an abnormal lL-2 production and proliferation of diabetic T cells (64). Thus, 
similar to the signaling defects described in NOD mice, human TCR signaling defects may 
hamper apoptosis induction during AlCD. Because of the important role ofFas in AICD, it is 
worth noting here that the apoptosis-associated molecule Fas-associated death domain protein 
(FADD)/MORTI is candidate for the human diabetes susceptibility region IDDM4 (35), and 
that the expression ofFas is highly impaired on leukocytes li'om type 1 diabetes patients (65). 
Together, these data indicate that AICD-mediated peripheral tolerance induction in 
diabetes-prone individuals is affected at the APC side by immature PGS2-expressing APC 
with antigen processing defects, resulting in suboptimal stimulation ofT cells. At the T cell 
side, TCR signaling defects and a resistance to apoptosis induction further contribute to the 
hampered AICD. 
Cytoldne vi'ithdrawal death: NOD and human activated T cells sUl'vive severe IL-2 dep-
rivation 
Cytokine withdrmval death may serve to remove the expanded population of lympho-
cytes after an antigen has been cleared successfully during a regular immune response (43). 
It may thus prevent autoimmune destruction caused by bystander-activation of autoreactive T 
cells. This tolerance mechanism also is afiected, as activated T cells from human diabetes 
patients require 20-100 times less IL-2 than normal T cells to escape apoptosis, and thus sur-
vive severe IL-2 deprivation (66). Similarly. activated lymphocytes from NOD mice exhibit 
a similarly increased resistance to apoptosis following IL-2 ,vithdrawal associated ,vith an 
upregulation of the anti-apoptotic Bcl-x protein in activated T cells (34). Takcn together, the 
increased resistance of lymphocytes in diabetes-prone individuals to apoptosis induced by 
growth factor withdra,val facilitates the survival of emerging autoreactive clones. 
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Regulatory T cells: Absence of certain regulatory T cell subsets, whereas innnature I-E-
AI'C rail to stimulate other regulatory T cell subsets 
Regulatory T cells control autoreactivc T cells that have escaped both central and 
peripheral tolerance induction mechanisms, Since diabetes in humans and NOD mice is 
thought to be mediated primarily by Th 1 cells, regulatory T cells include those cells that are 
able to downregulate autoreactive Th I cells. This fUllctional definition implies that regulato-
ry T cells may have various appearances (67). 
Deficiencies ill certain regulatory T cell subsets, including NKT cells and RT6+ 
T cells, arc associated with diabetes development in humans and animals. As already men-
tioned BB rats have a general deficiency in peripheral T cells due to the /yp mutation. This 
deficiency especially affects the establishment of the regulatory RT6+ T cell population (39). 
Another regulatOlY T cell subset, NKT cells, appears to be functionally deficient in NOD 
mice, BB rats and humans type I diabetes patients (68-72). NKT cells may be the main pro-
ducers of IL-4 upon initial stimulation (73). It has been postulated that the functional defi-
ciency ofNKT cells in the NOD mOllse leads to an impairment in Th2 cell function, result-
ing in a strongly polarized Th I phenotype (74,75). Indeed, the diabetes-protection induced by 
transfer ofNKT-enriched thymocytes in NOD mice can be neutralised by anti- IL-4 and anti-
IL-IO monoclonal antibodies in vivo, indicating a role for Th2 cytokines in NKT cell-J11edi~ 
ated protection (76). Arguing against a decisive role for the lack of regulatory NKT cells in 
disease induction are findings in Vcd4 TCR transgenic NOD mice. These mice carry a large 
number of peripheral NKT cells, but are only p",tially protected against diabetes (75). Thus, 
a functional defect in NKT cells most likely explains the lack of protection (72). 
In conclusion, celiain regulatory T cell subsets are (functionally) deficient during dia-
betes development. Other regulatory T cell subsets may not exert their suppressive actions 
because of an insufficient stimulation by APC. As already mentioned APC in human diabetes 
patients, BB rats and NOD mice have maturational detects. Immatme APC have been recog-
nized as relatively poor T cell stimulators as compared with mature and activated APC 
(53,54). Since the stimulation of iml1lunoreglllatory T cells requires a more activated APC 
than the activation of eHector T cells, immature APC may be unahle to activate rcgulatOlY 
T cells (77). The immature APC present in NOD mice, BB rats and human diabetes patients 
may thus be unable to activate regulatory T cells and induce peripheral tolerance. Indeed, the 
stimulation of regulatory T cells as measured in the autologous or syngeneic MLR in both 
human and animal diabetes is disturbed. Proliferation in the autologolls MLR is reduced in at 
least a subset of diabetes patients in all human studies (51,52,78-85) and to a lesser extent in 
healthy siblings that are at risk to develop diabetes (51,83). Also in BB rats (40) and NOD 
mice (48,86), the syngeneic MLR, which is the equivalent of the autologous MLR, is dis-
turbed. The reduced aceessOlY cell function in the IvlLR in NOD mice has been regarded as 
a reduced stimulation of regulatory T cells. The BB rat is an excellent model to study putaw 
tive functional defects of DC in relation to a detective suppressor/regulatory T cell expansion, 
since this popUlation ofT cells specifically expresses specific markers (such as RT6, CD8 and 
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low levels of CD45RC antigens) (87,88). By lIsing these markers, it has been shown that 
splenic DC from DP-BB induced expansion of different subsets ofrcgulatory T cells ill vitro 
as compared \vith those from MHC-identical \Vistar rats (50). In conclusion, the immaturity 
of APe present in NOD mice, BB rats and human diabetes patients affects the stimulation of 
regulatOlY T cells. 
The disturbed autologous or syngeneic MLR can be the result of the already described 
maturation defects in the DC lineages in diabetes-prone individuals. However, animal studies 
suggest that also defects in M<f> function may be involved in the disturbed MLR. In contrast 
to earlier studies, it has recently been described that the NOD syngeneic T cell proliferation 
in the MLR is not decreased, but significantly prolonged (63). The prolonged MLR response 
was observed using isolated splenic DC as stimulator cells, while earlier studies found defec-
tive MLR responses using unseparated splcnocytes as stimulator cells. This suggests that 
other splenic cells contribute to the depressed MLR observed in earlier studies. Likely candi-
dates are M<jl, as the already mentioned high PG production by M<jl of diabetcs-prone indi-
viduals leads to a high suppressive activity of 1v14>, inhibiting DC function in the syngeneic 
MLR. 
An insufficient stimulation of regulatory T cells may thus be the consequence of mat-
urational defects in the APC lineages in human and animal diabetes. Studies in the NOD 
mouse indicate that also altered expression levels of MHC molecules 011 peripheral APC con-
tribute to the absence of regulatOlY T cells during diabetes development. \Ve already dis-
cussed the unique NfHC class Il-I-Ag7 and the implications for central tolerance induction 
earlier in this review. J\1HC class lI-l-E molecules, or more specifically their absence in NOD 
mice, appear to be involved in the lack ofregulatOly T cells that are responsible for the main-
tenance of peripheral tolerance. NOD mice fail to express J\1HC I-E molecules due to a dele-
tion of the first exon of the En gene (R9). The absence ofI-E is required for diabetes patho-
genesis, since NOD mice transgenic for the wild type I-En gene fail to develop diabetes 
(90,91). Results from transgenic mice with I-E deficiency in specific components of the 
immune system have indicated that the protection mediated by expression ofI-E is not due to 
negative selection of autoreactive T cells in the thymus (91). Chimeric NOD mice trans-
planted with a I-E-expressing NOD thymus and regular NOD BM still develop disease, sug-
gesting that the absence of I-E in the thymus of NOD mice is not essential for diabetes 
development (92). The protection against diabetes in NOD-E mice, that express I-E on both 
thymus and BM-derived cells, suggests that regulatOlY cells function normally in the periph-
elY ofNOD-E mice (92). The absence of I-E expression on peripheral APC in regular NOD 
mice may facilitate diabetes development by altering the balance ofTh 1 versus Th2 cytokines 
produced by B cell-autoreactive T cells (93). Quantitative differences in I-E expression on 
peripheral APC that correlate \vith complete versus partial diabetes resistance in different I-E 
transgenic lines also correlate with the extent to which these lines activate IL-4-producing 
T cell responses to GAD65 (93). Although these results obtained for GAD65 should be con-
tinned llsing other antigens, it appears that the absence ofI-E on NOD peripheral APC may 
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skew the immune response towards a destructive Th 1 phenotype, lacking the balance of reg-
ulatoty Th2 cells. 
In summary, the function of regulatOlY T cells in the downregulation of autoreactive 
Thl cells is disturbed during diabetes development. Some of the regulatory T cells subsets, 
including RT6+ T cells in BB rats and NKT cells in NOD mice, BB rats and humans, arc func-
tionally deficient. Other regulatory T cell subsets arc not stimulated because of an immaturi-
ty of diabetic APC or because of the absence ofI-E expression on peripheral APC. 
Conclusion 
Tn both animal and human diabetes, many different aberrations in tolerance induction 
have been found. Some arc specifically occurring in the BB rat, the NOD mouse or humans, 
others are shared by all (see Tables 1 and 2). In positive selection during central tolerance 
induction, two major problems can be distinguished. First, a bias exists towards the selection 
of high-amnity CD4+ T cells, because of poor peptide-binding capacities of diabetes-associ-
ated MHC class II haplotypes. Second, these haplotypes are associated with a poor positive 
selection of regulatOlY T cells. Thus, the net result of positive selection is a population of 
high-affinity T cells that is partly deficient in regui,ltory T cells. Subsequently, disturbances 
in negative selection contribute to hampered central tolerance induction. First, the structure 
of the thymic stroma is disturbed, hampering negative selection at the appropriate time point 
in thymocyte selection. Second, diabetes-associated "tvlliC class II haplotypes do not ade-
quately delete autoreactive CD4+ T cells. Third, antigen processing defects cause an inefti-
eient MHC class I antigen presentation and therefore cause an inadequate deletion of autore-
active CDR+ T cells. Fourth, thymocytes themselves have major defects in apoptosis induc-
tion. Negative selection thus ends with a relatively high frequency of autoreactive T cells. 
Taken together, a T cell repertoire enriched for autoreactive high-affinity T cells is released 
into the periphelY after the inadequate central tolerance induction. 
Defective peripheral tolerance mechanisms provide additional problems for the main-
tenance of self-tolerance. The impaired APC-mediated T cell stimulation in conjunction with 
the constitutive APC PGS2 expression hamper AICD, whereas also TCR signaling and apop-
tosis defects appear to be involved in the suboptimal function of this peripheral tolerance 
mechanism. Autoreactive T cells, once they have been activated, survive severe IL-2 depri-
vation and thus bypass cytokine withdrmval death. Finally, the suppressive actions of regula-
tory T cells are affected by the absence of certain regulatory T cell subsets and the failure of 
APC to stimulate those regulatory T cells that arc present. Thus, the high-affinity autoreac-
tive T cells that reached the periphery do not die uJlon activation because of a disturbed AICD 
and a resistancc to cytokine deprivation and will not be suppressed in their functions because 
of an absence of regulatOlY T cells. The obvious end result of this defective tolerance induc-
tion is the development of autoimmunity. 
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In this review, we have sllmmarized many problems that T cells encounter during their 
education in diabetes-prone humans and animals. Knowing that stromal cells in the thymus 
act as teachers and developing thymocytes as students, \ve could state that underqualified 
teachers tty to teach unresponsive students about \vhat these students should or should not do. 
This obviously disturbed T cell education underlies the development of the T cell-mediated 
autoimmune disease diabetes in humans, BB rats and NOD mice. 
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Aim and outline of this thesis 
In the previous chapters, it has become clear that type 1 diabetes in humans and its ani-
mal models are multifactorial diseases, in which several genes and environmental factors are 
involved. In Chapter 1.1, the pathophysiology leading to diabetes in humans and animals has 
been revic\ved. The exact etiology of the disease, however, remains unclear. In Chapter 1.2, 
several immune defects have been described that predispose NOD mice, BB rats and humans 
to the development of autoimmunity. The immune defects in diabetes-prone individuals, how-
ever, are not specific for diabetes. Many of these defects can also be found in other autoim-
mune diseases. Thus, defects only in the immune system can not explain \vhy the f3 cells in 
the pancreatic islets of Langerhans are the main target of the autoimmune reaction during diaw 
betes development, whereas most other organs are spared. In fact, the presence of islelwreacw 
tive T cells is not unique to NOD mice; slleh cells have also been demonstrated in nonw 
autoimlllune prone mOllse strains. Thus, the lack of immunological tolerance cannot be the 
only cause of diabetes. 
In this thesis, we approach the hypothesis that abnormalities in the function and/or 
phenotype of the f3 cells in the islets of Langerhans render them susceptible for the autoim-
mllne attack. Thus, according to this hypothesis, the target organ itself determines the organ-
specificity of the autoimmune disease. \Ve follow a two-hit-model: in addition to a suscepti-
bility in the immune system that predisposes to the loss oftolerance in general, a susceptibil-
ity of the target organ is needed for organ-specific autoimmunity. In this study, we are espe-
cially interested in the interaction between target organ and nonwlymphoid cells, since the lat-
ter have been shown to playa role in both the immune and the endocrine system. Moreover, 
they are the first cells to appear in the inflammatory lesion. The NOD mouse was chosen for 
these studies, since the pathogenic process in this mouse bears many resemblances to the 
pathogenesis of human type I diabetes. 
\Ve first studied the identity of subtypes of non-lymphoid cells in pancreatic inflam-
matory infiltrates in NOD mice in which kinetically different pathogenic processcs occur 
(Chapter 2.1). In this study, we correlated the presence of specific subtypes of myeloid cells 
with aggressiveness ofthe lesion. \Ve next searched for abnormalities in the function and phe-
notype of the islets, which could potentially trigger the initial infiltration with non-lymphoid 
cells. \Ve found that NOD mice have an enhanced perccntage of abnormally large islets, des-
ignated 'mega-islets' (Chapter 3. I). J mportantly, the tirst infiltrating inflammatOlY APC are 
preferentially associated with these mega-islets. Moreover, we determined that the formation 
of these mega-islets, with concomitant infiltration, is especially pronounced in diabetes-prone 
NOD females and orchidectomized NOD males as compared to diabetes-resistant NOD males 
(Chapter 3.2). Thus, the kinetics of formation of mega-islets correlate with the development 
of disease. 
In search of the possible causes of mega-islet formation, a hyperinsulinemia was found 
that preceded islet hypertrophy. Islet hypertrophy could thus be the consequence of an 
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increased demand on the B cells that could not be fullllled by the available numbers. The 
hyperinsulinell1ia, in turn, Jllay be related to metabolic abnormalities that NOD mice experi-
cnce during their develoment in utero (Chapter 3,3), However, also infiltrating cells may con-
tribute to the hyperinsulinemia, since this correlates in time with the start of islet infiltration 
with APC. Cultures of isolated islets of Lallgerhans and isolated DC showed that infiltrating 
DC are indeed able to influence B cell activity (Chapter 3.4). Furthermore, the hyperinsu-
linemia may also partly be triggered by a hyperglucagonemia (Chapter 3.5). The association 
ofhyperinsulinemia with hyperglucagonemia suggests a generic abnormality in islet function. 
This is possibly related to ontogenetic deviation, since we find evidence for an abnormality 
in islet development in NOD mice (Chapter 3.5). 
The presence of f3 cell abnormalities in nconatal NOD mice may suggest that these 
early islet abnormalities are involved in the triggering of the organ-specific autoimmunity, 
However, although em'lier reports assume that autoimmune intiltration starts after weaning 
(i.e. at 3 weeks of age), an early influx of inflammatory cells can already be recognized in 
neonatal mice (Chapter 3.6). 
In conclusion, ,ve found evidence for severa I abnormalities in the islets of Langerhalls 
that potcntially trigger the organ-specificity of diabetes in the NOD mOllSC, Taking these find-
'ings into account, we discuss the putative etiology of NOD diabetes and present a hypothet-
ical scenario for the pathogenesis of the disease (Chapter 4, I), Furthermore, we discuss the 
implications of these findings for human type 1 diabetes. 
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Chapter 2.1 
Summary 
Islet~specific T cells arc essential in the development of autoimunc diabetes. The role 
of non-lymphoid cells is relatively unclear, although infiltration of dendritic cells and 
macrophages is the first sign of islet autoimmunity in diabetes-prone llonobese diabetic 
(NOD) mice. BDC2.5 is one of the autoreactive T cell clones isolated from NOD mice. 
Transfer of BDC2,5 T cells into young NOD mice accelerates diabetes development, where-
as transgenic expression of the BDC2.5 T cell receptor on NOD T cells (BDC2.5 TCR-Tg 
NOD) markedly reduces diabetes development. 
\Ve 8hm\' that, although the same antigen-specificity is involved, both models differ 
signiticantly in insulitis. BDC2.5 TCR-Tg NOD mice develop an extensive, but non-aggres-
sive, peri-insulitis by 3 weeks of age. In these large peri-islet infiltrates, resembling second-
ary lymphoid tissue, BMS+ macrophages (Mcp) are virtually absent. In contrast, BDC2.5 T 
cell clone transfer results in an aggressive insulitis ''lith small infiltrates, but relatively large 
numbers of BM8+ M.p. Infiltration of BMS+ Mcp therefore correlates with islet destl'llction. 
This is, however, not observed for all M<p; f\1ontsA+ M<P follow a reverse pattern and are 
present in higher numbers in BDC2.5 TCR-Tg than in transferred mice. ER-MP23+ Mcp are 
reduced in both transferred and transgenic mice compared ''lith wild-type NOD. 
Thus, this ShIdy underlines and extends previous data suggesting that MCP are impli-
cated in both early and late phases in diabetes development. Furthermore, our data imply that 
subsets of non-lymphoid cells have difierent roles in diabetes development. It is, therefore, 
important to recognize this heterogeneity when interpreting both in vivo and in vitro studies 
concerning non-lymphoid cells in diabetes. 
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Introduction 
Type I (insulin-dependent) diabetes mellitus (type I diabetes) is the result of an 
autoimmune destruction of the t1 cells in the islets of Langer hans (1). The disease is charac-
terized by a vety long pre-clinical period. In this period, several types of leukocytes accumu-
late first around the islets (a process called peri-insulitis) and subsequently infiltrate into the 
islets (insulitis). It is only when the vast majority of pancreatic fl cells are destroyed that the 
alteration of glucose-linked metabolism generates the classical signs of diabetes. The exten-
sive pre-clinical period provides a tool for prediction and prevention of the disease. 
To study the development of type 1 diabetes, animal models such as the nonobese dia-
betic (NOD) mouse and the BioBreeding (BB) rat have been employed. In both models, the 
first sign of islet autoimmunity is an accumulation of antigen-presenting cells (APC) around 
and in the islets (2,3). These APC include various types of dendritic cells (DC) and 
macrophagcs (111</». DC and M<j> arc characterized in the NOD mouse by markers such as 
CDllc, ER-MP23 and MO~'IA-I (3) and in the BB rat by MHC class II and EDI, but absence 
of acid phosphatase (2). The exact role of the difterent subtypes of myeloid cells is not 
known. Early infiltrating DC and accessory M$ are thought to pick up relevant autoantigens 
and to migrate to the draining lymph nodes to present the islet antigens in the paracOIiicai area 
to recirculating lymphocytes. B cells (4) and CD8+ T cells (5) are probably also important in 
these very early phases of the insulitis process, but these cells occur only at relatively low fre-
quencies. In time, the phase of peri-islet accumulation ofAPC is followed by a reaction of the 
draining lymph nodes and an accumulation of Band T lymphocytes around the islets, the lat-
ter in close apposition to the already aecumulated APC (3). Thc actual fl ccll killing is histo-
logically characterized by an infiltration into the islets of M$, whereas COg+ T cells (5) are 
also seen to infiltrate the islet. The histopathological picture of infiltration with scavenger 
type M$ is compatible with the view that 13 cell killing is at least in part a Thl phenomenon 
(6,7), where T cell-derived cytokines such as interteron-y activate .M$. 
In the destruction of the ~ cells, T cells are crucial. From the NOD mOllse, several 
islet-specific diabetogenic T cell clones have been isolated. One of these is the CD4+ T cell 
clone BDC2.5 (8), reactive to an as-yet unknown antigen localized on the membrane of the 
jj cell granule (9). Its in vitro eytokinc prottle is consistent with the phenotype of a Thl cell 
(10) and the clolle is able to transfer insulitis and diabetes to young NOD mice (11). Although 
the transterred insulitis is characterized by a relatively small lymphocyte infiltration, a rapid 
progression to diabetcs (within 2 to 3 weeks) is observed (II). 
Furthermore, a mouse model has been developed based 011 the transgenic (Tg) expres-
sion of the rearranged T cell receptor (TCR) genes from the BDC2.5 T cell clone on a NOD 
background (12). In contrast to the wild-type NOD, this TCR-transgenic NOD model is char-
acterized by an extensive lymphocyte infiltration frorn 3 "weeks of age onwards. Hmvever, the 
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diabetes incidence ofBDC2.5 TCR-Tg mice on the full NOD genetic background is strong-
ly reduced, compared \'lith wild-type NOD mice. 
Despite the use of the same diabetogenic TCR in both BDC2.5 models, different kinet-
ics of disease development are observed in these mice. \Ve asked whether these kinetic dif-
ferences could be related to differences in the presence of non-lymphoid cell subtypes, and 
thus if these models could provide us with the opportunity to study the role of subtypes of 
non-lymphoid cells in diabetes development. Therefore, we have analyzed the pancreatic 
int11tration of various subsets of DC (CDllc+, NLDC-145~, M<j> (BMS+, Monts-4+, 
ER-MP23+), T cells (CD4+, CDS+) and B cells (B220+) in both the BDC2.5 T cell clone 
transfer and the BDC2.5 TCR-transgenic (BDC2.5 TCR-Tg) NOD model. 
Results 
Pancreatic histopathology of BDC2.5 TCR-Tg NOD mice as compared with wild-type 
NOD mice 
The sequence of histopathological events preceding diabetes in wild type NOD mice 
is described in Table I, 
Table 1: hl.~ulitis in wild-l}l)(' NOD mice, 
stage 0: 
stage I (wk 3): 
stage II (wk 4-7): 
stage III (wk 7-10): 
stagc IV (week 10-17): 
stagc V (> wk 17): 
stage VI (» 17 wk): 
InIac! islet as observed in non-diabetes prone micc 
Intact islet, but an increase in perivascular and peridudular extracellular matrix and 
a perivascular increase orCDllc+, ER-i\,lP23+, i\'IO;'\'1A-I+ <I11d Bi\.'IS+ rvIq, and DC 
Islet surrounded by DC <Illd Iv14 with above-mentioned phenotypes; infiltration of islets 
by CDllc+ DC; a major intiltration by lymphocytes is still abscnt 
Paminsular recruitment of substantial numbers of CD4+ and CD8+ T lymphocytes and 
some B lymphocytes to the accumulation of DC and i\ltP 
Lymphocytes surrollnd the islet {peri-in suI it is) 
Lymphocytes and ER-i\'IP23+ and B/I .. a;+ i'vItjl infiltrate the islet 
Endstage; no insulin-producing cclls detectablc 
A representative infiltrate in a female NOD mouse is shown in Figure 1. In wild type 
NOD mice. CD lie + DC and ER-MP23+ M<jJ were the first intlammatoty cells appearing at 
the circumference of the islets at 4 to 7 weeks (3). The influx of these cells was substantial in 
the early phases, \vhereas only a few T cells (if any) were present at this stage, Thereafter, 
a slmvly increasing recruitment ofT cells and of APC was observed. 
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Figure 1: Iml11UllOhistoiogic<li characterizatioll of a representative insulitis (0 to f; originuimagnificution, x200) and 
of a relatively rare lymphoid tissue-type of peri-insulitis (g and h; original magnification, x45) in a female 15-week-
old NOD mouse. (a) Anti-insulin staining, showing the B cell mass; (b) COlIc, showing peri- and intra-islet accu-
I1mlation of these DC; (c and d) CD3 (T cells) and B220 (B cells), respectively. Nute that lymphocytes initially accu-
mulate around the islet (peri-insulitis); e) ER-!\,lP23, showing that histiocytcs accumulate at the islet-edge; (t) BlvfS, 
showing a peri-and intra-islet accumulation of these 1\01$; (g and h) CD3 (T cells) and R220 (13 cells), respectively. 
Note the high grade of organization as normally found in secondary lymphoid tissues and in the fiDC2.S TCR-Tg 
NOD mouse. 
In the BDC2.5 TCR-Tg NOD, however, both APC and lymphocytes were recmited at 
the same time. From about 3 ''leeks of age onwards, both APC and lymphocytes were pres-
ent in substantial numbers at the edge of the islets, and large peri-insulitis arcas were evident. 
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Figure 2: Immunohistological characterization ora representative peri-islet lymphoid cell accumulation in a BDC2.5 
TCR-Tg female NOD mouse, 4 weeks old. Original magnification x90. (a) Anti-insulin staining, showing the posi-
tion orthe j3 ccllmtlss; (b) CDllc, showing the accumulation orne at the islet-edge and in between the accumu-
lated lymphocytes; (c and d) CD3 (T cells) and B220 (B cells) respectively, showing the high grade oi'orgal1izalion 
of the accumulated peri-islet lymphocytes in separate T- and B cell areas reminisccnt of secondary lymphoid tissuc; 
(e) ERi'vfP-23, showing that histiocytcs, onc of the first types on.'f!f! accumulating at the islet-edge in ,,,ild-type NOD 
insulitis, can be found only in smallnumbcrs at the pcriphery of the secondary lymphoid tissue; (t) BTVfS, showing 
the conspicuous absence of scavenger type ivl!f!' similar to the situation seen in secondary lymphoid tissues; (g) 
Monts-4, showing that the lymphocyte peri-islet accumulation contains ~\'lonts-4+ i'vf!f! nonnaHy seen in secondary 
lymphoid tissucs; (h) ER-11P 12, sllOwing endothelial cells, particularly HEV (arrow) and lymphatics (astcrisk) dHlr-
acteristic of the secondary lymphoid tissue nature oflhe peri-islet lymphoid cell accumulations. 
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Moreover, the number ofER-MP23+ M$ was either strongly decreased or they were 
absent from the islets (Fig. 2e), In the phase of peri-in suI it is, we observed again clear dift-er-
ences between the BDC2.5 TCR-Tg NOD and the wild-type NOD. From 3 wecks of age, the 
large peri-insular infiltrates stayed velY pronounced in the BDC2.5 TCR-Tg NOD, until the 
end of our observation time. Tn wild-type NOD, however, well-developed peri-insular infil-
trates containing substantial numbers of lymphocytes could not be seen before the age of 
9 weeks (3). In the BDC2.5 TCR-Tg NOD, massive lymphocyte intiltrates were clearly larg-
er than the ones found in the wild-type NOD (Fig. 2), although the islet itself was not affect-
ed. The large lymphocyte infiltrates found in the transgenic animals had a high degree of 
organization. Band T lymphocytes were localized in separate areas (Fig. 2, c and d) within 
the infiltrate. As expected in an MHC class]] restricted TCR transgenic mouse, the l' cell 
illtiltrate consisted primarily of CD4+ T cells (results not shown). DC were found in all com~ 
partments of the intlammatory intiltrate (Fig. 2b), but especially at the interface of intact 
11 cells and the l' cell infiltrate (Fig. 2b). Moreover, two DC populations, characterized by 
CD 11 c and NLDC-145, were only partially overlapping. CD II c + DC were seen accumulat-
ed at the border of the l' eell intIltrate and intact p cells, and were hardly present in the l' cell 
area or in the islet mass (fig. 2b). NLDC-145+ DC were also found at the B celVT cell bor-
der) but ~ in contrast to CDllc+ DC ~ were also present intermingled with T cells and in the 
islet mass (13). In addition, high endothelial venules (HEV) as well as lymph vessels could 
be found in the l' lymphocyte peri-insular areas (Fig. 2h). The peri-insular infiltrates of the 
BDC2.5 TCR-Tg NOD mouse thus histologically resemble secondary lymphoid tissue, espe-
cially mucosa-associated lymphoid tissue (cg, Peyer's patchcs). The tlnding ofMonts-4+ M<jJ, 
normally present mainly in lymphatic tissue (14), is in agreement with this (Fig. 2g). 
Occasionally, this lymphatic tissue adjacent to islets was also found in advanced stages in 
wild-type NOD mice (Fig. I, g and h), although the majority of NOD islets had a peri-insllli-
tis with a non~characteristic architecture. Infiltration of leukocytes into the islets themselves 
was hardly observed in BDC2.5 TCR-Tg mice. 
In wild~type NOD mice, destructive insulitis was histologically characterized by an 
early infiltration of BMS+ M<jJ into the islets starting at 7 to 10 weeks. This infiltration of 
HMS+ MCP into the islets was especially pronounced in diabetes~prone female NOD mice, and 
\vas considerably less in male NOD mice that show a lower diabetes incidence. Destructive 
insulitis involving the influx of lymphocytes into the islet Illass occurred from 15 weeks 
onwards. In contrast to the regular NOD insulitis) BMS+ NICP were virtually absent in the 
BDC2.5 TCR transgenic NOD infiltrates, especially in later stages of infiltration (Fig. 21). 
Tn summary, BDC2.5 TCR~ Tg NOD mice developed extensive infiltrates resembling 
secondalY lymphoid tissue, with a virtual absence of BM8+ M<jJ. Although the intiltrates 
developed early and were extensive, they did not lead to fl cell destruction. 
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Pancreatic histopathology of BDC2.5 T cell clone transfel" as compared with wild-type 
NOD mice 
In young (14 days) NOD mice receiving transfers of the BDC2.5 T cell clone, a very 
fast and aggressive insulitis \vas observed, Almost 110 insulinwproducing cells could be detect-
ed at 10 days after the transfer. In relation to this, no sequential accumulation of APC and 
lymphocytes was observed. Only a velY limited accumulation of ER-:MP23+ M<p, which in 
wild-type NOD are among the first to surround the islets. was found (Fig. 3e). In contrast, 
there \vas an increased accumulation of CD 11 C + DC, simultaneously with an accumulation of 
lymphocytes (Fig. 3b). 
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Figure 3: Immunohistological characterization of a representative insulitis in a female NOD mouse (3 weeks old) 
transferred with the BDC2,5 T cell clone (10 days aftcr thc first transfer), Original nmgnitkation x360. (a) Anti-
insulin staining, showing the p cell mass; (b) CDllc, showing a relatively cnhanced accumulation of DC al the islet 
edge as compared with wild-type NOD insulitis; (e and d) CD3 (T cells) and B220 (B cells) respectively, Note that 
there is hardly any peri-insulitis, but a relatively small intiltratioll of single cel!s as compared with the wild-type 
NOD and certainly as compared with the BDC2.5 TCR-Tg NOD; (e) ER-I\,tP23, showing that histiocytes accumu-
late at the islet-cdge like in the wild-type NOD insulitis; (f) mv[S, showing an enhanced peri-and intra-islet accu-
mulation of these 1' ... 1$, 
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Compared with wild-type NOD mice and certainly to BDC2,5 TCR-Tg mice, the 
accumulation of lymphocytes ncar the islets was minor. In the exocrine pancreas, few Band 
T cells were found. B cells were especially present around the islets, and a few were also infil-
trating the islets (Fig, 3d), T cells (Fig, 3c) consisted of both CD4+ and CD8+ cells; using 
iml11l1llot1uorcscent staining on isolated peri-islet T cells it has previollsly been determined 
that CD4+ T cells appeared in larger numbers as compared with CDS+ T cells (K, Haskins, 
personal communication). Infiltrates in BDC2.5 T cell clone transferred mice did not show 
any degree of histological organization. In addition, only limited numbers of Monts-4+ Mcp 
were found (not shmvn), 
The most conspicuous observation in the BDC2.5 T cell clone-transferred mice was 
the strong and early infiltration with BMX+ scavenger type Met> around the islets and into the 
islet mass (Fig. 31). BMS+ M$ were also seen scattered throughout the exocrine pancreas. 
This highly increased involvement of BMS+ M$ contrasted the almost complete absence of 
such M<j> in the BDC2,5 TCR-Tg NOD inflammatory infIltrates, Also in the wild-type NOD 
insulitis, BMS+ M$ although infiltrating the islets, were found in significantly lower numbers 
compared with the tmnsfer model, especially in male but also in female mice, 
In summary, BDC2.5 T cell clone-transferred NOD mice developed small unorganized 
infiltrates, with a high number ofBMS+ M<j>, These infiltrates appeared to be highly aggres-
sive, as evidenced by the rapid loss of fl cells, 
Discussion 
Our data show that the (peri-)insulitis in the BDC2.5 T cell clone transfer model, the 
BDC2,5 TCR-Tg NOD model, and the wild type NOD model follow distinct inullunohisto-
morphological patterns \vith different involvement of non-lymphoid cell types. In the trans-
fer model, a rapid destruction of the p cells is associated with a progressive but relatively mild 
lymphocyte infiltration, whereas compared with wild-type NOD there is an extensive infil-
tration with BMS+ M<j>, In contrast, the BDC2,5 TCR-Tg NOD model showed a very early 
development and a long-lasting presence of lymphoid tissue around otherwise intact islets, 
although there was a low incidence of diabetes. This lymphoid tisslle was characterized by 
T and B cell zones, specifk Monts-4+ lymph nodal M<j> and CDllc+ DC, the presence of 
HEV, but a conspicuous absence ofBMS+ M<j>, 
The BDC2,5 T cell clone transfer model and the BDC2.5 TCR-Tg model also shared 
some histopathological features that differed from the wild-typc NOD, The wild type NOD 
shmved an initial phase of peri-islet accumulation of DC and M$ but a viriual absence oflym-
phocyte inllltration, However, both BDC2,5 models showed a simultaneolls early peri-islet 
accumulation of APC and lymphocytes. 
These data reveal several interesting differences in the kinetics of insulitis in NOD 
mouse models. In the TCR-Tg and in the transfer model, there is no separate phase of APC 
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infiltration preceding lymphocyte infiltration, whereas this phase is present in wild-type 
NOD. The absence of a separate phase of APC accumulation indicates that the influx of lym-
phocytes takes place with accelerated kinetics in both BDC2.5 models. This acceleration of 
intiltration is most likely due to an increased frequency of autoreactive T cells in both 
BDC2.S models compared with wild-type NOD. Bccause of the relatively low ti'equency of 
islet-specific T cells in the initial na'ive T cell pool of the wild-type NOD, its islet antigcn-
loaded DC need to interact with many nai've T cells to encounter an islet antigcn-specific-
TCR. Such conditions arc initially most optimally met in the pancreas-draining lymph nodes 
because of the recirculation of T cells via lymph nodal HEY and a specific accumulation in 
these nodes of islet antigen-loaded DC via the afferent lymph. The likelihood of such an 
encounter is minimal in the early small T cell infiltrates around the wild-type NOD islet. In 
both the BDC2.S TCR-Tg and T cell clone transfer model, there are already many islet-spe-
cific T cells in the repertoire early in life. Th is increases the likelihood of a specific DC-T cell 
encounter at the islet-edge itself Therefore, a presentation of autoantigens in lymph nodes 
may not be required in both BDC2.S models, whereas it is obligatory in wild-type NOD for 
clonal expansion ofT cells. 
Accelerated infiltration, however, does not lead to 11 cell destruction in the BDC2.S 
TCR-Tg NOD. The large, non-destructive infiltrates observed in this model are also observed 
in other TCR-Tg mouse-models with the cognate antigen expressed under the insulin pro-
moter or only locally expressed in the thyroid (IS). Autoreactive T cells are not deleted in the 
thymus in these TCR-Tg mice because of a lack of systemic expression of the autoantigen. 
The large peri-insular infiltrates developing in such models also do not lead to actual destl1lc-
tion, since the autoreactive T cells present likely have an impaired function. This impaired 
function of autoreactive T cells is retlected in a change in the sensitivity to TCR stimulation 
leading to diminished in vitro responsiveness to antigen and poor in vivo ability to provide 
B cell help (IS). It remains to be determined whether the T cells in the BDC2.S TCR Tg NOD 
are similarly dysfunctional. An alternative and, in our vicw, a more likely explanation for the 
strongly reduced 11 cell destruction in BDC2.S TCR-Tg NOD may be found in the number of 
BMS+ M<jJ in the intlammatory infiltrate. These BMS+ M<j> are virtually absent in BDC2.S 
TCR-Tg NOD, whereas they are abundantly present in the transfer model. In the wild-type 
NOD, BMS+ M<I> infiltrate the islets in diabetes-prone females, but not in diabetes- (but not 
insulitis-) resistant males (3). Together, these data strongly suggest that BMS+ M<jJ are a his-
tologicalmarker of the progression from peri-insulitis to I) cell destruction and diabetes. 
Various roles for these BMS+ Mcp could be envisaged. They may playa role simply in 
removing the cellular debris resulting from the autoimmune inflammation. Alternatively, 
BMS+ M<jJ could be the ultimate effectors in the ~ cell killing, possibly stimulated by T cells. 
It is also possible that BMS+ MCP induce some minor ~ cell damage that - by viliue of 
enhanced antigen release - leads to antigenic spreading and a fmihcr local triggering of 
T cells. In that case, the peri-insular accumulated APC have a role in a final local T cell stim-
ulation of the infiltrated T cells. Such a mechanism is compatible with a two-step model for 
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the development ofautoiml11unity (16).111 the first step, initial priming ofislet-specitic T cells 
with antigen occlirs in the lymph node and results ill the accumulation of lymphocytes in the 
target organ. In the second step, rcstimulation in the target organ by tissue-localized APC 
causes the lymphocytes to become destructive and clinically evident autoimmunity occurs. In 
general, the necessity of local restimulation ofT cells for their final activation would protect 
other tissues fwm bystander-induced damage by T cells that are accidentally activated in 
other organs. The local microenvironment ,vauld then be an important determinant in APC 
function and thus in the ultimate outcome of the autoimmune infiltration. 
'Which factors could determine the dift-erentiat influx of BMS+ Mq, in transgenic and 
transfer models'? An important determinant may be an extremely high frequency of unacti-
vated BDC2.5 TCR-carrying T cells in the BDC2.5 TCR-Tg versus a mildly raised frequen-
cy of activated and mature BDC2.5 T cells in the transferred NOD mice. Also in other mod-
els, the frequency of aut ore active T cells has been shown to determine the fate of these cells 
(17). Another determinant may be an almost complete absence of CDS+ T celis, due to the 
MHC class II restricted TCR in the BDC2.5 TCR-Tg NOD mice compared with BDC2.5 
T cell clone-transferred and wild-type NOD mice. However, transfer of CDS+ T cells in 
BDC2.5 TCR-Tg mice did not accelerate disease (1S), making this possibility less likely. 
Alternatively, in the BDC2.5 TCR-Tg NOD mice, regulatory interactions between the trans-
genic T cells and B cells, or CD4+ T cells expressing endogenous TCRn chains, may serve 
to attenuate the activity of the transgenic T cells. This possibility is likely given that, if bred 
on a NODscidbackground, all of the BDC2.5 TCR-Tg mice develop diabetes by 3 to 5 weeks 
of age (19). In the BDC2.5 TCR-Tg NODscid, there is a very extensive early inliltration, 
which is rapidly follmved by full-blown diabetes. The infiltrate resembles pancreatitis and, in 
contrast to those observed in the BDC2.5 TCR-Tg NOD, is highly disorganized and invasive. 
The inliltrate comprises many CD4+VB4+ T cells, likely expressing the cognate BDC2.5 
TCR, and BMS+ Mq, with a lew ER-MP23+ Mq, scattered throughout. 
On the basis of the differential involvement of non-lymphoid cell subsets in the 
presently investigated BDC-2.5-TCR-based models, we suggest that subtypes of non-lym-
phoid cells play different roles in diabetes development. Clearly, this notion needs further 
experimental investigation to delineate the functions of the distinct subtypes. However, this 
heterogeneity should be recognized when interpreting in vivo and in vitro studies concerning 
the role of non-lymphoid cells in diabetes developnlent. 
Materials and methods 
Animals 
BDC2.5 TCR-Tg NOD mice and NOD mice used for T cell clone transler studies were 
bred and maintained in the animal facilities at the Barbara Davis Center and the School of 
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Medicine at the University of Colorado Health Sciences Center in Denver, Colorado. The 
incidence of diabetes in NOD/bdc mice is 50% to 60% in females and 30% to 40% in males 
by 28 weeks of age. In the Denver colony, the BDC2.5 TCR-Tg NOD monse incidence of 
diabetes is 10% to 15% for both female and male mice by 28 weeks of age, and is thus strong-
ly reduced compared with wild-type NOD mice. This was not the case with earlier back-
crosses ofBDe2.S TCR-Tg, which only showed an extended lag period between initiation of 
insulitis and onset of diabetes (12). We wish to emphasize that the mice in the present study 
were BDC2.5 TCR-Tg on a full NOD background 
BDC2.5 TCR-Tg NOD mice were killed at 3 to 4, 6 to 7, 12, or 16 weeks of age. For 
clone transfers, mice (12 to 13 days of age) received an injection of 107 T cells, ip, and a week 
later received a second injection, again 107 cells. Animals ,vere killed 3 days after the second 
injection. The cloning and maintenance ofthe BDC-2.5 T cell clone was previously described 
(8). Wild-type NOD mice were bred and kept at the facility of the Department of 
Immunology, Erasmus University in Rotterdam, The Netherlands. The incidence of diabetes 
in this colony is 80% to 90% in females and 50% to 60% in males by 30 weeks of age. 
Immunohistochemistry 
For each age, 5 mice ,vere killed by cervical dislocation, pancreases were removed, 
embedded in OCT compound and frozen on dry ice. Tissues were stored at -80°C until 
immunohistochemistry was performed. Before sectioning, microscope slides were coated 
with a solution of 0.1 % gelatin/O.O 1% chromium-alum. Pancreas cryostat sections of 6 ~lln 
were prepared, coded and fixed for 2 min in 2% pararosaniline (20). After a wash with phos-
phate buffered saline ,vith 0.1 % Tween-20 (Merck-Schuchardt, Hohenbrunn bei _Mi.inchen, 
Germany) (PBS/Tween), slides were incubated with first step antibodies (Table 2) for 30 min 
at room temperature. BM8 (BMA Bioll1edicals, Augst, Switzerland) was used diluted 1:30 in 
PBS/Tween, anti-insulin (DAKO, Carpinteria, California) was used diluted 1:100 in 
PBS/Tween. All others were supernatants from hybridomas cultured at our department and 
used undiluted. Subsequently, slides were washed with PBS/Tween and incubated with per-
oxidase-conjugated goat-a-hamster-immunoglobulins (Ig) (to detect N418), rabbit-a-guinea-
pig-Ig (to detect a-insulin) or rabbit-a-rat-Ig (to detect all others) second step antibodies in 
the presence of2% normal mouse serum for 30 min at room temperature. After an addition-
al wash with PBS/Tween, slides were incubated with 0.05% (w/v) Ni-di-amino-benzidine 
(Ni-DAB) with 0.02% H202 and washed in water after 3 min. Finally, slides were counter-
stained for 3 min in nuclear fast red, dehydrated in a graded ethanol series, and mounted. For 
each stai~ling run, one slide was stained with second antibody only as a control for endoge-
nous peroxidase activity and non-specific binding of the second step, and a section of spleen 
was included as a positive control. 
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Table 2: Antibodies used for inllllUllohistochenlical study (21) 
t\'Ionoclona[ Ah 
RA3.6il2 
BlvlS 
ER-i'vIP12 
ER-jI"fP23 
KTJ 
53-6.72 
rvlonts-4 
HJ29-J9 
N41S 
NLDC-145 
Polyelonal An 
n-insulin 
References 
Specificity 
CD45R-antigcn; I3220-antigen 
t\'l$ with phagoc)1osing capacity 
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Chapter 3, I 
Summary 
[n the nonobese diabetic (NOD) mouse model for type I diabctes mellitus, the intlam-
matory infiltration of islets starts with an influx of dendritic cells (DC) and macrophages 
(MCP) at about 4 weeks of age. Around this time, NOD mice show endocrine abnormalities, 
indicated by a transient hyperillsulinemia that lasts until 8 weeks of age. Subsequently, they 
develop abnormally large islets of Lallgerhans, here designated as "mega-islets". NODscid 
mice, which lack functional lymphocytes, also exhibit transient hyperillsulincmia, but to a 
lesser extent. 
First, to determine the role of lymphocytes in the morphological islet abnormalities, 
we compared 6-weck-old (prediabetic) NOD and NODscid females regarding mega-islet 
development and accumulation of antigen-presenting cells (A PC), particularly CD II c + DC 
and ERMP23+ 1Vfcp. In NODscid mice, early APe intiltration and mega-islets \vere present, 
but less marked compared to NOD mice, thus suggesting a role of lymphocytes in mega-islet 
formation. In both NOD and NODscid mice, the APC intiltration was predominantly found 
around the mega-islets, suggesting a relationship between both parameters. Second, to ana-
lyze the rolc of fl cell hyperactivity in mega-islet formation, we studied the effect of shOlt-
term prophylactic insulin treatment on these parameters. Prophylactic instllin treatment 
decreased the percentages of mega-islets in both NOD and NODscid mice, indicating that 
j3 cell hyperactivity is also involved in mega-islet formation. 
In conclusion, mega-islet formation in mice with the NOD genetic background takes 
place under influence of both j1 cell hyperactivity and leukocytes. 
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Introduction 
Type I (insulin-dependent) diabetes mellitus (type I diabetes) is a T cell mediated 
autoimmune disease, in which the insulin~producing cells in the islets of Lallgerhans are 
attacked and destroyed by infiltrating leukocytes (1-3). The disease is characterized by a long 
pre-clinical period: symptoms of diabetes only develop "when less than 1 0% of the f3 cell mass 
is left. During this pre-clinical period, variolls autoantibodies directed against p cell antigens, 
including insulin and GAD (4-6), are circulating. This pre-clinical period provides an oppor-
tunity for prediction and prevention, and therefore needs intensive study. 
The NOD mouse is a commonly used spontaneous model for type I diabetes (2). In 
this model, the first recognized sign of autoimmunity is infiltration of APC in and around pan-
creatic islets (7,8). These APC include DC as well as Mq,. CDIIc+ DC acculllulate in and 
around female NOD islets frolll 3-7 weeks of age onwards. Simultaneously, ER-MP23+ Mq" 
which are normally present in the connective tissue in the NOD pancreas, migrate to the 
periphery of the islets (8). This early acculllulation of cells (of which the majority is presum-
ably monocyte-derived) plays an essential role in the development of the insuiitis, since pre-
vention of the early influx ofmonocytes stops the process (9). Only afler this early (peri-)islet 
accumulation of DC and l\.II$, large numbers ofT and B lymphocytes are recruited to the site, 
i.e., in NOD females li'on1 the age of 7- I 0 weeks onwards. In the BioBreeding (BB) rat, 
another spontaneous animal model for type 1 diabetes, insulitis also starts with an accumula-
tion of APC (10). The trigger for the early accumulation of DC and M<P in the prediabetic pan-
creas is still unknown. 
Autoimmune diseases might be caused by aberrations in the function of the immune 
system as ,veIl as in the target gland (7,11). In the prediabetic NOD mouse, several changes 
in the function of the islets of Langerhans have been described. From 4 weeks of age, predi-
abetic NOD mice females show signs of islet hyperfunction as evidenced by higher basal 
blood insulin levels and a lower glycemia as compared to mice of several control strains 
(12,13). Glucose tolerance tests also showed a more rapid blood insulin peak and a faster drop 
in blood glucose levels in prediabetic NOD mice compared to controls. Evidence for an early 
islet abnormality also has a morphological basis, since we previously showed a higher fre-
quency of hyperplastic islets ("mega-islets))) in prediabetic NOD mice compared to non-dia-
betic control strains (14). 
The question thus arises in what manner endocrine islet abnormalities arc related to the 
development of autoimmunity. We asked whether an association exists between islet hyper-
plasia, as a morphological sign of islet abnormality, and the development of the inflammato-
ry infiltrate. To address this question, we compared the development of islet hyperplasia 
(mega-islet development) in NOD and NODsci</mice. The latter lack mature T and B cells 
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due to the scid mutation, and thus neither develop lymphocyte insulitis nor diabetes (15). If 
mega-islet development would be caused by intiitratiug lymphocytes, this hyperplasia would 
not be observed in NODscid mice. In order to detine the relationship bet\veen infiltrating cells 
and islet hyperplasia more specifically, we investigated a putative correlation between infil-
trates and islet size in both NOD and NODscid mice. Finally, we wondered whether the pre-
viously observed B cell hyperactivity in itselfplays a role in the formation of mega-islets. For 
this purpose, we used prophylactic insulin treatment that is kI10\vn to decrease insulitis and 
diabetes incidence in rodents (16). In vivo administration of insulin is known to down regu-
late endogenous insulin secretion (17-20), Prophylactic insulin treatment can thus be used as 
a tool to prevent the development ofB cell hyperactivity and to study mega-islet development 
in the absence of slich hyperactivity. However, prophylactic insulin also affects tolerance 
induction towards islet antigens (21). Therefore, we studied the effect of prophylactic insulin 
treatment on islet hyperplasia in NODsdd mice in addition to NOD mice. In this way, we 
exclude indirect etl'ects of prophylactic insulin treatment on islet hyperplasia via lympho-
cytes. The results indicated that both islet hyperactivity in itself and infiltrating lymphocytes 
appear to be involved in the observed mcga-islet formation. 
Results 
NOD and NODscif/mice both develop increased percentages of mcga-islets, but this phc-
nomenon is less prominent in the NODschlmousc 
To determine the kinetics of mega-islet development and the contribution of infiltrat-
ing cells, we first compared the development of islet sizes in NOD, NODsci" and C57BLlIO 
females at different ages (Fig. I). Nlega-islets ,vere defined as islets with an area of more than 
10000 pixels at a magnification of 100x. 
At S weeks of age, the percentage of mega-islets was similar in the three strains 
(around 10% of the islets). Between 5 and 10 weeks of age, NOD and NODscid females 
developed significantly increased numbers of mega-islets (i.e. between lS-20% of the islets), 
whereas, in CS7BL/IO mice, the percentage of mega-islets remained constant (Le., around 
10% of the islets) (p<0.05 for both NOD and NODscidvs. C57BLlI0). At IS weeks of age, 
NOD mice exhibited a further increase in the number of mega- islets, which reached over 
20% of total islets. In contrast, in NODscid mice, the percentage of mega-islets remained sim-
ilar between 10 and 20 weeks of age (around \5-20% of the islets) (p<0.05 for NOD vs. 
NODscid). In NOD mice over IS weeks of age, islet size could not be measured because of 
the presence of destl11ctive insulitis, a phenomenon that does not take place in NODscid mice, 
In conclusion, mega-islet formation takes place after S weeks of age in both NOD and 
NODscid mice and appears to correlates in time with the progression of infiltration. However, 
the phenomenon is less prominent in NODscid mice, suggesting a contribution of infiltrating 
lymphocytes to mega-islet formation. 
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Figure I: Development of mega-islets, as n function of age, in NOD, NODscid and C57BLlI 0 mice (11=5 mkl'lage 
group). Results are percentages ofjotaillumbcr of is/CIs from 5 mice ill each age-strain group. 
Initial infiltration of DC, i\'l<P and lymphocytes is predominantly associated with mega-
islets, but is less pronounced in NODscid mice 
Since the start of mega-islet formation correlated in time with the initiation of a slIb-
stantiallcukocyte infiltration, we wanted to specify the relationship between mega-islet for-
mation and leukocyte infiltration in more detail. Therefore, the infiltration of the islets in rela-
tion to their size was compared in NOD and NODscid females at 6 weeks of age (the time at 
which there is a predominant infiltration of DC and M~ and, in NOD mice, only limited num-
bers of lymphocytes). The intensity of intiltration was measured in two ways. 
First, the percentage of islets infiltrated with ER-MP23+ M.p, CD II e + DC and lym-
phocytes \vas determined. CDt tc+ DC and lymphocytes both do not normally occur in the 
pancreas of control animals at this age. Hence, every positive cell in the pancreas was con-
sidered to be an infiltrating cell and thus an islet was de tined infiltrated if at least one posi-
tive cell was situated around and/or within the islet. For ER-MP23+ M<j>, this definition is dif-
ferent, because ER-MP23+ rVf~ are resident cells in the exocrine pancreas, but they are never 
localized in the islets of non-autoimmune prone control animals (8). Therefore, for 
ER-lvlP23+ Mq>, an islet ,vas defined infiltrated only if at least one positive cell was situated 
within the islet, and not if positive cells were only present around the islet. 
Second, the extent of infiltration per islet was determined by measuring the size of tile 
infiltrate. For lymphocytes, this \vas done by measuring the size of the lymphocyte intiltrate, 
which is localized next to the islet at this age (lymphocytes rarely infiltrate the islet itself at 
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this age) (Fig. 2). For CDlle+ DC and ER-MP23+ M<j>, this was done by measuring the per-
centage of islet surface positive for the CD II c or the ER-MP23 marker. In this way, APC 
infiltration is expressed as a density and thus corrected for the islet size that was measured. 
a b 
Figure 2: Development of peri-insulitis in an NOD female at 10 weeks of age. Staining for CD lie + DC, original 
magnification x250. Note thai CDllc+ DC already infiltrate the islet at stages in which lymphocyte accumulation 
around the islets is relatively limited (a). Lymphocytes, in contrast, lemn ;m in11ltrate ;Idjacent to the islet, e\'en if 
already high numbers oflyrnphocytes are present (b). 
CD II e + DC were preferentially associated with the mega-islets in 6-week-old NOD 
mice. The percentage of CD II c + DC-infiltrated islets was significantly higher in mega-islets 
compared to normal islets (p<O.OOI) (Fig. 3). It can, however, be argued that mega-islets have 
a higher chance of being infiltrated by an APC solely because of the bigger size of the area 
that is measured. Therefore, we also looked at the density of the islet infiltration withAPC in 
normal islets and mega-islets by expressing the CD 11 c + surface area related to the total islet 
surface area, \Ve found that the density of intiltration with CDllc+ DC was significantly 
higher in mega-islets compared to normal islets (p<O.OOOI) (Table I). To exclude the effects 
of lymphocytes, we determined DC-infiltration in NODscid mice, In these mice, as observed 
in NOD mice, the percentage of CD lIe + DC-infiltrated islets was significantly higher in 
mega-islets compared to normal islets (p~O.OI) (Fig. 3). However, differences between 
NODscid and NOD mice were observed: both the percentage of CD II c + DC-infiltrated islets 
(Fig. 3) and the density ofCDllc+ DC-islet infiltration (Table I) were significantly reduced 
in NODscid compared to NOD mice (p~O.O I and ]l~O.048, respectively). 
Table 1: The density of infiltration with CDlle+ DC and ER-i\1I'23+ i\I<p is higher in ll11'gll-islets as com-
pared to normal islets in NOD and NODsdd mie(' lit 6 w('d{s of lIg('. Statistical anal~'sis of the den-
sity of infiltration was done b~' the i\Jann-Whilne~' U Wilcoxon Rank Stlln W test. This test orders 
the measurements and gives each measuremenl a rank numbcr. The diffcrcnces hetween the groups 
are than ('sted based on their mean ranl{ numhel'. Mean ranks of Ihis percentage for ('at'll grouJl as 
determined by this ('st liS ,nil :IS the r:lnge of measurements are depicted in this table. Ip<0.05. 
Strain CDllc+ DC ER-i .... fP23+ i .... tp 
Density r;lI1gc .i ... lean rank Density range l\kan rank 
NODscid Normal islets 0-- 0.25 t6 0-2.2 t9 
1Tega-islets 0-0.40 Ig 0- t.7 27 
NOD Normal islets 0-2.4 34 0-- 2.9 4t 
r\'Icga-islets 0-2.t 55 0- 2.3 6t 
130 
------------------lsIet abnormalities and illsulitis in NOD(scid) 
120 
IT] normal islet NOD 6 wk 
100 II mega-islet 
80 
60 
40 
:;: 
20 r---o 
0 
120 
"0 
OJ 
-
100 ~ 
NODscid6 wk 
±O 80 <i= 
.s :1: r---o 
en 60 
-OJ ~ 40 
-0 20 
;? 0 0 
120 
NOD9wk 
100 
80 
60 
40 
20 
0 
CD11c+ DC ER-MP23+M0 Iymphocyles 
Figure 3: Compared to normal islets, mega-islets are prdcrcntially infiltrated with early inl1llrating APC and lym-
phoc}1es. An islet is detined as infiltrated with ER-~H)23+ i\'l$ if there is alleast one cell detected withilllhc islet, 
and detined as infiltrated wilh CDllc+ DC or lymphoc)1es if there is at least onc cell present within or arollnd the 
islet (see Result section). Results are percentages of total number of islets from 5 mice in each age-strain group. 
ER-MP23+ M.p also preferentially infiltrated mega-islets in NOD mice. The percent-
age ofER-J\1P23+ M$-infiltrated islets was significantly higher in mega-islets than in normal 
islets (p~O.OOOOI) (Fig. 3). Furthermore, the density of ER-MP23+ M<j> in tilt ration in these 
islets was higher in mega-islets than in normal islets (p~O.OOOI) (Table I). In NODscidmice, 
the percentage of ER-MP23+ M.p-infiltrated islets (Fig. 3) and the density of infiltration with 
ER-MP23+ M.p (Table I) were also significantly higher in mega-islets than in normal islets 
(p~O.OI and p~O.02, respectively). However, as observed for CDlle+ DC, the percentage of 
ER-MP23+ lvl.p infiltrated-islets (Fig. 3) was signiticantly lower in NODscid compared to 
NOD mice (p~O.02). 
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Although lymphocyte infiltration was minor in 6-\veek-old NOD mice, lymphocytes 
were also preferentially situated around mega-islets. The percentage of islets surrounded by 
lymphocytes was significantly higher in mega-islets than in normal islets (IFO.02) (Fig. 3) 
and the area of the lymphocyte infiltrate was larger near the mega-islets as compared to the 
normal islets (p~O.OO I) (Table 2). Later, at 9 weeks of age, the percentages of inliltrated islets 
(Fig. 3) and the area of the lymphocyte infiltrate (Table 2) were significantly higher in mega-
islets compared to normal islets (p<O.OOI in both cases). As expected, lymphocytic infiltra-
tion was completely absent in NODscid mice, 
Table 2: The sizc of the lymphocyte infiltrate neal' mega-islets is higher than 11(':11" lIormal islets in NOD mice 
of 6 and 9 weeks of age. Stlltistical analysis of the density of infiltration was dOlle by the i\Jallll-
Whitney U Wilcoxon Ranl{ Sum ,,, tcst. This test orders the measurements and giws each meas-
urement a rank numhel~ The differences between thC' groups lire than tested based on their mean 
rllnk number. i\(ean ranks of this percentage for C'ach grollp llS dl'{crmined by this test as wC'1I as the 
range of lllC'asurcments are depicted in this tahle. Ip<o.os. 
Strain Age Lymphoc}1es 
Size range /I.-fean rank 
NOD 6 weeks Normal islets o - ~907 87 
"i\.fega-islets 0-2R514 97 
NOD 9 weeks Nonmll islets 0- 59865 45 
i\kga-islets 0-53249 68 
In conclusion, the tirst infiltrating cells are preferentially found near the mega-islets. 
This is the case for both early intiltrating APC and lymphocytes. The association between 
mega-islets and early infiltrating APC can be found in NOD and NODscid mice, although 
APC infiltration in NODscid mice is relatively limited as compared to NOD mice. 
l)rophylactic insulin treatment prevents mega-islet fOl'mution in both NOD and 
NODscid mice 
Since j3 cell hyperactivity was increased before the appearance of mega-islets 
(7,13,14), we wondered whether it could be a contributing lactor in their formation, in addi-
tion to immune cell infiltration. \Ve thus assessed the effect of prophylactic insulin treatment, 
known to down-regulate I' cell activity (17-19), in NOD and NODscid mice. In the latter, 
lacking functional lymphocytes, ,ve therefore avoided the tolerizing effects of insulin on lym-
phocytes (21). Figure 4 shows that prophylactic insulin treatment, administered from 3 to 
6 weeks of age, decreased significantly the percentage of mega-islets in NOD mice 
(p=O.003), confirming previous data (14). Moreover, it also decreased this percentage in 
NODscid mice to a similar extent (p<O.OOI). It should be noted, however, that the percent-
ages of mega-islets in both groups of placebo-treated NOD and NODscid mice were higher 
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than in untreated controls (Fig. I). This increase in mega-islet frequency is most likely 
explained by the stress induced by repeated placebo injections, since an increased islet mass 
has been observed after repeated placebo injection (22). 
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Figure 4: Prophylactic insulin treatment prevents mega-islet development in bolh NOD and NODscid mice. NOD 
females and NOOscid females were subcutaneously treated from 3 weeks to 6 weeks of age, with insulin or diluent. 
Results are percentages oftolalnumber of islets from 8 mice in each group. 
In conclusion, down regulating () cell activity by means of prophylactic insulin treat-
ment reduces mega-islet formation in both NOD and NODscid mice. This suggests that the 
islet activity in itself plays a role in initiating mega-islet formation. 
Discussion 
In this study, we show that the largest islets or mega-islets, which arc observed more 
frequently in NOD and NODscid mice than in controls, are preferentially associated \vith 
early infiltrating leukocytes. This concerns DC and M<j> in both NOD ancI NODscid mice, and 
lymphocytes in NOD mice. In NODscid mice, mega-islet formation is less prominent than in 
NOD mice, suggesting that lymphocytes contribute to mega-islet formation. Moreover, p cell 
metabolic activity itself appears to playa role, since its down-regulation by an early and short 
prophylactic insulin treatment decreased the percentages of mega-islets in both NOD and 
NODscid strains. 
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In this study, we show that NOD mice had a higher fraction of mega-islets than con-
trol C57BL/IO mice. In a previous study, we observed a comparable difference lIsing Balb/c 
mice as a control strain (14). Moreover, our results on f) cell hyperplasia in NOD and 
NODscid mice are in agreement with studies showing a large j3 cell mass in prediabetic NOD 
mice or in insulitis-free NOD stocks (NODscid, NOD-NON H-2nbl and NOD B2m null (23). 
Mega-islet formation in NOD mice is associated in time with the appearance or the first infil-
trating cells. Both the start of the p cell hyperactivity (as assessed by incrcased blood insulin 
levels) and the initiation of infiltration with DC and Mcj> take place around 4 weeks of age 
(12,13). In BB rats, there arc also indications for a prediabetic fl cell hyperactivity in relation 
to immune infiltration, Earlier studies showed an enhanced B cell sensitivity to glucose and 
an increased insulin secretion by inflamed islets from non-diabetic BB-DP rats, compared to 
non-inflamed islets from the same or from a control strain (24). Therefore, a period of tran-
sient islet hyperactivity and hyperplasia associated with the initiation of infiltration appears 
to precede fl cell exhaustion and fl cell death in both the NOD mouse and the BB rat. 
In addition to an association in time, there is also a relationship regarding their mutu-
allocation: mega-islets are preferentially associated with early int1ltrating APC and lympho-
cytes. The association of APC intiltration and rnega-islets could already be found at 6 weeks 
of age in NOD mice. At this age, the number of mega-islets in NOD mice is similar to that 
found in control mice. Since control mice do not exhibit leukocyte infiltration, it could be 
suggested that the NOD mega-islets function differently than the control ones. Interestingly, 
at this same age increased circulating insulin levels can be found in NOD mice (12,13). 
Two major mechanisms could underlie the association between mega-islets and 
inflammatory infiltrates. First, the abnormal islet function could be the cause of APC infil-
tration, via, for example, insulin chemotaxis (25,26). Second, mega-islet formation could be 
the consequence of the inflammatory infiltrates, via the influence of released factors. Tn var-
ious other endocrine organs, leukocytes have been shown to influence endocrine cell growth 
and/or nmction (27-29). As discussed below, both mechanisms may be at play. 
First, f3 cell hyperactivity could contribute to the mega-islet formation by attracting 
leukocytes. Since insulin is known to down regulate its own secretion (17-19) and to decrease 
pancreatic insulin content in NOD mice (20), \ve used it to prevent the transient f3 cell hyper-
activity which we previously described 1[om4 to 8 weeks of age in mice with the NOD genet-
ic background (12,13). Here, \ve confirmed that prophylactic insulin treatment is able to 
reduce mega-islet formation in NOD mice (14). However, since the treatment could act on 
lymphocytes, via the induction of tolerance to insulin (21), we also prophylactically treated 
NODscid mice, which lack functional lymphocytes. Insulin treatment was able to prevent 
mega-islet formation in NODscid mice as efficiently as in NOD mice. These results therefore 
suggest a role tor ~ cell hyperactivity in mega-islet formation. 
Second, we assessed whether leukocytes could influence mega-islet formation. The 
results obtained in NODscid mice shows that this mechanism is also playing a role. Although 
both NOD and NODscid lemales showed an early DC and M<iJ infiltration and an early hyper-
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insulinisl11 (12,13), latcr followed by the presence of mega-islets, nevertheless, clear differ-
ences were observed between the hvo strains. The first difference is the reduced infiltration 
of CD 11e+ DC and ER-MP23+ Mrp in NODscid females. Lower levels of CD II e + and 
F4/80+ cells were also suggested in another study (30), and the differences are thus quanti-
lied here. One explanation for this reduced APC infiltration might be related to the decreased 
function of APC in NODscid mice. Indeed, APC isolated il'om NODscid islets arc much less 
eficctive in stimulating diabetogenic T cell clones than those isolated from NOD islets. 
Transfer of diabetogenic T cell clones in vivo improves the antigen-presenting function of 
NODscid islet APC (31). Thus, lymphocytes and/or their products regulate the function and 
phenotype of APC. The second difference between the two strains is that NODscid females 
did not only show a reduced APC infiltration, but also showed a less pronounced hyperin-
sulinism (13) and fewer mega-islets. Indeed, mega-islet formation is higher in NOD than in 
NODscid mice only after 10 weeks, i.e., a fe\v weeks after the beginning of the lymphocyte 
infiltration that then regularly progresses. These data, therefore, suggest an in vivo stimula-
tory effect of the lymphocyte compartment on islet cell function and growth in NOD mice. 
In conclusion, a close association is shown for the first time between early target organ 
abnormalities and the initiation of leukocyte infiltration in a spontaneolls model of type 1 dia-
betes. The precise sequence of cellular events is still unknown, but the differences bel\veen 
NOD strains (NOD and NODscid) and control strains show that some inherent degree of 
B cell hyperactivity exists. It has been suggested previously that a period of islet hyperactiv-
ity may be crucial in the development of autoimmunity (7). Hyperactive p cells are more 
prone to autoimmune reactions because of high levels of autoantigens, adhesion and MHC 
molecules and because of a higher sensitivity to cytokine-induced damage (7,32-34). The 
importance of the target gland abnormality for diabetes development is also indicated by the 
fact that both hyperinsulinemia and mega-islet formation are more pronounced in diabetes-
prone NOD females compared to less diabetes-prone NOD males. In line with this, orchidec-
tomy of NOD males leads to increased percentages of mega-islets and a higher diabetes inci-
dence (manuscript submitted). This initial target organ abuormality could attract APC (and 
lymphocytes in NOD mice), which in turn cause a further stimulation of islet activity. Such a 
vie\v is supported by the association of infiltrates and mega-islets and by the differences in 
mega-islet formation between NOD mice (with high APC and lymphocyte infiltration) and 
NODscid miee (with limited APC and no lymphocyte infiltration). The resulting B cell 
exhaustion and/or destruction would trigger the b cell activity of other still unaftected islets, 
in order to maintain normal blood glucose levels. Thus, a vicious circle may have started 
resulting in clinical onset of diabetes. 
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Materials and methods 
Animals 
NOD, NODscid and C57BLlI0 female mice were bred under specific pathogen-li'ee 
conditions at the facilities of the H6pital Necker, Paris, France. The animal facilities and cafe 
followed the norms stipulated by the European Community. The incidence of diabetes in the 
NOD colony is, by 200 days of age, 80% for females and 40% for males. Mice were killed at 
5, 10, 15 or 20 weeks of age for the assessment of islet size without any treatment, and at 
6 weeks of age for the evaluation of the DC, M!fJ and lymphocyte infiltration in relation to 
islet size after treatment (placebo or insulin). 
Insulin treatment 
Sixteen NOD females and sixteen NODscid females were treated from 3 weeks (wean M 
ing) to 6 weeks of age. In this group, eight NOD lemales and eight NODscid females were 
treated with 0.25 U Protamine-Zinc-insulin (Organon, Oss, The Netherlands) per day, eight 
mice froill each strain served as controls and were treated with the same volume of vehicle 
(placebo-treated group). All mice were weighed and assessed for glycemia at 3 and 6 weeks 
of age. Prediabetic NOD mice (with basal nonfasting glycemia < II mmoVI, as assessed by 
Glukotest, Boehringer-Mannheim, Mannheim, Germany) were used only for immunohisto-
chemical analyses. 
Antibodies 
ER-MP23, identifying mouse macrophage galactose specitIc (MMGL)+ 
MHC-class n+ Mq, (8,35), was lIsed as a rat-ant i-mouse hybridoma culture supernatant. 
N418, identifying CD 11c+ DC (35), was used as a hamster-anti-mouse hybridoma culture 
supernatant. B cells were identified by guinea-pig anti-porcine-il1sulin polyclonal antibody 
(Dako Glostmp, Denmark), which was used diluted I :250 in phosphate buffered saline (PBS) 
with 0.1 % Tween (Merck; Darmstadt, Germany) (PBS/Tween). ER-MP23 was detected with 
horseradish peroxidase (HRP)-conjugated rabbit-anti-rat immunoglobulins (Dako). N418 
was detected with HRP-conjugated goat-ant i-hamster immunoglobulins (Jackson 
ImmulloResearch Laboratories, Inc.; \Vest Grove, Pennsylvania, USA). Anti-insulin was 
detected with HRP-col\illgated rabbit-anti-gllinea pig immunoglobulins (Dako). 
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Mice were killed by cervical dislocation after rapid retro-orbital bleeding. Their pan-
creases were removed, embedded in OCT (Sakura, Zoetenvoude, The Netherlands) com-
pound and frozen in n-hexane on diy-ice chilled alcohoL Tissues were stored at -80°C until 
immunohistochemistry was performed. Before sectioning, microscopic slides were coated 
with a solution of 0.1% gelatinelO.Ol% chromium-alum. After a wash with phosphate-
buffered saline with 0.1% Tween-20 (Merck, Schuchardt, Germany) (PBS/Tween), slides 
were incubated with first step monoclonal antibodies for 30 min at room temperature in 
a moist chamber. Subsequently, slides were washed ,vith PBS/Tween and incubated with sec-
ond step antibodies in the presence of 2% normal mouse serum for 30 min at room tempera-
ture. After an additional wash with PBS/Tween, slides werc incubated with 0.05% (wtlvol) 
Ni-di-amino-benzidine (Ni-DAB) (Sigma, SL Louis, USA) with 0.02% H202 and washed in 
PBS/Tween after 3 min. Finally, slides were eounterstained for 3 min in nuclear fast red, 
washed in water, dehydrated in a graded ethanol series, and mounted. For each series of pan-
creas sections, one slide was stained with second antibody only as a control for endogenous 
peroxidase activity and non-specific binding of the second step. A section of spleen was 
included as a positive control. 
Quantification of immunohistochemistry 
The surface area of the islets and the infiltrate as well as the percentage of islet surface 
positive for CD lie + DC or ER-MP23+ M<jJ were assessed via a VIDAS-RT image analysis 
system (Kontron Elektronik GmbH! Carl Zeiss, \Veesp, the Netherlands). Measurements were 
performed using a magnification of 100x. Results of measurements were expressed in pixels. 
At a magnification of 100x, the size of one pixel is 1.13xlO-6 mm2. For the measurement of 
islet sizes, sections were stained with anti-insulin and a nuclear fhst red counterstaining. For 
all measurements, islets were encircled by the researcher in such a way that the whole islet 
was measured and not only the area positive for insulin. For the measurement of APC infil-
tration, sections were stained with N418 or ER-MP23 and a nuclear fast red counterstaining. 
Statistical analysis 
Statistical comparison ofthe percentage of mega-islets between groups was carried out 
using the X2-Test. The Mann- \Vhitney U \Vilcoxon Rank Sum \V Test was lIsed to determine 
statistical significance for difterences in the absolute amount of infiltration and the X2-Test 
for ditlerences in the percentage of large islets and the percentage of infiltrated islcts. The 
level of significance was set as p < 0.05. For measurements of islet size, a mean of 190 islets 
was analyzed for every age-strain group of 5 mice. For measurements of infiltration, a mean 
of 60 islets was analyzed for every age-strain group of 5-8 mice. 
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Chapter 3.2 
Summary 
Female nonobcse diabetic (NOD) mice more frequently develop autoimmune diabetes 
than NOD males. Orchidectomy afthe latter aggravates insulitis and diabetes. Since clear dif-
ferences in immune function have not been observed between prediabetic females and males, 
before or after castration, we hypothesized that sex-related differences in diabetes incidence 
are related to target organ-specitic actions of sex steroids. Previously, we showed that predi-
abetic NOD females develop hyperinsulincmia and subsequently mega-islets. Infiltration of 
the first inflammatOlY leukocytes is predominantly associated with these mega-islets. Here, 
we determined the relationship between sex hormones, mega-islet formation and infiltrating 
cells in NOD and NODscid mice. 
Mega-islet formation was reduced in NOD males compared to NOD females and 
orchidectomy increased it, indicating a relationship between androgen levels and mega-islet 
formation. Moreover, enhanced mega-islet formation in castrated NOD males \vas associated 
with increased numbers of infiltrating leukocytes. Castrated NODsdd males also exhibited 
increased mega-islet formation and dendritic cell infiltration, indicating that lymphocytes are 
not required for castration-induced effects. 
In conclusion, we show that androgens influence pancreatic islets and subsequent 
autoimmune infiltration in NOD and NODscid mice. This suggests that the gender difference 
in diabetes incidence in NOD mice is related to target organ-specific androgen effects. 
142 
----------------- Sex steroids and islet abnormalities in NOD(sdd) 
Introduction 
The sexual dimorphism of autoimmune diseases - females have a higher incidence 
than males - is well knmvn in both humans and animal models (1-4). This difference is gen-
erally assumed to be caused by the effects of sex steroids on the immune response, particu-
larly the inul1unosuppressivc effects of androgens (2,4-6). 
Also in lhe nonobese diabetic (NOD) mouse model of type I (insulin-dependent) dia-
betes mellitus (type I diabetes), females become diabetic earlier and in higher frequency than 
males. Castration of males leads to an incidence comparable to that observed in females, 
whereas treatment \vith androgens prevents the development of diabetes in female NOD mice 
(7,8). It is generally assumed that the autoimmune process in NOD females and castrated 
males progresses due to the absence of immunosuppressive androgens. HO\vever, data com-
paring various immunological parameters between NOD females and males, and between 
castrated and control animals of both sexes, have not given conclusive evidence to support 
such a vie\v. Splenic T cell proliferation, IL-2 production and antibody production against 
sheep red blood cells do not reveal any spontaneous sex difference or any effect of castration, 
while leukocyte phenotype analysis showed only minor differences (7), In addition, autoim-
mune inflammatOlY infiltration is not ahvays predominant in temales: while a NOD female 
preponderance exists for the development of insulitis and sialoadenitis (7,9), dacryoadenitis 
is preferentially found in NOD males (lO). Taken together, these observations in NOD mice 
question the general vicw that sex steroid effects on the immune system explain the observed 
gender difterence in diabetes incidence. Alternative1y, sex hormones may directly affect the 
target organ and thus influence the susceptibility for autoimmunc attack. 
In the NOD pancreas, the tirst sign of autoimmunity is an early accumulation of 
macrophages (M<j» and dendritic cells (DC) around the islets of Langerhans (peri-insulitis) 
(11,12), These cells are assumed to function as antigen-presenting cells (A PC), Subsequently, 
numerous T and B lymphocytes are reclllited to the site and the progressive insulitis leads to 
the destruction of the insulin-prociucing p cells located in the core of the islet of Langerhans. 
Tn the NODscid mouse, an early peri-islet APC accumulation also takes place, but to a lesser 
extent (13). Due to the lack of functional lymphocytes, however, neither lymphocyte insuli-
tis nor diabetes develops in these mice (14), Wilh age, bolh NOD and NODscid females 
exhibit increased numbers of large-sized islets ('mega-islels') (12,15), The imporlance of 
these mega-islets for diabetes development is indicated by the observation that the early infil-
trating APC are preciominantly situated next to these mega-islets in both strains (12,15). This 
is particularly the case for CDllc+ dendritic cells (DC), 
The causes of mega-islet development are not ktlO\vn. Islet hypertrophy occurs con-
secutively to endocrine abnormalities, suggesting a role for these abnormalities in mega-islet 
development. :More specifically! a transient !1 cell hyperactivity is observed in NOD mice, 
particularly females, that is closely associated in time to the emergence of APC infiltration 
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(16,17). Interestingly, an aberrant sexual d imorphisl11 in insulin response to a glucose load 
exists in NOD mice: females produce, as early as 6 weeks of age, higher insulin levels than 
males (16). This glucose response pattern is opposite to the one found in normal rodents (16). 
:Moreover, insulitis progresses more rapidly in NOD females than in males, possibly as a COI1-
sequence of this ~ cell hyperactivity (16-18), Thus, fUllctional endocrine abnormalities in 
NOD mice precede the formation of mega-islets and subsequent autoimmune infiltration. 
Moreover, these abnormalities seem to be especially marked in diabetes-prone NOD females, 
\Ve hypothesized that the sensitivity for autoimmune attack as observed in NOD 
females was related to sex steroid effects on the target organ instead of on the immune sys~ 
tem. Therefore, we have studied the effect of castration on the islet of Langerhans by meas~ 
uring early mega-islet development, APe infiltration and the relationship between these two 
parameters. By using both NOD and NODscid mice, we determined the contribution of lym-
phocytes to islet abnormalities developing upon castration. 
Results 
A gender bias in mcga~islet formation exists in NOD und NODsdd mice 
Previous studies showed early hypertrophy of pancreatic islets, leading to 'mega-islet' 
formation in NOD and NODscid female mice (12,15). To assess a possible sexual dimor-
phism in mega-islet formation, we measured islet size in NOD and NODscid mice of both 
sexes at 5,10 and 15 weeks of age. :Mega-islets were defined as islets with an area of more 
than 10000 pixels at a magnitication of 100x. 
Fiye~week~old females and males of both strains had comparable percentages of 
mega-islets (Fig. 1). At to weeks of age, however, significant difterences in the percentages 
of mega-islets were observed between females and males regardless of the strain. NOD and 
NODscid females had higher percentages of mega-islets than NOD and NODscid males 
(p<0.05 tor NOD females vs. NOD males; p<0.05 for NODsci" females vs. NODsci" males). 
However, after the appearance of this sexual dimorphism in mega-islet development in both 
NOD and NODscid mice, a strain difterence developed, as observed at IS weeks of age. 
Significantly higher percentages of mega~islets were observed in NOD females and males 
compared to sex-matched NODscid mice (p<0.05 tor NOD females vs. NODscid females; 
p~0.05 for NOD males vs. NODsci" males). This suggests that lymphocytes playa role in 
later phases of mega~islet development in NOD mice. 
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Figure 1; Development oflllega-islets as a function ofnge in NOD and NODscid females and males, Results are per-
centages of total number of islets from 5 mice. Note a significant diHerencc bclw('cn males and females at J() weeks 
of age, and a signHicant diJlerence between NOD and NODscid mice, regardless of the sex, at 15 weeks of age. 
Castration enhances mega-islet formation in NOD and NODscid males and increases 
diabetes incidence in NOD mules 
As shown in Figure 2, orchidectomy of NOD and NODscid mice at 4 weeks of age 
significantly increased the fraction of mega-islets at 10 weeks of age (p<O.OOI for NOD 
males; p<O.05 for NODscid males), This increase is especially marked in NOD males, lead-
ing to a significant difference between orchidectomized NOD and NODscid males (p<O.OO I). 
if) 
~ 
0. 
o 
o 
o 
o 
~ 
wmsham 
lIocx 
NOD NODscid 
* 
* 
* 
Figure 2: Presence of mega-islets in orchidectomized and sham-operated IO-week-old NOD and NODscid males. 
Results are percentages of total number of islets from 6-8 lllicelag~ group. Orchidectomy results in a rise in the per-
centage of mega-islets. i\foreover, this cfiect is significantly higher in NOD compared to NODscidmales. 
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\Ve also confirmed previolls findings that orchidectomy at 4 weeks of age significant-
ly increased diabetes prevalence in NOD males (data not shown), 
Castration enhances DC infiltration around and/or into the islets of NOD and NODsciti 
males 
Since CD lIe + DC accumulate around as well as within the islet (Fig. 3); we measured 
intiltration in the peri-islet area and in the islet itself at 10 weeks of age (for details: see 
Materials and Methods section). 
,', 
Figure 3: The ioc(ltioll ofCD11c+ DC (black) and lymphocytes in islet infiltrates (NOD female, 10 weeks old), i: 
islet; P; peri-islet are(l; L: lymphocyte int1ilrate. Originnl magllit1cation x64. 
Figure 4 shows that orchidectomy in NOD mice enhanced the accumulation of 
CDllc+ DC in both the islet itself(4.4 vs. 1.1 % of the islet surface area was occupied by DC 
in the orchidectomized vs. sham-operated group, p<O,OOO I) and in the peri-islet area (19.2 VS, 
6.7 % for orchidectomy vs, sham-operated, p<O,QOOl). Tn NODscid mice, the accumulation 
ofCDl1c+ DC was also significantly enhanced in the peri-islet area after orchidectomy (2.7 
VS. 1.4 % for orchidectomy vs. sham-operated, p<O.OOI), but in the islet itself, the difference 
did not reach statistical significance (0,38 vs. 0.25 % for orchidectomy vs. sham-operated). 
NOD and NODscid mice dillered significantly with regard to peri-islet or intra-islet 
CDllc+ DC infiltration (Fig. 4). In sham-operated NOD males, CDllc+ DC infiltration was 
more extensive than in NODscid males, both in the islet itself (1.1 VS. 0.25 % for NOD VS, 
NODscid, IFO.OOOI) as well as in the peri-islet area (6.7 vs. 1.4 %, p<O.OO I). After orchidec-
tomy, this difference increased both in the islet itself(4.4 vs. 0.38 %, p<O.OOOI) as well as in 
the peri-islet area (19.2 vs. 2.7 %, p<O.OOOI). This suggests that lymphocytes are likely to 
playa role in the extent of peri- and intra-islet DC infiltration in the NOD mouse. 
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Figure 4: CD II c + DC int1ltmtion in orchidectomized and sham-operated IO-week-old NOD and NODscid maJcs. 
Inl1ltrating DC are distinguishcd with regard to their location: with the islets or in the peri-islet inflammatory infil-
trate. The amount of infiltrating cells is expressed relative to the islet or peri-islet surl1l1.:e area (see iv[aterials and 
ivrethods). Note that orchidectomy of NOD and NODscid males leads to an cnhanced accumulation of CD 11c+ DC 
around the islets. In NOD mice, orchidectomy also leads to an enhanced infiltration of CD lie + DC into the islets. 
As expected for this ,lge, peri-islet infiltration is significantly higher than the intHtratioll of the islet itself. tvlorcovcr, 
CDllc+ DC infiltration in NOD males is signiHcantly higher as compared to that in NODscid males. 
Castration tends to enhance islet-related lymphocyte infiltration in NOD males 
Figure 5 shows that orchidectomy of4-week-old NOD mice increased the lymphocyte 
infiltration, when measured at IO ''leeks of age. Indeed, the median size of the lymphocyte 
infiltrate was 856 pixels for sham-operated NOD males and 2398 pixels for orchidectomized 
NOD. However, this difference tended only toward significance (p~O.088). As expected, 
NODscid mice did not exhibit any lymphocyte infiltration. 
NOD 
Figure 5: Dcvelopment of lymphocyte infiltration in orchidec-
tomized and sham-openlted lO-week-old NOD males. 
Orchidectomy tended to increasc the size of the lymphocyte inf1l-
trate (p=O.OSS). 
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Discussion 
In the NOD mouse model of type 1 diabetes, females arc more prone to diabetes 
development than males, despite the absence of clear differences in peripheral immune fUllc-
tion bet\vecn both sexes (7). Similarly, castrated males show an enhanced diabetes incidence 
without obvious changes in peripheral immune function (7). Therefore, we hypothesized that 
a target organ-specific effect of sex steroids is operative in diabetes development. This study 
shmvs that orchidectomy induces early islet abnormalities in male NOD mice, indicated by 
the increase in mega-islet formation in castrated animals. Simultaneously, orchidectomy 
enhances early APC infiltration in NOD and NODscid mice. The effect of orchidectomy on 
both mega~islet formation and APC infiltration is stronger in NOD than in NODscid mice, 
indicating that lymphocytes enhance the eftect of androgen deprivation. 
The relationship between sex steroids, mega-islet formation and leukocyte infiltration 
can be explained in difterent ways. On the one hand, the eftects of orchidectomy on the 
development of early islet abnormalities in male NOD mice may be achieved via a direct 
inl1uence of sex steroids on islet cells and/or glucose homeostasis. On the other hand, sex 
steroids may affect the function of leukocytes that accumulate around and in the islets, and 
thereby cause islet abnormalities. The data presented here and those from the literature sug-
gest that both mechanisms may he at work. 
There are several indications that the islet itself can respond to sex hormones. 
Functional studies suggest that sex steroids might directly and/or indirectly influence islet 
function in normal animals. There is a sexual dimorphism in glucose homeostasis in normal 
rodents, with males showing higher nonfasting basal glycemia and insulinemia than temales 
(16,19). This difference is related to the opposite etTects of androgens and estrogens on 
insulin sensitivity of cells: androgens lower insulin sensitivity, while estrogens increase it 
(20-22). Accordingly, partial pancreatectomy-induced diabetes in normal rodents is more fre-
quent in males than in females and its effect is reversed, in each sex, by castration (23). 
Finally, estrogen administration in rodents and orchidectomy in various species have been 
described to induce" cell hypcrplasia andlor islet hypertrophy (24-26). Thus, our tinding in 
NOD mice that orchidectomy led to all increased percentage of mega-islets in prediabetic 
NOD males (before any noteworthy lymphocyte infiltration) and in NODscid males is fully 
in line with the earlier observations in other strains and species that sex steroids influence 
II cell function. 
Do sex steroids act directly at the f3 cell level through specitic receptors? Estrogen and 
progesterone receptors are indeed present in B cells (27-30). However, to the best of our 
knowledge, androgen receptors have not been shown in f3 cells. In addition, we ourselves 
were unable to detcct the presence of these receptors in (3 cells (unpublished observation). 
These data make a direct efiect of androgens at the f3 cell level unlikely. 
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If indeed B cells lack androgen receptors, is there an alternative explanation for the 
observed gender difference in diabetes incidence and the effect of orchidectomy in NOD 
mice? Sex steroids also have recognized effects on leukocyte function, It could be argued that 
sex steroids induce prediabetic islet abnormalities via an eftect on leukocytes, either lym-
phocytes or APC, which accllmulate around the islets. 
\Ve show here that orchidectomy affects mega-islet formation and APC infiltration in 
lymphocyte-deficient NODscid mice. This indicates that at least part afthe sex steroid effect, 
if achieved indirectly, can be mediated via non-lymphoid cells, APC are likely candidates as 
mcdiators of sex steroid effects. In general, a close physical and functional interaction 
between the endocrine system and APC has been observed for virtually all cndocrine organs 
(31,32). In the thyroid, pituitary and the gonads, DC and Illacrophages play an imp0l1allt role 
in the regulation of hormone secretion (31,32). An additional study also suggests possible 
efJects of APC on islets and a role of sex steroids in this interaction. In mice that express inter-
feron-y as a transgene in their f3 cells, interferon-y-stimulated duct cell proliferation is 
stronger in females than in males. However, if the pancreatic influx ofMCP that OCClil'S in these 
mice is prevented, the proliferation in males is increased until the level found in females. 
Thus, interferon-g stimulation of duct cell proliferation is mediated part trough the MCP, which 
inhibits such growth in males (33). In conclusion, APC appear to be important communica-
tors in the interactions between the endocrine and the immune system. How could sex steroids 
influence the interactions between APC and islet cells? Sex steroids are knmvn to modulate 
cytokine production by leukocytes, in particular by mononuclear phagocytes (6). 
Furthermore, APe are able to convert pro-hormones to active androgens (34). Taken togeth-
er, these notions support the view that sex steroids influence APC function and thus might, 
via these cells, also influence the islet cells. 
The effects of orchidectomy on mega-islet formation are stronger in NOD males than 
in NODscid males, however. This suggests that lymphocytes also contribute to mega-islet for-
mation in NOD mice. A direct lymphocyte-mediated effect of changes in androgen levels, 
hmvever, is unlikely, since mature lymphocytes lack androgen receptors (6). How then can 
the reduced effect of castration on mega-islet formation in NODscid mice compared to NOD 
mice be explained? Androgens might act indirectly on lymphocytes by influencing products 
secreted by other cells present in the islet environment (35). Moreover, circulating estrogens, 
which persist in NOD males after castration, may have direct and similar immunostimulato-
ry effects on lymphocytes from NOD females and castrated males, not counterbalanced by 
the presence of androgens (1,5,6). Also a role for infiltrating APC in this process can be envis-
aged. NODscid have a reduced DC infiltration compared to NOD mice (this report for males, 
(13,15) for females), Therefore, the difference between NOD and NODscid mice in mega-
islet formation upon orchidectomy could be explained via effects on difterent numbers of 
infiltrating DC, 
In conclusion, both leukocytes and islet cells themselves appear to playa role in the 
formation of mega islets after castration. In this experimental setting as ,yell as in spontaneous 
disease, B cell hyperactivity and islet hypertrophy might be crucial in the development of dia-
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betes. Hyperactive islets are known to express elevated levels of cell adhesion ligands, major 
histocompatibility complex CMHC) molecules and autoantigens, ,,,hich may enhance the 
~ cell-sensitivity to the cytotoxic effects of cytokines (18). "Ve have previollsly demonstrated 
that prophylactic insulin treatment, which prevents insulitis and diabetes incidence, decreas-
es mega-islet formation (12). Here we show that orchidectomy is associated with an increase 
of both mega-islet formation and incidence of diabetes in NOD mice. Moreover, orchidecto-
my enhances the early accumulation ofCDllc+ DC around and in the islets of NOD mice 
and NODscid mice concomitantly with mega-islet formation. Together, these studies supp0l1 
the view that mega-islets are closely associated with and possibly functionally involved in the 
development of insulitis and subsequently diabetes in NOD mice. Since NODscid mice lack 
functional lymphocytes, the stage of destructive insulitis is not reached in this strain. 
Taken together, in this report we highlight the notion that sex steroids are important 
factors in the complex interrelationship between the islets of Langerhans and early infiltrat-
ing leukocytes in mice with the NOD genetic background. Sex steroids influcllce early pre-
diabetic morphological islet abnormalities, as orchidectomy increases mega-islet formation 
and associated APC infiltration. This effect is enhanced by the presence of functional lym-
phocytes. In addition, an effect of androgens on islet cells either directly or indirectly via infil-
trating APC, provides an explanation for the observed gender difference in diabetes incidence 
in NOD mice. 
Materials and Methods 
NOD colony, diabetes incidence and orchidectomy 
NOD and NODscid mice \vere bred under specific pathogen-fl'ee conditions at the 
facilities of the Hopital Necker, Paris, France. The animal facilities and care followed the 
norms stipulated by the European Community. Mice were fed standard pellets and water ad 
libitum and were maintained at 22° C on a 12h light dark cycle. The incidence of diabetes in 
the NOD colony is 80% for females and 40% for males by 200 days of age. 
NOD and NODscid males were divided into 2 experimental groups: the first group 
undenvent either orchidectomy under avertin anesthesia at 4 weeks of age, the second group 
was sham-operated to exclude the nonspecitlc effects of the operation itself. Mice were rou-
tinely checked for success of orchidectomy. One \veek after orchidectomy of NOD mice, cir-
culating testosterone levels, assessed according to reference 17, had fallen il-om 12±2.l ng/ml 
to 35.1±9.5 pg/ml (IFI2). At the same time, circulating estradiol did not fall signiticantly: 
63±13 pg/ml versus 46±10.5 pg/ml (n~9). For diabetes incidence assessment, 15 mice were 
included in each group. Animals were considered diabetic when glycemia was higher than 
II IllmoVI using Glukotest (Boehringer-Mannheim, Mannheim, Germany). 
150 
---------------- Sex steroids and islet abnormalities in NOD(scid) 
To assess the eilect of castration on immunohistochemical parameters (islet size and 
illfiltratiollwi(h CDllc+ DC alld lymphocytes), mice were used at JO weeks of age (S/group), 
Unmanipulated NOD and NODscidtemaies and males were also used at 5,10 and 15 ''leeks 
of age for the measurement of islet size (5 mice/group). 
Antibodies 
Islets were identified by guinea-pig anti-insulin polyclonal antibody (Dako, Glostrup, 
Denmark), which was used diluted I :250 ill phosphate buffered salille (PBS) with 0, 1% 
Tweell-20 (Merck-Schuchardt, Hohellbrullil bei Miillchell, Germany) (PBS/Tween), Anti-
insulin binding was detected \vith HRP-conjugated rabbit-anti-guinea pig immunoglobulins 
(Dako), N4IS, identitying CDllc+ DC (18), was used as a hamster-an(i-mouse hybridoma 
culture supernatant. N418 was detected with HRP-conjugated goat-ant i-hamster 
immunoglobulins (Jackson Immul10Rescarch Laboratories, Inc" \Vest Grove, Pennsylvania, 
USA), Lymphocyte infiltrates were identified morphologically by means of a nuclear fast red 
counterstaining (Fluka, Buchs, Switzerland). 
Immunohistochemistry 
Mice were killed by cervical dislocation aner bleeding from thc orbital sinus under 
ether anesthesia, Pancreases were removed, embedded in a,c.T, compound (Saklll'a, 
Zoctcrwoucie, The Netherlands) and frozcn in dry ice-chilled isopentane for immunohisto-
chcmical studies, Tissues wcre stored at -80°C until immunohistochemistry was perform cd, 
Bcfore sectioning, microscopic slides were coated with a solution of 0.1% gelatine/O.Ol% 
chromium-alum. Pancreas clyostat sections of 6 mm \vere prepared from central regions of 
the pancreas that included sufficient numbers of islets. Only one section of each pancreas was 
stained and measured to assure that an individual islet is not examined more than once. 
Sections were fixed for 2 min in 2% hexazotized pararosaniline (Sigma, St. Louis, USA) (36). 
After a wash with phosphate-buffered saline with 0.1% Tween-20 (PBS/Twecn), slides were 
incubated with first step monoclonal antibodies for 30 min at room tempcrature, 
Subsequcntly, slidcs wcrc washed with PBS/Tween and incubated with second step antibod-
ies in the presence of2% normal mouse serum for 30 min at room temperature, After an addi-
tional wash with PBS/Tween, slides were incubated with 0,05% (w/v) Ni-di-amino-benzidine 
(Ni-DAB) (Sigma, st. Louis, USA) with 0,02% H202 and washed in water after 3 min, 
Finally, slides \vere counterstained for 3 min in nuclear fast red, dehydrated in a graded 
ethanol series, and mounted. For each series of islet sections, one slide was stained with sec-
ond antibody only as a control for endogenous peroxidasc activity and nonspecific binding of 
the second step, A section of spleen was included as a positive control. 
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Quantification of immunohistochemistry 
Total and marker-positive surface areas of infiltrated islets were assessed via a 
VlDAS-RT image analysis system (Kontron Elektronik GmbH! Carl Zeiss, Weesp, The 
Netheriands).1vleaslIrcmcnts were done at a magnification of 100x. The results of the meas-
urements were expressed in pixels. At a magnification of I OOx, the size of one pixel is l.13x 
10-6 nUTI2 
For the measurement of islet sizes, islets were identified by means of an anti-insulin 
staining, For the measurement of infiltration, islets, peri-islet areas and lymphocyte infiltrates 
were recognized morphologically and encircled by the investigator. Figure 3 shows the defi-
nition of the islet area (I), the peri-islet area (P) and the lymphocyte infiltrate (P). 
CDllc+ DC are present mainly in peri-islet location, but also within the islet. 
Therefore, CD I I c + DC infiltration in the periwislet and islet areas was measured and 
expressed relative to periwislet and islet area size, respectively. For lymphocyte infiltrates, 
infiltrates were expressed as absolute intiltrate sizes in pixels, since lymphocytes are not yet 
infiltrating the islets at the age under investigation but rather form a cuff at the side of the 
islet. The size of this cuff is directly related to the number of lymphocytes present. Therefore, 
it is not necessary to express lymphocyte infiltration relative to islet size. Thus, DC infiltraw 
tion is expressed in a relative manner, whereas lymphocyte intiltration is expressed absolutew 
Iy. 
For all measurements, the results were analyzed for the total number of islets in a 
given experimental group, and not per individual mouse. The reason for this was that there 
was an extensive variability in the progression of the disease, hence in the number of islets 
available for analysis prior to destruction. A mean of 170 islets was analyzed for every age-
strain group of 5 to 8 mice. 
Statistical analysis 
The X2-Test was used to analyze differences in the prevalence of diabetes at 23 weeks 
of age between the orchidectomized and sham-operated mice. Also statistical comparison of 
the percentage of mega-islets behveen groups \vas carried out lIsing the X2-Test. Statistical 
comparison of the amollnt of infIltration with CD I I c + DC and of the amount of lymphocyte 
infiltration betv.'een groups \vas carried out by the Mann-'Vhitney U-Wilcoxon rank Sum \V 
Test. The level of significance was set as p<O.05. 
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Chapter 3.3 
Summary 
Abnormalities of immune function arc not sufiicient to explain the organ/cell speci-
ticity of an autoimmune disease, for example B cells in diabetes. Among defects existing at 
the islet level in prediabetic non obese diabetic (NOD) mice, \ve previously described a tran-
sient hyperinsulinemia followed by evidence of f1 cell hyperplasia. A modified il1 situ 
hybridization technique was used to determine if these effects were accompanied by changes 
in insulin transcriptional activity. 
\Ve found that NOD neonates express higher levels of pre pro insulin primary transcript 
than age-matched C57BL/6 mice. To manipulate insulin transcriptional activity, NOD moth-
ers were treated \vith insulin during the last two weeks of gestation. \Ve observed a down-reg-
ulation of~ cell hyperactivity in female neonates only. By contrast, the same insulin treatment 
applied to NODscid mothers, devoid of functional lymphocytes, increased f-3 cell activity. 
In conclusion, mice with the NOD genetic background appear to have a relatively high 
level of ~ cell activity, reflected first in insulin transcriptional activity, that precedes any evi-
dence of islet abnormalities or autoimmunity and may involve both genetic and environmen-
tal (maternal and fetal) factors. 
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Introduction 
The NOD mouse is the most widely used animal model for type I (insulin-dependent) 
diabetes mellitus (type I diabetes) (1,2). Despite extensive research, however, the etiology of 
the disease is still largely unknown. In NOD mice, as in human (pre)diabetic patients, sever~ 
aI abnormalities of immune fUllction exist. These abnormalities, ,vhich include aberrant phe-
notypes and/or functions of thymocytes, antigen-presenting cells (APC), and lymphocytes, 
may hamper tolerance induction leading to autoimillunity (3-5). However, similar abnormal-
ities have been found in other autoimmune diseases and if they explain the predisposition to 
autoimmunity in general, they do not explain the organ/cell-specificity of the autoimmune 
disease, in particular, that off~ cells in diabetes (6). 
\Vc therefore hypothesized that abnormalities of the islets of Langerhans, ill addition 
to those in the immune system, are required for the development of the autoimmune reaction 
at the pancreas level. \Ve have previously reported a transient hyperinsulinemia, which coin-
cided in time \vith the first pancreas-infiltrating leukocytes (7-9). This hyperinsulinemia was 
followed by the formation of large islets, or mega-islets (10). These mega-islets were prefer-
entially associated with subsequent infiltrating cells (A PC and lymphocytes), indicating 
a close relationship between these islet abnormalities and the development oCthe autoimmune 
reaction (II). 
\Ve then addressed the question of the cause of the hyperinsulinemia, which develops 
from 4 weeks of age oll\vards, i.e., directly after weaning. The weaning period corresponds to 
a dietetic shift from maternal milk (rich in fatty acids and poor in carbohydrates) to laborato-
ly chow (poor in fatty acids and rich in carbohydrates) (8,12). Evcn in normal rodents, this 
dietetic shift is knmvn to activate f3 cells that have been at rest until weaning because of the 
low glucose-containing maternal milk. Since prediabetic NOD mice exhibit f3 cell hyperac-
tivity immediately after weaning, we wondered \vhether this was due to a previous glucose 
stimulation or so-called « glucose-priming effect » (8,13,14). Such a priming encct may 
occur in NOD fetuses, due to possible abnormalities of glucose homeostasis in NOD moth-
ers. 
The measurement of insulin levels in neonatal mice is, hmvever, difficult. To circum-
vent this problem, we determined whether hyperactivity is present at the transcriptional level 
in the pancrcata of NOD neonates. For this purpose, we developed an ill situ hybridization 
technique, that evaluates the rate of pre pro insulin II mRNA expression. A cRNA probe com-
plementary to the second intron of insulin II gene was constl1lcted that specifically detects the 
presence of primary transcripts of this gene (15). The primary transcripts are rapidly 
processed to mature mRNA and transported into the cytoplasm. For example, ill vitro studies 
with corticotrophs demonstrate that the half-life of a primary transcript is only 5-8 min, com-
pared "with up 8 hr tor the mature form of mRNA (16). The conceptual basis of our assay rests 
on two facts. First, the levels of intronic sequences, detected by nuclease protection and il1 
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situ hybridization reflects more consistently the transcription rate at the nuclear leveL Second, 
in metabolically hyperactive ~ cells, insulin production is up~regulated at all points of con-
trol, including transcriptional activity. 
Using this technique we found that I-day-old NOD neonates exhibit high levels of pre-
proinsulin 2 primary transcript expression compared to age-matched C57BL/6 mice, but the 
strain difference disappears within the first ,veek of age. Moreover, we tried to prevent this 
neonatal i> cell hyperactivity by treating the NOD mothers with insulin during the last two 
weeks of gestation. 'Ve observed a sexual dimorphism in the response of NOD neonates to 
insulin treatment: the () cell hyperactivity was down-regulated in female neonates but not in 
males. NODsdd mice lack functional lymphocytes and do not develop insulitis and diabetes 
(17) but develop a degree of hyperinsulinemia and increased mega-islet formation (8,11). 
Interestingly, no sexual dimorphism in the response to maternal insulin treatment was 
observed in NODscid neonates, but in contrast increased B cell hyperactivity \vas observed. 
Results 
The distribution of preproinsnlin II primary transcript expression is heterogenolls 
, 
a b 
c d 
Figure I. Preproinsulin II primary transcript (pplns II) expression is restricted to the nucleus of a sub-population of 
B cells in the islet. 11/ situ hyhridi7l1tion for the ppIns II was carried out on paraftin-emhedded sections as described 
in materials and methods. Serial pancreatic sections for (a) ill situ hybridization and (b) illllllunostaining for proin-
sulin (dark grey) and glucagon (black); (c) using an anti-sense probe specific signal for prIns II were restricted to 
the nucleus ofa subsct ofP eells; (d) when ill situ hyhridi7ation was carried out with a sense probe, there was a com-
plete absence of staining. 
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To determine whether B cell hyperactivity is present in NOD neonatal pancrcata, all 
intervening sequence assay was utilized, that exploited the short half-life of primary tran-
scripts in the nucleus as all indirect measure of transcriptional activity. In serial sections 
stained for the pril11a!y transcript or proinsuiin and glucagon (Fig. I a and b, respectively), 
a specitic signal is localized to the B cell area of a subpopulation of islets when compared to 
proinsulin and glucagon staining. Figure Ie shows a high pmver vie,,, p cell nuclei stained for 
preproinslilin II primary transcripts. Staining is restricted to the nucleus although not all 
nuclei arc stained in a given islet. Sections hybridized \vith sense probes have a complete 
absence of staining (Fig. ld), similar to sections pre incubated with RNase before hybridiza-
tion (not shown). 
NOD neonates have high levels of preproinsnlin primnl'y transcript expression 
Using a semi-quantitative approach to gauge the level of transcriptional activity, we 
measured the number of positive nuclei per islet area at 4 different thresholds of staining 
intensity. Threshold values were arbitrary assigned to encompass the range of staining inten-
sities. It is \vorth noting here that, in both strains at all ages, the smallest islets exhibit the 
highest numbers of positive nuclei (results not shown). 
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Figure 2. Transcriptional activity is increased in neonatal NOD mice. /11 situ hybridization for the pplns II was car-
ried out on paraftin-elllbedded sections as described in materials and methods. A VIDAS image analysis system was 
used to semi-quantit)1 the number and intensity of stained nuclei. The graph shows the number of nuclei stained per 
islet area at different arbitrarily 'Issigned thresholds of intensity (25,50,75 and 100) in NOD and C57B1I6 miee dur-
ing the early developmental period. Mean ± SEi'vf of 10 mice per age group in each strain. 
\Ve also show that I-day-old NOD neonates have a significantly greater number of 
stained nuclei when compared to age-matched C57BLl6 miee (Fig. 2). This effect is signifi-
cant in a three way ANOVAcomparing strain, age and threshold (p<lO-6 in each case). More 
specifically, post-hoc analyses show that the effect is significant between the two strains at 
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I day of age and at all threshold levels (p values li'om 0.02 to 0.00003). However, the differ-
ence between strains drops with age slich that at 7 days of age there is no significant differ~ 
cncc, Thus, NOD neonates have more hyperactive p cells than C57BL/6 neonates, but this 
difference disappears within the first week of life. 
IHnternnl insulin treatment decreases the level of preproinsnlin primary transcl'ipt 
expression in female NOD neonates, but not males 
\Ve then investigated whether the B cell hyperactivity observed in NOD neonates is 
due to possible maternal abnormalities of glucose homeostasis. \Ve therefore treated NOD 
mares with insulin (I Ull OOg bw) during the last two weeks of gestation. In this experiment, 
we analyzed separately female and male neonates for B cell hyperactivity, because of a pos-
sible interaction of androgens with insulin action (insulin resistance) (7,18,19). As can be 
seen from Figure 3, maternal insulin treatment significantly decreases the level of preproin-
sulin transcriptional activity in female NOD neonates (p<0.0006, post-hoc analyses), but not 
in males, This sexual dimorphism in insulin response was observed in two separate experi-
ents, 
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Figure 3. Insulin treatment of NOD mothers diminishes preproinslliin II primary transcript (ppIns II) expression in 
female NOD neonates only. Results are expressed as in Figure 2. The graph shows the number ofnudei staincd per 
islet arca at one threshold of intensity (50), in l-dny-old NOD mice from mothers treated with vchicle or insulin 
(I U/I OOg ow). l'<,'fean ± sm .. ! of 4 miee per treatment group in each sex. 
l\'Iaternal insulin treatment increased preproinsulin primary transcript expression in 
both sexes of NODscid nconates 
Insulin is normally not able to cross the placental barrier (20), however, in the case of 
NOD mice, insulin antibodies are able to transport the hormone into the fetal circulation 
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(21,22). Under these circulllstances, insulin \vould be able to exel1 complex effects on the 
fetuses and not only act by regulating maternal glucose homeostasis. NODsdd mice also 
exhibit a certain degree of hyperinsulininemia after weaning but, because of their lack of 
functional lymphocytes, do not develop insulitis and diabetes (8). We thought that the use of 
NODscidwould be of help to overcome the problem of the possible presence of insulin anti~ 
bodies and therefore treated NODscid mothers during the last two weeks of gestation and 
shldied the pallcreata of their progeny. As can be seen in Figure 4, the level of pre pro insulin 
transcriptional activity significantly increased in female NODscid neonates (p<0.03), while 
for male NOD neonates only a trend was observed. 
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Pigurc 4. Insulin treatment of NOo'l'cid mothers increases preproinsulin II primary transcript expression in both 
sexes ofNODscid neonates. Results [Ire expressed as in Figure 3 at one threshold of intensity (50). ~ .. lcan ± SEi\·l of 4 
mice per treatment group in each sex. 
Discllssion 
\Ve previously demonstrated a transient hyperinsuiinemia in prediabetic NOD mice, 
starting after wcaning (7). Here, we analyzed whether this hyperinsulinemia could be the 
result of an in utero « glucose~prill1ing » effect on fetal B cells, because of possible maternal 
abnormalities of glucose homeostasis (8). Due to the ditIiculty of measuring circulating 
insulin in mouse neonates, we set tip an ill situ approach to assess B cell activity in their pan-
creata. 
We showed that NOD neonates exhibit increased fl cell activity at birth compared to 
age-matched C57BLl6 neonates. However, it should be underlined that the distribution of 
preproinsulin II primary transcripts is highly heterogenous. Indeed, all islets do not express 
preproinsulill II primary transcripts and not all nuclei in a given islet. Moreover, the differ-
ence between the two strains disappears within the tirst week of age. At this age, pups are fed 
from birth onwards by low glucose-containing maternal milk that induces a B cell rest which 
lasts lIntii weaning. \Ve then tried to determine \vhethel' the B cell hyperactivity observed in 
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NOD neonates was linked to maternal abnormalities of glucose homeostasis. Indeed, ifmost 
of the NOD mothers arc not diabetic at the beginning of gestation, some ofthcm become dia-
betic during gestation or in the post-partum period. 
In order to answer this question, we treated NOD mothers during the last two weeks 
of gestation at a dose of insulin that lowers glycemia by 50% 2 hI' aftcr injection and decreas-
es maternal peri-insulitis and insulitis by about 50% in both cases (results not shO\vn), \Vhile 
levels of B cell activity are similar in temale and male NOD neonates from vehicle-treated 
NOD mothers, maternal insulin treatment exclusively dmvn-regulates it in female neonates. 
The reason for this sexual dimorphism in f3 cell reactivity of NOD neonates remains to be 
determined. \Ve expected a down-regulation of~ cell activity in neonates, due to a better con-
trol of maternal glucose metabolism. Practically, insulin does not cross the placental barrier 
unless insulin antibodies are present (20). Indeed, insulin antibodies have been described in 
NOD mice (21,22). In such a case, insulin might control its own secretion at different levels: 
at the level of the central nervous system, particularly, during the neonatal period, and at the 
pancreas level in opposite ways (23-26). The sexual dimorphism could take place at both lev-
els. It is possible also that androgens, produced by male fetuses before birth (27), induce 
a state of insulin resistance, thereby leading to overworked j1 cells (8). 
We thought that the NODscid model, devoided of functional lymphocytes, but also 
exhibiting post-weaning hyperinsulinemia (8), can overcome the possible problem of insulin 
transfer through the placental barrier, In the progeny of insulin treated NODscid mothers, ,ve 
do not observe a sexual dimorphism in f3 cell reactivity to insulin, but in contrast an up-re-
gulation in both sexes, An explanation could be the existence of abnormalities of glucose 
homeostasis in mice ,vith the scid mutation, and in particular in NODscid, but to the best of 
our knowledge this has not been described. However, it is worth noting, here, that nude 
BALB/c mice, which are deprived of thymus, exhibit several endocrine effects including 
impaired glucose tolerance at very young age and peripheral insensitivity to insulin (31, 32), 
In this regard, the non fasting basal glycemia of NODscid mothers compared to that of NOD 
was slightly higher I day after delivery, whether they have been vehicle- or insulin-treated, 
in relationship to higher glucagonemia (unpublished results), Therefore, it cannot be exclud-
ed that a state of insulin resistance in NODscid mothers may trigger the peculiar B cell 
response of their female and male progeny, 
In conclusion, NOD mice exhibit two ,vaves of B cell hyperactivity: one immediately 
after birth, which appears to be down-regulated by maternal Imv-glucosc containing milk, 
The second wave ofB cell hyperactivity is observed after weaning, when neonates experience 
a dietetic shift to high-glucose containing laboratory chow, at a time at ,vhich f3 cells are stim-
ulated even in normal rodents. This second wave of ~ cell hyperactivity could result from an 
in IIfera glucose priming effect of fetal 13 cells, which could be down-regulated, at least in 
female NOD neonates by maternal insulin treatment during gestation, However, other mech-
anisms could be involved in the second wave of ~ cell hyperactivity, such as a stimulatOlY 
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eft-eet on insulin secretion of cytokines, for example IL-I, ,vhich are produced by the early 
intiltrating APC in the islet periphery (9,28,29), This second period of j) cell hyperactivity 
might be of importance in the pathogenesis of diabetes. Hyperactive endocrine cells are more 
prone to autoimmune reactions because of higher levels of autoantigens, adhesion and 1v1HC 
molecules and because ofa higher sensitivity to cytokine-induced damage (6). 
Finally, if the maternal environment appears to be ofimportance in the control of NOD 
neonatal () cell activity, we call not exclude a genetic component. Moreover, the environment 
of the fetus (for example, the presence of androgcns) may also be at play in controlling 
B cells. Therefore, the (3 cell reactivity in NOD mice appears to be a complex event, which 
occurs velY early in life and could depend on genetic and environmental (maternal and fetal) 
factors. It remains to determine whether the down-regulation of the first wave of the !1 cell 
hyperreactivily is able to modify the evolution of the disease. 
Materials and methods 
Animals and treatments 
NOD, NODscid alld C57BLl6 mice were bred under specific pathogen-tree conditions 
at the £1cilities of the Hopital Necker, Paris, France. The animal facilities and care followed 
the norms stipulated by the European Community. The incidence of diabetes in the NOD 
colony is, by 200 days of age, 80% and 40% for females and males, respectively (7), 
C57BL/6 and NOD mice were sacrificed at t day, and 1, 2 and 4 weeks of age in the morn-
ing for pancreas sampling. Seven-week-old NOD and NODscid females were mated, with the 
morning of the appearance of the vaginal plug being taken as the day zero of gestation. Then, 
they "were injected subcutaneously once a day in the late afternoon with 1.0 U human 
insulinllOO g body weight (Ultratard, NovoNordisk, Boulogne-Billancourt, France) or with 
the vehicle from days 9 to the last day of gestation (30), Vehicle- or insulin-treated NOD and 
NODscid mothers were sacrificed 1 day after delivery at the same time as the neonates. 
Before sacrifice, NOD and NODscid mothers were rapidly bled, as previously described (7), 
to assess their glycemia using the glucose-oxidase method (Biotm! glucose enzymatic color, 
Biotrol, Paris, France). Pancreata from NOD mothers were fixed in Bouin's solution (Sigma, 
Saint-Quentin-Fallavier, France), followed by 10% formalin (Merck, Paris, France) and 
paraftin-embedded. Sections were cut at 4 pill and stained with hematoxylin eosin (Merck) to 
assess the degree of insulitis (31), 
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Tissue pl'eparation 
One- and 7-day-old animals were decapitated. Their tissues were immersion-fixed 
overnight in freshly prepared 4% paraformaldehyde. Animals over 14 days old \vere anaes-
thetized with avcrtin (Sigma), flushed with PBS containing heparin (10 U/ml) and 0.5% wlv 
NaN02 and perfused with 4% para formaldehyde. Tissues were harvested and placed in flxa-
tive for a further 2 hours. A ftcr fixation tisslies were washed in 70% alcohol and embedded 
in paratlin using routine procedures. Sections of 4-5 ~l1n were cut and placed on 3-amino-
propyltriethoxysilane (Sigma) coated slides and stored at RT. 
Construction of the murine Ins IT IVS probe 
A cRNA probe specific for the pril11aty transcript of preproillsulin II was generated 
based on a previous method (16). PCR primers were designed that spanned 354 bp of the sec-
ond intron (representing 72% of its sequence). The amplification product was generated by 
standard RT-PCR amplification from total pancreatic extracts as described previously (32) 
and puritled on a 6% polyacrylamide gel. The resulting cDNA fragment Was ligated into 
a pGETvI-T Easy vector (Promega, Charbonnicres, France) according to manufactures' 
instructions. Plasmid DNA was prepared from recombinant clones, linerized, proteinase K 
digested and phenol/chlorot'Onn extracted. Digoxigenin (DIG)-Iabeled sense and anti-sense 
probes ,vere synthesised t}'om appropriately linerized DNA using the hi vitro translation sys-
tem in the presence of DIG-ll-UTP, according to manutactures' instructions (Boehringer 
Mannheim, Mannheim, Germany) with SP6 or T7 RNA polymerase. The DNA template was 
digested by DNase I and the RNA probe NH4CI precipitated and purilled by spin column 
chromatography (Clonteeh, Palo Alto, Cal. Probes were aliquoted and stored at -70YC. 
In situ hybridization 
Tissue sections were deparaftlnized, cleared and i'ehydrated then subjected to pro~ 
teinase K digestion (l00 llg/ml) for 30 min at 25YC. The reaction was stopped with 0.2% 
glycine and sections were re-ttxed in 4% paraformaldehyde for 10 min. Sections were then 
rinsed in H20, dehydrated and air-dried. Sections were then covered with 30-40 l" of 
hybridization buffer (HB) pH 6.8, containing 100 nglml of DIG-labeled antisense or sense 
probe, 300 mM NaCI, 10 mM Na2HP04, 10 mM Tris-CI, 50 mM EDTA, 50% deionised for-
mamide, 5% dextran sulphate, 100 ~lg/ml tRNA, 100 ~lg/ml sonicated salmon DNA. Sections 
were incubated overnight at 50YC in covered .chambers humidified with HB without probe 
and 50% t'Ormamide to maintain vapour pressure. After hybridization sections were incubat-
ed t'Or 4 hrs in 2 changes ofHB without probe and 50% formam ide at 50¥C to remove probe, 
washed 3x in RNase buffer (600 mM NaCI, 10 mM Tris-HCI pH 7.2, 50 mM EDTA) and 
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incubated with 30 ~tg/ml RNase for 60 min at 37¥C. Slides were washed in PBS and inclI-
bated in 2 changes of 2x SSC at 63YC for 60 min. Slides were then washed in Tris-buffered 
saline containing 0.05% Tween 20 (TNT) and incubated overnight at 4YC with anti-DIG 
F(ab) fragments (Boehringer) at a dilution of 1/750. At the end o[the incubation slides were 
washed first in TNT, then in alkaline Tris-bufter saline containing 50 mM MgC12 pH 9,5. 
Slides were then placed in slide mailers containing 4,5 ~tg/ml nitroblue tetrazolium (NBT) 
(Boehringer) and 3.5 [Ig/m! 5-Brolllo-4-chloro-3-indolyl-phosphate Na2 (BCIP) (Boehringer) 
and left upright at RT for 4-6 hL Positive control sections were checked for staining intensi-
ty then sections were washed in butTer containing 10 111M EDTA, dehydrated and mounted in 
Eukitt. 
Immunohistochemistry for proinsnlin and glucagon 
Double labeling was performed on 4 pm sections cut from paraftin-cmbedded tissues. 
After dewaxing and rehydrating, the tissues were washed in Tris-saline buffer (O.1M Tris-
HCI, pH 7.5, 0.15M NaCI, 0.05% Tween 20). Sections were incubated with optimally dilut-
ed guinea pig anti-insulin serum (Lineo Research Inc., St. Charles, 1\10) and rabbit anti-
glucagon serum (Chemicon International Inc, Temecula, CA) overnight at 4YC. Slides were 
thoroughly washed in Tris-saline bufier and incubated first with s\'line anti-rabbit IgG conju-
gated with alkaline phosphatase (DAKO, Trappes, France) for 30 min at RT, rinsed and then 
incubated with rabbit anti-guinea pig IgG conjugated \'lith horseradish peroxidase (DAKO, 
Trappes, Prance) for a ftll1her 30 min. Sections were rinsed first in Tris-saline bufier (pH 7.5), 
then briefly in alkaline Tris-saline buffer (pH 9.5 containing 50 mM MgCI2). Immunoreactive 
glucagon was revealed using a substrate consisting 01'0.34 mg/ml NBT and 0.18 mg/ml BeIP. 
Slides were protected from light and periodically checked for staining intensity. The reaction 
was stopped by returning sections to neutral pH in Tris-saline buffer containing 10 mM 
EDTA. Slides were washed thoroughly for at least 30 min, then reacted with the peroxidase 
chromogen diaminobenzidine (Sigma) in PBS with 0.02% H202 for 1-2 min. Slides were 
finally rinsed in water counterstained with methyl green (Fluka, Buchs, Switzerland), dehy-
drated through alcohol, cleared and mounted. 
Image analysis 
We performed a semi-quantitative analysis of preproinsulin II expression via 
a VIDAS-RT image analysis system (Kontron Elektronik GmbH! Carl Zeiss, Weesp, The 
Netherlands). "Measurements were done at a magnification of20x. Islets were identified under 
phase contrast and circled. Positively stained nuclei inside individual islets were enumerated 
at four thresholds of staining intensity. To correct for the int1uence of islet size, data are 
expressed for each islet as the number of positive nuclei per 1000 pixels. It should be realized 
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that the intensity of staining differs between different experiments while the threshold levels 
arc set. Therefore, the data arc relative and can only be compared within and not between 
experiments. 
Statistical analysis 
Values are mean ± SEM of 4 to 10 neonates per age group in each strain depending on 
the experiment. For each animal, 3 noncontiguous sections were analyzed. Data were ana-
lyzed with Statistica software (Statsoft, Tulsa, OK). Possible effects of strain, age and treat-
ment were analyzed using ANOVA for each variable investigated. Post-hoc analysis, using 
the Tukeys HSD method ,vas performed when effects and interactions were significant 
(p<O.05), as assessed by ANOYA. 
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Summary 
The pathogenic process causing autoimmune diabetes in the nonobese diabetic (NOD) 
mOllse starts around 4 weeks of age "'with all accumulation of antigenwpresenting cells (APC), 
especially CD II c + dendritic cells (DC), around the pancrcatic islets of Langerhans. 
Concomitantly, a hypcrinsulincmia is observed, "which may either be cause or consequence of 
the initial APC infiltration. To determine whether infiltrating DC can cause such an islet 
abnormality, we have performed experiments in which isolated DC afC co-cultured with iso-
lated islets of Langerhans. 
We tirst show that islets isolated frcshly from 6-8 week old prediabetic NOD mice 
have higher insulin and glucagon contents than islets of C57BL/6 control mice. Moreover, as 
is the case in vivo, islets from prediabetic NOD mice do secrete morc insulin in vitro than age-
matched C57BL/6 mice. Only in NOD cocultures, the addition of DC results in an increased 
secretion of insulin; glucagon secretion is not enhanced under these conditions. 
These findings indicate that infiltrating DC may playa role in the islet hyperactivity, 
observed both ill vitro and ill vivo, and which might sensitize the NOD islet for autoimmune 
attack. 
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Introduction 
The nonobese diabetic (NOD) mouse is a widely used model for type I (insulin-
dependent) diabetes mellitus (type 1 diabetes) (I ). In this model, autoimmunity towards 
pancreatic islets of Langer hans starts with an accumulation of antigen-presenting cells (APC) 
around the islets of Langerhans. These APC include ER-MP23+ macrophages (M<j» and 
CD II c + dendritic cells (DC) (3,4). Subsequently, lymphocytes accumulate at the periphery 
of the islets (peri-insulitis). APC and lymphocytes start to infiltrate the islets (insulitis) only 
after this peri-islet lymphocytic infiltration. This process, which is associated with the infil-
tration of BMS+ M$ into the islets, ultimately results in the destruction of the insulin-pro-
ducing B cells and the gcncration of symptoms of hyperglycemia (3,4). 
Little is known about the initial trigger for the early accumulation of APC around the 
islets. In this respect, the islet itself may play an important role in initiating its own destruc-
tion (5), Several islet abnormalities have been shown in the NOD mouse that coincide in time 
with the first signs of APC infiltration, such as a transient hyperinsulinemia (6) and hyper-
glucagonemia (Pelegri et aL, submitted) and the formation of an increased frequency oflarge 
islets (7). 
These pre-insulitic islet abnormalities may playa role in the breakdown of immuno-
logical tolerance towards the insulin-producing B cells by attracting DC (5). These DC may 
be attracted because of the aberrant endocrine function, since DC have been shown to regu-
late endocrine cell function and growth in several endocrine organs (8), For example, rela-
tively large numbers can be found in the anterior pituitary, where DC form a subgroup of the 
network of folliculo-stellate cells (9) that regulates the hormonal responses of neighbouring 
endocrine cells (10,11). In the ovary and the testis, APC playa role in the regulation of ovu-
lation (12) aud in growth and steroid production of granulosa, theca, luteal and Leydig cells 
(8,13,14). DC arc also present in low numbers in the normal thyroid (15,16) and modulate the 
growth of thyrocytes (17). Cytokines, such as IL-I, IL-6 and TNF, playa major role in these 
modulating actions (8). For pancreatic islets, however, a similar regulating role of DC has not 
been shown. 
Thus, a physiological response may explain the specific attraction of DC towards dys-
functioning islets. However, the islet abnormalities coincided in time with the influx of APC, 
leading to the possibility that the abnormalities are the consequence and not the cause ofinfil-
trating APC. Thus, the exact relationship between early islet abnormalities and early infiltrat-
ing APC in the NOD mouse model of type I diabetes is unclear at present. 
In this study, we address the question whether DC are able to influence the activity of 
pancreatic islet cells. For this purpose, we have isolated islets and cultured them in the pres-
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cnce of isolated DC to determine their effects on islet activity, as assessed by insulin and 
glucagon secretions and contents. Furthermore, we compare the effect of DC on islets isolat-
ed fro111 normal C57BL/6 and autoimmune-prone NOD mice. 
Results 
NOD islets contain and secrete more insulin in vitro than C57BL/6 islets 
\Ve previollsly showed a transient hyperinsulincmia in prediabetic 4- to 8-week -old 
NOD mice, when compared to mice from various control strains, in particular the C57BL/6. 
This transient hyperinsulincmia was rapidly followed by an increased fl-equency of so-called 
mega-islets in NOD mice. \Ve therefore assessed whether a similar NOD/C57BL/6 difference 
in insulin secretion and/or content could also be observed il1 vUra. Indeed, the insulin contents 
of islets isolated from prediabetic (8-week-old) NOD mice measured at the start of the incll-
bation (immediately ex vivo) wcrc significantly higher than in C57BLl6 mice (I4797±3332 
versus 6192±815 flU/well, p<O,004), Moreover, islets from prediabetic (8-week-old) NOD 
mice secreted significantly more insulin in a 24h-culture than those from C57BL/6 mice at 
the stimulating concentration of glucose used (II mM) (p<O,002) (Fig, I), This is accompa-
nied by a significant decrease of insulin contents after 24 h incubation only in the NOD strain 
(p<O.0006, Fig. 1). The enhanced insulin secretion by NOD islets il1 vUra is reminiscent of 
the hyperinsulinemia which can be found at the same age in NOD mice ill vivo. 
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Figure I; Insulin content as a function of culture time in islets from C57BLl6 and NOD mice (len l1gure) and insulin 
secretion during 24h of culture (right tigure). NOD mice have significantly higher insulin contents than C57BLl6 
mice dircctly ancr isolation. After 24h of culture, insulin content in NOD and C57BLf6 mice are comparable, due to 
a significantly higher insulin secretion of NOD islets. 
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Thus, the behaviour of the islets in these culture conditions reflects their behavior il1 
vivo, since NOD females have higher blood insulin responses than C57BL/6 females to 
intraperitollcally glucose administration (6). 
NOD islets haye higher glucagon contents than C57BLl6 islets 
Since insulin- and glucagon-secretions are tightly co-regulated, we also investigated 
islet glucagon contents and secretion. As already observed for insulin contents, glucagon COll-
tents were also significantly highcr in NOD islets than in C57BLl6 oncs at the start of the 
incubation (I9540±3970 pg/wcll for NOD and 10771±1737 pg/well for C57BLl6, p<O.03) 
(Fig. 2). We previously demonstrated significantly higher blood glucagon levels in predia-
betic NOD mice ill vivo as compared to control C57BL/6 mice (Pelegri et aI., submitted). 
Indeed, after a 24 h in vitro incubation at high glucose concentrations, glucagon secretion 
appeared to be higher in islets from NOD than li'om C57BLl6 mice, although this difference 
was not statistically significant (Fig. 2). However, islet glucagon contents after 24 h of cul-
ture were significantly decreased in NOD islets, but not in C57BLl6 islets (1'<0.02, Fig. 2). 
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Figure 2: Glucagon content in is\cts from C57BLl6 and NOD mice directly after isolation and after 24 hours of cul-
ture (len figure) and glucagon secretiun during 24h oCculture (right J1gure), After isolation, NOD mouse islets have 
signiJ1cantly higher glucagon contents than C57BLl6 islets, Aftcr 24h of culture, glucagon content in NOD and 
C57BLl6 mice afe comparable, related to a higher glucagon secretion of NOD islets, 
NOD DC stimulate islet insulin release in vitro, whereas C57BLl6 DC have no effect 
To determine whether inflltrating DC could cause early islet abnormalities, co-culture 
experiments were performed in which three different DC concentrations were added to islets 
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of the same strain. In C57BL/6 mice, the addition of DC did not significantly affect in vitro 
islet insulin release, regardless of the DC concentration llsed (Fig. 3). However, the addition 
of NOD DC at the two lowest concentrations to NOD islets significantly stimulated islet 
insulin release (1'<0.02) (Fig. 3). 
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Figure 3: Insulin secretioll in co-cultures of C57BLl6 and NOD islets with different numbers of syngeneic DC. 
Lower concentrations of NOD DC, but not C57BLl6 DC, stinllliatc islet insulin release in vitro. 
The addition of DC from either NOD or C57BLl6 to their syngeneic islets did in no 
case significantly influence islet glucagon release (Fig, 4). 
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Figure 4: Glucagon secretion in co-cultures of C57BLl6 and NOD islets with dillerent numbers of syngeneic DC. 
DC rrom both NOD and C57BLl6 mice do not signiticantly influence islet glucagon release ill vitm. 
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It is worth noting that morphological changes \vere observed only in the C57BL/6 DC-
islet-coculture after 24h of incubation, but not in the NOD coculhuc, In C57BL/6 cultures, 
DC appeared to be attracted to the islets and intermingled with a few fibroblasts around the 
islets. Moreover, the appearance of small, duct-like structures was observed in these C57BL/6 
DC-islets cocuihlres, 
In summary, in these experiments NOD mouse DC were able to stimulate islet insulin 
secretion, but not glucagon secretion. DC from control mice did not aft-ect islet insulin, nor 
gl ucagon release. 
Discussion 
The presence of leukocytes such as DC in normal endocrine glands and their role in 
the physiological control of endocrine function raises questions about their possible patho-
physiological role in endocrine autoimmunity. Suggestive of such a pathogenic role is the 
observation that the accumulation of DC in the endocrine target organ is usually the first sign 
of self-reactivity. This is observed at the thyroid and the islet level in spontaneolls animal 
models of endocrine autoimmunity, such as the BB-rat (18) and the NOD mouse (3). The 
presence orDC has also been described in human endocrine autoimmunity, in the thyroid (16) 
and in pancreatic islets (19). In NOD mice, the presence ofCDllc+ DC coincides in time 
with the appearance of early islet abnormalities. Therefore, \ve approached the question 
whether early islet abnormalities are cause or consequence of DC infiltration. In order to 
answer this question, we performed cocuitul'es of isolated islets of Langerhans and DC of 
NOD and control C57BLl6 mice. 
\Ve first found that NOD islets isolated from 6-8 weeks old mice contain more insulin 
and glucagon than islets tl-om C57BL/6 mice. Furthermore, NOD islets secrete in p3l1icular 
more insulin. These ill vitro findings clearly parallel our previous results hI vivo, since from 
4-8 wceks of age, NOD mice show an islet hyperactivity, as evidenced by elevated basal 
blood insulin levels and increased insulin response to intra-peritoneal glucose administration 
(6). There is also, but to a lesser extent, an increase of blood glucagon levels in NOD mice at 
4-8 weeks of age (Pelegri et aI., submitted). 
111 vlvo, islet hyperactivity is followed in time by an islet hypertrophy, as evidenccd by 
an increased number of velY large islets, that start to develop between 5 and 10 weeks of age. 
Both APC and lymphocytes arc preferentially situated ncar these mega-islets (Rosmalen et 
aI., submitted). This association between infiltrating cells and mega-islets is especially strong 
for the CDllc+ DC. This association may be explained by two non-mutually exclusive pos-
sibilities: mega-islets, by virtue of an enhanced release of antigen and other fhctors, may 
specifically attract these infiltrating cells; alternatively, infiltrating cells may primarily accu-
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mulate in the islet area tor an as yet unknown reason, and cause the islet hyperactivity 
observed in vivo and ill vitro, followed by islet hYPCl1rophy. 
The current coculture experiments of NOD DC and islets suggest that the second pOSw 
sibility may playa role. \Ve show that NOD DC stimulate islet insulin release ill vitro, where-
as DC li·om C57BLl6 mice have no such effect when added to C57BLl6 islets. Thus, the accu-
mulation of DC around the islets can contribute to the observed endocrine islet abnormalities. 
It is worth noting here that a similar mechanism seems to take place in the BB rat thyroiditis. 
In this model, the initial influx of DC coincides in time \'lith abnormalities in thyroid T3 pro-
duction and an enhanced proliferation of thyroeytes (17). 
From our current data we can not conclude whether the enhanced insulin release in 
cocultures fl'om NOD DC and islets is due to aberrations in the DC or in the islets. 
Preliminary experiments indicate that C57BL/6 DC are not able to affect insulin release of 
NOD islets significantly. These data suggest that the enhanced insulin release, as observed in 
cocultures of NOD islets and NOD DC, can be attributed to an aberrant DC function in NOD 
mice. These experiments however await confirmation. 
Thus, NOD DC, but not C57BLl6 DC seem to stimulate syngeneic islet function. It 
can not be excluded, however, that contaminating cells in splenic DC isolates, such as lym-
phocytes, contribute to the observed insulin release of NOD islets cocultured with DC. Since 
islets cocultured with DC do not show any signs of destruction, it is unlikely that direct lym-
phocyte- (or DC-) mediated islet cell-cytotoxicity as the cause for the enhanced insulin lev-
els in the culture medium. Finally, a significant stimulating DC eft-ect was only observed at 
the two lowest DC concentrations, suggesting that too Illany DC, as added in the highest con-
centration, were able to inhibit a fully stimulated [3 cell function. This can be explained by the 
fact that cytokines, such as the APe-product IL-l, may stimulate or inhibit islet function 
depending on their concentration (20,21). Thus, cells that secrete such cytokines may exert 
opposite efiects on the islets, depending on their cell number. Therefore, the enhanced insulin 
release that is observed in NOD cocuitul"es is not likely to be due to cytotoxic eft-ects of con-
taminating cells. 
Finally, it should be noted that in both spontaneous animal models (22,23) and human 
autoimmune diabetes (24,25), APC have been shown to be abnormal in their immune regula-
tory function. These defects in immune regulation are thought to be important in the loss of 
tolerance towards self-components. However, as DC have, besides antigen presentation, an 
additional function in endocrine regulation, it is tempting to speculate that this function may 
also be abnormal. In line with this, it has been shown that DC of autoimmune-prone BB rats 
are defective in regulating the growth of thyrocytes (17). 
In conclusion, DC appear to play an important role in the communication between the 
immune system and the pancreas in the pathology of type 1 diabetes. This makes them inter-
esting candidates for a role in causing endocrine autoimmunity. 
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Materials and methods 
Animals 
NOD and C57BL/6 female mice were bred under specitic pathogen-free conditions at 
the facilities of the Hopitai Necker, Paris, France, The animal facilities and care foIlo:wed the 
norms stipulated by the European Community. The incidence of diabetes in the NOD colony 
is, by 200 days of age, 80% for females and 40% for males. For eoeliiture experiments, DC 
and islets were isolated from 6 to 8-week-old C57BLl6 control and prediabetic NOD mice. 
Isolation of islets 
Ten mice were sacrificed by cervical dislocation for a given islet isolation, their pan-
creases were removed and cut into small pieces in PBS supplemented \vith 5% fetal calf 
senltn (Biological Industries, Kibbutz Beit Haemek, Israel), 100U/ml penicillin I I OO~lg/ml 
streptomycin (GibeD BRL, Life Technologies, Cergy Pontoisc, France) and 0.05% glucose 
(Laboratoires Mel'am, Rhone Poulenc, TVfelun, France) (PBS/5% FCS). Thesc pieces were 
incubated with thorough shaking with 40 mg collagenase P (Boehringer rVfannheim, 
Mannheim, Germany) in 8 ml PBS supplemented with 15% FCS, penicillin/streptomycin and 
glucose, t'Or 6 minutes at 37°C. \Vhen pieces had visibly dispersed, the digestion was stopped 
by the addition of ice-cooled PBS/ 5% FCS and the tissue digest was washed 3 times in ice-
cooled PBS/5% FCS. Islets wcre puritied as follows on a discontinuous Euro-Ficoll density 
gradient, obtained by adding 34%, 23%, 20% and II % (w/v) Ficoll 400 (Sigma, St Quentin 
Fallaviel', France) to Euroeollins solution (Fresenius France, Division Biosedra Pharma, 
Louviers, France). After removal of the last washing supernatant, 3 IllI of 34% Euro-Ficoll 
were mixed with the pelleted tissue digest. To this tissue layer, 3 ml of23% Euro-Ficoll, 2 ml 
of20% Euro-Ficoll and 2 ml of II % Euro-Ficoll were gently added. Purified islets wcre col-
lected from the upper two intertaces and washed hvice in PBS/5% FCS. Islets were kept on 
ice in MEM glutamax (Gibco) supplemented with 10% FCS, 1% sodium-pyruvate (Gibco), 
1 % non-esscntial amino acids (Gibeo), I % penicillin-streptomycin and aprotinin (2000 
KIUlml) (Bayer Pharma, Puteaux, France). MEM glutamax (5.5 mM glucose) was also sup-
plcmented with extra glucose as the culture medium throughout the study contained ILl 111M 
glucose to mimick high glucose levels ill V;\lO. 
The purity of islets was checked with a dithizone staining. For this staining, 1 ml 
DMSO (Sigma) was added to 30 mg dithizone (Sigma). PBS was added to a final volume of 
10 ml, and the solution was filtered through a 0.2 ~1111 mesh. 200 ~tl of DMEM with purified 
islets was added to 150 ~li of tile dithizone solution in a petri-dish with grid. Islets were count-
ed and checked for purity. 
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Isolation of DC 
Three mice were sacrificed by cervical dislocation, their spleens were removed, 
pooled and cut into small pieces. Cells were incubated for 60 minutes at 37 DC with 130 U/ml 
collagenase III (Worthington Biochemical, Freehold, NY) and O.lmg/ml DNAse! (li"Oll1 
bovine pancreas, grade II; Boehringer Mannheim GmbH, Germany) in RPM! (Gibeo) sup-
plemented with 25 1111V1 Hepes and 1 % penicillin/streptomycin, The tissue was teased through 
a 40 mm filter and washed with RPMI supplemented with 25 mM Hepes, I % penicillin/strep-
tomycin and 10% FCS (RPMIIFCS). All washing steps included centrifugation for 5 minutes 
at 400g. The cell pellet was resuspended in elythroeyte shoek buffer (NH4CI 9.84 g/I, 
KHC03 I g/I, EDTA O. I mM) and incubated for 10 minutes on icc. Cells were washed again 
with RPMIIFCS, resuspended in RPMVFCS at 107 eclls/ml and cultured overnight at 37DC 
and 5% C02- Non-adherent cells were collected and resuspended in RPMIIFCS at a concen-
tration of 1-2.107 cells/ml. Two 1111 of the cell suspension was layered on top 01'2 111114% 
Nycodenz (Nycomcd Pharma As, Oslo, Norway) in RP.MIIFCS, This gradient was centrifu-
gated for 20 min at 530 x g and the interphase was collected. The interphase was mixed with 
RPMIIFCS I: I and this mix was centrifuged for 10 min at 400 x g. Finally, the cells were 
washed with RPMTIFCS. The purity of the DC was checked by FACS-staining using N4IS-
FITC identitying CDlle+ DC, and the resulting cell suspension was about 70% CDI le+ 
Contaminating cells were primarily B IYI11I}hocytes. 
Islet-DC co cultures and insulin and glucagon determination 
Islets and DC were used immediately after isolation and counting. Incubations were 
performed in 24-well plates (Falcon, Polylabo, Strasbourg, France). 20 islets were distributed 
per well with or without varying numbers of DC (1.104, 5. I 04, 1.1 05). The total volume of 
incubation was 500 ~ll/\vell. 
Part of the wells without DC were used immediately after the distribution ofthe islets 
in order to determine total insulin and glucagon contents at the beginning of the culture. 
Supernatants and islets were collected and sonicated for lOs in 500 [II acid-ethanol (1.5% 
(v/v) IN HCl in 75% ethanol). After overnight extraction at 4°C, the samples were stored at 
-20°C until the insulin or glucagon concentration was determined by radioimmunoassay. 
The wells containing islets with or without DC were cultured for 24h at 37°C in an 
atmosphere of 5% C02 in humidified air. The incubation media of islets alone (controls) or 
cocultured \vith DC were collected and frozen at -20De prior to RIA for insulin or glucagon. 
For the measurement of the islet hormone contents after 24h incubation, islets were collect-
ed in 500 ~tl of acid-ethanol as described above, The extracts were stored at -20°C before 
RIA. Insulin and glucagon concentrations in medium were determined using standard RIA 
kits (SB-INSULIN CT, CIS Biointernational, Gif-sur-Yvette, France for insulin; Biodata, 
Pharmacia, Saint-Quentin-cn-Yvelines, France for glucagon). 
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Statistical analysis 
All data are expressed as mcan ± SEM (n~8/group). Statistical significance for differ-
ences in insulin and glucagon levels was determined by means ofa 2-way ANOVA, Post-flOC 
analysis, llsing the Newman-Kellis test, was performed when ANOVA revealed that effects 
and interactions were significant (p<O.05), 
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Summary 
Although several defects in immune function have been observed in prediabetic and 
diabetic animals and humans, these do not explain the organ specificity of the autoimmune 
reaction. In the search for prediabetic islet abnormalities, we previollsly found transient 
hyperinsulincmia in nonobcse diabetic (NOD) mice. To determine whether hypcrglucagone-
min might playa role in triggering this hyperinsulinemia, variolls C( cell parameters were 
compared in NOD, lymphoc)1e-deticient NODscid and control C57BLl6 females from birth 
onwards. 
Before weaning, blood and pancreatic glucagon levels were significantly lower in 
NOD and NODscid compared to C57BLl6 mice. In contrast, after weaning, glucagonemia 
was higher in NOD and NODscid than in C57BLl6 mice. To analyze in situ a cell behavior, 
glucagon imlllunohistochemistry was combined with image analysis, so as to calculate the 
number of islets of a given size and the percentages of islet glucagon-positive areas as a fUBc-
tion of islet size, From birth onwards, the percentages of glucagon-positive areas were high-
er in NOD pancreata than C57BL/6. This difference was principally observed at the level of 
small-sized islets in NOD mice, while only a trend was found in NODscid. Moreover, NOD 
and NODscid mice, particularly at I day of age, had twice as many velY small islets as 
C57BLl6 mice. 
These data suggest that, before weaning, NOD, and to some extent NODscid, pancre-
ata contain more immature islets (as ret1ected by their small size and high percentages of 
glucagon-positive areas, concomitant ,vith lower glucagon secretion and storage) than 
C57BL/6 pancreata. This islet immaturity might playa role in the initiation of islet autoim-
munity. 
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Introduction 
Despite extensive genetic and immunological research, the complex etiology and 
pathogenesis of type I (insulin-dependent) diabetes mellitus (type I diabetes) remain unre-
solved (1). In addition to investigations in humans, t\vo spontaneous animal models of the 
disease have been helpful in these studies, namely the bio-breeding rat and the Ilonobese dia-
betic (NOD) mouse (2,3). In all cases, type 1 diabetes is a polygenic disease, with multiple 
defects in various immune-cell types (2,3). However, these immune dysfullctions cannot 
explain the organ specificity of the autoimmune process. It has been suggested that abnor-
malities in the islet itself may play an important role in the breakdown of tolerance towards 
islet p cells (4). 
In our search for such prediabetic islet anomalies, \ve demonstrated a rather surprising 
but transient p cell hyperactivity in prediabetic NOD mice (5). Indeed, we observed higher 
insulin levels and lower glycemia values in 4- to 8-\veek-old NOD mice, particularly females, 
as compared to mice t}'om variolls control strains (4). Hyperinsulinemia was also shared to 
some extent by the NODscid mouse, "which lacks fUllctionallymphocytcs and therefore does 
not develop lymphocytic insulitis or diabetes (6). l-lyperinsulinemia in NOD and NODsci" 
mice appears just after the change of diet at weaning, which normally takes place at about 
3 weeks of age in all mice. It is also worth noting that this is the time at which the primary 
infiltrating immune cells (dendritic cells and macrophages) begin to reach the periphery of 
the islets of Langerhans in both NOD and NODscid mice (4,7,8). Hyperactive islets may be 
essential for the progression of the disease in NOD mice, since islets in the activated state are 
known to express elevated levels of cell~adhesion ligands, major histocompatibility complex 
molecules and autoantigcns, which may heighten the sensitivity of B cells to the cytotoxic 
effects of c)10kines (9). 
The cause of the transient !1 cell hyperactivity observed in NOD and NODscid mice is 
not known. Experimental data suggest that hypergiucagoncmia, among other factors, might 
be involved in NOD f3 cell hyperactivity. Hyperglucagonemia stimulates insulin secretion in 
vitro by pancreata from normal animals and those with spontaneous type 2 diabetes (10~12). 
Indeed, hyperglucagonemia has been described in prediabetic (2-month-old) NOD mice, 
compared to their ICR littermate controls (13). Therefore, we hypothesized that hyper-
glucagonemia ,vas involved in the transient NOD ~ cell hyperactivity. To investigate in 
greater depth the role of glucagon in p cell hyperactivity, we determined a cell presence and 
activity in mice with the NOD genetic background (NOD and NODscid) as compared to con-
trol mice (C57BL/6). This assessment was done from birth to 10 weeks of age, because the 
autoimmune reaction involving antigen-presenting cells and lymphocytes progresses during 
this time frame at the NOD pancreas level, but clinical onset of diabetes is not yet observed. 
NODscid mice, which also show transient hyperinsulinemia but no insulitis or diabetes due 
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to the absence of functional lymphocytes, were lIsed to distinguish between the early 
endocrine abnormalities that exist on a NOD genetic background and therefore precede the 
lymphocytic intiltration, and those that arc induced by infiltrating lymphocytes as observed 
in NOD mice. 
Results 
NOD and NODscid blood glucagon levels are lower before and higher after weaning 
compared to C57BLl6 mice 
To investigate whether hyperglucagoncmia could play a role in the previously 
observed ~ cell hyperactivity in NOD mice, we determined nonfasting blood glucagon levels 
in NOD, NODscid and C57BL/6 mice. Figure 1 shows circulating glucagon levels as a func-
tion of age in the three strains. 
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figure I: Basal nonHlsting blood glucagon levels in C57BLl6, NOD <lnd NODsdd femules as a function of age. 
Values [lrc expressed as means ± SElvJ (n=15/age/strain). Individually, strain and age significantly affected nonfast-
iug blood glucagon levels (p<O.O I and p<1O-6, respectively) and there was also a significant strain x age interaction 
(p<to-6). 
\VhiIe blood glucagon levels decreased with age in all strains, the patterns of decrease 
differed between the control strain (C57BLl6) and the strains with the NOD genetic back-
ground. In C57BLl6mice, as was already described for normal rodents (14-18), glucagon lev-
cIs ,vere relatively high before weaning and declined significantly thereafter. In pm1icuiar, 
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glucagon levels in C57BLl6mice at 7 or 14 days of age were significantly higher than those 
found at later time points (p<l O~4): the most significant decline was observed bet\veen days 
14 and 28 of age in close relationship to \veaning that occurs at 2 I days of age. In NOD and 
NODscid mice, a decrease of blood glucagon concentrations was also observed with age, but 
it was delayed and less marked compared to C57BLl6. 
These different kinetics of blood glucagon concentrations in NOD and NODscid mice 
were the reflection of differences in circulating glucagon levels at a given age. Before \vean-
ing, on days 7 and 14, nonfastillg blood glucagon concentrations were significantly higher in 
C57BLl6 than in NOD (p<O.Ol) and NODscid (p<O.05) mice. By contrast, after weaning, 
glucagon concentrations in NOD and NODscid were constantly higher than those in C57BL/6 
mice, with differences reaching significance at some time points, in particular on days 28 and 
56 (p<O.05 and p<10-4, respectively). 
In summmy, blood glucagon levels at different ages differ between control mice and 
mice with the NOD genetic background. Before weaning, NOD and NODscid mice have 
lmyer circulating glucagon levels and, after weaning, higher glucagon levels than control 
C57BLl6 mice. 
NOD and NODscid mice have low glucagon pancreatic contents before weaning COIll-
pared to C57BLl6 mice 
The lower blood glucagon levels in NOD and NODscid mice before weaning might be 
due to either Imv synthesis, low secretion or enhanced glucagon turnover, In an attempt to 
ans,ver this question, we determined the amount of pancreatic stored glucagon in NOD, 
NODsci" and C57BLl6 mice. 
Because of the marked grmyth of the pancreas after birth, it is common to express the 
pancreatic glucagon content as ng of glucagon/mg of pancreas (17,19,20) (Fig. 2). In this 
case, pancreatic glucagon contents were significantly decreased in all strains after weaning as 
compared to before weaning (p<IO-4 for C57BLl6 and NODscid; p<O.05 for NOD mice). 
This decreased pancreatic glucagon content that we observed in all strains has been described 
in other rodents (21,22), and is due to the marked growth of pancreatic tissue, particularly the 
exocrine compartment. \Vhile there was no significant difference in relative pancreatic stored 
glucagon amounts between the three mouse strains after weaning, before weaning, a differ-
ence between control and NOD strains was observed: 7-day-old C57BL/6 mice had signifi-
cantly higher pancreatic glucagon contents than age-matched NOD (p< 1 0-4) and NODscid 
(p<0.05) mice. At 14 days of age, the difference between C57BLl6 and NODscid mice was 
still significant (p<O.O I). 
Therefore, before weaning, mice with the NOD genetic background are characterized 
by low circulating glucagon levels and low glucagon pancreatic contents, compared to 
C57BLl6 mice. These data might suggest low glucagon synthesis ill mice with the NOD 
genetic background before weaning as compared to control mice. 
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Figure 2: Pancreatic glucagon contents in C571:3L16, NOD and NOD.I'cit! females as a function of age. Values arc 
expressed as means ± smvl (n=15/agc/strain). Individually, strain and age significantly aficcted pancreatic glucagon 
contents (p<1O-6 in both cases) and there was a significant strain x age interaction (p<O.OI). 
NOD mice haye a higher a/fJ cell ratio in their islets than C57BL/6 mice before weaning, 
especially in vcr)' small and slllall islets 
To determine whether the strain-related differences observed in glucagon parameters 
were reflected in morphological differences at the islet level, we examined islet characteris-
tics combining immunohistochemistry and image analysis to quantify the data. 
An example of the immunohistochemical data obtained in pancreata from 7Mday-old 
female C57BL/6 and NOD mice is given in Figure 3. Figure 3a shows a pancreas section from 
a C57BL/6 mouse stained for insulin and glucagon. At this age) the few glucagonMpositive 
a cells are located at the periphery of large islets surrounding the f3 cell core) characteristic 
typical of a mature islet with a low alB cell ratio. In contrast) sections of age-matched female 
NOD pancreata (Fig. 3) b and c) show small clusters of glucagon positive a celis) which only 
occasionally contain insulin-positive 1-3 cells. In addition) in NOD mice) many small islets are 
observed) that seem to have a large proportion of glucagon-positive a cells around the periph-
elY of the Il cell core, characteristic of a high n/ll cell ratio (Fig. 3d). 
\Ve first determined the percentage of islet areas that contained glucagon-producing 
cells in all islets from CS7BLl6, NOD and NODscid mice as a function of age, regardless of 
their size (Fig. 4a). Considering all ages together) the percentages of glucagon-positive areas 
in all islets were significantly higher in NOD than in C57BLl6 (p<O.OO I) and NODseid 
(p<O.OI) mice (with the latter two being comparable). When comparing NOD and C57BLl6 
mice at a given age) the percentages of glucagon-positive areas in islets were significantly 
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higher in NOD mice only before weaning at 1 and 14 days of age (p<O.OS) and tended 
towards significance at 7 and 21 days of age (0.05<p<0.07). Thus, beforc weaning, NOD 
mice exhibited high H/I) cell ratio in their islets, but low glucagon levels in the circulation and 
pancreas, in contrast to C57BL/6 mice which, at the same age, had the opposite endocrine 
parameters. 
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Figure 3: Sections of 7-day-uld fCllwie C57BL/6 (a) and NOD (b-d) mouse p<lllcreata stained for immunoreactive 
glucagon (black) and insulin (dnrk grey) (original magnitication a to d; x16 or x25). Small glucagon-positive islets 
are present throughout the tissue of NOD (b-d) but nol C57BLl6 mice (a). I\'Jany insulin-containing islets in NOD 
mice have unusually large proportions of glucagon positive « cells at their pcriphcry (d), as compared to age-matched 
C57BLi6 (a). 
To analyze further the distribution of the glucagon-positive areas in the various strains, 
we arbitrarily classified islets based on their size: less than 2000 pixels (very small), 2000 to 
SOOO pixels (small), SOOO to 10000 pixels (medium) and more than 10000 pixels (large). The 
percentages of glucagon-positive areas were then calculated separately for the difterent islet 
size classes. Figure 4b shows that, when considering all ages together, NOD mice had sig-
nificantly higher percentages of glucagon-positive areas in the very small islets compared to 
CS7BLl6 mice (p<O.OI), while NODscid mice only showed a trend towards signiticantly 
higher values compared to CS7BLl6 mice (p~0.076). However, NOD and NODscid mice did 
not difter significantly concerning the percentages of glucagon-positive areas in the very 
small islets. NOD mice also had higher percentages of glucagon-positive areas compared to 
CS7BLl6 mice in small islets (2000 to SOOO pixels) (p<O.OOI, data not shown), but not in 
islets of more than 5000 pixels. Thus, the higher percentages of glucagon-positive areas in 
NOD mice, compared to CS7BLl6, are principally accounted for by the "elY small and small 
islets. 
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Figure 4: Glucagon-positive areas given as percentages of total islet area in all islets and in very small islets (less 
than 2000 pixels) in C57BLl6, NOD and NODscid temales as a function of age. Values are expressed as means ± 
smvl (n=6/age/strain). (a) Concerning all islets, both strain (p<O.OOI) and age (p<O.05) ailected glucagon positivity, 
but the Iwo variables did not interact significantly. (b) Conccming the very small islets (less than 2000 pixels), 
ANOVA revcaled etfects of strain (p<0.02) and age (p<0.05), but no significant interaction between the Iwo vari-
ables. 
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Both NOD and NODscid mice have lIlore vcry small islets than C57BL/6 mice dnring 
the eariy postnatal period 
So far, \ve have shown that mice with the NOD genetic background exhibit !mver basal 
glucagon secretion and lower pancreatic glucagon stores than control mice, together with 
higher alp cell ratios, particularly in NOD mice. These data suggest the presence of imma-
ture islets in NOD mice as schematized in Figure 5, since such islets are characterized by low 
glucagon synthesis, secretion and content, despite high n/f> cell ratios (16-18). 
NOD C57BL 
glucagon secretion low ] low synthesis high] high synthesis pancreatic glucagon content low high 
% glucagon+ area high low 
in small islets 
% very small islets high low 
o--@--
maturation of the islet of Langerhans 
Figure 5; Schema summarizing the diftercnt parameters of (( cell behavior in NOD and C57BLl6 mice before wean-
ing o11d their relationship to islet development. Islets of NOD mice exhibit characteristics of immature islets, where-
as islets ofC57BLl6 mice exhibit characteristics of mature islets. 
Finally, we addressed the question whether the numbers of these very small and small 
immature islets differ between NOD, NODscid and C57BLl6 mice. Indeed, the striking find-
ing was that both NOD and NODscid mice had, on a percentage basis, hvice as many velY 
small islets (less than 2000 pixels) as C57BLl6mice at bilth (p<O.OOI) (Fig. 6). A signiticant 
difference between strains was still observed at 7 days (p<O.05), but had disappeared by 14 
days. Hmvever, no significant difference ,vas observed between strains for the percentages of 
small islets. 
In sUl11maty, betore weaning, NOD mice, and to some extent NODscid mice, had more 
islets with signs of immaturity than C57BL/6 control mice. 
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Figure 6: Frequency ofver), small islets (less than 2000 pixels) in C57BLl6, NOD and NODscid remales as a func-
tion of age. Values are expressed as means ± SEi'v[ (n=6/agC'/strain). Ooth strain and ag(: sigllit1cllntly affected the per-
centages oevery smull islets (p«1.01), but the two variables did not interact significantly. 
Discllssion 
The data presented above illustrate several differences in u. cell behavior between mice 
with the NOD genetic background and control C57BL/6 mice, particularly before weaning. 
The most conspicuous difference ,vas the presence in 1- and 7-day-old NOD and NODsdd 
mice of high numbers ofvelY small islets ,,,ith relatively enhanced air) cell ratios, especially 
in NOD mice. 1Vforeover, the presence of these small~sized islets is associated, during the 
early postnatal period, ''lith low blood glucagonemia and Im'l pancreatic glucagon stores. 
Taken together, these features are characteristic of immature islets and suggestive of per-
turhed islet development in mice with the NOD genetic background. 
Normally, the neogenesis of islets from duct epithelial cells occurs during embtyonic 
development and very early postnatal life (18,23). Normal rodent islet development andlor 
regeneration is characterized by increased numbers of small islets and frequent connections 
between islets and ducts (24-26). In the fetal rat, a cells are the most numerous endocrine cell 
type, accounting for over 2% of the total pancreatic mass at 16 days of gestation (16), The 
characteristic pattern of central p cells and peripheralnon-p cells is not established until day 
20 of gestation. By birth, the differential growth rates of the various endocrine cells result in 
a predominance of (3 celis, leading to a decreased alB ratio, while the glucagon content per 
u. cell increases sharply (17), 
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In normal rodents, glucagoncmia and pancreatic glucagon contents arc knmvn to be 
high during the Ileonatal period and to decline sharply thereafter (14-18). 
Hypergiucagoncmia, immediately after birth, is considered to be an adaptative mechanism to 
coullterbalance the normally occurring neonatal hypoglycemia (14,15) alld was observed here 
before wcaning in C57BL/6 mice, but also in all normal mouse strains we investigated 
(unpublished results), It is worth noting here that basal glucagoncmia before weaning was 
significantly lower in mice with the NOD genetic background than in C57BL/6 mice, con-
comitant with Im'1 glucagon contents and high numbers of very small islets '''lith a high u/!) 
ratio, as assessed immunohistochcmically. According to what is known about islet differenti-
ation, these characteristics are suggestive of the presence of more immature islets in NOD 
(and also to some extent NODscid) mice than in C57BLl6 (Figure 5). 
Later, Le., after weaning, NOD and NODsdd mice experienced relative hyper-
glucagonemia, thereby confirming the results obtained by others (13). This hyperglucagone-
mia might be due to an endocrine imbalance at the islet level or be attributable to the increas-
ing numbers of leukocytes arollnd the islets. For example, cytokines, such as interleukin-l, 
are known to stimulate glucagon secretion in vivo and in vitro (27-29). Recently, we observed 
that interleukin-l was able to stimulate in vivo glucagon secretion in prediabetic NOD 
females (unpublished results). Moreover, since glucagon is known to stimulate insulin secre-
tion (10-12), it cannot be excluded that the relative hyperglucagonemia postweaning might be 
partly responsible for thc basal hyperinslilinemia that we previously observed, particularly in 
NOD females, tiom 4 weeks of age onwards (5). Such a sequence of events has already been 
described in C57BLlKs mice, a spontaneous model of type 2 diabetes (12). 
Tn light of the concepts described above, our data suggest that newborn NOD mice, 
and also to some extent NODscid mice, harbor more immature islets with fcatures character-
istic of neogenesis, i.e., very small size associated \vith large glucagon-positive areas and 
diminished capacities to synthesize and secrete glucagon. Other investigators have also 
described postnatal developmental islet abnormalities in the NOD mouse. For example, very 
high percentages of adult j) stem cells (SaM +/PDXI +) wcre found in 4-week-old NOD mice 
compared to lCR mice (40% versus 10%, respectively) (30). The numbers of these stem cells 
increased thereafter in parallel with the mononuclear infiltration. It should be underlined that, 
in NOD and NODscid mice, the early islet infiltration occurs at the islet periphery where 
a cells are located (4,7). This situation is intriguing, since the normal blood flow within the 
islet follows a j) to c< direction (31). Therefore, infiltrating leukocytes would not have to pass 
the 0.: cells at the islet periphery to reach the p cells, which are considered to be the main tar-
get of the autoimmune reaction. \Vhile there is some evidence that a cells themselves might 
also be a target in type 1 diabetes (32-35), they appear to be spared from autoimmune destruc-
tion. This selective protection might be due to the expression of the Fas-ligand on the u. cells 
of normal mice and prediabetic NOD mice (36). 
191 
Chapter 3,5 
In conclusion, the disturbances that we observed in NOD a cell neogenesis might 
reneet subtle abnormalities in islet development, which may cause or stem from f1 cell dys-
function, resulting in increased B cell sensitivity or even targeting of the autoimmune reac-
tion. Intriguingly, in this regard, delayed development of the salivary glands, another target 
of the autoimmune reaction in mice with the NOD genetic background, has also been 
described recently (Humphreys-Be her ct aI., personal communication). These observations 
point to a previously unrecognized role for organ development in the triggering of an autoim-
mune disease. In addition to the essential defects in immune function that determine the SllS-
ceptibility to the development of autoimmunity, such developmental target-organ abnonnali-
ties may be involved in the tissue specificity of autoinll11Une diseases, like autoimlllune dia-
betes, 
Materials and methods 
Animals 
NOD, originally provided by Clea Japan Inc, (Tokyo, Japan), NODscid and C57BLl6 
females were bred at the animal facilities of H6pital Necker, Paris, France, under specific 
pathogen-free conditions, according to the norms stipulated by the European Comlllunity. 
They were antibody-free for the 13 viruses tested, including diabetogenic viruses (37). Mice 
were fed standard pellets and water ad libitum and maintained at 22°C on a 12 11 light - dark 
cycle. Nondiabetic NOD females (with basal nonfasting glycemia < 11 l11molll, as assessed 
by Glukotest, Boehringer-Mannheim, Mannhcim, Germany) were used. In our NOD colony, 
during the time of this investigation, overt diabetes appeared in females from the 12th \veek 
of age onwards and 80% of them had become diabetic by 6 months of age. 
IHeasurement of blood and llanCl'catic glucagon 
In all cases, unanesthetized animals \vere bled in less than 2 min by retroorbital punc-
ture. As previously shmvn, this technique avoids stress-induced metabolic changes, at least 
during the sampling time (38). In each series of experiments, difterent groups of animals of 
various ages (7, 14,28,42,56 and 70 days old) were bled at different times to avoid the 
hyperglycemic effect of repeated orbital puncture (38), Blood samples were supplemented 
with recombinant aprotinin, 30,000 klU/ml (Bayer Inc., Kankakee, IL,), kept 011 ice, cen-
trifuged at 13,000 x g for 2 min at 4°C, and stored at -20°C, Mice were then killed by cervi-
cal dislocation. Pancreata were rapidly removed, weighed and homogenized in 15 lUI of cold 
acid ethanol extractionllledium (1.5% (v/v) I N HCI in 75% ethanol), After addition ofanoth-
cr 101111 of extraction medium, the homogenates \vere centrifuged (800 x g for 15 min, 4°C), 
and the supernatants were left standing overnight at 4°C. The pH of the supernatants was 
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adjusted to 8.5 with ammoniulll hydroxide and, after centrifugation (800 x g for 15 min, 4°C), 
51111 of each supernatant were stored at - 20°C until assayed. Glucagon concentrations were 
determined using a standard radioimmunoassay kit (rabbit anti-human glucagon, Biadata, 
Pharll1acia, Saint-Quentin-en-Yvciincs, France). Pancreatic glucagon contcnts are expressed 
as ng/mg of pancreas, as commonly used (17,19,20). 
IIllI1l u n ohistochcmistry 
Six pancreata for each strain were removed at 1,7, 14,21,28,56 and 70 days of age. 
After excision, they were immediately embedded in OCT (Tissue-Tek, Miles, Elkart, IN), 
frozen in dty ice-cooled isopentane and stored at _80°C until sectioning. Cryostat sections, 
6-~ll11 thick, were cut, dried overnight and n'ozen at _20°C ulltil being subjected to labeling. 
Tissues used for double-labeling experiments were l1xed in Bouin's solution (Sigma, Saint-
Quentin-Fallavier, France) and paraftln-embcdded; 4~tl11-thick sections were cut. 
Sections were allowed to thaw at room temperature for 30 min. After being fixed in 
acetone for 10 min, slides were washed in phosphate-buttered saline (PBS) - 0.05% Tween 
20 (Tw). Sections were incubated with prediluted rabbit anti-human glucagon (Dako, 
Trappes, France) for 30 min. After washing in PBS-Tw, sections were incubated with the sec-
ondary antibody, biotinylated swine anti-rabbit Ig (Dako), diluted 11100, for 30 min, Alter 
rinsing in PBS-Tw, Avidin-Biotin Complex (Vectastain kit, Vector, Burlingame, CA) was 
added for 20 min. After further \vashing, the bound complex was developed with 3-amino-9-
ethyl-carbazole (Sigma) in 50 mM sodium acetate. After 2.5 min, the reaction was stopped 
with distilled water. After rinsing in PBS-Tw, sections were counterstained with Mayer's 
hemalum solution (Merck, Paris, France) and mounted in Furamount aqueous mounting 
medium (Dako). Negative controls were performed with reagents supplied by Dako. 
Double labeling was performed on 4-pm sections cut from paraffin-embedded tissues. 
After dewaxing and rehydration, the tissues were washed in Tris-saline buft'cr (0.1 M Tris-
HCI, pH 75, 0.15 M NaCI, 0,05% Tw), Sections were incubated with optimally diluted 
guinea pig anti-insulin serum (Linco Research Inc., St. Charles, lvIO) and rabbit anti-glucagon 
serum (Chemicon International Inc, Temecula, CA) overnight at 4°C. Slides were thorough-
ly washed in Tris-saline buft'cr and incubated first with alkaline phosphatase-conjugated 
swine anti-rabbit JgG (Dako) for 30 min at roOI11 temperature, rinsed and then incubated with 
rabbit anti-guinea pig IgG coupled to horseradish peroxidase (Dako) for a further 30 min. 
Sections were rinsed first in Tris- saline buffer (pH 7.5), then brietly in alkaline Tris-saline 
buffer (pH 9.5 containing 50 111M lVlgCI2)' Tmmlilloreactive glucagon was revealed lIsing a 
substrate consisting of 0.34 mg/ml ofnitrobille tetrazolium chloride (Boehringer .Mannheim) 
and 0,18 Illglml of 5-bromo-4-ehloro-3-indolyl phosphate (Research Organics Inc., 
Cleveland, OH). Slides were protected from light and periodically checked for staining inten-
sity. The reaction was stopped by returning sections to neutral pH in Tris-salille butfer COIl-
taitling 10 mM EDTA. Slides were washed thoroughly for at least 30 min, then reacted with 
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the peroxidase chromogen dial11inobenzidine (Sigma) in PBS with 0,02% H20 2 for I to 2 
min. Slides were tinally rinsed in water, counterstained with methyl green (Fluka, Buchs, 
Switzerland), progressively dehydrated through alcohol baths, cleared, and mounted. 
Quantification of immunohistochemistry 
All islets from each glucagon-labeled section were considered. The area of each islet 
was measured using a YJDAS-RT image analysis system (Kontron Elektronik GmbH/Carl 
Zeiss, \Veesp, The Netherlands), The counterstaining enabled easy identification of the islets 
\vhich were encircled by hand and then the computer program automatically calculated the 
area of each islet in pixels, and determined the glucagon-positive area and the percentage of 
glucagon-positive area of each islet. "Measurements were made at a magnification of IOOx, at 
which the size of one pixel is 1.13 x 10-6 mm2 
For the analysis of some data, islets \vere arbitrarily classified into various groups 
according to their size: very small (area less than 2000 pixels), small (2000 to 5000 pixels), 
medium (5000 to 10000 pixels) and large (more than 10000 pixels), The percentages of 
glucagon-positive areas were then determined for each class of islets. 
The total number of islets was counted for a strain at a given age (onc section per 
mouse and per agc, n=6 mice for each age group of a given strain). The total numbers of islets 
were: on day I (78-95), day 7 (119-154), day 14 (119-181), day 21 (138-175), day 28 (85-
110), day 56 (68-102) and day 70 (100-203), 
Statistical analyses 
All data are expressed as means ± SETVI. Possible effects of strain and age were ana-
lyzed using ANOYA for each variable investigated. Post hoc analysis, using thc Newman-
Kellis test, was performed \vhen eftects and interactions wcre significant (p<O.05), as 
assessed by ANOVA. \Vhen the interaction \vas not signiticant, planned comparisons were 
made. 
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Summary 
In a tew species, macrophages (M<I» and dendritic cells (DC) have been observed in 
the pancreas during early stages of normal development. This finding is possibly relevant for 
the devclopment of type I diabetes, in which these cells are thought to be the tirst infiltrating 
cells around weaning, then leading to insulitis development. However, the presence of these 
antigen-presenting cells (APC) during postnatal pancreas growth in control and diabetcs-
prone mouse strains has never been investigated. 
Here, we compare during the tirst month of life the numbers of APC (CDllc+ DC, 
ER-MP23+ and BM8+ M<I» in three control strains and in NOD and NODscid mice. The lat-
tcr lack fllllctionallymphocytcs and do not progress to diabetes in contrast to NOD mice. In 
mice with the NOD genetic background, inflammatory APC infiltration is usually thought to 
start around weaning (3 weeks of age). We shm'1 that low numbers of CD 11 C + DC arc pres-
ent in control postnatal pancreata, while enhanced numbers arc observed in NOD and 
NODscid mice from birth onwards. NOD mice also exhibit higher numbers of ER-MP23+ 
M$ at bilih compared to control strains. Finally, high numbers of BMS+ M$ are observed at 
birth in all strains investigated These cells disappear more or less progressively during the 
first month oflite. APC-Iocations are similar in all strains, i.e., in peri-vascular, peri-ductular, 
peri-islet areas and in septa. 
In conclusion, the inflammatory lesions observed in NOD mice after \veaning resem-
ble phenomena observed transiently during normal postnatal pancreas development. 
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Introduction 
Type I (insulin-dependent) diabetes mellitus (type I diabetes) is the result of an 
autoimmune destruction of the ~ cells in the pancreatic islets of Langerhans. In the sponta w 
neous models of the disease, the NOD mOllse and the bio-breeding (8B) rat, the infiltration 
of macrophages (Mq,), dendritic cells (DC) and lymphocytes around the islets of Langerhans 
is considered to be the most precociolls lesion (1-4). In this so-called peri-insulitis, MCP and 
DC likely function as antigen-presenting cells. In NOD females, CD II c + DC have been 
shown to acclllllulate from 3-5 \veeks of age onwards around and within the islets of 
Langerhans (5,6). At the same time, ER-MP23+ Mq" that are normally present in the NOD 
pancreas connective tissue, migrate to the periphcIY of the islets with some cells penetrating 
into them (I). The early APe accumulation plays an important role in the development of 
insulitis, since prevention of carly monocyte influx stops the autoimmune process and pro~ 
tects from diabetes development (7). It is only after the early DC and ER-MP23+Mtj> accu-
mulation, i.e., from 7-10 weeks of age onwards, that large numbers ofT and B lymphocytes 
and BM8+ scavenger Mtj> are recmited to the islets in NOD females (I). 
DC and Mq, are also ollen found around the ducts, especially in early stages of the dis-
ease (t ,8- I 0). The relationship between peri-ductular infiltration and insulitis is still largely 
obscure. However, it should be noted that the islets of Langerhans originate from the ductal 
epithelial cells (11). In this regard, an association between phenomena taking place at the duct 
and/or the islet level (such as neogenesis and regeneration) and infiltration involving M<f> 
and/or lymphocytes has been observed in several situations, not necessarily associated with 
autoimmune autoimmune diabetes. For example, in an animal model of non-autoimmune 
type 2 diabetes, the OLETF rat, a moderate leukocyte infiltration exists in and around the 
islets of Langerhans in young rats (12). This infiltration is followed by fibrosis of the islets 
and hyperplasia of the pancreatic ducts aner 12 weeks. Intlammatory infiltrates within the 
pancreas and insulitis have also been observed in several situations involving (auto-)immune 
responses (13,14), and in various mice transgenic for cytokines or growth factors, some of the 
latter associated with strong pancreatic regeneration (15,16). Moreover, M$ playa major role 
in the processes of pancreatic degeneration and regeneration which take place aner duct lig-
ation-induced pancreatitis (17,18). Finally, an association between pancreas growth and the 
presence of leukocytes also exists in humans. Early studies have noted a lymphocytic infil~ 
tration during normal human fetal pancreas development concomitant to degeneration of the 
islets (19). More recent data confirm the presence of leukocyte infiltrates in the exocrine pan-
creas, including a few DC and lymphocytes in the islet vicinity, as a normal feature ofthe fetal 
and neonatal hllm~n panereata (20-23). T~ken together, these observations in varions species 
suggest that leukocytes may playa role during normal pancreas development or regeneration. 
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In normal mOllse strains, however, the presence of APC in the developing pancreas has 
never been investigated. PancrcCls development, including islet differentiation from ducts 
(neogenesis), takes place in controlmOllse strains at least until wcaning (3 ,veeks of age) (24). 
During the postnatal period, apoptosis of B cells and other cell types is observed (25). 
Therefore, it can not be excluded that leukocytes are normal but transient constituents of the 
developing pancreas. \Ve therefore analyzed from 1 day to 4 weeks of age, the numbers and 
localization ofCDllc+ DC and ER-NIP23+ and BMS+ 1\1$ in the pancreata of va rio liS con-
trol strains (C57BLl6, DBA/2 and BALB/e). We also approached the question whether early 
postnatal APC infiltrates are altered in mice with the NOD genetic background compared to 
control strains and we therefore studied their presence in NOD and NODscid strains. The lat-
ter lacks functional lymphocytes and does not progress to tbll insulitis and diabetes (26), but 
shares with the NOD mouse the early APe infiltration (5). Our data show that a transient APC 
infiltration is a normal feature of the postnat.al developing mOllse pancreas, regularly associ-
ated with islet neogenesis. Several diflcrences have been observed between normal mouse 
strains and diabetes-prone NOD mice, in terms of kinetics and APC numbers but not local-
ization. 
Results 
Low densities of CDllc+ DC are pr~sellt in control pancreata, wherens enhanced num~ 
bers arc present in NOD and NODscitlmice from birth ollwards 
18~~~---------------------------, 
16 
E 14 
..§ 12 
!!!. 
(jj1O 
u 
+u 8 
~ 6 
o 
04. 
2 
o 
Figure I: Numbers of CD II c + DC in pancreata ofvariolls mouse stwins (IS a fimetion of age. The numbers of cells 
were counted (lnd expressed per mm2 of total pancreatic surface mea in each stwin, (IS assessed by image analysis. 
A group of 5 mice (one section per mouse W(lS analysed per age-stmin (mean values ± SEt,,'l). COl Jc+ DC are pres-
ent in higher numbers in NOD and NODscid mouse pancreata than in controls. 
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Figure I shmvs that CD 11 c + DC were found in the pancreata of all strains investigat-
ed during the postnatal period, but in vcry low numbers. The numbers ofCDllc+ DC were 
stable in a given strain during the first four weeks of age. There was, however, a difference 
betwecn the strains (1'<10-6, as asscssed by ANOVA). Higher densities of CD I Ic + DC were 
observed consistently from birth onwards in strains with the NOD genetic background. This 
effect was significant, at I day of age, for NODscid compared to C57BLl6 and DBA/2 mice 
(1'=0.03 and p=O.OI, respectively, by post-flOC analyses) and tended towards significance for 
NOD versus DBA/2 and NODscid versus BALB/c mice (jl~0.06 and p~0.08, respectively). 
At 4 weeks of age, CD I Ie + DC values were significantly higher in NOD compared to 
C57BLl6 and DBAl2 mice (p~0.025 and p~0.035, respectively). These differences represent 
the start of the classical insulitis in NOD mice (5,6). 
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Figure 2: Immunohistochemistry Jor CD Ile+ DC, ER-!vlP23+ and m.Js+ j>,'f¢ in control strain pancreata. (a) COil c + 
DC in 4-week-old DIJAl2 mouse (original magnification xI6); (b) ER-!\JP23+ :-'1$ in a 2-wcek-old C57HLl6 (orig-
inal magnification :,;]6); (c ilild d) ER-i'.'fP23+ M¢I in 4-wcck-old C57BU6 ilnd BALB/c mice (uriginill magnifica-
tion xI6); (e and l) BM~+ M$ in 4-wcek-old C57BLi6 (original magnification x25). Regardless of the cell type, locu-
tions in peri-vascular, peri-dllctular and peri-islet areas and septlls me obscrved in control pancreata. 
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Concerning their localization, in allmollse strains the fe\" CD 11 c + DC appeared to be 
scattered throughout the pancreas at the youngest ages investigated, when the inul1ahlrity of 
the pancreas was still obviolls. Then, they were progressively found around vessels, ducls and 
islets, even in normal strains (Fig. 2a), At 4 weeks of age, however, CD tic + DC could be 
observed inside the islets in NOD mice, \vhereas they stayed around the islets in control mice. 
High densities of ER-i\,IP23+ I\'I~ arc present in control pancreata, whereas enhanced 
Ilumbers are present in NOD neonates 
As shown in Figure 3, relatively high numbers of ER-MP23+ Mt» were observed in all 
strains, at least during the first 3 weeks, followed by a drop at 4 weeks of age. This age effect 
turned out to be highly significant (p<1 0-6, ANaYA). Numbers obtained in 4-wcek-old mice 
were significantly lower compared to those obtained at I day of age for C57BLl6, DBAf2, 
BALBle and NOD mice, at I week of age for C57BLl6, NOD aud NODscid mice, and at 
2 weeks of age for NOD and NODsdd (p values from 0.05 to 0.0001, post-hoc analyses). 
Moreover, there were also differences between the strains (p~0.02, ANaYA). At I day of age, 
significantly higher numbers ofER-MP23+ M$ were observed in NOD mice compared to all 
other strains, including NODsdd (p values fi'om 0.02 to 0.0002, post-hoc analyses). 
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Figure 3: Numbers of ER-!\,IP23+ r-.'I~ in pancrcata of various mouse stmins as a function of age. Results are 
expressed as in Figure I. High numbers ofER-ivIP23+ Mer arc prescnt in control pancreata during the postnatal peri-
od, but enhanced numbers are present in I-day-old NOD neonates. 
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With regard to the localization, ER-MP23+ Mq, appeared rather dispersed within the 
pancreas at 1 day and I week of age. Typically, these Me» were embedded in the connective 
tisslie separating the epithelial compartments. Beyond 1 \'leek of age, ER-MP23+ Mq> were 
observed, particularly, in peri-vascular, peri-ductular and peri-islet areas as ,yell as in inter-
lobular areas in all strains (Fig. 2b,c,d). In 4-week-old NOD mice but not in other strains, 
some ER-MP23+ Mq, could also be found inside the islets, as was the case for CD II c + DC. 
A decrease iII BMS+ Mq, dcnsity occurs iII all strains aftcl' birth 
Mc.p, that is observed in control strains, is delayed in NOD and NODsicd mice, The 
BM8+ Mq, represent a third leukocyte type present in the pancreas in early postnatal phases. 
As was observed for ER-MP23+ Mq" relatively high numbers ofBM8+ Mq, were observed 
shortly afler birth (Fig. 4). The numbers of BM8+ Mq, decreased significantly with incrcas-
ing age (p< 10-6, ANOVA). Interestingly, this decrease appeared earlier in control strains than 
in strains with the NOD genetic background. The decrease was already significant between 
I day of age and I week of age for C57BLl6 and DBAl2 (p~O.OI and IFO.OOOl, respective-
ly, post-hoc analyses), or I wcek and 2 weeks of age for BALB/c (p~O.OI). In NOD and 
NODscid mice, a significant decrease in the number of BMS+ Mcp \vas also observed, but this 
occurred later in time, between 2 and 4 weeks of age (p~0.03 and p~O.OOOI, respectively). 
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Figure 4: Numbers ofBlvlS+ r-.,·Iq, in panere<ltn ofv<lriollS mouse strains as a function of age, Results are expressed as 
in Figure 1. Note the highest numbers of B!vI8+ ~vlq, <It birth in pallcreata of all stmins except NODscid, 
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Moreover, at a given age, there were many significant differences between the variolls 
strains concerning density of BMS+ MeV. The most pertinent differences were the following: 
C57BLl6 showed the highest levels of BMS+ M<i> observed at I day and I week of age COI11-
pared to all other strains (p values between 0.005 and 0.0001, post-hoc analyses) and, 
NODscid contained, at I day of age, the lowest levels compared to all other strains, includ-
ing NOD (p values from 0.03 to 0.000 I). At 2 weeks of age, NOD and NODscid mice exhib-
ited significantly higher numbers of BMS+ M<j> than two of the control strains (DBAl2 and 
BALBlc, p values between 0.04 and 0.00 I), but this effect was found to be no longer signit~ 
icant at 4 weeks of age, the time of maximal decrease ofBM8+ Mcp numbers in all strains. 
Considering their localization, BM8+ M$ appeared to be either scattered throughout 
the pancreas or already grouped together in peri-islet or peri-acinar areas at birth. Thereafter, 
they were cOl11monly observed in peri-vascular, peri-ductular and per-islet areas and septa in 
all strains (Fig. 2e,t). Remarkably, BMS+ M<i> were also sometimes localized at the places of 
islet neogenesis, i.e. the differentiation of islets from ducts, An almost continuous line of 
BM8+ Mcp surrounded the ducts and the islets and appeared to accumulate at the interface 
between both structures (Fig. 2e), Such pictures were regularly observed in all strains until 
4 weeks of age. 
APe are present in the samc locations in mice with the NOD gcnetic background and 
control mice 
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Figure 5: Serial staining for ER-ivfP23+ M!fJ (a,c) and B!\.,lS+ 1'Iq, (b,d) in the pancreas ofa I-clay-old NOD mouse. 
The locations ofER-ivrP23+ and Br\'IS+ ivlq, are not different in postnatal NOD and control pancrcata (Fig. 2). 
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Serial stainings were done to assess the localization of both types of M$ in the NOD 
after birth. Figure 5 shows two examples of staining for ER-MP23+ and BMS+ M<I> on serial 
pancreatic sections from l-day-old NOD mice. The first example (Fig. Sa and b) illustrates 
that both types of cells arc scattered throughout the exocrine pancreas, in particular in peri-
acinal' localization. Most of the time (if not always), ER-MP23+ and BMS+ M</> do not colo-
calize. The second sample (Fig. 5c and d) shows both cell types in peri-vascular, peri-ductu-
lar and peri-islet arcas. ER-MP23+ and Blv18+ M<I> can be observed close to the same struc-
tures, in particular the peri-vascular-ductular pole oflhe islet. However, \vhen scattered in the 
pancreas, both stainings do not colocalize. lYforeover, v.'hen Figures 2 (showing data obtained 
in control mice) and 5 (concerning NOD mice) are compared, it appears that the locations of 
ER-MP23+ and BMS+ M<I> in the postnatal period are not different between control and NOD 
mice. 
Discussion 
This study shows the presence ofa transient APC infiltration as a normal feature oflhe 
developing pancreas. In postnatal pancreata, low numbers of CD I 1 c + DC and relatively high 
numbers of Brvr8+ and ERHMP23+ Mel> are present. However, a strong decrease in both cell 
types takes place after weaning in these strains. The localization of these Mel> in normal strains 
is strikingly similar to that classically described in NOD mice during early insulitis after 
weaning. 
Among the DC and Mel> subsets present in normal strains, the most remarkable data 
concern the presence and localization of Brvrs+ M$. These cells are present in high numbers 
at birth and progressively decline during the first month of life. At 4 weeks of age, Le., after 
weaning, virtually no BM8+ Mel> are detectable in all control strains, confirming previous data 
(I). ER-MP23+ M<I> are also present at relatively high levels in normal strains from birth 
onwards, but their numbers are quite similar among all these strains and stable during the first 
hvo weeks of life. A decrease is observed at 4 weeks of age, but low numbers of ERH~1P23+ 
Mcp persist, which is consistent with their presence in normal adult mouse pancreas (1), 
CDllc+ DC are observed in control strains at Imv and stable numbers during the first month 
of life. It is worth noting here that the decline of high numbers ofBMS+ and ER-MP23+ M<I> 
correlates in time with the completion of postnatal pancreas development (11,24,25). 
In terms of cell densities, some difterences are observed between control strains and 
strains with the NOD genetic background. In contrast to control strains, NOD strains tend to 
have higher numbers of APC as early as birth. This is the case for ER-MP23+ M</> in NOD 
mice and CD II c + DC in NOD and NODscid mice. The presence of increased numbers of 
some types of APC as early as birth in mice with the NOD genetic background should be 
underlined, since the classical periHinsulitis is assumed to start at about 3 weeks of age (I). 
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1n this regard, an ongoing autoimlllune reaction in the NOD fchlS, "which could be responsi-
ble for increased local APe densities, has already been postulated on the basis of an ill u/ero 
T cell activation (27). Another intriguing strain difference in terms of cell densities at birth is 
observed between NOD and NODscid mice: the latter showed signiticantly lower numbers of 
ER-MP23+ and BMS+ M", compared to NOD mice at 1 day of age. The reason for this lower 
APC number in the pancreas is unclear. Possibly, APC number and/or function could be 
decreased in NODscid mice due to relative immaturity of their APC as a result of absence of 
functional lymphocytes. This is illustrated by the finding that APC isolated from NODscid 
islets arc much less efiective in stimulating diabetogenic T cell clones than those isolated 
from NOD islets (28). In addition, transfer ofT cell clones in vivo improves the antigen-pre-
senting function of NODscid APC (2S). 
Another strain difference between control mice and mice with the NOD genetic back-
ground concerns the kinetics of cell disappearance, In particular, NOD and NODscid mice 
show stable BMX+ M~ numbers during the two first weeks of age follmved by a decrease at 
4 weeks of age. The decline in Bl'vf8+ l'vl$ in these strains is not as progressive as that 
observed in control strains and appears delayed. The reason of the abnormal BMS+ Iv!", kinet-
ics remains unknmvn. Several genetic and functional defects have been described at the APC 
level in NOD mice. These defects include defective FcyRII gene expression, deficient differ-
entiation and function, such as antigen presentation, decreased cytokine secretion and 
enhanced arachidonic acid metabolism (29-33), BMS+ M~ are known to reappear later dur-
ing the progression of insulitis in NOD mice and are thought to playa critical role in the final 
destruction of the islets (1,34). It could be suggested that the delayed BMS+ M", decrease 
reflects all early influx of infiatnmatOlY cells. 
The second intriguing result of this work is that APC in control postnatal pancreas are 
present in similar locations (i.e., peri-vascular, peri-ductular and peri-insular) as are the tlrst 
infiltrating APC in spontaneous animal models of type 1 diabetes (1,35,36). The peri-ductu-
lar localization ofAPC and lymphocytes has been repeatedly noted in these models (I,S-IO), 
but the reason for this infiltration is still poorly understood, Our present data on the presence 
of leukocytes in neonatal control animals might shed light on this phenomenon. Tissue 
remodeling phenomena (islet neogenesis, j1 cell replication and apoptosis of various cell 
types) exist in the pancreas ofnol'l11al rodents, and particularly in mice until ,veaning (24,25). 
At present, nothing is known about the mechanisms occurring during islet neogenesis, which 
lead to the detachment of the islet from the duct and the ruphlre of the basal membrane sur-
rounding both structures. The processes through which pancreatic interlobular septa develop 
are unknown. APC might be normally involved in these developmental processes, since they 
have a \vell-recognized role in tissue remodeling (synthesis and degradation of extracellular 
matrix) and apoptosis induction (37-39). Moreover, DC and M", are also able to produce 
many of the cytokines and growth factors known to be implicated in normal pancreas 
development (11,40). It is worth noting that we show here that APC are especially present in 
remodeling tissue locations in control mice as ,veil as in mice with the NOD genetic back-
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ground during the postnatal period. These non~lymphoid cells, fUllctioning as APC, might 
also be involved in the induction of peripheral immune tolerance to self (neo?)antigens 
expressed during pancreas development (41), 
In conclusion, myeloid cells can be found in the postnatally developing pancreas of 
control mOllse strains as well as strains with the NOD genetic background. NOD mice, how-
ever, exhibit higher numbers of some types of these cells as carly as 1 day of age, although 
the classical peri-insulitis/insulitis is usually thought to start after 3 weeks of age. The loca-
tion of leukocytes in neonatal pancreas is similar in all strains investigated, in particular in 
peri-ductular and peri~islet areas of islets. It is worth noting that lesions observed in NOD 
mice anel' weaning resembled, to some extent, phenomena normally observed in control mice 
during the postnatal period, 
Materials and methods 
Animals 
NOD, NODscid, CS7BL/6, DBA/2 and BALB/c female mice were bred under specif-
ic pathogen-free conditions at the facilities of tile H6pital Necker, Paris, France, as previolls-
ly described (42), The animal facilities and care followed the norms stipulated by the 
European Community. The incidence of diabetes ill the NOD colony is, by 200 days of age, 
80% for females (42). ~11ice of different strains ,vere sacrificed at 1 day, and 1,2 and 4 weeks 
of age for evaluation of the DC and wl1l intiltration. 
Antibodies 
N418, a hamster-anti-mouse CDllc antibody, was used to identifY DC (43) and 
ER-~11P23, a rat-anti-mouse M1l galactose-specific lectin (l'vf~IIGL) was llsed to detect a par-
tiCldar subset ofM1l (43). Both antibodies were used as undiluted hybridoma culture super-
natants. BM8, a rat anti-mouse antibody, identifying a 125 kD cell surface protein of scav-
enger macrophages (43), was obtained li'Oll1 BMA (BMA Biomedicals AG, Augst, 
Switzerland) and diluted 1/50, BM8 and ER-MP23 binding was detected with horseradish 
peroxidase (HRP)-conjugated rabbit-anti-rat immunoglobulins (Dako, Glostrup, Denmark) 
diluted at 11100, N418 was detected with HRP-conjugated goat-anti-hamster immunoglobu-
lins (Jackson ImmunoResearch Laboratories, Inc., \Vest Grove, Pennsylvania, USA) diluted 
at 11200, 
hum u noh istochemistry 
~IIice of difterent strains were killed by cervical dislocation after rapid retro-orbital 
bleeding, Their pancreata were removed, embedded in OCT (Tissue-Tek, Miles, Elkart, IN) 
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compound and frozen in n-hexane on dry-ice chilled alcohol. Tissues were stored at -80°C 
until immunohistochemistry was performed. Pancreas clyostat sections of 6 mm were fixed 
for 10 min in acetone. After a wash with phosphate-buffered saline with 0.05% Twccn-20 
crvferck, Paris, France) (PBS/Tween), slides were incubated with first step monoclonal anti-
bodies for 30 min at room temperature in a moist chamber. Subsequently, slides ,,,ere \'lashed 
t,vice with PBS/Tween and then incubated with second step antibodies in the presence of2% 
normal mOllse serum for 30 min at room tcmperahlre. After an additional wash with 
PBS/Tween, slides were incubated \vith_3-all1ino-9-ethylcarbazole (AEC, Sigma, Saillt-
Quentin-Fallavier, France) as substrate in 50 mivl sodium acetate with 0.02 % H202_and 
\vashed in \vater after 3 min. Finally, slides were counterstained for 3 min in hematoxylin 
eosin UvIerck), dehydrated in a graded ethanol series, and mounted. For each series of pan-
creas sections, one slide was stained with second antibody only as a control for endogenous 
peroxidase activity and nonspecific binding of the second step. A section of spleen or lymph 
nodes was included as a positive control. 
Quantification of hUIllUIlohistochemistry 
The surface areas of the pancrcata were assessed via a VIDAS-RT image analysis sys-
tem (Kontron Elektronik GmbH/ Carl Zeiss, \Veesp, the Netherlands). Pancreata were encir-
cled by the researcher and then measurements were performed and expressed in pixels lIsing 
an objective magnification of2x. At a magnification of2x, the size of one pixel is 1.20* 10-4 
mm2. The mean vallies of the surfaces of the pancreatic sections for the various strains were 
0.4-1.55 mm2 at 1 day of age, 1.4-2.5 111m2 at I week of age, 2,6-4.5 mm2 at 2 weeks of age 
and 15-19 mm2 at 4 weeks of age. The numbers of positive cells, counted by two different 
investigators, were then expressed per mm2 of total pancreatic surface area, 
Statistical analysis 
Statistical significance for differences in cell numbers was determined by means of a 
two-\vays analysis of variance (ANOVA) followed by Newman-Keuls post-hoc analysis. The 
level of significance was set as p<0.05, For all measurements, a total of 5 mice (one section 
per mouse) \vas analyzed per age-strain combination. 
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Chapter 4.1 
Summary 
NOD mice develop autoimmunity towards islets ofLallgerhans around weaning (i.e. 
3 weeks of age). The etiology of this immune attack is unkt10\vn, but many studies have sug-
gested the involvement of a defective regulation of the immune function (1). This explana-
tion, however, does not take into account that the autoimmune process is strongly organ-spe-
cific. Abnormalities in immune regulation may therefore explain the predisposition to autoim-
munity in general, but additional factors then determine the target of the autoimmune attack. 
\Ve hypothesize that abnormalities in islet differentiation and/or function trigger the immune 
system towards islet autoimmunity. In this chapter; we will discuss the islet abnormalities we 
observed in NOD mice, together with their role in the initiation of the autoimmune response. 
Moreover, we will elaborate on the relevance of these observations for type I (insulin w 
dependent) diabetes mellitus (type 1 diabetes) development in humans. Finally, we will make 
suggestions for future research based on the results described in this thesis. 
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Insulitis 
In order to characterize the role of islet abnormalities in the initiation of pancreatic 
infiltration, a thorough knowledge of the pattern of leukocyte infiltration during the initiation 
of insulitis and during the subsequent islet destruction is required. Therefore, we compared 
insulitis as observed in \viJd type NOD mice to rapidly destructive insulitis in NOD mice 
transferred with the diabetogenic T cell clone BDC2.5 and to non-destructive insulitis in 
NOD mice transgenic for the BDC2.5 T cell receptor (Chapter 2.1). The use of these models 
enabled llS to study the roles of the non-lymphoid cells in a destructive and in a non-destnlc-
live insuiitis, respectively. In wild-type NOD mice, the first sign of infiltration is thought to 
be an accumulation of CDllc + dendritic cells (DC) around the islets, from about 3-4 weeks 
onwards. This accumulation is present both in the destructive and in the non-destructive 
lesions. At the same time, ER-MP23+ and MOMA-I+ macrophages (M",), normally present 
in the exocrine pancreas, migrate to the periphery of the islets. In lymphocyte-deficient 
NODscid mice, the same APC infiltration takes place, albeit with lower numbers of cells 
(Chapter 3.1). Thus, the int1ux of APC occurs, in part, independent ofT cells. The APC are 
thought to pick up islet cell antigens and migrate to the pancreas-draining lymph nodes to 
present these antigens to T cells. Activated islet cell-specific T cells subsequently migrate to 
the pancreas and home around the islets, a process cal1ed peri-inslliitis. The subsequent infil-
tration of APC and T cells into the islets is called insulitis. In Chapter 2.1, it is shown that 
destructive insulitis correlates \'lith BM~rj- M$ infiltration. Destructive insulitis will tinally 
lead to ~ cell destruction and the resulting symptoms of diabetes. 
B ceJl hyperplasia is associated with illsulitis 
In Chapter 2.1, we showed that the accumulation of CD lie + DC and ER-MP23 + Mcp 
is among the first signs of insulitis in NOD mice. Because we hypothesized that pancreatic 
infiltration by DC and M$ was due to islet abnormalities, we analyzed various endocrine 
parameters in NOD islets at dincrent time points in the insulitis process. \Ve tirst described 
an increased number of very large islets in NOD mice, which we called "mega-islets" 
(Chapter 3.1). These mega-islets are found at increased frequency from 10 weeks of age 
onwards in NOD strains, and consist mainly of B cells. 
The importance of mega-islets for diabetes pathogenesis is underlined by the follow-
ing observations. First, the infiltrating cells are initially predominantly situated near mega-
islets. This is the case for both CDllc+ DC and ER-MP23+Mcp (in NOD and NODscidmice) 
and lymphocytes (in NOD mice) (Chapter 3.1). Second, mega-islet formation parallels dia-
betes incidence: mega-islet formation is delayed and reduced in non-diabetes-prone NOD 
males compared to diabetes-prone NOD females (Chapter 3.2). Furthermore, the enhanced 
diabetes incidence in orchidectomized NOD males as compared to non-manipulated NOD 
males is associated with all increased mega-islet formation and higher numbers of islet-infil-
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trating leukocytes. This influence of orchidectomy can also be found in NODscid males, indi-
cating that mega-islet formation after orchidectomy is not the result of lymphocyte-induced 
damage (Chapter 3.2). Moreover~ preventing the development ofmcga-islets by prophylactic 
insulin treatment also prevents the development of insulitis and diabetes in NOD mice 
(Chapter 3.1). In NODscid mice, prophylactic insulin treatment decreases mega-islet forma-
tion and APC infiltration. These results in NODscid mice indicate that the diabetes-protective 
effect ofprophyJactic insulin treatment is not obtained solely via the induction of tolerance to 
insulin, ,,,hieh is olle of the important autoantigcns in diabetes (2-4). 
Together, these observations indicate an important link behveen these mega-islets, 
leukocyte infiltration and diabetes development. The critical role of the islet mass in insulitis 
initiation is also indicated by the finding that a pre-insulitic rcduction of the islet mass by 
pancreatectomy protects NOD mice from diabetes (5,6). 
~ cell hYlleractivity appears concomitantly with pel'i-insulitis 
In addition to islet morphology, we analyzed islet function at the age at which the ini-
tiation of pancreatic infiltration takes place. \Ve observed a transient hyperinsulinemia in 
NOD and NODsdd mice,. which precedes mega-islet development. This hyperinsulinemia 
starts at 4 weeks of age, reaches its maximal value at 6-8 weeks of age, and returns to control 
levels at to weeks of age (7). The period of hyperinsulinemia is accompanied by rather low 
glycemia in both strains and a high insulin response to i.p. glucose injection in NOD mice. 
These data indicate that NOD, and to some extent, NODscid j) cells are hyperactive in terms 
of insulin secretion. The hyperinsulinemia develops concomitantly with the pancreatic APC 
infiltration and precedes mega-islet development in both strains. 
Interestingly, pancreatic insulin contents are not different behveen NOD and control 
strains at 10 weeks of age, although NOD mice have significantly more mega-islets at this 
age. The observation of a low staining intensity for insulin in NOD mega-islets but not in 
smaller islets may explain these findings, because it suggests a low insulin content "within 
mega-islets. It is therefore tempting to hypothesize that mega-islets, which appear to exhibit 
signs ofa decreased j) cell activity, correspond to those that have been previously hyperac-
tive. Moreover, hyperinsulinemia in NOD mice returns to control levels at 10 weeks of age, 
an age at which there is not enough T cell-mediated ~ cell damage to explain this decrease. 
In addition, this decrease also occurs in NODscid mice, in which there are no functional lym-
phocytes. Together, these observations suggest that there is a progressive and lymphocyte-
independent trend toward p cell exhaustion in mice with the NOD genetic background. 
Therefore, islet function appears to play an important role in the initiation of the dia-
betogenic process in NOD mice. It is worth noting that islet activity is influenced by many 
different envirollmental and hormonal parameters (8). Interestingly, many of these fhctors 
also influence diabetes incidence in NOD mice. 
216 
------------------ Islet abnormalities in the etiology of diabetes 
Tn conclusion, islets of young prediabetic NOD mice appear to be transiently hyper-
active in terms of insulin secretion. This hyperactivity takes place during the post-weaning 
period, concomitantly with the initiation of infiltration. The transient hyperactivity is pro-
gressively followed by islet hypertrophy, resulting in an increased formation of mega-islets. 
These mega-islets are preferentially associated with all types of inflltrating cells. However, it 
is at present not clear whether these islet abnormalities are cause or consequence of the ini-
tial APC accumulation. 
I'otcntial causes of f) cell hyperactivity 
The next step was to analyze the putative causes of the hyperinsuiinemia and subse~ 
quent mega~islet development. These islet abnormalities could have several non-mutually 
exclusive causes, including alterations in the (regulation of the) insulin gene, insulin-resist-
ance, metabolic abnormalities in the prenatal period, infiltrating cells and/or their products, 
and hyperglucagonemia. 
Mutations in the insulin gene and / or alterations in the regulation of insulin gene 
expression may calise difterences in islet function between NOD mice and control mice. To 
the best of Ollr knowledge, however, there are no data available on either the insulin gene 
itself, or the regulation of its expression in the NOD mouse. 
Insulin-resistance is a major cause ofhyperinsulinemia, particularly in type 2 diabetes. 
\Ye investigated differences in insulin sensitivity between control and NOD strains, but they 
appeared to be only subtle (7 ,~). 
Hyperinsulinemia in young prediabetic NOD mice can also be related to metabolic 
abnormalities in NOD mothers. Indeed, most NOD mothers exhibit disturbed glucose home-
ostasis (as indicated by an abnormal glucose tolerance and even overt diabetes) during gesta-
tion, in particular after the first or second gestation (P. Homo-Delarche, unpublished obser~ 
vations). As a consequence, NOD fetuses already experience high glucose levels in utero. 
Hyperinsulinemia in NOD mice starts at weaning, a perioe! at which there is a shift from 
maternal milk (low in carbohydrates and high in lipids) to laboratory chmv (high in carbohy-
dratcs and low in lipids). This shift triggers, even in normal mouse strains, a "wake up" of the 
j3 cells, \vhich have been at rest because of the low glucose content of maternal milk from 
birth until weaning. However, the in litera high glucose levels in NOD mice may lead to a rel-
atively higher insulin sccretion at \veaning, because of the existence of the so~called glucose-
priming effect. This efiect predicts that the more the B cells have been stimulated previously, 
the higher their insulin response to a rise in glucose levels will be (8). \Ve therefore investi H 
gated the presence of hyperactive j3 cells in NOD neonates lIsing in situ hybridization to the 
second intron of preproinsulin 2. \Ve shmved that NOD neonates have more hyperactive 
f3 cells than control neonates do, but this difterence disappears \vithin the first week of life 
(Chapter 3.3). Moreover, maternal insulin treatment during the last hvo weeks of gestation 
can reduce this B cell hyperactivity. This study indicates that a glucose-priming effect of NOD 
f3 cells can trigger part of the post-weaning hyperinslllinemia. 
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Since the initial pancreas intiltration appears concomitantly with hyperinsuiincmia, we 
thought that infiltrating cells and their products lllay also be involved in the observed post-
weaning islet hyperactivity. Low concentrations of cytokines, such as IL-J, arc able to stim-
ulate insulin and glucagon secretion in vivo and in vitro, \vhile high concentrations arc 
inhibitory and C)1otoxic to B cells (9, I 0). In syngeneic eoeuitures of isolated islets of 
Langerhans and DC from 8-week-old mice, we found that NOD mOllse DC stimulate islet 
insulin release, while DC tl'om control mice do not (Chapter 3.4). Moreover, isolated NOD 
islets also produce more insulin in V;(1'O than islets from control mice. These data indicate that 
f3 cell hyperactivity may be partially induced by DC that accumulate around the islets. 
Finally, hyperinsulinemia could, partly, be the result of hyperglucagonl?mia (11,12). 
Because the tirst infiltrating cells are situated in the islet pcriphery, where mainly a <;ells are 
present, this hypothesis should also be taken into consideration, particularly because of the 
stimulating effects of certain cytokines on glucagon secretion. \Ve indeed detected a slight 
hyperglucagonemia in NOD and NODscid mice, which parallels in time the hyperinsuline-
mia (Chapter 3.5). Thus, a post-weaning u. cell hyperactivity might also contribute to the 
observed ~ cell hyperactivity, as has already been described in animal models of type 2 dia-
betes (12). 
In conclusioll, these studies indicate that several factors might contribute to the hyper-
insulinemia and, possibly, to the subsequent mega-islet development: (A) metabolic abnor-
malities in NOD mothers via the glucose-priming effect; (B) intiltrating cells and/or their 
products; and (C) hyperglucagonemia. This hypergiucagonemia, another intriguing sign of 
the transient islet hyperactivity observed in prediabetic NOD mice, led us to explore various 
parameters of u. cell behavior in NOD mice at various time points tl'om birth onwards. 
Potential causes of hyperglucagonemia 
\Ve studied a cells in greater depth for several reasons. First, as already mentioned, a 
cells arc located at the periphery of the islet, in close vicinity to the initial intiltrating cells, in 
contrast to ~ cells which form the islet core. This situation, in itselt: is intriguing because the 
normal blood flow within thc islet follows a 13---+ u. direction (13). Therefore, if the initial infil-
trating leukocytes were following the normal blood flow, they would not have to pass the a 
cells at the islet periphery to reach the j) cclIs, which are considered to be the main target of 
the autoimmune reaction. Second, while (J. cells appear to be spared from autoimmune 
destruction, there is some evidence that they themselves might be a target in human type I 
diabetes (14-17). Consequently, the close proximity of" cells to the initial infiltrating cells 
may affect a cell function to some extent, possible explaining the observed hyperglucagone-
mia. Third, glucagon secretion is tightly modulated by the gamma amino butyric acid 
(GABAcrgic) innervation, that contains the GABA~synthesizing enzyme glutamic acid dccar-
boxylase (GAD), a major autoantigcn in typc I diabetes. \Ve studied the GABAergic inner-
vation and inflammatory cells as potential causes of hyperglucagonemia in more detail. 
218 
Islet abnormalitics in the etiology of diabetes 
The GABAergic innervation inhibits the secretion of glucagon and somatostatin (18). 
\Ve hypothesized that a progressive loss ofGABAergic innervation would result in decreased 
(I. cell inhibitioll, and thus hyperglucagonemia. Indeed, we showed that leukocytes surround-
ing GAD-containing fibers arc present in the vicinity of islets ''lith incipient peri-insulitis at 
4 to 5 weeks of age. Moreover, the OABAergie innervation disappears gradually in NOD but 
not in control mice and, interestingly, more rapidly in diabetes-prone NOD females than in 
NOD males (19). Therefore, the OABAergic innervation could be among the first targets of 
the autoimmune process in NOD mice. 
Because of the proximity of APC and a cells, we studied the effect of DC addition on 
glucagon secretion by isolated islets of Langerhans. Both the spontaneous glucagon release 
and pancreatic islet glucagon content arc higher in islets isolated from NOD mice than in 
those ofihe control strain, thus confirming the ill vivo data. However, the addition of DC does 
not alter significantly glucagon secretion by NOD islets. From this experiment, it can be con-
cluded that NOD DC are not able to stimulate in vitro glucagon secretion. This docs not, how-
ever, exclude a contribution of DC and other inflammatory cells to the observed hyper-
glucagonemia ill vivo. In fact, we showed that in V;I'O administration of the APC-product 
IL-I stimulates glucagon in NOD mice (Homo-Delarche, unpublished results), The absence 
of a stimulating efiect of DC on glucagon secretion by isolated islets ill vitro may be due to 
the enhanced insulin secretion that is induced by these DC. The resulting high insulin con-
centration in the culture medium will inhibit islet glucagon secretion. 
Thus, both a loss of GABAergic innervation and, perhaps, surrounding cytokincs pro-
duced by the appropriate carly infiltrating cells might be involved in the observed hyper-
glucagonemia. However, both t1lCtors are secondary to the islet infiltrative process. They 
might contribute to the observed hyperglucagonemia, and via that to the observed B cell 
hyperactivity and islet hyperplasia, but they can not explain the etiology of the diabetogenic 
process. The reason for the initial islet infiltration remains unclear. 
Search for abnormalities of islet de"elopment in the early postnatal period 
It should be kept in mind that we observed a transient neonatal f1 cell hyperactivity, 
which clearly preceded and thus might initiate the post-weaning islet infiltration. The obser-
vation of neonatal transient B cell abnormalities sllggests that post-weaning islet abnonnali-
ties might be the consequence of earlier abnormalities that spontaneollsly fade away after 
birth but reappear at time of B cell wake-up at weaning. Abnormalities of islet development 
could, in this scenario, account for both the post-weaning a and B cell hyperactivity. 
Therefore, we studied in greater depth the presence of islet abnormalities in neonates with the 
NOD genetic background, 
At birth, the frequency of very small islets is considerably increased in both NOD and 
NODscid mice compared to control mice (Chapter 3.5). These velY small islets contain high 
percentages of a cells and low percentages of B cells. At the same time, i.e. before weaning, 
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circulating blood glucagon levels and pancreatic glucagon contel~t are low. These data should 
be interpreted in the context of normal islet development, which is illustrated in Chapter 3.5. 
During normal development, immature islets arc small and contain many u. celis, which pro-
duce ollIy low amounts of glucagon. \Vhcll islet development progresses, the islet grows, 
mainly because of the expanding B cell traction. The endocrine cells mature and start to pro-
duce high amounts of hormones. Therefore, the very small islets with high numbers of a cells 
but a low glucagon secretion and a low glucagon content, as observed in NOD and NODsdd 
mice, arc reminiscent of immature islets. The presence of these immature islets suggests an 
increased islet neogenesis in NOD and NODscid mice. 
This islet neoformation lllay be the result of the neonatal ~ cell hyperactivity: a new 
wave of islets may be needed to later replace the already hyperactive ones that will become 
exhausted, Recently, we also observed disturbances in the neonatal pancreatic expression of 
apoptosis-associatcd molecules and extracellular matrix proteins, both of which are involved 
in islet neogenesis, Also others have obtained data suggestive ofa disturbed islet development 
in NOD mice. Structurally normal islets of I-month-old NOD mice contain a large percent-
age of SOlv!+ IPDX-I + cells. a cell type thought to represent an embryonic islet precursor cell 
(20). The presence of such cells in the islets again suggests an altered islet maturation in NOD 
mice. Interestingly, an altered islet maturation has also been suggested in the BB rat (21,22). 
Early defects in islet maturation may have important consequences for tolerance induction 
towards islet celis, since the expression of self-antigens during the perinatal period is critical 
for the establishment of self-tolerance (23.24). 
birth weaning 
t 
o 
t 
increased islet 
neogenesis 
2 
insulitis 
t 
4 
loss of GABAergic innervation 
6 8 to 
aqe (weeks) 
diabetes 
t 
mega-islet 
formation 
12 
Figure 1: The development in time of the various islet abnormalities we found in NOD mice. 
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In sUll1mmy, we investigated the presence of islet abnormalities that could trigger the 
diabetogenic process in NOD mice. The development in time of the various islet abllonllali-
ties we found in NOD mice is summarized in Figure 1, \Ve postulate that an altered islet mat-
uration occurs in NOD mice. 
Since the classical insulitis in NOD mice starts after ''leaning, the observation of 
neonatal islet abnormalities seems to point to abnormalities that arc inherent to the islets and 
not secondary to infiltrating cells. Hmvever, when examining NOD and NODscid pancreas-
es directly after birth, we observed increased numbers of APC as compared to various con-
trol strains (Chapter 3.6). Interestingly, various types of APC have been observed in locations 
similar to those observed in NOD mice after \veaning, i.e, in peri-vascular, peri-ductular, peri-
islet areas and septa, During islet neogenesis, these APC are often associated \vith develop-
ing islets, The APC infiltration decreases in time in all control strains and reaches velY low 
levels in the post-weaning period, the time point at \vhich islet development is also complet-
ed, These observations raise the question whether APC playa role in normal pancreas 
development. It should be realized that leukocytes have a \vell-recognized role during 
embryogenesis, For example, fi1<p play an important role in organ remodeling (25), In light of 
the disturbed APC function in NOD mice (Chapter 1.2), it is tempting to speculate that this 
disturbed function is not restricted to immune functions, but also involves the putative role 
for APC in pancreas development, and perhaps more particularly in islet neogenesis, 
In conclusion, neonatal islet abnormalities in NOD mice (as evidenced by high num-
bers of hyperactive f3 cells accompanied by increased numbers of islets in neoformation) 
coincides with an early APe infiltration, Further studies are required to determine whether the 
disturbances in islet development are a calise or a consequence of the early leukocyte accu-
mulation in the pancreas of NOD mice, 
Etiology of diabetes in NOD mice: a scenario 
In NOD mice, islet abnormalities may result ill all increased susceptibility to autoim-
mune destruction, according to the scenario that is illustrated in Figure 2. At birth, the pres-
ence of islets with high numbers of hyperactive f3 cells and increased islet neogenesis is 
accompanied by pancreatic APe infiltration, After birth, these abnormalities progressively 
normalize to control strain levels, At weaning, hyperinsulinemia and hyperglucagonemia are 
found, concomitant with the classical APe infiltration followed by lymphocyte infiltration, 
The initiation of the classical insulitis correlates to the rise in blood glucose levels duc to 
a shift tl'om maternal milk to laboratOlY chow, Islet hyperactivity results in f3 cell exhaustion, 
as evidenced by the normalization of hyperinsulinemia, followed by subsequent islet hyper-
trophy. This hypertrophy is dependent on f3 cell hyperactivity, since it can be down-regulated 
in NOD and NODscid mice by prophylactic insulin treatment 
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The hypertrophy is also dependent on sex steroids! particularly 011 the ahsence of 
androgens, as ,veil as on the presence of lymphocytes. The resulting mega-islets are prefer-
entially associated with early infiltrating APC and lymphocytes. 
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Figure 2: Etiology of autoimmune diabetes in NOD mice 
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Thus, a central phenomenon in this scenario is the occurrence of islet hyperactivity. 
There arc several mechanisms via which hyperactivity increases the sensitivity of the target 
organ for autoimmune attack. Hyperactive endocrine cells are more prone to autoimmune 
reactions because of higher levels of autoantigens, adhesion and MHC molecules and also 
because of a higher sensitivity of the cells to cytokine-induced damage (26-29). Moreover, 
~ cell hyperactivity can lead to the formation of neo-epitopes. One of the most interesting 
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candidates in this regard is proillsulin. In normal humans and animals, only very small 
amounts of proinsulin are released from the pancreas into the circulation. However, under 
sustained f3 cell stimulation, there is no time for the conversion of proinsulin to insulin to be 
completed, resulting in an increase in proinsulin secretion (30), \Vhen proinsulin-reactive 
T cells are deleted by the transgenic expression of proinsulin on ["tHe class II-bearing cells 
(including those in the thymus), both insulitis und diabetes are prevented (31). This indicates 
that proinslliin might function as a hidden cryptic epitope initiating the autoimmune-driven 
pancreatic intlltration in NOD mice. The subsequent lymphocyte-induced /3 cell damage 
results in higher insulin demands for the remaining /3 cells, leading them to become hyperac-
tive as \vell. In this way, a vicious circle is started that results in the development of clinical 
symptoms of diabetes. 
I\Iechanisms via which islet nbnormalities can lead to a B cell specit1c autoimlllune dis-
ease 
From the scenario described above, it is evident that endocrine abnormalities are not 
restricted to p cells, but rather involve the entire islet. How compatible is this with the pre-
sumed (J cell specificity of the autoimmune attack? 
First, central tolerance induction in the thymus may be different for insulin compared 
to the other islet hormones. Two major differences have been found in the thymic expression 
of insulin compared to glucagon, somatostatin and pancreatic polypeptide (PP). The tirst dif-
ference is that prosomatostatin, proglucagon and proPP appear to be expressed at relatively 
higher levels than prepl'Oinsulin (32). The second diftercllce is that preproinsulin is expressed 
on thymic DC, whereas proglucagon, prosomatostatin and propp are expressed OIl thymic rVl<p 
(33). The presence of insulin on thymic DC is especially interesting in light of the disturbed 
DC fUllction in NOD mice (Chapter J .2). In this regard, lower levels of preproinsulin are 
found in NOD mouse thymus than in control thymus, whereas the levels of expression for the 
other pancreatic hormones are identical between the strains (32). In conclusion, the differ-
ences in thymic expression between insulin and the other islet hormones might lead to dif-
ferences in tolerance induction towards these hormones. 
Second, pancreas-autoimmunity in animal models of type I diabetes might not be as 
p cell specitic as lIsually thought (34). The loss of p cells results in dramatic metabolic and 
clinical consequences, in contrast to the loss of other cndocrine islet cells. Furthermore, as 
mentioned beforc, the specificity of both the cellular and humoral immune response may not 
be directed against B cells exclusively. In addition, the expression of virtually all recognized 
autoantigens, except proinsulin and insulin, is not restricted to f3 cells. j\lloreover, p cells are 
relatively more vulnerable to cytotoxins than other islet cells (35). For example, NO induces 
expression of the apoptosis-inducing molecule Fas on J3 cclls only and not on other islet cells 
(36). In summary, autoimmunity may not be as specific for B cells as is generally assumed. 
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Relevance of the findings on islet abnormalities in NOD mice for human type 1 diabetes 
In neonatal diabetes-prone NOD mice, we found indications for a disturbed islet 
development, consisting of a tlrst wave of [3 cell hyperactivity and increased neogenesis asso-
ciated with a slight inflammation. These abnormalities normalize in time, but a second wave 
of islet hyperactivity is observed after weaning, accompanied by a second wave of leukocyte 
infiltration, evenhmlly resulting in [3 cell destruction. In humans, similar processes may play 
a role in the pathogenesis of type 1 diabetes. 
Due to the lack of available prediabetic pancreatic tissue, it is virtually impossible to 
determine ,vhether abnormalities in islet development playa role in the pathogenesis of 
human type 1 diabetes. Nevertheless, indirect evidence suggests that an aberrant islet 
development may be implicated in at least some patients. During normal human islet 
development, a physiological infiltration of leukocytes occurs (37-40). The composition of 
this infiltration is similar to that found in a child with recent-onset diabetes (39). This sug-
gests a link between the physiological occurrence of leukocyte infiltrates during islet 
development and the pathophysiological infiltration of the pancreas during the initiation of 
autoimmunity. 
Furthermore, a genetic basis may underlie a role for islet development in the etiology 
of human type 1 diabetes. For example, polymorphisms in the NeuroD/~2 gene, that maps to 
chromosome 2q32 where lODM7 is also located (41), have been linked to human type I dia-
betes. A variant (Ala45Thr) in the NeuroDfl32 gene was found to be associated with type I 
diabetes in Japanese patients, but this association is not necessarily found in all subgroups of 
diabetes patients (42,43). Interestingly, this gene is thought to be essential for the mOlpho-
genesis or differentiation of insulin-producing [3 cells in mice (44). 
The developmental abnormalities in NOD mice results in a transient prediabetic islet 
hyperactivity. In humans, there are also indications for islet hyperactivity preceding clinical 
diabetes. As already mentioned, an increased proinsulin secretion takes place in hyperactive 
~ cells (30). Elevated basal or glucose-stimulated proinsulin and connecting (C-) peptide lev-
els have been obsetved in healthy siblings of type I diabetes patients with no evidence of 
autoilllmunity (45,46). These data may support a role for an aberrant ~ cell activity in human 
type 1 diabetes, Interestingly, peripheral blood T cells of individuals at risk react to a peptide 
that spans the B-chain of insulin and the C-peptide of pro insulin (47). This epitope can be 
considered a cryptic epitope, since normally it would be cleaved during conversion of pro-
insulin to insulin. Remarkably, this epitope bears marked similarity to a peptide of GAD65 
(47). Ivloreover, proinsulin antibodies are detected in patients and first degree relatives 
(48,49), Interestingly, no association with HLA type was found for the proinsulin antibody 
response, in contrast to insulin autoantibodies and leA, sllggesting that the humoral response 
to proinsulin determinants is under separate genetic control (49). 
In humans, a transient [3 cell hyperactivity may have a genetic basis. Genetic studies 
identified the IDD!H2 loclis that maps to a variable number of tandem repeat (VNTR) min~ 
224 
----------------- Islet abnormalities in the etiology of diabetes 
isatellites upstream the insulin gene. The sh0l1 class I VNTR alleles predispose to type I dia-
betes, while the long class III have a protective effect (8). Intriguingly, several groups have 
reported that protective class III VNTR alleles in human adult or fetal pancreata are associat~ 
ed with lower insulin mRNA levels than class I alleles (50,51). It is diftlcult to reconcile the 
association of lower insulin mRNA levels in the pancreas with the finding that class III VNTR 
alleles are dominantly protective against type 1 diabetes. However! our data in NOD mice 
indicate that higher insulin mRNA levels associated with class I VNTR alleles may enhance 
the susceptibility of the f3 cells for autoimmune destruction, 
Another indication for the involvement of an aberrant B cell activity in the pathogen~ 
esis of type 1 diabetes in humans is the observation that factors that intluence j1 cell activity 
are also known to intluence diabetes incidence. For example, prophylactic insulin treatment 
of subjects at risk of developing diabetes has been shmvn to delay the onset of overt disease 
(52,53). Finally, environmental £1ctors known to trigger diabetes, such as infections, diet 
modification, trauma, surgely, cold, emotional stress and onset of puberty, can all affect 
peripheral insulin demand by creating a transient state of insulin-resistance (8,27,54). 
Tn conclusion, in human type I diabetes, endocrine and immune abnormalities similar 
to those observed in NOD mice may playa role in the etiology and pathogenesis of the dis-
ease. Because of the heterogeneity of the human patient popUlation and the polygenic basis 
of the disease, these phenomena are likely to be present in only a subgroup of the patients. 
Suggestions for future research 
Based on the shldies described in this thesis, we suggest that an abnormal islet 
development, in possible relationship with a defective APC function, is involved in the initi-
ation of islet autoimmunity in NOD mice. An extensive study, in particular during the fetal 
period, comparing islet development in NOD mice ,,,ith that in non-diabetes-prone control 
strains may shed light on the postulated developmental islet abnormalities. Special emphasis 
should be placed on the developmental pattern of expression of the major autoantigcns 
involved in autoimmune diabetes in NOD mice. 
NOD mice exhibit developmental islet abnormalities and leukocyte defects. Moreover, 
alterations in the differentiation and/or function of islet cells were consistently accompanied 
by the presence of elevated numbers of leukocytes in the pancreas. The possible rcgulatOlY 
role of leukocytes in islet development and function theretore deserves further investigation, 
both in normal and diabetes-prone strains. 
Our studies show different episodes of!3 cell hyperactivity il'om birth onwards. An 
aberrant regulation of the expression of the insulin gene might contribute to this phenome-
non. A study of the regulation of insulin gene expression in NOD mice and humans at risk for 
diabetes development is required to investigate this possibility. 
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Chapter 4.1 
In conclusion, the studies described in this thesis suggest that, in type I diabetes, the 
pancreatic islet of Langer hans is not an innocent victim of the autoimmune attack, Rather, it 
plays an active role in the cross~talk with the immune system, both at the level of its own 
development and Iatcr in its destruction. In the pathogenesis of autoimmune diabetes, morc 
(and earlier) relationships between leukocytes and pancreatic islets might occur than previ-
ously recognized. Leukocytes may regulate the activity of islets in a normal physiological 
way. However, for a rcason slill to be elucidated, APC in islets start to present autoantigens 
and induce al1 imlllune response, The physiological role of APC turns in a pathogenic role. 
Thus) the attraction between APC and islet cells during diabetes development appears to he 
a "fatal attraction)" ultimately leading to f) cell death. 
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Summary 
Type I diabetes mellitus (type I diabetes) is the resuit of aT celi-mediated autoim-
mune destruction of the insulin-producing !3 cells in the pancreatic islets of Langerhans. The 
cause of this self-destruction is not known. Clinical symptoms of the resulting glucose intol-
erance occur ,vhen morc than 90% of the B cells arc destroyed. Hence, human type 1 diabetes 
patients do only present in a hospital \vhen the autoimmune process is virtually finished. This 
fact disqualifies human type I diabetes patients as suitable subjects for the research of the ini-
tiation phase of type 1 diabetes. To study this early, decisive phase in the autoimmune 
process, animal models are needed. The most widely used animal model for type 1 diabetes 
is the nonobese diabetic (NOD) mouse. The NOD mouse spontaneously develops diabetes in 
a manner that closely resembles the human situation, and is thus suitable for the study of the 
initiation phase of type 1 diabetes. 
Several abnormalities in immune function have been suggested to underlie the patho-
genesis of autoimmune diabetes in NOD mice. These abnormalities do however not explain 
the organ-specificity of the autoimmune process. \Ve hypothesized that abnormalities in the 
target organ, in addition to abnormalities in the immune system, are essential for the 
development of J) cell-specific autoimmunity. In this thesis, \ve investigate the role of abnor-
malities in the islets of Langerhans in the etiology of autoimmune diabetes. 
For this purpose, we first characterized the inflammatory intiltration of pancreatic 
islets with non-lymphoid cells in NOD mice, experimentally manipulated to show kinetical-
ly different pathogenic processes. We determined that the influx ofBMS+ Mq, correlates with 
aggressiveness of the lesiou. Furthermore, ER-MP23+ Mq, and CDllc+ DC are cells that 
accumulate around the islets in the initial stages. 
\Ve then searched for abnormalities in the function and phenotype of the islets that 
could potentially trigger the initial infiltration with non-lymphoid celis. We fonnd that NOD 
mice have an enhanced percentage of abnormally large islets, designated 'mega-islets'. 
Importantly, in early stages of infiltration antigen-presenting cells (APC) are preferentially 
associated with these mega-islets. This association suggests that mega-islet formation is an 
important event during diabetes development. This hypothesis is further supported by the 
flnding that kinetics of mega-islet formation correlate with the development of disease, since 
it is especially pronounced in diabetes-prone NOD females and orchidectomized NOD males 
as compared to diabetes-resistant NOD males. In addition, preventing the formation of mega-
islets by prophylactic insulin treatment also prevents the development of diabetes. Thus, 
mega-islet fOl1nation may be essential for diabetes to occur in NOD mice. 
Several factors are shown to contribute to mega-islet formation. As already indicated, 
the sex difierence, and thus the levels of sex steroids playa role. Preceding the generation of 
mega-islets, a hyperinsulinemia was found, suggesting that islet hypertrophy is the conse-
quence of an increased insulin demand. The start of this hyperinsulinemia is associated ,vith 
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the shift in diet that occurs at weaning, when maternal milk (poor in carbohydrates) is 
replaced by laboratory chow (rich in carbohydrates). 
The dysregulated response to changing dietary conditions may be related to metabol-
ic abnormalities that NOD mice experience during their development illll/era, Indeed, hyper-
active B cells can already be found in neonatal animals, These abnormalities normalize with-
in one \'leek after birth, possibly because of the neonatal diet of maternal milk. Also infiltrat-
ing cells may contribute to the hyperinsulinemia, since the development of islet infiltration by 
APC correlates in time with the development of hyperinsulinemia. Co"cultures of isolated 
islets of Langerhans and DC showed that infiltrating DC are indeed able to influence j) ccll 
activity, Another factor that contributes to prediabetic hyperinsulinemia in NOD mice is 
hyperglucagonemia, The association of hyperinsulinemia with hypergiucagonemia suggests 
a generic abnormality in islet function. 1ndeed, \'le find evidence for all abnormality in islet 
development in neonatal NOD mice, since the islets in neonatal NOD mice resemble imma-
ture islets. It can not be concluded, however, that these neonatal islet abnormalities are the 
cause of the initial islet infiltration in NOD mice. \\Then analyzing the numbers of APC in 
neonatal pancreas, we found that NOD mice have higher numbers of APC in their pancreas 
compared to non"diabetes prone mice. Hence, the neonatal islet abnormalities may be related 
to an early influx of int1ammatory cells. 
Taken together, in this thesis, we approached the question whether abnormalities in the 
islets of Langerhans, in addition to abnormalities in the immune system, are involved in the 
development of autoimmune diabetes in NOD mice. \Ve found several islet abnormalities, 
always accompanied by an inflammatory infiltrate. Thus, intrinsic islet abnormalities may 
indeed playa role in the etiology of NOD autoimmune diabetes, Furthermore, \'le showed that 
infiltrating leukocytes can cause islet abnormalities. Thus, a complex cross~talk between anti~ 
gen~presenting cells and islets exists during development of autoimmune diabetes in NOD 
mice. A similar interaction may be important in the development of type I diabetes in 
humans. 
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Samellvattillg voor lliet-ingewijden 
Suikerziektc, of diabetes mellitus, komt voor bij ongeveer 5% van de westersc be vol-
king. Suikerziekte ontstaat doordat het honnoon insuline er niet is (type 1 diabetes) of niet 
goed werkt (type 2 diabetes). Insuline is Ilodig am de brandstof van het lichaam, suiker, te 
kunnen gcbruikcn. Type 1 diabetes antstaat meestal bij kindercll, die dan de rest van hun 
leven insuline moetcn spuitcn. Type 2 diabetes ontstaat mcestai bij anderen en kan over het 
algemeen met medicijnen worden behandcld. Dit proefschrift gaat over type I diabetes. 
Type 1 diabetes is cell gevolg van cell vergissing van het afweersystecm. De taak van 
het afwcersystecm is het beschennen van het lichaam tegen bactcrien en virussen. De cellen 
van het afwcersysteem patrouilleren door het lichaam en maken bacterien en virllssen die ze 
tegenkomen onschadelijk. Soms maakt het afweersysteelll een vergissing, en vernietigt in 
plaats van een bacterie of virus een stllkje van het eigen lichaalll. In dat geval is er sprake van 
een autoimmuunreactie. Autoimmuunreacties zijn de oorzaak van ziektes zoals reuma (waal' 
het ufweersysteem de ge\vrichten beschadigt), M.S. (waar het de zenuwen beschadigt), en 
type I diabetes. Bij type 1 diabetes vernietigt het afweersysteem de j) cellen in de alvlees-
klier. Deze j) cellen liggen samen met andere cellen in groepjes in de alvleesklier. Deze groep-
jes cellen worden de eilanden vnn Langerhans genoemd. De f3 cellen maken insuline; als ze 
vernietigd worden kan het lichaam dlls geen insuline meer makell en ontstaat type I diabetes. 
Het is niet bekend \vaarom het afweersystecm plotseling de f1 cellen aan gaat vallen. 
De meeste wetenschappers denken dat fouten in het afweersysteem ervoor zorgen dat dit sys-
teem het verkeerde doelwit vernietigt. Deze theorie kan echter niet uitleggen \vaarom deze 
fouten in hel afweersysteem bij som~llige mensen leiden tot een afwcerreactie tegen de 
gewrichten en dus tot rellll1a, terwijl bij andere mensen de B cellen worden aangevallen en dus 
diabetes ontstaat. Oak wij denken dat type 1 diabetes patienten fouten in het afweersysteelll 
hebben, maar wij gaan er bovendien van uit dat er ook touten in de B cellen zijn. Door deze 
touten in de B cellen komt het datjuist deze cellen worden vernietigd door het afweersysteell1. 
De vraag die wordt onderzocht in dit proefsehrift is: zijn er fouten in de !3 cellen die kunnen 
verklaren waaroll1 het afweersysteem de vergissing maakt am deze cellen te vernietigen? 
Deze vraag kan heelmoeilijk onderzocht worden in mensen met diabetes. Dat komt 
doordat mensen meer dan 90% van hun B cellen kunnen missen voordat zc er iets van merken. 
Op het moment dat mensen ontdekken dat ze diabetes hebben, is de ziektc dus meestal al 
jaren ongemerkt aan de gang. Het is dus niet mogelijk am in mensen te onderzoeken hoe de 
ziekte is ontstaan. Onderzoek naar het ontstaan van diabetes gebeurt daarom in proefdieren. 
Bij dieren komt net als bij mensen oak diabetes voor. Door dieren met diabetes met elkaar te 
kruisen, krijg je op den duur een stam van dieren die alleman 1 diabetes ont\vikkelen. Op deze 
manier is de NOD llluis gelllaakt, het meest gebruikte proefdier vaal' onderzoek naar type I 
diabetes. Deze mllis ontwikkelt diabetes 01' een manier die erg lijkt OJ) de ontwikkeling van 
type t diabetes bij de mens. Bovendiell weten we precies op welke leeftijd de autoinllllUUnH 
reactie begint in de NOD muis. 
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In NOD muizen kan dus de vraag worden onderzocht of fouten in de p ccllen een rol 
spelen bij de vergissing van het afweersysteem am deze 13 cellen te vernietigen. \Ve hebben 
op verschillende manieren deze vraag proberen te beantwoorden. Allereerst hebben \ve via de 
microscoop bekeken wat er precies gebeurt in de eilanden van Langerhans 01' het moment dat 
de autoilllllluunreactie begint. \Ve zagen dat bepaalde ccllell van het afweersysteem, de zoge~ 
naamde antigecn presenterendc cellen, zich verzamclden rond eilanden van Lallgerhans die 
abnonnaal groat waren doordat er heel veell) cellen in zaten. Ook hebben we gekeken of de 
13 cellcn weI nonnaal wcrkten, door te bepalen hoeveel insuline de NOD muizen in hun bloed 
hadden op het moment dat de autoimllluunreaetie begint. Het bleek dat de muizen 01' dit 
moment te veel insuline in hun bIoed hadden. Het lijkt er dus op dat er inderdaad fouten zijn 
in de f3 cellcn, die lllisschicn een uitlcg Zijll vaal' de vergissing van het afweersysteem. 
Bovendicn hebben \ve gcvollden clat, als we dcze fouten corrigeren met medicijllen, de 
autoimmuunreactie afnccmt. 
Maar deze resuitaten leverdell natllurlijk nieuwe vragen op. Hoe komt het eigenlijk dat 
de 11 cellell niet normaal \verken in NOD lllllizen? \Ve hebben gevonden dat di! van veel din~ 
gen athangt. Dc Illoeders van NOD muizen hebben vaak zelf al sllikel7;iekte als ze drachtig 
zijn, en daardoor hebben ze veel slliker in hun bloed. Dat zou gcvolgen kunnen hebben Vaal' 
de ontwikkeling van de NOD jongen. \Ve hebben inderdaad gcvonden dat de eilallden van 
Langerhans niet normaal ontwikkelen in NOD muizen. Het zou ook kunncn dat andere hor~ 
monen ervoor zorgen dat er te vee I insuline wordt gemaakt. De hoeveelheid insuline in het 
bloed hangt stcrk af van de hoeveelheid van andere honnonen, zoals de geslachtshormollen 
en glucagon. 
We hebben gezocht naar fouten in de (3 cellen in de eilanden van Langerhans die 
zouden kunnen uitleggen waarom het afweersysteem per vergissing deze cellen vernietigt. 
\Ve hebben eell aantal fouten gevonden, maar we kUllllen niet zeker zeggen of dcze fouten ook 
eeht de oorzaak zijn van de vernietiging door het afweersysteem. De reden is dat we oak 
hebben gevonden dat dc alltoimmuunreactie misschien veel eerder begint dan we tot ntl toe 
dachten. We weten dus niet zeker of aile fouten die we hebben gevonden er al echt zijn voor~ 
dat de autoimlllllunreactie begint. Ais dat niet zo is, kunnen aUe gevonden afwijkingen 
namelijk het gevolg zijn van de alltoimmuunreactie in plaats van de oorzaak. 
Wij hebben geconcludcerd dat fouten in het afweersysteem en in de j3 cellen elkaar 
versterkcn, en er samen Vaal' zorgen dat de antigeen presenterende cellen zich random de 
eilanden van Langerhans verzamelen. De aantrekkingskracht tussen f3 cellen en antigeen pre~ 
sentercnde cellen van het afweersysteem is uiteindelijk een fatale aantrekkingskracht: de 
13 cellen worden door de cellen van het afweersysteem vernietigd en er ontstaat suikerziektc. 
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Bedallkt 
De muziek is de moedertaal van het hart. 'Vat is dus een belere 111etafoo1' 0111 mijn 
dankbaarheid uit te drukken dan een 11l1lzikale. Dit proefschrift is geen solo-concert, maar 
eerdcr een symfonie met cen leidende melodic. Heel vcelmensen hebben, ieder op hun cigen 
manier, cell partij vaal' hun rckcning genomen. Sommige inslrul11cnten zijn van nature wat 
dominantcr aamvezig dan andere, maar daannee niet automatisch van grotere invloed. De lei-
clende melodic krijgt .iuist klank en kleur door de tonen die zachtjcs op de achtergrond 111CC-
klinken of die gcsuggereerd ,vorden en door de stiltes die vallen. 
Hierbij wil ik aIle betrokkenen bedankcn voor het eindresultaat dat we samen bcrcikt 
hebben. Het met namen noemen van personen impliceert echter oak dat andere l11enSell, die 
evenzecr l11ee hebben gespeeld, niet genoel11d wordell. Daarom hoop ik dat al diegenen die ik 
bij het schrijven in gedachten heb gehad zich herkennen in cell ofmeer van de hicrnavolgende 
beschrijvingen. 
BovenaI dank aan de leermeesters die crvoor hebben gezorgd dat ik in de positic kwa111 
am op dit niveau mce te spelen. Zij hebben me gelccrd dat eell goed musiclls iemand is die 
perfect speelt, maar een waardevoll11usicus iemand die daarnaast de muziek in al zijn facetten 
overzict en dit overzicht kan ovcl'dragen op het ge'jntercsscerde publiek. Het beIangrijkste wat 
ze me hebben bijgebracht, is dut het leven hannonischer is aIs het niet aileen uit muziek 
bestaat. 
Dank aan de componisten van het project, die ervoor zorgden dat deze symfonie 
geschreven werd. lk realiseer me wei dat er van het oorspronkelijke stuk weinig overeind is 
gebleven, het is meer geworden tot eell soort improvisatie die zeer vaag aan het oorsponke-
Iijke them a herinnert. Maar in de ll1uziekgeschiedenis zijn belangrijke vernieuwingen juist 
ontstaan als de oude regels werden losgelaten. 
Dank aan de dirigenten, die de improvisaties in toom hielden en de repetities in 
Rotterdam en ParUs verzorgden. Bovendien lieten ze mij de verschillende interpretaties vall 
het ruwe materiaal horen. Speciaal dank aan de dirigenten die na cen slechte generale in de 
laatste fase de podiumvrees in toom hie1den en voor voldoende vertrouwen in cen gocde 
uitvoering zorgden. 
Dank oak aan de l11ede~spelers in binnen~ en buitenland. En vooral ook aan dicgenen 
die weliswaar niet direct aan deze symfonie mcespeclden, maar er wei voor zorgden dat de 
repctities en mijn leven buiten de repetities gezellig waren. 
Bovendien zijn er veel ondersteunende diensten bij een concert betrokken. Dank aan 
de menscn die mijn bijdrage aan het concert mogelijk hebben gel11aakt, de instrul11enten 
hebben verzorgd, de publieiteit hebben gedaan, de partijcn hebben geeorrigcerd en aile 
verdere praktische zaken hebbcn geregeld. 
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Maar ook vooral dank aan het pnbliek, dat de moeitc nam om belangstelling te tonen. 
Tijdens cell lange repetitieperiode als dcze gebeuren cr altijd onvoorzicne dingen. Tenslottc 
wil ik dan ook vooral aile luisterendc oren, onontbccrlijk voor een 1l111sicus, bedanken. 
Het belangrijkste in de ll1uziek staat niet in de noten. Het belangrijkste van eell pro~ 
motie staat dan ook niet in het proefschrifl. Een prol11ovendus Ieert meer van de experimenten 
die niet geIukt zijn dan van die die onmiddellijk sliccesvol waren. Net zoals een 11111sicus 
aileen voorllitgang boekt door iets tc spelen wat hij nag niet beheerst. Daarnaast geldt voor 
zowel de 1l111ziek als de wetenschap dat het gcheel meer is dan de afzonderlijkc delen. Juist 
het bereiken van dit samenspcl is het verschil tussen een kakofonie en een sYll1follie en dus 
hetgene waar de speier het meeste van Ieert. 
Een symfonie is nooit at' ~aangezien dat ZOli betekenen dat deze perfect zon zijn~ maar 
kan altijd verbeterd worden. Het volgende concert dwingt een musiclls am zijn aandacht tc 
verleggen. In dat opzicht is een concert een momentopname, die de lading van de repetities 
en de h.--walitciten van de speIer wellicht niet gocd weerspiegclt. Maar \vel een moment wam 
naar uitgekcken is tijdens nuttige maar vooral oak tegenvallende repetities. Daarom wil ik 
afsilliten met een tekst uit "Ease on down the road" uit "The \Viz", 0111 aan terug te denken 
tijdens de repetities van het volgende concert: 
'Calise there 1110)' be tillies 
When YOII thinkyoll /ostyollr lIIind-
And the steps YOII 're takin' 
Leave YOII three, fOllr steps behind 
'Calise the road YOII 're 1 va/kin , 
Might be long sOllletime, 
Bllt jllst keep 011 steppill' 
AndyoII'1I be/llst/ine! 
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Curriculum vitae 
De schrijfster van dit proefschrift werd geboren op 25 november 1971 in 8emmel, cen 
dorp gelegen tussen Arnhem en Nijmegen. In diezelfde plaats volgde zij van 1984 tot 1990 
het Atheneum aan de Scholengemecnschap Oost-BctLlwc. In het jaar 1989-1990 wcrd, naast 
het examcnjaar Atheneum, de vooropJeiding dwarsfluit aan het conservatorilll11 in Arnhem 
gevolgd. In 1990 besloot ze toch aan de universiteit te gaan studercll, en de keus vicl op de 
studie mcdische biologic aan de Ulliversiteit Utrecht. Tijdens deze studie ,vas ze aetief in 
diverse cOllllnissies op het gebied van het onderwijs. In 1993 began ze tevens aan de shldie 
psychologic aan de Rijksuniversiteit Leiden. In april 1995 wcnl het doctaraal in de mcdische 
biologic behaald, met als hoofdvakken immunologie en moleculaire neum-endocrinologie. 
Op I mei 1995 begon ze als A.l.O. onder leiding van Prof H.A. Drexhage (Immunologic 
Rotterdam) en Dr. F. Homo-Delarche (H6pital Necker, Parijs) aan het in dit proefschrift 
beschreven onderzoek, en besloot ze haar shIdie psychologie voorlopig te onderbreken. Een 
gcdceIte van het in di! proefschrif1 beschreven onderzoek werd uitgevoerd in Parijs. Tijdens 
ham promotie heeft ze diverse vormen van onderwijs gegcven, onder,andere in de histologie 
en in de klinische immunologic, Ook lleeft ze zelf deeigenomen aan diverse cursussen, zoals 
stralingshygiene niveau 3, the Oxford examination in English as a foreign language-Higher 
level, speeialistisehe cursussen van de onderzoekschool Molecular Medicine en wetenschaps-
-theater. Bovendien \vas ze aetief als vertegenwoordiger van het wetenschappelijke personeel 
in tijdelijke dienst in de stafvan de vakgroep, en nam ze deel aan de organisatie van de jaar-
lijkse wetenschappelijke dag van de onderzoekschool Molecular Medicine. In 1996 werd de 
studic psychologie weer hervat, en ze koos voor de afstudeerrichting sociale en organisatie-
psychologic, In augustus 1998 is ze Clim laude als socialc- en organisatie-psychologe afge-
studeerd op een onderzoek naal' wcrken in multicuIturele bedrijven, Sincls 1 mei 1999 is ze 
verbonden aIs postdoc aan Immunologie Rotterdam, alwaar ze werkzaam is onder leiding van 
Prof W. van Ewijk op een project gefinancierd door het Diabetesfonds Nederland. Het doer 
van dit project is het genereren van eell faag untistof specifiek voor autoreactieve T cellen in 
type I diabetes. 
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The author of this thesis ,vas born on November 25, 1971 in Bemmel, a village sihw{-
ed between Arnhem and Nijmegen. From 1984 to 1990, she attended the Oost-Betuwe 
Athenaeum High School in Bemmel. From 1989 to 1990, she combined High School with 
flute study at the music conservatory in Arnhem. In 1990, she decided to shldy med ieal biol-
0gy at Utrecht University. During this period, she was a member of several committees 
focussing on education. She combined her study in Utrecht with the Shldy of psychology at 
Leiden University from September 1993 onwards, specializing in social and organizational 
psychology. In April 1995, she received her Master of Science degree in medical biology, 
with majors in immunology and molecular neuro-endocrinology. She began her Ph.D. in i'vfay 
1995 under the supelvision of Prof. H.A. Drexhage (Immunology Rotterdam) and Dr. F. 
HOll1o-Delarche CHapital Necker, Paris). Some of the studies described in this thesis ,vere per-
formed at the lab in Paris. During her Ph.D.-period, she has taught diverse courses, including 
histology and clinical immunology. She also participated in various courses herself, includ-
ing radionuclides level 3, the Oxford examination in English as a foreign language-Higher 
level, several advanced courses organized by the postgraduate school Nrolecular Medicine 
and scientific theater. She also ,vas the representative of the junior scientiflc personnel in the 
staff of the depm1ment, and she participated in the organization of the annual scientific day 
of the postgraduate school rVfolecular Medicine. In August 1998, she graduated cum laude 
with her Master of Arts in psychology, having done research on multicultural organizations. 
Since May I, 1999 she has been working as a postdoc at Immunology Rotterdam. The proj-
ect she works on is subsidized by the Dutch Diabetes Fund, and is under the supervision of 
Prof. \V van Ewijk. The aim of this project is the generation ofa single-chain phage-antibody 
against autoreactive T cells in type 1 diabetes mellitus. 
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